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This research developed and validated QSPKR models for predicting in-vivo human, 
systemic biologically relevant PK properties (i.e., reflecting the disposition of the unbound drug) 
of four, preselected, pharmacological classes of drugs, namely, benzodiazepines (BZD), 
neuromuscular blocking agents (NMB), triptans (TRP) and class III antiarrhythmic agents 
 (AAR), as well as PK allometric scaling (PK-AS) models for BZD and NMB, using pertinent 
human and animal systemic PK information (fu, CLtot, Vdss and fe) from published literature. 
Overall, lipophilicity (logD7.4) and molecular weight (MW) were found to be the most 
important and statistically significant molecular properties, affecting biologically relevant 
systemic PK properties, and the observed relationships were mechanistically plausible: 
For relatively small MW and lipophilic molecules, (e.g., BZD), an increase in logD7.4 was 
associated with a decrease in fu, an increase in Vdssu and CLnonrenu, suggesting the prevalence of 
nonspecific hydrophobic interactions with biological membranes/plasma proteins as well as 
hepatic partitioning/DME binding.  Similar trends were observed in fu and Vdssu for intermediate 
to large MW, hydrophilic molecules (e.g., NMB). 
However, although similar trends were observed in fu and Vdssu for relatively hydrophilic, 
intermediate MW molecules (e.g., TRP), and a heterogeneous class (e.g., Class III AAR), logD7.4 
and MW were found to be highly correlated, i.e., the indepdendent effects of logD7,4 and MW 
cannot be assessed  NMB, TRP and Class III AAR show mechanistically diverse clearance 
pathways, e.g., hepatobiliary, extrahepatic, enzymatic/chemical degradation and renal excretion; 
therefore, effects of the logD7.4 and/or MW are note generalizable for any of the clearances 
across classes. 
PK-AS analyses showed that Vdssu and Vdss scaled well with body weight across animal 
species (including humans) for BZD.  Overall, within the limitations of the methods (and the 
sample size), ‘acceptable’ predictions (i.e., within 0.5- to 2.0-fold error range) were obtained for 
Vdssu and Vdss for BZD (and fu correction resulted in improvement of the prediction); however, 
none of the CLtot predictions were acceptable, suggesting major, qualitative interspecies 
differences in drug metabolism, even after correcting for body weight (BW). 
 NMB undergo little extravascular distribution owing to their relatively large MW and 
charged nature, and, as a result, a high percentage of acceptable predictions was obtained for 
Vdss (based on BW).  Similarly, the prediction of CLren (based on BW and glomerular filtration 
rate, GFR) was acceptable, suggesting that NMB are cleared by GFR across species, and there 
are no interspecies differences in their tubular handling.  On the other hand, CLtot (and/or 
CLnonren) could not be acceptably predicted by PK-AS, suggesting major differences in their 
clearance mechanisms across animal species. 
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CHAPTER 1. Introduction 
 
1.1 Background and Significance 
The discovery and development of new candidate drug molecules is a cost-1, resource- and time-
consuming1 process. This is in part due to the high attrition rates of drug candidates that enter 
clinical development, such that, approximately, only 1 in every 10 ultimately become marketed 
as therapeutically safe and effective drugs2,3. When the reasons for such high attrition rates were 
investigated, the lack of favorable human pharmacokinetic (PK) properties (“druggability”) of 
the candidates3, 4 has been reported to be one of the most prominent causes. This suggests that 
the process by which new drugs are discovered and developed could benefit greatly if (a) there 
were better preclinical characterization of absorption, distribution, metabolism, elimination and 
toxicological properties (ADMET)5 of each candidate, and (b) the predicted human PK 
characteristics were deemed ‘acceptable’ (e.g., oral bioavailability and duration of exposure are 
projected to be appropriate for conducting pivotal efficacy studies) early in the development. 
Therefore, the development and application of reliable quantitative methods to predict human 
drug disposition may decrease the overall attrition of drug candidates during clinical 
development by reducing the number of candidates with unacceptable PK characteristics. 
Furthermore, selecting only compounds with likely acceptable PK properties for their intended 
therapeutic use could maximize the ultimate clinical utility and market success. Consequently, 
several studies have investigated the use of (a) approaches, such as, quantitative structure PK 
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property relationships (QSPKR), which can be used for prospective in-silico screening of 
potentially important lead candidates with favorable ‘drug-like’ properties6,7, and/or (b) 
experimental methods such as, interspecies PK-allometric scaling (AS)8–13 approaches, based on 
disposition in the preclinical species, physiologically-based-PK (PBPK) modeling14 and in-vitro-
to-in-vivo extrapolation (IVIVE)3 etc.  
The aim of this research project is to develop and validate mathematical/statistical in-silico 
models for predicting biologically relevant human PK properties of select pharmacological 
classes of compounds, namely, benzodiazepines (BZD), neuromuscular blocking agents (NMB), 
triptans (TRP) and class III antiarrhythmic agents (AAR) using two approaches, QSPKR 
modeling and interspecies PK-AS.  
The anticipated findings will help in supporting the rational application of quantitative methods 
in drug discovery and development and screening of new drug candidates with more favorable 
‘druggable’ properties and better integration of physicochemical/molecular properties with 
PK/ADME properties of already existing drugs.  
 
1.2. Quantitative Structure Pharmacokinetic Relationships 
The introduction of quantitative structure-activity relationships (QSAR) in the 1960s was 
pioneered by Hansch and co-workers15, who investigated quantitative relationships between 
physicochemical properties and in-vitro potency at the target for homologous series of 
compounds. A lot of work has been carried out over the past few decades in developing 
analogous relationships between structural/molecular properties of compounds (homologous 
series of compounds sharing a common structural scaffold or structurally diverse compounds), 
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determined either by computational or experimental means and relating them to experimental in-
vitro and/or in-vivo PK properties in preclinical animal species and humans5,16–29.  
One of the overarching goals in the development of new drugs is to identify early an acceptable 
therapeutic dosing regimen (both in terms of how much and how often the drug needs to be 
dosed, see Figure - 1.1 below) that results in adequate patient compliance and effective therapy. 
In order to achieve this objective, in-silico approaches such as QSPKR models can be useful to 
adequately predict the disposition of drug candidates. For instance, (a) the dosing interval is 
usually affected by systemic PK properties, such as volume of distribution at steady-state (Vdss) 
and total (systemic) body clearance (CLtot), while; (b) the dose amount is affected by oral 
bioavailability (for drugs administered by the oral route) and CLtot. The QSPKR paradigm
17,30 is 
shown in Figure 1.1 below. 
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The present work is unique relative to published in the literature in the following respects: 
1. A few QSPKR studies in the literature attempted to predict the apparent CLtot (i.e., CLtot/Foral) 
and apparent Vdss (i.e., Vdss/Foral) after oral administration to humans (from the results of 
preclinical species)8,31,32. Any observed trends are difficult to mechanistically interpret 
because these relationships cannot be unambiguously attributed to the systemic component 
(i.e., systemic CLtot and Vdss) versus the presystemic component (i.e., Foral). Furthermore, in 
order to avoid the confounding effects of system-dependent factors, such as gastrointestinal 
(GI) absorption (possible incomplete solubility and/or permeability in GI tract); and also 
system-independent factors such as, formulation properties etc., only the systemic PK, i.e., 
exclusively after I.V. administration, were considered in the present work.  
2. Each relevant PK property value reported in the literature was carefully scrutinized and 
included only after critical evaluation of study design, type of subjects, dosing regimen, PK 
sampling schedule, PK analysis and bioanalytical assay procedures etc. Specific importance 
was given to PK sampling schedule - i.e., only studies in which (a) adequate blood sampling 
was performed for at least 2-3 terminal half-lives (t1/2); and (b) the analytical technique used 
to quantitate plasma and urinary concentrations was sensitive over the adequate sampling 
period, were included in the database.  
3. In order to differentiate mechanistically between renal and nonrenal elimination pathways, 
the fraction of the drug excreted unchanged in the urine (fe) was compiled from the urinary 
excretion studies following I.V. administration, after ensuring that the urine samples were 
collected completely for at least 2 - 3 terminal t1/2. Additionally, renal clearance (CLren) 
estimates were compiled from studies following oral administration, provided they were 
estimated from the ratio of amount of drug ultimately excreted in the urine unchanged (A∞) 
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relative to systemic exposure (AUC∞). After differentiating the systemic CLtot into CLren and 
nonrenal (CLnonren) pathways, separate QSPKR relationships for each of them were 
investigated, in order to better understand and mechanistically interpret the 
molecular/structural properties, potentially affecting the respective clearance pathways.  
4.  A fundamental assumption in PK/pharmacodynamics (PD) is that only the unbound drug is 
available for absorption, distribution, metabolism, excretion and interaction with the PD 
targets. Therefore, QSPKR (and AS-PK) models were built for the biologically relevant, i.e., 
unbound PK properties (after correcting the reported in-vivo systemic PK variables for PPB). 
Such relationships with the unbound systemic human PK properties have rarely been 
explored in the literature.  
5. The QSPKR model building and validation process followed strict statistical rules using 
univariate and multivariate log-linear regression, collinearity amongst molecular/PC 
variables was considered, based on the criteria of r > 0.80, in order to address the possibility 
of statistical interactions between the molecular properties. Next, potentially important 
molecular/PC covariates were screened by univariate regression based on the criteria - r2 > 
0.3, p < 0.05 (i.e., the molecular/PC variable accounts for greater than 30% variability in the 
PK variable, and a finding that the slope of the relationship is significant at p < 0.05). Finally, 
multivariate log-linear regression (MLLR) was carried out in forward inclusion followed by 
backward elimination manner and validated using leave-out-one method by cross-validation.   
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However, the following limitations of the information in the database need to be considered 
carefully before interpreting the findings.  
1. The majority of the compounds in the final human PK(/PD) database are (tested and/or) 
approved for clinical use, i.e., it is implied that these compounds possess acceptable 
‘druggable’ molecular/PC properties. However, unfortunately, it does not contain 
compounds, which were tested in humans, but failed to reach the marketplace, at least in 
part due to their poor druggability. This suggests that there is an inherent, systematic 
(publication) bias in the selection of compounds.    
2. Furthermore, even for the compounds that have been included in the database, there were 
several missing values in their molecular/PC and/or PK properties (in human and preclinical 
species), especially, plasma protein binding (PPB) and urinary excretion data, and, 
therefore, the results should be carefully interpreted, especially for the unbound clearance 
pathways.  
3.  Primary PK variables reported in the literature were collected from multiple clinical 
pharmacology studies (e.g., diazepam33–38). Each of the reported values may be subject to 
bias and imprecision, depending on the study characteristics such as study design, 
characteristics of the study subjects, PK sampling times, PK analysis and bioanalytical 
procedures etc. In cases, where drugs were administered at more than one dose level (or 
dosing regimen), dose-proportionality in the systemic PK was evaluated, subject to 
availability of pertinent information; if not, it was assumed. In case of any obvious PK non-
linearities, systemic PK at the lowest dose level was used for analysis. Similarly, 
concentration-independent PPB and/or red blood cell (RBC) binding was assumed in cases 
where there was inadequate evidence in the literature.  
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4. The final values of PK variables in the database were estimated as mean values from 
multiple studies and did not account for intersubject/interstudy variability. 
5. For relatively lipophilic compounds, e.g., BZD (and few NMB), that are subject to extensive 
metabolism (both hepatic as well as extrahepatic), fe (and thus CLren) values were poorly 
estimated due to very low values for fe less than 1%. For certain drugs, e.g., TRP and Class 
III AAR, extrahepatic clearance was assumed based on the fact that CLnonren
Blood (or CLnonren) 
exceeds hepatic blood flow (LBF) (or in a few instances, exceeding the cardiac output) with 
the absence of adequate mechanistic evidence in the literature. 
6. The molecular/PC properties may sometimes be collinear, i.e., highly correlated with one 
another, which makes it difficult to separate the effects of one over the other.  
7. There are several algorithms available for computing the molecular/structural PC properties, 
but they may differ in the estimation method(s). Thus, selection of the appropriate PC 
variables becomes very important. Certain PC properties, although showing significant 
trends, may be difficult to interpret mechanistically compared to others.  
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The choice of the two-dimensional molecular/structural PC properties was based on their 
biological plausibility and their widespread use in the literature6,29,39,40. They are considered as 
“bulk” properties, because they do not contain information that may confer specificity towards 
the interaction with the PK - relevant biological entities (such as membranes, intra/extracellular 
proteins etc.) unlike those with PD targets. These molecular/PC properties include molecular 
weight (MW), polar surface area (PSA), logarithm of the partition coefficient (logP), pKa, 
number of rotatable bonds (nRot), number of hydrogen bond acceptors (HBA) and number of 
hydrogen bond donors (HBD). Additionally, the logarithm of the distribution coefficient (logD) 
was estimated based on logP and pKa using equations (shown in Chapter 3).   
For the purpose of in-silico screening and identification of “druggable” lead candidate(s) for 
further development, experimental determination of the molecular/PC properties is a tedious and 
time consuming process. Therefore, for QSPKR studies, they are estimated computationally and 
were estimated in a similar manner.   
 
1.3. Interspecies PK - Allometric Scaling (PK-AS) 
Allometry assumes anatomical, physiological and biochemical similarity (other than body size) 
across animal species and is used to study relationships of different physiological variables as a 
function of body size, usually, BW41,42. It is based on the relationship between physical 
compartment, organ size, perfusion rate and BW, characterized by the power model: 
Y = a*(BW)b   ….. Eq 1.1 
Where Y is the parameter of interest (e.g., PK property like CLtot, Vdss, etc.) and a and b are the 
intercept and exponent (coefficient) of the allometric equation, respectively. Various 
physiological volumes and organ perfusion rates have been allometrically scaled; the obtained 
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AS exponents are shown in Table 2.1 (in Chapter 2). In general, physiological volumes scale 
with AS exponent close to 1.0, while the organ perfusion rates scale with a factor of between 0.7 
to 0.8.  
PK-AS approaches have been widely used in literature for predicting human PK from preclinical 
in-vivo animal PK studies10,11. However, there is a lot of variability in this approach, such as, 
choice of the animal species for predicting human PK, choice of the PK endpoints, scaling and 
validation methods, etc. For example, Ward et al. studied the systemic PK properties (after I.V 
administration), namely CLtot
11 and Vdss
10 for 103 compounds in rats, dogs, monkeys and 
humans. They found that (BW-based) AS scaling approaches using two animal species was less 
successful in predicting human CLtot than LBF-based methods using a single species. In 
particular, with the compounds in the dataset, human CLtot and Vdss predictions from monkey 
seemed to be the most accurate and least biased compared to predictions from other animal 
species. They also concluded that r2 is not a good measure for characterizing the predictive 
ability of the allometric relationship, but rather propose to assess bias (% mean prediction error) 
and imprecision (% root mean square error).  
Mahmood et al8,12,13,43,44 proposed several correction factors that may improve the AS 
predictability from preclinical species, e.g., including maximum lifespan potential or brain 
weight correction, rule of exponents, and in-vitro correction. Additionally, other quantitative 
approaches explored the use of mechanistic correction factors based on LBF and glomerular 
filtration rate (GFR) (especially for drugs which are primarily renally excreted), etc. 
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Assumptions 
Overall, AS is based on the assumption that there are anatomical, physiological and biochemical 
similarities among animals, and physiological parameters scale based on BW across species. 
Following are the assumptions that underpin each of the individual prediction methods 
CLtot-prediction methods: 
1. Single species-BW based scaling without fu correction - there are no 
qualitative/quantitative interspecies differences in PPB, metabolic pathways, intrinsic 
clearance and excretory functioning. 
2. Single species-BW based scaling with fu correction - there are no qualitative/quantitative 
interspecies differences in metabolic pathways, intrinsic clearance and excretory 
functioning; and PPB differences are accounted for by fu correction.  
3. Single species - LBF-based scaling without fu correction - there are no 
qualitative/quantitative interspecies differences in PPB and B:P ratio; clearance occurs 
primarily via hepatic route.  
4. Single species - LBF-based scaling with fu correction - there are no 
qualitative/quantitative interspecies differences in B:P ratio; Clearance occurs primarily 
via hepatic route; and PPB differences are accounted for by fu correction.  
5. Single species - GFR-based scaling without fu correction - there are no 
qualitative/quantitative interspecies differences in PPB; Clearance occurs primarily via 
renal routes by net glomerular filtration and that there are species differences in tubular 
pathways. 
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6. Single species - GFR-based scaling with fu correction - Clearance occurs primarily via 
renal routes by net glomerular filtration and that there are species differences tubular 
pathways; and PPB differences are accounted for by fu correction. 
 
Vdss-prediction methods: 
1. Single species-BW based scaling without fu correction - there are no 
qualitative/quantitative interspecies differences in PPB and tissue binding 
2. Single species-BW based scaling with fu correction - there are no qualitative/quantitative 
interspecies differences in tissue binding; and PPB differences are accounted for by fu 
correction. 
 
Qualitative differences across species, in terms of the existence of different drug metabolizing 
enzymes (DME), differences in the enzyme expression, activity and affinity has been extensively 
documented in literature45,46. Similarly, quantitative differences across the animal species in the 
amount of CYP content per mg protein47. Differences in the Phase II metabolism via 
glucuronidation have been reported, e.g., rhesus monkey and dog liver microsomes have shown 
7- to 5-fold higher UGT1 activity than human liver microsomes respectively48, 49.  
Concentrations of plasma proteins, e.g., α-acid glycoprotein (AAG), are known to be different 
across the animal species, i.e., smaller animal species have higher concentrations than larger 
animals (See Table 2.2 in Chapter 2). Furthermore, since basic drugs commonly bind to AAG, 
this could be a possible explanation for quantitative interspecies differences in PPB. There are 
several genetic polymorphisms reported for several isoforms in humans that may or may not be 
relevant in the preclinical species.  Similarly, the influence of covariates such as age, gender etc., 
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on the systemic PK both in humans as well as in preclinical species may also contribute to 
quantitative/qualitative species differences, which may further contribute to species differences, 
complicating PK-AS approaches.  
 
 
Limitations of PK-AS 
The PK-AS approach is empiric, based on the assumption that PK properties can be scaled by 
body size only and there are little/no intrinsic, i.e., size-independent, qualitative species 
differences with respect to PPB, tissue distribution, DME etc. Furthermore, for compounds that 
are metabolized by extrahepatic routes, biliary excretion pathways involving (active) transport by 
drug transporters, species differences in these mechanisms, differences in expression and affinity 
towards transporters, etc., may cause significant prediction errors. Lastly, in order for better 
predictions, a large range in BW is desired, i.e., when predicting human systemic PK properties, 
corresponding data from species that have BW both smaller as well as larger than human BW are 
ideally sought, which is typically not available. 
 
1.4. Overview - Selection of Drug Classes  
Most of the QSPKR studies in the literature are either based on (a) congeneric series of 
compounds, which share a similar structural scaffold (but only differ in the functional groups or 
substituents) and typically act at a common biological target (e.g., receptor, enzyme, etc.)39,40,50–
52; or (b) heterogeneous datasets, which include compounds from different structural scaffolds 
and/or belong to different pharmacological classes, i.e., have different mechanism of action9,10,28. 
While the use of a homologous series primarily aims at identifying the contribution of particular 
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substituent/functional groups at specific positions of the molecular scaffold, the range in the 
molecular/PC and/or PK property space is, in general, narrow and overlaps, and the identification 
of important (bulk) molecular/PC descriptors becomes difficult. Furthermore, the use of MLLR 
methods on heterogeneous datasets may neglect interaction(s) amongst the molecular descriptors 
(i.e., highly correlated molecular/PC variables).  
In the present work, defined pharmacological classes of compounds, namely, benzodiazepines 
(BZD), neuromuscular blockers (NMB), triptans (TRP) and class III AAR, were selected 
because the underlying assumption is that the drug-target interactions are driven by (specific) 
molecular properties while the drug-biomolecule interactions during systemic disposition (PK) 
depend predominantly on (bulk) PC properties. Compounds belonging to each of the 
pharmacological class are known to hit a (respective) specific molecular target, e.g., gamma 
amino butyric acid (GABAA) receptors in the CNS for BZD, post-ganglionic nicotinic 
acetylcholine receptors (nAChR) at the neuromuscular endplate for NMB, post-synaptic 
serotoninergic (5-HT1B/1D) receptors in the CNS for TRP and cardiac K
+ channels for class III 
AAR. Additionally, (in general), compounds to respective classes share a similar structural 
scaffold (within each class). Lastly, there was adequate literature on I.V. human PK for a 
sufficient number of compounds (in each class) enabling the QSPKR analysis.  
The ultimate utility of these QSPKR models in the drug discovery/development relies on the 
property space5 both in terms of molecular/PC as well as PK, i.e., the larger is the property 
space(s), the more general is the applicability of the models, and the more likely they are to 
successfully predict the PK of a new compound.  
 
.   
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CHAPTER 2. Research Hypotheses 
 
Using the publicly available PK/PD information on the drugs/compounds belonging to these four 
pharmacological classes, namely, BZD, NMB, TRP and Class III AAR: 
 
Research Hypothesis I:  
Molecular/PC properties affect the in-vivo human systemic disposition of drugs, and the effect of 
these (bulk) molecular/PC properties on the biologically relevant human systemic PK properties 
is similar across pharmacological classes, while the drug-target (i.e., PD) interactions are driven 
by more specific molecular properties. In order to test this hypothesis: 
a. Pertinent human systemic PK/PD properties of these select pharmacological classes of 
compounds were collected from the biomedical literature, and FDA website (for drug label, 
biopharmaceutic drug reviews, new drug application approval documents), and, 
subsequently, their biologically relevant PK properties were estimated. 
b. Molecular/PC properties were derived computationally. 
c. The effect of these different molecular/PC variables on PK/PD properties was explored 
statistically, and, as appropriate, relationships were compared across the different 
pharmacological classes.  
d. QSPKR models were developed for predicting biologically relevant human systemic PK 
properties and validated for their predictive performance.   
 16 
Research Hypothesis II: Human systemic PK properties can be predicted by scaling from 
available in-vivo animal systemic PK properties using inter-species PK-AS approaches. In order 
to test this hypothesis: 
a. Pertinent animal in-vivo systemic PK properties of the BZD and NMB were collected from 
the biomedical literature, and, subsequently, their biologically relevant animal PK properties 
were estimated. 
b. PK properties of BZD were compared across the different species  
c. Allometric relationships were explored statistically using systemic and biologically relevant 
animal PK for BZD and NMB. 
d. Different allometric-based prediction methods were assessed and validated for their 
predictive performance.  
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1 CHAPTER 3. Quantitative Structure Pharmacokinetic 
Relationships (QSPKR) 
 
3.1.  Introduction 
Good predictability of any QSPKR model depends on the property space, both in terms of the 
underlying molecular/PC properties as well as systemic PK properties of the compounds that 
are included in the dataset to develop and validate the model. The larger the property space 
(i.e., large dispersion of the individual properties), the better the predictability and thus the 
applicability of the model, in terms of the prediction of PK properties for new molecules 
within the property space.  
BZD, NMB, TRP and Class III AAR were chosen for developing QSPKR models because the 
compounds/drugs belonging to each class (a) hit a common biological target, e.g., BZD at 
GABAA receptors, TRP at 5-HT1B/D receptors etc., (b) share a common molecular scaffold (at 
least the majority of them) and (c) show considerable diversity in molecular/PC as well as 
systemic PK variables, and the property spaces that these classes encompass have not been 
explored. Furthermore, there was substantial publicly available information in the biomedical 
literature on the systemic PK after intravenous (I.V.) administration for a sufficient number of 
compounds of each class. Lastly, there were no obvious PK nonlinearities reported for any of 
these pharmacological classes. Thus, the objective of the current study was to develop and 
validate QSPKR models to predict the biologically relevant human PK. 
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3.2. Specific Aims 
o Collect and compile valid human systemic PK/PD properties from the literature. 
o Estimate biologically relevant PK variables in humans. 
o Assess the effect of different molecular/PC descriptors on various PK/PD variables. 
o Develop and validate QSPKR models for biologically relevant PK properties. 
 
3.3. Methods I 
3.3.1. Computation of Molecular/PC Properties 
 
Molecular/PC descriptors, namely MW, (most acidic or basic) pKa, logP, and two-
dimensional molecular descriptors, namely PSA, MV, nRot, HBA, HBD were obtained using 
SciFinder Scholar (version 2014; Chemical Abstracts Service: Columbus, OH) for BZD, 
TRP and class III AAR, while ACD/Labs (version 12.01, Advanced Chemistry 
Development, Inc., Toronto, ON, Canada, 2014) was used for NMB (due to the lack of 
availability of that information in SciFinder).  
The name of the compound was entered into the “substance identifier” column in SciFinder 
or ACD/Labs and the molecular structure was reviewed to confirm the selected compound, 
and the values for the respective properties were compiled. Furthermore, lipophilicity, 
characterized by logD7.4 (calculated logD at a physiologically relevant pH of 7.4) was 
estimated based on the (most acidic/basic) pKa and pH using the following equations6:  
logD7.4  = logP - log (1+ 10
7.4 - pKa)       …. for acids … Eq 3.1 
logD7.4  = logP - log (1+ 10
pKa - 7.4)       …. for bases … Eq 3.2 
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Rationale: The PC descriptors used in the current project were chosen because they are 
reported to likely affect the human systemic PK properties29. Additionally, logD7.4 is 
considered preferable over logP because it is believed to be a more reliable (and 
physiologically relevant) marker for lipophilicity for compounds with ionizable functional 
groups6. 
3.3.2. Compilation of Systemic PK Properties 
 
The biomedical literature was searched exhaustively for original research and/or review 
articles on human (and animal) systemic PK/PD properties of 20 BZD (including a GABAA 
receptor antagonist), 16 NMB (15 non-depolarizing blockers and 1 depolarizing blocker), 7 
TRP and 7 Class III AAR.  
PK studies (including the ones that had urinary excretion data) in which the selected 
compounds are administered exclusively by the I.V route to healthy humans were considered. 
In case of clinical studies aimed to investigate, e.g., (1) effect of a certain compromised 
physiological condition such as renal or hepatic disease/dysfunction, or (2) effect of drug-
drug interactions, or (3) absolute oral bioavailability; only the treatment arm with healthy 
subjects, drug of interest alone after I.V were considered. In studies where the pertinent PK 
properties were not reported, but the (mean) plasma concentration - time plots were 
available, the respective concentration-time plots were digitized using GraphClick (version 
3.0.2, Arizona, AZ), and non-compartmental PK analysis54 was performed to estimate 
systemic PK variables. Lastly, oral administration studies were considered if both plasma and 
urinary concentrations were collected over time to estimate renal clearance (see Table 3.2) 
Values for fu were obtained from in-vitro PPB studies, at concentrations in the therapeutic 
range (and ascertaining the absence of any nonlinearities). Blood-to-plasma (B:P) ratios were 
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obtained from ex-vivo or in-vitro studies with whole blood and plasma from healthy humans. 
RBC partitioning (γ) values were estimated from fu and B:P ratio using pertinent equations 
(see Table 3.2) 
In-vivo systemic PK properties, namely total body clearance, CLtot, volume of distribution at 
steady-state, Vdss (or volume of distribution at pseudo steady-state, Vdpss) and fraction of the 
dose excreted ultimately unchanged into urine, fe, were compiled after critical evaluation of 
study design, type of subjects, dosing regimen, PK sampling schedule, PK analysis and 
bioanalytical assay procedures etc. Particular importance was given to plasma and urine 
sampling schedule - i.e., adequate sampling should have been done for at least 2-3 terminal 
half-lives (t1/2); and if the analytical technique used to quantitate plasma and urine 
concentrations was sensitive over the adequate sampling period. In the majority of studies, 
Vdss values were reported; however, in studies where volume of the drug in the central 
compartment (Vdcc) and micro-rate constants (k12, k21) were available for a two 
compartmental model, Vdss was estimated
54.  
In case the systemic PK properties were collected from multiple studies, the arithmetic mean 
was calculated across studies. BW-correction of the systemic PK properties was performed 
based on widely reported values reported in literature for AS-PK, a body weight for animals 
(see Table - 3.2) and 70 kg for humans55. Each individual study compiled and included 
respective PK property value is presented in a comprehensive manner in Appendices I 
through IV.  
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3.3.3. Compilation of PD Properties 
In order to evaluate if the drug molecule-PD target interactions are driven by and can be 
explained by the (bulk) molecular/PC properties for the different pharmacological classes of 
compounds, their (pertinent) respective in-vitro/ex-vivo/in-vivo PD properties, were 
compiled.  
In-vivo, the main molecular target of BZD is the postsynaptic inhibitory, gamma amino 
butyric acid (GABAA) receptor. Binding affinities (Ki) of BZD to GABAA receptors were 
compiled from in-vitro studies investigating the displacement of (pre-incubated) radiolabeled 
ligands, e.g., [3H]-diazepam or [3H]-flunitrazepam, in the presence of increasing 
concentrations in homogenized rat/human brain.  
The underlying assumption in these studies is that BZD (competitively) inhibit the 
radiolabeled ligand, which can be assayed by liquid scintillation counting of the unbound 
radiolabeled ligand (which is usually separated, accounting for non-specific binding).  
TRP, on the other hand show high selectivity and potent agonist activity at the serotoninergic 
receptors, namely 5-HT1B/1D subtypes
56 (which are presumed to be the molecular targets for 
alleviating migraine pain57,58). Thus, binding affinities (Ki) of TRP to 5-HT1B/1D were 
compiled from in-vitro studies investigating the displacement of (pre-incubated) radiolabeled 
ligands, e.g., [3H]-eletriptan or [3H]-sumitriptan, in stably transfected cell lines (HeLa) 
expressing human 5-HT1B/1D receptors.   
In the case of NMB, in-vivo PD properties namely, equilibration rate constant between 
plasma and biophase, (keo), plasma concentration producing half-maximal effect (cpss
50) and 
steepness of the concentration - effect relationship (γ) were compiled from in-vivo human PD 
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studies after ensuring that the same PD endpoint, i.e., 95% depression in the muscle twitch 
following ‘train-of-four’ stimulus was considered.   
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Table 3.1: List of Physiological Variables in Humans and Various Animal Species 
Species 
BW TBW IW EW 
Plasma 
Volume 
Blood 
Volume 
LBF RPF GFR 
(kg) (l/kg) (ml/min/kg) 
Mouse 0.02 0.73   0.05 0.09 90 40 15 
Rat 0.25 0.67 0.37 0.30 0.03 0.05 55 21 5.2 
Rabbit 2.5 0.72 0.47 0.25 0.04 0.07 71 21 3.1 
Rhesus Monkey 5 0.69 0.49 0.21 0.04 0.07 44 17 2.1 
Dog 10 0.60 0.33 0.28 0.05 0.09 31 12 6.1 
Human 70 0.60 0.34 0.26 0.04 0.07 21 10 1.8 
AS Exponent 0.98 0.97 0.98 1.01 1.01 0.83 0.84 0.79 
 
BW - Body weight; TBW - Total body water space;  IW - Intracellular water space; EW - Extracellular 
water space; LBF - Liver blood flow; RPF - Renal plasma flow and GFR - Glomerular filtration rate 
AS - Allometric Scaling Exponent  
Values compiled from reference55 
 
 
 
 
3.3.4. Estimation of Biologically Relevant PK Variables 
A fundamental assumption in PK/PD is that only the unbound drug is available for 
disposition, i.e., distribution, metabolism and elimination. Therefore, the compiled PK 
variables, Vdss, CLtot, CLren, CLnonren were corrected for PPB, to obtain their biologically 
relevant variables, i.e., only for the unbound drug, namely, Vdss
u, CLtot
u, CLren
u, CLnonren
u and 
CLint
In-vivo; the equations used are shown in Table 3.2 below.   
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Table 3.2: Estimation of In-vitro/In-Vivo Systemic PK Variables 
In-vivo/In-vitro PK Variable Equation 
Red blood cell (RBC) 
Partition Coefficient (γ) 
𝛾 = (
𝐵:𝑃−(1−𝐻)
𝐻∗𝑓𝑢
); H=hematocrit (0.46)59 for humans 
Vdss 
𝑉𝑑𝑠𝑠 = 𝑉𝑑𝑐𝑐 ∗ (1 +
𝑘12
𝑘21
) 
 
𝑉𝑑𝑠𝑠 = 𝐶𝐿𝑡𝑜𝑡 ∗ (
𝐴
𝛼2
+
𝐵
𝛽2
𝐴
𝛼 +
𝐵
𝛽
) 
For a 2-compartmental model, after I.V. bolus 
administration 
Vdss
u Vdss
u = Vdss/fu 
CLtot CLtot = CLren + CLnonren 
CLren 
CLren = fe * CLtot  
(fe  = fraction of the dose excreted ultimately unchanged in 
urine after I.V. administration) 
 
CLren = U∞/AUC∞  
(After P.O. or I.V. administration: 
U∞ = Amount ultimately excreted unchanged in urine, 
AUC∞ = Area under the plasma concentration-time curve 
from 0 - ∞) 
CLnonren CLtot - CLren 
CLtot
u CLtot
u = CLtot/fu 
CLren
u CLren
u = CLren/fu 
CLnonren
u CLnonren
u = CLtot
u - CLren
u 
CLnonren
blood (assuming 
absence of extra-hepatic 
metabolism) 
CLnonren
blood = CLnonren/(B:P) 
Hepatic extraction ratio 
(ERhep) 
ERhep = CLnonren
blood/Qhep  
(Qhep = hepatic blood flow, 21 ml/min/kg for humans) 
CLint
In-vivo CLint
In-vivo = (Qhep*CLhep)/((fu/B:P)*(Qhep - CLhep)) 
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3.3.5. PK Classification of Drugs 
For mechanistic interpretation of the observed/reported as well as of the biologically relevant 
PK data, the classifications shown in Table 3.3 were followed for all the drugs. 
 
 
Table 3.3 - Categorization By PK Properties 
  PK Property Categorization Cut-off 
Based on PPB 
High PPB fu < 10% 
Intermediate PPB 10% < fu < 90% 
Low PPB fu > 90% 
Based on route of metabolism 
Highly metabolized, and hepatic metabolism is the major 
elimination pathway (assuming there is no extrahepatic 
metabolism and no biliary excretion) 
fe < 20% 
Based on hepatic extraction ratio (ERhep) 
Low ERhep ERhep < 0.3 
Intermediate ERhep 0.3 < ERhep < 0.7 
High ERhep ERhep > 0.7 
Based on extra-hepatic metabolism 
Evidence of extrahepatic metabolism CLnonren
Blood > Qhep 
Based on renal handling 
Compounds renally cleared by net glomerular filtration CLren
u = GFR 
Compounds renally cleared by net tubular reabsorption CLren
u < GFR 
Compounds renally cleared by net tubular secretion CLren
u > GFR 
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3.3.6. Physiological Interpretation 
Fraction of the drug unbound in plasma (fu): It is one of the important biologically relevant 
PK properties, since only the drug that is not bound to plasma proteins (e.g., albumin, alpha-
acid glycoprotein, etc.) is available for tissue distribution, metabolism, elimination and drug-
target receptor binding. High PPB (low fu) may prevent the drug from being widely 
distributed (i.e., low Vdss) and/or cleared (e.g., low ERhep or low CLren), although unbound 
drug may show wide distribution (high Vdss
u), and/or have high clearance (e.g., high hepatic 
intrinsic clearance, CLint or high unbound renal clearance CLren
u).   
B:P ratio: It is the reported ratio of whole blood to plasma concentrations and (a) depends on 
fu and RBC partition coefficient (γ), i.e., low B:P ratio may result from high PPB (low fu); 
and/or high affinity of drug to RBC may result in a high B:P. Furthermore, B:P ratio allows 
the estimation of γ (from fu, see Table - 3.2) and determines the blood clearance, CLnonrenBlood, 
to compare with the LBF. 
RBC partition coefficient (γ): Apart from plasma proteins, drugs may also bind to RBC in the 
blood, which in turn may limit their distribution and/or elimination. Therefore, it is another 
important biologically relevant PK property, and denotes the ratio of concentration of the 
drug in the RBC to that unbound in plasma (i.e., after correcting for PPB). Physiologically, 
higher γ indicates higher affinity of the drug to RBC relative to plasma water, potentially due 
to binding to RBC membranes and/or intraerythrocytic proteins.  
Volume of distribution at steady-state (Vdss): It is the apparent volume that the drug occupies 
at steady state, i.e., when the unbound concentrations throughout the body are equal. Since 
only the unbound drug in plasma will be available for tissue distribution, Vdss has to be 
corrected for fu (Vdss
u), so as to be interpreted mechanistically by comparing it to various 
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physiological body compartments/spaces55 (e.g., plasma volume, blood volume, intracellular 
and/or extracellular water, total body water etc., listed in Table - 3.1).  
Total clearance (CLtot): It is the volume of plasma that is completely cleared of the drug per 
unit time. Further separation of the elimination pathways of CLtot can be accomplished based 
on fe data into CLren and CLnonren. 
Renal clearance (CLren): Since only the unbound drug in plasma can undergo glomerular 
filtration (GFR) and/or tubular secretion, CLren has to be corrected for fu to obtain 
biologically relevant CLren
u in order to evaluate the net tubular secretion/reabsorption (See 
Table 3.3) 
Nonrenal clearance (CLnonren): It indicates clearance by all the pathways other than renal, 
namely, hepatic (i.e., metabolism and/or biliary excretion) and/or extrahepatic, which may 
include metabolism in the RBC, hydrolysis in the plasma and/or tissue, etc. CLnonren
blood is 
physiologically more meaningful than plasma clearance, since the organs are perfused by 
blood (not just plasma). Also, mechanistically, the blood clearances can be compared to 
organ blood flow(s), e.g., LBF; and if CLnonrenal
blood exceeds LBF, it suggests extrahepatic 
clearance. (See Table 3.3)  
Hepatic extraction ratio (ERhep): It reflects the intrinsic ability of the liver to extract drug (as 
reflected in the difference in the hepatic artery (and portal vein) - hepatic vein 
concentrations). Based on a widely used hepatic venous equilibration/”well-stirred” model60, 
ERhep is affected by CLint (intrinsic ability of the liver to clear the drug in the absence of flow 
and binding restrictions), fu and Qhep (hepatic blood flow). 
ERhep = fu*CLint/ (Qhep + fu*CLint) …. Eq 3.3 
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Receptor binding affinity (Ki): It indicates intrinsic binding affinity of the drug molecule to 
the target receptor.  
keo: It characterizes the equilibration rate constant between plasma and biophase (i.e., where 
the drug-targets are present). It is inversely related to the time it takes for this equilibration to 
occur.  
Cpss
50: It is the concentration in plasma at steady-state producing half-maximal effect (cpss
50), 
when the unbound plasma and biophase concentrations are equal.  
 γ (PD): It characterizes the steepness/slope of the concentration - effect relationship.  
  
3.4. Methods II - Statistical Analyses 
 
3.4.1. Descriptive Statistics 
Statistical distributions for molecular/PC, in-vivo human systemic and in-vitro PK/PD 
properties were investigated, and mean, median, quartiles and fold-range 
(maximum/minimum) for each variable was reported. Most PK(/PD) variables exhibited 
skewed distribution(s) and/or wide dispersion and, therefore were log-transformed for 
regression analyses.  
All the statistical analyses were performed using JMP 11.0 (SAS, Cary, NC).  
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3.4.1.1. Collinearity Analyses 
Correlation analyses for both PC and PK/PD variables were assessed using correlation 
matrices, based on the criterion set a-priori, i.e., (absolute value of) correlation 
coefficient (r) > 0.8. If PC covariates were found to collinear, only one of them was 
used (based on mechanistic plausibility) for further regression analyses.   
3.4.1.2. Univariate Screening of Molecular/PC Covariates 
All (potentially important) molecular/PC descriptors that may affect the biologically 
relevant PK/PD properties were screened. For this, the univariate linear relationships 
of (log-transformed) PK/PD variables as a function of PC variables were studied. 
Goodness of fit statistics was evaluated using r2 (which characterizes the variability in 
the PK/PD (dependent) variable that can be accounted for by the PC (independent) 
variable). Relationships with r2 ≥ 0.3 (i.e., 30% explained variability) and a p-value 
<0.05 were used as cut-offs for choosing a PC covariate. Furthermore, the slopes of 
the univariate relationships were used to evaluate the sensitivity (S) of changes in the 
PK variable changes in the relative to PC variable. 
 
3.4.2. Final QSPKR Model Building and Evaluation 
Final QSPKR model building for the biologically relevant systemic PK variables was 
performed by stepwise, multiple log linear regression (MLLR) - an initial forward inclusion 
step, followed by a backward elimination step. Goodness of fit statistic, r2 and p < 0.05, and 
the sensitivity (S) (and its precision) for the final QSPKR model were reported. 
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3.4.3. Cross - Validation 
The predictive performance of the final QSPKR model was evaluated by cross-validation 
(CV) by leave-out-one (LOO) method61 using RStudio v0.96.33062.  
This method leaves out one observation from the entire dataset and uses it for validation, 
while the rest of the dataset is used as the training set. This is then repeated until each 
observation is left out once (serving as the validation ‘set’). For each model, the excluded 
observation is predicted and the cross-validated explained variance (q2) is calculated61 using 
the equation below.  
 
𝑞2 = 1 −  
∑(𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑−𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑)2
∑(𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑−𝑀𝑒𝑎𝑛)2
 …. Eq 3.4 
A model with q2 ≥ 0.40 is considered acceptable61. 
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2 CHAPTER 4. QSPKR of BZD 
 
4.1. Background 
BZD are used therapeutically as sedatives, hypnotics, anticonvulsants, and these effects arise 
from their action in the CNS. Within the CNS, the main molecular target of BZD is the 
postsynaptic inhibitory neurotransmitter, namely, gamma-amino butyric acid (GABAA) receptor. 
BZD act as allosteric modulators of the GABAA receptor, increasing the affinity of GABA at its 
receptor, resulting in higher chloride conductance, and overall potentiating the (inhibitory) 
effects of GABA in the CNS63. The therapeutic effects, by large, are dependent on the half-live 
of the drug (and active metabolites), e.g., short acting (0 - 6 h) for pre-anesthesia prior to surgery, 
intermediate (6 - 24 h) acting for insomnia, long acting (> 24 h) for treating anxiety, 
convulsions64. In general, BZD are small MW and lipophilic compounds, mostly unionized so as 
to facilitate the permeation through blood-brain barrier in order to reach the CNS target. Most of 
the BZD are structural analogues and share a common scaffold (1, 4, benzo-diazepin ring, shown 
in Figure 4.1). A brief account of structure - activity relationship (SAR)65,66 of BZD is given 
below.   
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Figure 4.1 - Common Structural Scaffold - 1, 4 - Benzodiazepine 
 
The known SAR is as follows: 
Rings A & B: 
1. Methylation of N at position 1 increased the therapeutic potency (anxiolytic activity) 
2. Substitutions of 1 - 2 with either imidazo- or triazo- ring (e.g., alprazolam, midazolam) 
resulted in significant increase in receptor binding affinity. 
3. A hydrogen-bond-accepting group substituent at position 2 is important for interactions with 
hydrogen bonding donating site in the GABAA receptor. 
4. Substituents at position 3 and 8 are involved in ionic interactions with the GABAA receptor. 
5. A strong electronegative (electron withdrawing group) group at position 7 increased 
therapeutic potency by several-fold.  
 Ring C: 
4-1. It is involved in hydrophobic interactions with the GABAA receptor 
4-2. Substitution at position 2’ increased therapeutic potency   
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4.2. Results 
4.2.1. PC/Molecular Property Space of BZD  
   The final PC/molecular and human systemic PK/PD database consists of twenty BZD, 
including three metabolites, N-desmethyl diazepam (N-DMD), chlor-desmethyl diazepam (Chor-
DMD), N-desmethyl adinazolam (N-DMAD) as well as flumazenil, a GABA antagonist. 
Structurally, most of the BZD in the final dataset share the 5-aryl, 1, 4-BZD scaffold (see Figure 
4.1), thus exhibiting fairly similar values for nRot, HBA, HBD, which is also evident from low 
diversity (2- to 3-fold, n = 20) in these properties (as shown in Table - 4.1) except for Ro 48-
6791 and Ro 48-8684, with higher nRot and HBA. BZD are relatively low MW (ranging from 
271 to 412 Da, n = 20) compounds.  
For all the BZD in the final dataset that have two pKas, only pKa1, i.e., due to weakly acidic 
group (e.g., -OH group) (n = 7) is relevant at physiological pH of 7.4, while the rest of the BZD 
are all bases (n = 13), and only pKa2 (i.e., due to weakly basic group e.g., -NH2) is relevant. All 
BZD are lipophilic, i.e., logD7.4 > 1 (ranging from 1.10 to 3.78, except N-DMAD with a logD7.4 
of 0.75). The majority of BZD in the current dataset are unionized at pH 7.4, and, therefore, the 
estimated logD7.4 values are identical to the SciFinder predicted logP. N-DMAD (the least 
lipophilic BZD in the dataset) is present in the form of cationic species (55% ionized) at 
physiological pH of 7.4, consequently, its logD7.4 value is lower than its respective SciFinder-
predicted logP. On the other hand, although Ro 48-8684 is present predominantly in the form of 
cationic species (66% ionized), the impact of ionization is less pronounced, i.e., its estimated 
logD7.4 (2.97) is comparable to SciFinder-predicted logP (3.38), possibly owing to the presence 
of large aromatic functional groups (as evident from its high MW relative to the rest of BZD in 
the database).  
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   Descriptive statistics (as shown in Table 4.2) show that mean and median values are 
comparable for most of the molecular/PC properties. The low dispersion (relatively low standard 
deviations and range) is indicative of their low diversity of the molecular/PC property space. 
Based on the acceptance criteria set a-priori for collinearity i.e., r ≥ 0.80, MW is highly 
correlated with MV (r = 0.81, n = 20), MV with nRot (r = 0.84, n = 20) and nRot with HBA (r = 
0.83, n = 20) (shown in Table 4.3). Thus, logD7.4, MW, PSA, HBA and HBD were used for 
subsequent analysis (i.e., MV and nRot were excluded).  
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Table 4.1 - Molecular/PC Property Space of BZD 
Label Drug 
MW 
(Da) 
logP 
pKa 
1 
pKa  
2 
LogD  
at pH 7.4 
% 
Ionized 
at pH 7.4 
Charge 
at pH 7.4 
PSA 
(A2) 
MV 
(cm3/  
mol) 
nRot HBD HBA 
1 Chlordiazepoxide 300 2.49  2.38 2.49 0%  53 231 1 4 1 
2 Clonazepam 316 2.52 11.21 1.55 2.52 0%  87 210 2 6 1 
3 Clorazepate 315 2.54  3.43 2.54 0%  79 215 2 5 2 
4 Diazepam 285 2.80  3.40 2.80 0%  37 226 1 3 0 
5 N-DMD 271 2.78 11.72 3.22 2.78 0%  42 205 1 3 1 
6 Chlor-DMD 305 2.94 11.58 2.22 2.94 0%  42 214 1 3 1 
7 Lorazepam 321 2.38 10.80 0.17 2.38 0%  62 211 2 4 2 
8 Nitrazepam 281 2.36 11.35 2.55 2.36 0%  87 201 2 6 1 
9 Flunitrazepam 313 2.13  1.68 2.13 0%  79 225 2 6 0 
10 Oxazepam 287 2.22 10.94 1.17 2.22 0%  62 202 2 4 2 
11 Temazepam 301 2.20 11.70 1.58 2.20 0%  53 223 2 4 1 
12 Adinazolam 352 1.27  7.09 1.10 33% Cation 46 268 3 5 0 
13 N-DMAD 338 1.09  7.48 0.75 55% Cation 55 246 3 5 1 
14 Alprazolam 309 1.92  2.37 1.92 0%  43 226 1 4 0 
15 Midazolam 326 3.80  6.03 3.78 4%  Cation 30 240 1 3 0 
16 Triazolam 343 2.08  2.29 2.08 0%  43 235 1 4 0 
17 Ro 48-6791 412 3.05  6.36 3.01 8% Cation 80 307 7 8 0 
18 Ro 48-8684 411 3.38  7.59 2.97 61% Cation 67 318 7 7 0 
19 Brotizolam 394 2.46  2.01 2.46 0%  71 220 1 4 0 
20 Flumazenil 303 2.15  0.86 2.15 0%  64 217 3 6 0 
 N 20 20   20   20 20 20 20 20 
 Mean 271 2.43   2.38   59 232 2 5 1 
 Maximum 412 3.80   3.78   87 318 7 8 2 
 Minimum 324 1.09   0.75   30 201 1 3 0 
 -fold range 2 5   5   3 2 7 3 2 
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Table 4.2 - Descriptive Statistics of PC/Molecular Properties of BZD 
 
N Mean SD 95% CI Minimum 10% 25% Median 75% 90% Maximum 
MW (Da) 20 324 40.7 305, 343 271 281 300 314 342 409 412 
LogD7.4 20 2.4 0.66 2.1, 2.7 0.8 1.2 2.1 2.4 2.8 3.0 3.8 
PSA (A2) 20 59 17.4 51, 67 30 37.5 43 59 77 86.3 87 
MV (cm3/mol) 20 232 31.9 217, 247 201 202 212 224 239 303 318 
nRot 20 2.3 1.77 1.4, 3.1 1 1 1 2 2.8 6.6 7 
HBA 20 4.7 1.42 4.0, 5.4 3 3 4 4 6 7 8 
HBD 20 0.7 0.74 0.3, 1.0 0 0 0 0.5 1 2 2 
 
 
 
Table 4.4 - Correlation Matrix of PC/Molecular Variables of BZD 
 
MW (Da) LogD7.4  PSA (A2) 
MV 
(cm3/mol) 
nRot HBA HBD 
MW (Da) 1.00       
LogD7.4  0.05 1.00      
PSA (A2) 0.24 -0.05 1.00     
MV (cm3/mol) 0.81 0.06 0.02 1.00    
nRot 0.70 0.03 0.42 0.84 1.00   
HBA 0.53 -0.11 0.76 0.56 0.83 1.00  
HBD -0.44 -0.07 0.23 -0.51 -0.21 -0.20 1.00 
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4.2.2. Humans Systemic PK/PD Property Space of BZD       
The final mean in-vitro/in-vivo human systemic PK and ex-vivo/in-vitro PD properties compiled 
from various studies in the literature are shown in Table - 4.4 and 4.6, respectively and the 
estimated biologically relevant PK properties in Table 4.5. Appendix 1 contains all the 
supplemental information with respect to the in-vitro/in-vivo human systemic PK and ex-vivo/in-
vitro PD data compiled for each of the compound from the literature.  
There is considerable to large diversity in the in-vitro/in-vivo systemic PK/PD properties of BZD 
in the current dataset ranging from 20- to 1950-fold (n = 5 - 17). The descriptive statistics for 
these PK/PD variables (shown in Table 4.7) indicate that the mean values for most of them 
(except fu, and B:P ratio) are greater than their respective median values. Owing to this skewed 
distribution and high diversity, all the systemic PK/PD variables (except fu, B:P ratio and γ) were 
log transformed for further analysis. Several correlations are observed between the in-vitro/in-
vivo human systemic and biologically relevant PK variables (shown in Table 4.8). Most of these 
correlations are mechanistically plausible, e.g., CLnonren
u is highly correlated (r = 0.99, n = 8) 
with CLtot
u, and fe values for most of the BZD ranges between 0.02 - 11% (except for N-DMAD, 
whose fe = 72%), suggesting the contribution of renal pathways towards total clearance is low for 
BZD.  
PPB of BZD in the final dataset varies 33-fold (n = 17). With the exception of N-DMAD (the 
least lipophilic BZD in the dataset with logD7.4 of 0.75, and fu of 65%) and flumazenil, the 
majority of the BZD show a high degree of PPB, probably owing to their high degree of 
lipophilicity. There is larger diversity in the Vdss
u values (118-fold, n  = 16) than Vdss values (20-
fold, n = 19). Furthermore, it is observed that the mean Vdss
u value (21.5 l/kg) is higher than Vdss 
value (1.5 l/kg). Therefore, it seems that the high Vdss
u values (for most of the BZD) are offset 
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by high PPB (i.e., low fu), resulting in low Vdss values, suggesting that BZD tissue distribution is 
restricted by PPB. Vdss
u values for all the BZD in the dataset exceed BW (70 kg) (except for the 
most hydrophilic N-DMAD and flumazenil, whose estimates are close to 1 L/kg), indicating they 
undergo moderate to extensive extravascular distribution into tissues, and, also potential binding 
to plasma membranes etc. CLtot
u varies 74-fold (n = 17) while CLtot varied 1550-fold (n = 20, Ro 
48-6791 with Ro 48-8684 showing a relatively high CLtot but lacking fu and fe data). The high 
CLtot
u values seem to be offset by high PPB (i.e., low fu), resulting in low CLtot values for the 
majority of BZD with available information.  
The contribution of renal pathway towards CLtot is low (fe ≤ 10%) for all the BZD in the dataset 
with available information (n = 9), except for N-DMAD (fe = 71%), suggesting they are all 
subject to extensive hepatic metabolism (with no obvious evidence of extrahepatic clearance 
pathway(s) for any of the BZD). CLren
u estimates for all the BZD in the dataset with available 
information (n=9) are higher than GFR (1.7 ml/min/kg), suggesting they undergo net renal 
tubular reabsorption, except for N-DMAD, which shows CLren
u value greater than GFR, 
suggesting it undergoes net renal tubular secretion (potentially involving drug transporters as it is 
positively charged at pH 7.4).  
Based on the CLnonren estimates (n=9), relative to LBF of 21 ml/min/kg, midazolam and 
flumazenil show intermediate (to high) ERhep, while the rest of BZD with available information 
show low ERhep, either because of low hepatic CLint (e.g., chlordiazepoxide, lorazepam, 
nitrazepam etc.) and/or high PPB (e.g., diazepam, oxazepam etc.). The B:P ratio for most BZD in 
the current dataset with available information (n = 9) show values of less than 1.0; the plausible 
explanation is the high degree of PPB (e.g., diazepam, chlordiazepoxide) and/or low RBC 
partitioning, γ (e.g., midazolam). However, the B:P ratios for Ro 48-6791 and Ro 48-8684 are 
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higher than 1.0, which is possibly be due to high RBC binding and/or low PPB. CLnonren
Blood 
values for BZD in the dataset with available information (n=5) are lower than LBF (21 
ml/min/kg), confirming that these BZD are low ERhep compounds. In general, CLnonren
blood values 
are much lower than respective CLnonren
plasma, except for midazolam, for which CLnonren
blood is 
greater than CLnonren
plasma possibly owing to low B:P ratio and/or high PPB. The contribution of a 
specific metabolic pathway (fpathway) e.g., CYP3A, CYP2C19 etc., towards the total clearance 
estimated from in-vivo drug - drug interaction studies using specific inhibitors (e.g., 
ketoconazole, itraconazole etc.) and pharmacogenetic studies (e.g., poor vs. extensive 
metabolizers of diazepam) is indicated in Appendix - 1.  
For compounds with available information (n = 6), fpathway via CYP3A is the primary elimination 
route for alprazolam (75%), midazolam (80%), triazolam (95%) and brotizolam (80%), while for 
chlordiazepoxide (35%) it is found to be relatively low. CYP2C19 is the major elimination 
pathway for diazepam (83%).  
BZD binding affinity (Ki) to GABAA relative to [
3H] Diazepam varies 245-fold (n = 11); and Ki 
relative to [3H] Flunitrazepam varies 1950-fold (n = 11). Early BZD discovery was based on the 
synthesis of the metabolites (e.g., flunitrazepam, oxazepam etc.) of the already existing BZD 
(nitrazepam and diazepam, respectively) and were evaluated for improved potencies, and 
therefore, there is such a large diversity in the binding affinities. 
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Table 4.4 - In-vitro and In-vivo Human PK Systemic Properties of BZD 
 
In-vitro 
PK Variables 
In-vivo PK Variables 
Drug 
fu 
[%] 
B:P 
Rati
o 
Vdss/Vdps
s 
[l/kg] 
CLtot 
[ml/min/kg
] 
fe  
[%] 
CLren 
[ml/min/kg
] 
CLnonren 
[ml/min/kg
] 
Chlordiazepoxid
e 
5.1% 0.66 0.39 0.44 1.0% 0.0044 0.44 
Clonazepam 14% . 3.0 0.91 . . . 
Clorazepate . . 0.22 0.020 11% 0.0022 0.018 
Diazepam 2.0% 0.58 1.1 0.39 
0.30
% 
0.0012 0.39 
N-DMD 3.2% . 1.2 0.17 . . . 
Chlor-DMD 3.2% . 3.9 0.26 . . . 
Lorazepam 9.6% . 1.3 1.2 
0.50
% 
0.0062 1.2 
Nitrazepam 13% . 1.9 0.83 1.0% 0.0083 0.82 
Flunitrazepam 22% 0.75 2.4 1.7 . . . 
Oxazepam 5.2% 1.0 0.60 1.1 1.0% 0.011 1.1 
Temazepam 3.1% . . 1.4 . . . 
Adinazolam 30% 0.70 1.0 5.8 . . . 
N-DMAD 65% . 0.68 2.9 71% 2.1 0.85 
Alprazolam 32% 0.78 0.91 0.81 . . . 
Midazolam 3.7% 0.55 0.87 7.0 
0.15
% 
0.010 6.9 
Triazolam 11% 0.76 0.60 2.7 . . . 
Ro 48-6791 . 1.3 2.4 31 . . . 
Ro 48-8684 . 1.4 4.3 31 . . . 
Brotizolam 9.8% . 0.66 1.6 . . . 
Flumazenil 58% 0.94 0.87 15 
0.10
% 
0.015 15 
N 17 9 19 20 9 9 9 
Mean 17% 0.86 1.5 5.3 9.6% 0.24 3.0 
Maximum 65% 1.4 4.3 31 71% 2.1 14.8 
Minimum 2.0% 0.58 0.22 0.020 
0.10
% 
0.0012 0.018 
-fold range 33 11 20 1550 710 1778 834 
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Table 4.5 - Biologically Relevant In-vivo Human PK Properties of BZD 
Drug 
Vdssu/Vdpssu 
[l/kg] 
CLtotu 
[ml/min/kg] 
CLrenu 
[ml/min/kg] 
CLnonrenu 
[ml/min/kg] 
CLnonrenBL 
[ml/min/kg] 
γ 
Chlordiazepoxide 7.7 8.7 0.087 8.6 0.084 5.2 
Clonazepam 21 6.3 . . . . 
Clorazepate . . . . . . 
Diazepam 57 20 0.060 20 0.087 4.5 
N-DMD 39 5.4 . . . . 
Chlor-DMD 124 8.3 . . . . 
Lorazepam 13 13 0.064 13 . . 
Nitrazepam 15 6.6 0.066 6.5 . . 
Flunitrazepam 11 7.6 . . . 2.0 
Oxazepam 12 21 0.21 20 0.050 21 
Temazepam . 44 . . . . 
Adinazolam 3.4 19 . . . 1.1 
N-DMAD 1.0 4.5 3.2 1.3 . . 
Alprazolam 2.9 2.6 . . . 0.78 
Midazolam 24 189 0.026 189 12 0.60 
Triazolam 5.5 25 . . . 4.3 
Ro 48-6791 . . . . . . 
Ro 48-8684 . . . . . . 
Brotizolam 6.8 16 . . . . 
Flumazenil 1.5 26 0.03 26 9.9 1.5 
N 16 17 8 8 5 9 
Mean 22 25 0.50 36 4.4 4.6 
Maximum 124 189 3.2 189 12 21 
Minimum 1.0 2.6 0.026 1.3 0.050 0.60 
-fold range 118 74 125 145 233 36 
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Table 4.6 - In-vitro/Ex-vivo (Relative) BZD-GABAA Binding Affinities (Ki) 
 
Mean Relative Receptor Affinity  (Ki) 
(in nM) 
Drug [3H] Diazepam [3H] Flunitrazepam 
Chlordiazepoxide 567 780 
Clonazepam 2.3 1.1 
Clorazepate 44 . 
Diazepam 14 19 
N-DMD 8.8 5.6 
Lorazepam 2.8 1.4 
Nitrazepam 16 11 
Flunitrazepam 3.2 2.2 
Oxazepam 40 21 
Temazepam 38 . 
Alprazolam . 4.2 
Midazolam . 0.40 
Triazolam 2.6 0.50 
N 11 11 
Mean 67 77 
Maximum 567 780 
Minimum 2.3 0.40 
-fold range 245 1950 
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Table 4.7 - Descriptive Statistics of Human Systemic PK/PD Variables of BZD 
 N Mean SD 95% CI Minimum 10% 25% Median 75% 90% Maximum 
Vdss (L/kg) 19 1.5 1.2 0.92, 2.1 0.22 0.39 0.66 1.0 2.4 3.9 4.3 
CLtot (ml/min/kg) 20 5.3 9.4 0.88, 9.7 0.020 0.18 0.53 1.3 5.1 29 31 
CLren (ml/min/kg) 9 0.24 0.69 -0.29, 0.78 0.0010 0.0010 0.0030 0.0080 0.013 2.1 2.1 
CLnonren (ml/min/kg) 9 2.9 4.9 -0.84, 6.7 0.020 0.020 0.40 0.80 4.1 15 15 
fu (%) 17 17 19 7.2, 27 1.9 1.9 3.4 9.8 30 59 65 
Vdss
u (L/kg) 16 22 31 4.9, 38 1.0 1.3 3.9 11 23 77 124 
CLtot
u (ml/min/kg) 17 25 43 2.4, 47 2.6 4.1 6.4 13 23 73 189 
CLren
u (ml/min/kg) 8 0.52 1.1 -0.39, 1.4 0.030 0.030 0.10 0.10 0.28 3.2 3.2 
CLnonren
u (ml/min/kg) 8 36 62 -17, 88 1.3 1.3 7.0 16 24 189 189 
CLnonren
Blood (ml/min/kg) 5 4.4 5.9 -3.0, 12 0.050 0.050 0.065 0.090 11 12 12 
B:P Ratio 11 0.86 0.28 0.67, 1.1 0.55 0.55 0.66 0.76 1.0 1.4 1.4 
RBC Partitioning  9 4.7 6.3 -0.22, 9.5 0.60 0.60 1.3 2.0 4.9 21 21 
[3H] Diazepam RRA (nM) 11 67 166 -44, 179 2.0 2.2 3.0 14 40 462 567 
[3H] Flunitrazepam RRA (nM) 11 77 233 -80, 234 0.40 0.50 1.0 4.0 19 628 780 
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Table 4.8 - Correlation Analysis of Human Systemic PK Variables of BZD 
 Vdss 
(L/kg) 
CLtot 
(ml/min/kg) 
CLren 
(ml/min/kg) 
CLnonren 
(ml/min/kg) 
fu 
Vdssu 
(L/kg) 
CLtotu 
(ml/min/kg) 
CLrenu 
(ml/min/kg) 
CLnonrenu 
(ml/min/kg) 
Vdss (L/kg) 1.00         
CLtot (ml/min/kg) 0.34 1.00        
CLren (ml/min/kg) -0.66 -0.33 1.00       
CLnonren (ml/min/kg) 0.38 0.99 -0.39 1.00      
fu  -0.02 0.80 0.24 0.76 1.00     
Vdss
u (L/kg) 0.81 0.05 -0.62 0.09 -0.38 1.00    
CLtot
u (ml/min/kg) 0.41 -0.03 -0.43 -0.01 -0.51 0.63 1.00   
CLren
u (ml/min/kg) -0.74 -0.42 0.99 -0.48 0.13 -0.67 -0.40 1.00  
CLnonren
u (ml/min/kg) 0.48 0.01 -0.48 0.04 -0.49 0.69 0.99 -0.46 1.00 
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4.3. QSPKR Analysis, Model Building and Evaluation 
The results of the univariate regression of the in-vitro/(log-transformed) in-vivo biologically 
relevant and reported PK/PD variables as a function of the molecular/PC descriptors are 
summarized in Tables 4.9 and 4.10 respectively. MW shows significant univariate relationships 
(r2 ≥ 0.30 and p < 0.05) with log (CLtot); logD7.4 with fu, log (Vdssu), log (CLnonrenu), and log 
(CLren); HBA shows a significant relationship with fu; and HBD with Log (CLtot) and γ (RBC 
partitioning). These relationships are shown in Figures 4.2 - 4.8 (please refer Table 4.1 in page 
34 for the individual compounds representing the numbers shown in all the plots in this chapter). 
There are only a few other relationships in which PC/molecular variable(s) explained more than 
30% of the variability in the PK/PD variable, but the slope was not statistically significant from 
zero. During the final (multivariate) model building process (using MLLR with forward 
inclusion followed by backward elimination), logD7.4 was found to be the single most important 
determinant affecting biologically relevant systemic PK of BZD (discussed below), and the final 
models are summarized in Table 4.11. Overall, the final QSPKR models developed for BZD 
gave acceptable predictions (q2 ≥ 0.40) for Vdssu and CLnonrenu only.  
4.3.1. Effect of LogD7.4 on Systemic and Biologically Relevant PK Variables for BZD 
There is a significant negative association between logD7.4 and fu, i.e., an increase in logD7.4 is 
associated with decrease in fu (increase in PPB) for BZD (Slope = -0.20, r
2 = 0.51, n = 17) as 
shown in in Figure 4.2. A significant positive association is observed with each of (log-
transformed) Vdss
u (Slope = 0.57, r2 = 0.61, n = 16), CLnonren
u (Slope = 0.66, r2 = 0.81, n = 16) 
and CLren (Slope = -0.88, r
2 = 0.56, n = 9). Overall, due to the offsetting effects of logD7.4 on fu 
and Vdss
u; and fu and CLnonren
u, their uncorrected counterparts, i.e., Vdss and CLnonren, 
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respectively, did not depend on logD7.4. Although there is a positive association of CLtot
u with 
logD7.4, the slope is insignificant, and a plausible explanation for such a finding may be because 
of the limited diversity in logD7.4 for BZD (range: 0.75 to 3.8). The contribution of renal 
pathways for majority of the BZD (except N-DMAD) within the dataset with available 
information is negligible (fe < 1%), and as a result CLren values are very low, which limits the 
confidence in these estimates.  
  
 
 
 
 
 Table 4.9 - Univariate Regression Between PC/Molecular Descriptors and Biologically Relevant PK Variables of BZD 
 
fu 
 
Log  
(Vdssu) 
[l/kg] 
Log  
(CLtotu) 
[ml/min/kg] 
Log  
(CLrenu) 
[ml/min/kg] 
Log  
(CLnonrenu) 
[ml/min/kg] 
Log  
(CLnonrenBlood) 
[ml/min/kg] 
γ 
MW  
(Da) 
N.S. N.S. N.S. 
n =8 
r2 = 0.40 
Slope = 0.019 
N.S 
N.S. 
n = 5 
r2 = 0.66 
Slope = 0.059 
N.S 
N.S 
LogD7.4  
n = 17 
r2 = 0.51 
Slope = -0.20 
-0.31, -0.092 
n = 16 
r2 = 0.57 
Slope = 0.61 
0.31, 0.90 
N.S. N.S 
n = 8 
r2 = 0.81 
Slope = 0.66 
0.35, 0.98 
N.S. N.S 
PSA (A2) N.S N.S N.S N.S N.S N.S N.S 
HBA 
n = 17 
r2 = 0.33 
Slope = 0.099 
0.022, 0.18 
n = 16 
r2 = 0.26 
Slope = -0.20 
-0.49, -0.011 
N.S. N.S. N.S N.S N.S 
HBD N.S N.S N.S N.S N.S 
n = 5 
r2 = 0.44 
Slope = -0.89 
N.S. 
n = 9 
r2 = 0.86 
Slope = 8.3 
5.3, 11.3 
 
In red: r2 ≥ 0.30 and p<0.05; 
In italic and red: r2 ≥ 0.30 but p>0.05 or r2 < 0.30 but p<0.05; 
N.S = Not Significant (r2 < 0.30 and p>0.05);   
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Table 4.10 - Univariate Regression Between PC/Molecular Descriptors and Reported PK/PD Variables of BZD 
 
Log  
(Vdss) 
[l/kg] 
Log  
(CLtot) 
[ml/min/kg] 
Log  
(CLren) 
[ml/min/kg] 
Log  
(CLnonren) 
[ml/min/kg] 
Log RRA (Ki in nM)  
[3H] Diazepam 
[3H] 
Flunitrazepam 
MW  
(Da) 
N.S. 
n = 20 
r2 = 0.40 
Slope = 0.012 
0.0050, 0.019 
n = 9 
r2 = 0.35 
Slope = 0.028 
N.S. 
N.S N.S 
n = 11 
r2 = 0.35 
Slope = -0.030 
N.S. 
LogD7.4  N.S N.S 
n = 9 
r2 = 0.56 
Slope = -0.88 
-1.6, -0.18 
N.S N.S N.S 
PSA (A2) N.S N.S N.S N.S N.S. N.S. 
HBA N.S 
n = 16 
r2 = 0.29 
Slope = 0.29 
0.065, 0.52 
N.S N.S N.S N.S 
HBD N.S 
n = 20 
r2 = 0.36 
Slope = -0.62 
-1.0, -0.21 
N.S 
n = 9 
r2 = 0.32 
Slope = -0.54 
N.S. 
N.S N.S 
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Table 4.11 - Final Multivariate QSPKR Models for BZD 
Final QSPKR Model N Slope (95% CI) r2 q2 
fu = 0.63 - 0.20 * LogD7.4 17 - 0.20 (-0.31, -0.09) 0.51 0.33 
Log (Vdss
u) = - 0.38 + 0.60 * LogD7.4 16   0.60 (0.30, 0.90) 0.57 0.40 
Log (CLnonren
u) =  - 0.40 + 0.66 * LogD7.4 8   0.66 (0.35, 0.98) 0.81 0.66 
                                  q2 ≥ 0.40: Acceptable 
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        Figure 4.2: fu vs. logD7.4 for BZD            Figure 4.3: Vdssu vs. logD7.4 for BZD 
                                    
                        
Figure 4.4: CLnonrenu vs. logD7.4 for BZD 
 
(Please refer Table 4.1 in Page 34, for the list of the individual compounds labeled in the figures 4.2 - 4.4) 
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     Figure 4.5: fu vs. HBA for BZD             Figure 4.6: γ vs. HBD for BZD 
                                 
 
                      Figure 4.7: CLtot vs MW for BZD      Figure 4.8: CLtot vs HBD for BZD 
                         
(Please refer Table 4.1 in Page 34, for the list of the individual compounds labeled in the figures 4.5 - 4.8) 
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4.4. Discussion 
Structurally, most of the BZD in the current dataset share the 5-aryl, 1, 4-BZD scaffold and, 
overall, their PC/molecular property space has low diversity (2- to 3-fold, n = 20). BZD are 
relatively low MW (ranging from 271 to 412 Da, n = 20) lipophilic, i.e., logD7.4 > 1.0 (ranging 
from 1.10 to 3.78, except for N-DMAD with a logD7.4 of 0.75), acids (n = 7) or bases (n = 13), 
and the majority of them are unionized at pH 7.4 (except N-DMAD and Ro 48-8684).  
Most of the BZD are extensively PPB and their Vdss
u values indicate moderate to extensive 
extravascular distribution into tissues, potential binding to plasma membranes, possibly owing to 
their high degree of lipophilicity and hydrophobic interactions. It seems that the high Vdss
u 
values are offset by high PPB, resulting in low Vdss values, suggesting that their extravascular 
tissue distribution is restricted by PPB. CLtot
u varies 74-fold (n = 17) while CLtot varies 1550-fold 
(n = 20). Again, high CLtot
u values seem to be offset by high PPB, which resulted in low CLtot 
values. Most of the BZD with available information in the dataset are highly metabolized (i.e., fe 
≤ 10%), with no obvious evidence of extrahepatic clearance pathway(s). CLrenu values for all the 
BZD in the dataset with available information (n=9) suggest that they undergo net renal tubular 
reabsorption (except for NDMAD).  
Based on the CLnonren values (n=9), midazolam and flumazenil show intermediate (to high) 
ERhep, while the rest of BZD with available information show low ERhep, either because of low 
hepatic CLint (e.g., chlordiazepoxide, lorazepam, nitrazepam etc.) and/or high PPB (e.g., 
diazepam, oxazepam etc.). For the compounds with available information (n = 6), metabolism by 
CYP3A is the primary nonrenal, hepatic elimination route for alprazolam (fpathway = 75%), 
midazolam (80%), triazolam (95%) and brotizolam (80%), while, for chlordiazepoxide (35%), it 
is found to be relatively low. CYP2C19 is the major hepatic elimination pathway for diazepam 
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(83%). Although lipophilicity was found to be the major determinant affecting CLnonren
u (CLint) 
for BZD, the contribution of the specific metabolic pathway reflects the affinity towards DME, 
wasn’t captured using the molecular/PC descriptors. 
The B:P ratio for most BZD in the current dataset with available information (n = 9) show values 
of less than 1.0, and the plausible explanation is either high PPB (e.g., diazepam, 
chlordiazepoxide) and/or low RBC partitioning (e.g., midazolam). Overall, there is large 
diversity in the in-vitro/in-vivo systemic PK/PD properties of BZD in the current dataset ranging 
from 20- to 1950-fold (n = 5 - 17).  
LogD7.4 is found to be the important determinant affecting biologically relevant systemic PK 
properties, namely, fu, Vdss
u
 and CLnonren
u:  
(a) An increase in logD7.4 is associated with a decrease in fu, suggesting that they bind to 
plasma proteins primarily by hydrophobic interactions. Similar relationships were observed 
in other studies reported in the literature with corticosteroids (n = 11) in humans40, 
adenosine A1 receptor agonists
67 (n = 12) and barbiturates (n = 12) in rats68 as well with a 
heterogeneous dataset of 554 compounds29. Lucek et al69 reported the role of hydrophobic 
binding of various derivatives 1, 4-BZD to human plasma proteins by incorporating 
lipophilic substituents.  
(b) A significant positive association is observed between Vdssu and logD7.4 for BZD in the final 
dataset suggesting that their extravascular distribution with tissue, cellular plasma 
membranes etc., is also driven by hydrophobic interactions. Similar relationships were 
observed for Vdss
u in humans and cats as a function of reversed-phase HPLC retention 
times70,71, and human Vdss
u as a function of octanol : buffer partition coefficients71.  
 54 
(c) Non-specific hydrophobic interactions with the drug metabolizing enzymes or partitioning 
into the hepatocytes seem to be plausible explanation for positive association and CLnonren
u 
and logD7.4.  
Due to the offsetting effects of logD7.4 on fu and Vdss
u; and fu and CLnonren
u, their uncorrected 
counterparts, Vdss and CLnonren, respectively, did not depend on clogD7.4.    
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A significant positive association was observed between HBD and RBC partitioning (γ), and this 
trend seems to be driven by oxazepam, which shows the highest RBC partitioning, although it 
has only two HBD.  
Overall, BZD-GABAA interactions seem to be driven by more specific molecular interactions, 
while nonspecific hydrophobic interactions with biological membranes and/or body tissues and 
metabolizing enzymes seem to affect biologically relevant human PK properties such as Vdss
u 
and CLnonren
u.  The final QSPKR models of BZD gave acceptable predictions for Vdss
u and 
CLnonren
u.  
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3 CHAPTER 5. QSPKR of NMB 
 
5.1. Background 
NMB are routinely used during the administration of anesthesia to facilitate surgical access to 
body cavities, especially the abdomen and thorax without hindrance from the voluntary or reflex 
muscle movement72. The therapeutic selection of NMB is based on achievement of a 
pharmacokinetic profile consistent with the duration of the interventional procedure, i.e., rapid 
equilibration between the plasma and effect site, resulting in immediate onset, but the duration 
dependent on the procedures (lasting from a few minutes to several days/weeks)63. Based on 
their mechanism of action, NMB are classified into  
(a) Depolarizing blocking agents, e.g., succinylcholine (SCh): Their initial action is to depolarize 
the postsynaptic membrane (with nicotinic acetylcholine, nACh receptors) by opening the ion 
channels, in a similar manner as acetylcholine (ACh). However, SCh persists for longer duration 
at the neuromuscular junction (primarily due to its resistance to acetylcholinesterase, AChE, 
hydrolysis) causing prolonged depolarization, resulting in inactivation of nACh, by continuing 
neuromuscular blockade.  
(b) Non-depolarizing blocking agents: They compete with ACh to bind with the nACh 
(competitive antagonists) and do not possess intrinsic activity, thus preventing depolarization at 
the NM endplate and causing neuromuscular blockade. Their action can be overcome by 
increasing ACh concentrations in the synaptic cleft by administering AChE inhibitors like 
neostigmine etc.  
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Structurally, NMB possess either a aminosteroid (ASN) (Figure 5.1) or benzylisoquinolinium 
(BIQ) scaffold (Figure 5.2); a brief account of structure activity relationships (SAR)63,73–75 for 
each.  
Figure 5.1 - ASN Structural Scaffold 
 
 
 
Figure 5.2 - BIQ Structural Scaffold 
 
 
SAR  
In general, NMB are large, bulky and rigid molecules. Substituents (e.g., mono or poly 
substituted benzyl groups and/or larger complex ring systems) on or around quaternary 
ammonium “cationic head” are considered favorable for high NMB potency. The distance 
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between the quaternary groups is typically around 1.0 nm. In general, alkyl substituent greater 
than methyl or ethyl on the quaternary ammonium group(s) reduced potency.  
For NMB with ASN scaffold, highest potency was seen if quaternary substituents were present at 
2- and 16- positions and additional substitutions at 3- and 17- contributed positively to NMB 
effects. For NMB with BIQ scaffold, the higher the methoxy substitutions each of BIQ nucleus, 
the higher is the potency (owing to the hydrophobic interactions with the nicotinic receptor).  
 
In-vivo PD properties namely, equilibration rate constant between plasma and biophase, (keo), 
concentration in plasma producing half-maximal effect (cpss
50) and steepness of the 
concentration - effect relationship (γ) were compiled from in-vivo human PD studies after 
ensuring that the same PD endpoint, i.e., 95% depression in the muscle twitch following ‘train-
of-four’ stimulus was considered. 
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5.2. Results 
The final PC/molecular and human systemic PK/PD database consisted of sixteen NMB, fifteen 
of which were non-depolarizing blockers, including two metabolites, Org 7268 and Org 9488 of 
vecuronium and rapacuronium, respectively, and one depolarizing blocker, namely, 
succinylcholine, SCh. 
5.2.1. PC/Molecular Property Space of NMB  
The PC/molecular property space exhibited by NMB in the current dataset is presented in Table - 
5.1 (median values were presented instead of mean values because of SCh, which skewed the 
distributions, see below). Structurally, NMB in the current dataset exhibit two common scaffolds 
- (a) relatively older generation compounds with aminosteroid (ASN) nucleus, (n = 9) and (b) 
relatively newer generation compounds with benzylisoquinolinium (BIQ) nucleus (n = 5); while 
fazadinium and SCh are classified under the miscellaneous category. With the exception of SCh 
(MW = 290 Da), the NMB in the current dataset show fairly large MW (ranging from 444 - 1035 
Da, n = 15). At physiological pH (7.4), all NMB are basic (n = 16), with two positive charges (as 
quaternary nitrogens). Despite the lack of the information on a few NMB in the current database, 
there is a fairly large diversity (7-fold, n = 12) in the logD7.4 values ranging from -5.00 to 2.08, 
and the majority of them are hydrophilic, i.e., logD7.4 < 1.0 (n = 10, i.e., excluding rapacuronium 
and fazadinium).  
Overall, the PC/molecular property space shown by a few properties e.g., logD7.4, nRot (8-fold, n 
= 11), etc., is relatively more diverse than the others (2- to 4-fold, n = 11-12), based on the NMB 
in the current dataset with available information. Although the compounds within each structural 
class (ASN and BIQ) exhibit fairly similar values for PC/molecular properties and thus low 
diversity in their respective property spaces, the compounds with a BIQ scaffold show 
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significantly higher mean values for MW, nRot, PSA and HBA compared to those with an ASN 
scaffold (shown in Tables 5.3 and 5.2, respectively).  
The descriptive statistics of PC/molecular variables are shown in Table 5.4; the mean values are 
higher than the corresponding median values suggesting that the underlying distributions are 
skewed. Based on the acceptance criteria set a-priori for collinearity (i.e., r ≥ 0.80), MW is 
highly correlated with PSA (r = 0.90, n = 11), MW with nRot (r = 0.86, n = 11) and MW with 
HBA (r = 0.90, n = 11), PSA with nRot (r = 0.97, n = 11), PSA with HBA (r = 0.99, n = 11) and 
nRot with HBA (r = 0.97, n = 11) (shown in Table 5.5). Thus, logD7.4, MW, and HBD were used 
for subsequent analysis (i.e., PSA, nRot and HBA were excluded). 
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Table 5.1 - Molecular/PC Property Space of NMB 
 
Label Drug 
MW 
(Da) 
logP 
LogD   
at pH 7.4 
PSA 
(A2) 
nRot HBD HBA 
A
S
N
 
1 Rocuronium  530 -0.21 -0.40 59 7 1 6 
2 Pipercuronium 603 . . . . . . 
3 Pancuronium 572 -1.2 -1.2 53 6 0 6 
4 Vecuronium 558 0.62 -0.26 56 6 0 6 
5 Org 7268  516 0.55 -0.38 50 5 1 5 
6 Rapacuronium 598 2.6 1.7 . . . . 
7 Org 9488  556 . . . . . . 
8 Org 9489 572 . . . . . . 
9 Org 9453 586 . . . . . . 
B
IQ
 
10 Alcuronium 667 -3.1 -3.1 47 8 2 6 
11 Doxacurium 1035 -2.1 -2.1 163 29 0 18 
12 Mivacurium 1029 0.37 0.37 145 30 0 16 
13 Atracurium 929 -0.27 -0.27 126 26 0 14 
14 Cisatracurium 933 -0.27 -0.27 126 26 0 14 
 15 Fazadinium 444 2.1 2.1 43 4 0 6 
 16 Succinylcholine 290 -5.0 -5.0 53 11 0 6 
  N 16 12 12 11 11 11 11 
  Median 579 -0.23 -0.33 56 8 0 6 
  Maximum 1035 -2.6 2.1 163 30 2 18 
  Minimum 290 -5.0 -5.0 43 4 0 5 
  -fold range 4 8 7 4 8 2 4 
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Table 5.2 - Molecular/PC Properties of NMB with ASN Scaffold 
 
Label Drug MW (Da) logP 
LogD   
at pH 7.4 
PSA (A2) nRot HBD HBA 
A
S
N
 
1. Rocuronium  530 -0.21 -0.40 59 7 1 6 
2. Pipercuronium 603 . . . . . . 
3. Pancuronium 572 -1.2 -1.2 53 6 0 6 
4. Vecuronium 558 0.62 -0.26 56 6 0 6 
5. Org 7268  516 0.55 -0.38 50 5 1 5 
6. Rapacuronium 598 2.6 1.7 . . . . 
7. Org 9488  556 . . . . . . 
8. Org 9489 572 . . . . . . 
9. Org 9453 586 . . . . . . 
  N 9 5 5 4 4 4 4 
  Mean 
(95% CI) 
566 
(543, 588) 
0.47 
(-1.2, 2.2) 
-0.10 
(-1.4, 1.2) 
55 
(48, 61) 
6 
(5, 7) 
0.50 
(-0.04, 1.4) 
6 
(5.0, 6.5) 
  Maximum 603 2.59 1.71 59 7 1 6 
  Minimum 516 -1.18 -1.18 50 6 0 5 
  -fold range 1.2 3.8 2.9 1.2 1.2 1 1.2 
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Table 5.3 - Molecular/PC Properties of NMB with BIQ Scaffold 
 
 Drug MW (Da) logP 
LogD   
at pH 7.4 
PSA (A2) nRot HBD HBA 
B
IQ
 
1. Alcuronium 667 -3.1 -3.1 47 8 2 6 
2. Doxacurium 1035 -2.1 -2.1 163 29 0 18 
3. Mivacurium 1029 0.37 0.37 145 30 0 16 
4. Atracurium 929 -0.27 -0.27 126 26 0 14 
5. Cisatracurium 933 -0.27 -0.27 126 26 0 14 
 N 5 5 5 5 5 5 5 
 Mean 
(95%CI) 
920 
(733, 1104) 
-1.1 
(-2.9, 0.73) 
-1.1 
(-2.9, 0.73) 
121 
(66, 177) 
24 
(13, 35) 
0.40 
(-0.70, 1.5) 
14 
(8, 19) 
 Maximum 1035 0.37 0.37 163 30 2 18 
 Minimum 667 -3.07 -3.07 47 8 0 6 
 -fold range 1.6 3.4 3.4 3.5 3.8 2.0 3.0 
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Table 5.4 - Descriptive Statistics of PC/Molecular Properties of NMB 
 
N Mean SD 95% CI Minimum 10% 25% Median 75% 90% Maximum 
MW (Da) 16 651.0 214.93 536.6, 765.7 290.0 397.8 536.5 579.0 863.5 1030.8 1035.0 
LogD7.4 12 -0.7 1.95 -2.0, 0.5 -5.0 -4.4 -1.9 -0.3 0.2 2.0 2.1 
PSA (A2) 11 83.7 45.85 52.9, 114.5 43.0 43.8 50.0 56.0 126.0 159.4 163.0 
nRot 11 14.4 10.82 7.1, 21.6 4.0 4.2 6.0 8.0 26.0 29.8 30.0 
HBD 11 0.4 0.67 -0.1, 0.8 0.0 0.0 0.0 0.0 1.0 1.8 2.0 
HBA 11 9.4 4.98 6.0, 12.7 5.0 5.2 6.0 6.0 14.0 17.6 18.0 
 
 
 
 
Table 5.5 - Correlation Matrix of PC/Molecular Variables of NMB 
 
MW (Da) LogD7.4  PSA (A2) nRot HBA HBD 
MW (Da) 1.00      
LogD7.4  0.14 1.00     
PSA (A2) 0.90 -0.01 1.00    
nRot 0.86 -0.11 0.97 1.00   
HBA 0.90 0.01 0.99 0.97 1.00  
HBD -0.17 -0.23 -0.42 -0.39 -0.43 1.00 
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5.2.2. Human Systemic PK/PD Property Space of NMB  
The final median (instead of mean values were presented because of their skewed distribution) 
in-vitro and in-vivo human systemic PK/PD properties compiled from various studies in the 
literature are shown in Table - 5.6 and 5.12, respectively, and the estimated biologically relevant 
PK properties in Table 5.9. Appendix 2 contains all the supplemental information with respect to 
the in-vitro/in-vivo human systemic PK and in-vivo PD data compiled for each of the compound 
from the literature. 
There is considerable to large diversity in the in-vitro/in-vivo systemic PK/PD properties of 
NMB in the current dataset with available information, ranging from 4- to 266-fold (n = 8 - 16). 
Within the NMB with ASN scaffold, the systemic and biologically relevant PK/PD property 
space is relatively less diverse (Tables 5.7, 5.10 and 5.13) ranging from 1.4- to 26-fold and 
shows relatively lower mean values, while NMB with the BIQ scaffold show a more diverse 
space (Tables 5.8, 5.11, 5.14) ranging from 1.3- to 224-fold and in general, higher mean values 
(which are not statistically different from those with ASN scaffold).  
The descriptive statistics for these PK/PD variables are shown in Table 5.15 and for a few of 
these variables, the mean values are higher than the median values. Furthermore, owing to the 
skewed distribution and considerable diversity, all the systemic PK/PD variables (except fu, fe, 
keo and γ) were log transformed for further analysis.  
Several correlations are observed between the in-vitro/in-vivo human systemic and biologically 
relevant PK variables of NMB (shown in Table 5.16). However, most of these correlations are 
mechanistically plausible, e.g., (a) CLtot
u is highly correlated with CLnonren (r = 0.92, n = 14), 
while CLtot is highly correlated with CLren
u (r = 0.91, n = 13) and CLnonren (r = 0.84, n = 15), 
suggesting that few NMB (within the dataset with available information) show significant renal 
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clearance while the rest have significant nonrenal clearance mechanisms; (b) Vdss was highly 
correlated (r = 0.94, n = 14) with Vdss
u, suggesting that, overall, PPB of NMB (in the current 
dataset) is not significant.  
Overall, PPB varies 4-fold (n =14) and the majority of NMB in the dataset are not extensively 
bound to plasma proteins, i.e., they show relatively high free fraction in plasma, possibly because 
of their low lipophilicity. On average, NMB belonging to each structural class, i.e., ASN- and 
BIQ-scaffold, show similar values for fu, however, NMB with ASN scaffold show more diversity 
(4-fold, n = 8), while NMB with BIQ scaffold show comparable values. Vdss
u varies 24-fold (n 
=14) compared to Vdss (12-fold, n = 16), and their mean values are comparable, suggesting that 
PPB did not offset the Vdss
u (because NMB are not extensively PPB, see above). The higher 
diversity in Vdss
u values relative to Vdss may be due to greater diversity in PPB. The majority of 
NMB have Vdss
u values much lower than BW (70 kg), suggesting they undergo little 
extravascular distribution (primarily into the extra and/or intracellular water, 0.2 - 0.3 l/kg), 
which is true for NMB within each structural class. MW and/or charged nature of the 
molecule(s) could be plausible explanation(s) for the lack of extravascular/trans-membrane tissue 
penetration (i.e., low Vdss
u values).  
Most of NMB show clearance through renal pathways (fe ranging from 5% to 72%, n = 14). 
Overall, there is considerable diversity in the CLren
u values (11-fold, n = 13), and it is comparable 
between the structural classes. With the exception of mivacurium, the rest of NMB have CLren
u 
values lower than GFR (1.7 ml/min/kg), suggesting that (a) they are potentially poorly filtered in 
the glomerulus, due to their large size and/or (b) they undergo net tubular reabsorption possibly 
involving drug transporters. Mivacurium shows CLren
u value close to RPF, suggesting it 
undergoes net tubular secretion, possibly involving of drug transporters. 
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Overall, CLnonren varies 266-fold (n = 15). CLnonren of NMB in the current dataset with BIQ 
scaffold show large diversity (224-fold, n = 5) and encompasses diverse mechanisms e.g., (a) 
mivacurium is the newest generation NMB that was designed to have immediate onset of action, 
and undergoes rapid hydrolysis by plasma cholinesterase76,77 (see Appendix 2), which is a 
plausible explanation for having CLnonren value exceeding cardiac output (i.e., blood-flow 
independent, extrahepatic clearance pathways). (b) atracurium and cisatracurium are known to 
undergo chemical degradation via Hoffman elimination78 (see in Appendix 2), occurring both in 
plasma and tissue compartments (i.e., in an organ-independent manner). (c) alcuronium and 
doxacurium have CLnonren values lower than LBF (21 ml/min/kg) and are low ERhep drugs 
(assuming B:P ratio is close to 1 and there are no extrahepatic clearance pathways).  
There is relatively low diversity in CLnonren values (13-fold, n = 9) of NMB with ASN structural 
scaffold and available information in the current dataset; all of them have CLnonren values lower 
than LBF, suggesting they are low ERhep drugs (assuming B:P ratio is close to 1 and there are no 
extrahepatic clearance pathways). SCh (in the miscellaneous category) undergoes enzymatic 
hydrolysis and thus exhibits extrahepatic clearance pathways. 
In-vivo PD properties, namely, equilibration rate constant, keo varies 4-fold (n = 8), Cpss
50 (in 
mM) varies 68-fold (n = 9), and sigmoidicity varies 4-fold (n = 9) (shown in Table 5.12). 
Overall, the equilibration half-lives ranges from 3 - 14 minutes, which are orders of magnitude 
smaller than the respective terminal plasma half-lives, suggesting that NMB, in general, 
equilibrate rapidly with their target compartment. Furthermore, it can be observed that the keo 
values are lower (i.e., slower equilibration half-lives) and for NMB with BIQ scaffold (and SCh 
within miscellaneous category) than for NMB with ASN scaffold. There were considerable 
differences in the molar potencies (Cpss
50) between the NMB. The sigmoidicity (γ) for all the 
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NMBs is found to be much greater than 1, suggesting that the PD effects (neuromuscular 
blockade) changes are very sensitive to the changes in the biophase concentrations. SCh, a 
depolarizing NMB shows the highest sigmoidicity (2-3 fold higher) relative to all the other 
nondepolarizing NMB.   
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Table 5.6 - In-vitro and In-vivo Human PK Systemic Properties of NMB 
 
 
In-vitro 
PK 
Variable 
In-vivo PK Variables 
 
Drug 
fu 
[%] 
Vdss 
[l/kg] 
CLtot 
[ml/min/kg] 
fe  
[%] 
CLren 
[ml/min/kg] 
CLnonren 
[ml/min/kg] 
A
S
N
 
Rocuronium  65% 0.21 3.5 25% 0.88 2.6 
Pipercuronium 98% 0.32 2.6 41% 1.1 1.5 
Pancuronium 75% 0.22 1.6 58% 0.93 0.70 
Vecuronium 48% 0.20 5.0 7% 0.35 4.6 
Org 7268  69% 0.26 4.3 18% 0.77 3.5 
Rapacuronium 38% 0.32 8.3 9% 0.75 7.6 
Org 9488  . 0.21 1.2 53% 0.62 0.58 
Org 9489 39% 0.46 5.8 8% 0.46 5.3 
Org 9453 28% 0.18 6.9 5% 0.35 6.6 
B
IQ
 
Alcuronium . 0.31 0.90 72% 0.65 0.25 
Doxacurium 53% 0.20 2.5 26% 0.65 1.8 
Mivacurium 71% 0.19 72 7% 5.1 67 
Atracurium 57% 0.15 6.3 6% 0.38 5.9 
Cisatracurium 62% 0.15 5.0 16% 0.80 4.2 
 Fazadinium 49% 0.19 2.1 50% 1.1 1.1 
 Succinylcholine 80% 0.040 37.0 . . . 
 N 14 16 16 15 15 15 
 Median 59% 0.20 4.7 18% 0.80 3.5 
 Maximum 98% 0.46 72 72% 5.1 67 
 Minimum 28% 0.040 0.90 5% 0.35 0.25 
 -fold range 4 12 80 14 15 266 
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Table 5.7 - In-vitro and In-vivo Human PK Systemic Properties of NMB with ASN Scaffold 
 
 
In-vitro PK 
Variable 
In-vivo PK Variables 
 
Drug 
fu 
[%] 
Vdss 
[l/kg] 
CLtot 
[ml/min/kg] 
fe  
[%] 
CLren 
[ml/min/kg] 
CLnonren 
[ml/min/kg] 
A
S
N
 
Rocuronium  65% 0.21 3.5 25% 0.88 2.6 
Pipercuronium 98% 0.32 2.6 41% 1.1 1.5 
Pancuronium 75% 0.22 1.6 58% 0.93 0.70 
Vecuronium 48% 0.20 5.0 7% 0.35 4.6 
Org 7268  69% 0.26 4.3 18% 0.77 3.5 
Rapacuronium 38% 0.32 8.3 9% 0.75 7.6 
Org 9488  . 0.21 1.2 53% 0.62 0.58 
Org 9489 39% 0.46 5.8 8% 0.46 5.3 
Org 9453 28% 0.18 6.9 5% 0.35 6.6 
 N 8 9 9 9 9 9 
 Mean 
(95% CI) 
58% 
(28%, 77%) 
0.3 
(0.2, 0.3) 
4.4 
(2.5, 6.2) 
25% 
(9%, 41%) 
0.7 
(0.5, 0.9) 
3.7  
(1.7, 3.7) 
 Maximum 99% 0.5 8.3 58% 1.1 7.6 
 Minimum 28% 0.2 1.2 5% 0.3 0.6 
 -fold range 4 3 7 12 4 13 
 
 
Table 5.8 - In-vitro and In-vivo Human PK Systemic Properties of NMB with BIQ Scaffold 
 
Drug 
fu 
[%] 
Vdss 
[l/kg] 
CLtot 
[ml/min/kg] 
fe  
[%] 
CLren 
[ml/min/kg] 
CLnonren 
[ml/min/kg] 
B
IQ
 
Alcuronium . 0.31 0.90 72% 0.65 0.25 
Doxacurium 53% 0.20 2.5 26% 0.65 1.8 
Mivacurium 71% 0.19 72 7% 5.1 67 
Atracurium 57% 0.15 6.3 6% 0.38 5.9 
Cisatracurium 62% 0.15 5.0 16% 0.80 4.2 
 N 4 5 5 5 5 5 
 Mean 
(95% CI) 
61% 
(48%, 73%) 
0.2 
(0.1, 0.3) 
17.4 
(-20.8, 55.5) 
25% 
(-8%, 59%) 
1.5 
(-1.0, 4.0) 
15.9 
(-19.8, 51.6) 
 Maximum 71% 0.3 72.2 72% 5.1 67.1 
 Minimum 53% 0.2 0.9 6% 0.4 0.3 
 -fold range 1.3 1.5 80.2 12.0 12.8 223.7 
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Table 5.9 - Biologically Relevant In-vivo Human PK Variables of NMB 
 
Drug 
Vdssu 
[l/kg] 
CLtotu 
[ml/min/kg] 
CLrenu 
[ml/min/kg] 
CLnonrenu 
[ml/min/kg] 
A
S
N
 
Rocuronium  0.32 5.4 1.4 4.1 
Pipercuronium 0.33 2.7 1.1 1.6 
Pancuronium 0.29 2.1 1.2 0.90 
Vecuronium 0.42 10.3 0.72 9.6 
Org 7268  0.38 6.2 1.1 5.1 
Rapacuronium 0.84 21.9 2.0 19.9 
Org 9488  . . . . 
Org 9489 1.2 14.9 1.2 13.7 
Org 9453 0.64 24.6 1.2 23.4 
B
IQ
 
Alcuronium . . . . 
Doxacurium 0.38 4.7 1.2 3.5 
Mivacurium 0.27 101.7 7.1 94.6 
Atracurium 0.26 11.1 0.77 10.4 
Cisatracurium 0.24 8.1 1.3 1.5 
 Fazadinium 0.39 4.3 2.1 2.1 
 Succinylcholine 0.050 46.3 . . 
 N 14 14 13 13 
 Median 0.4 9.2 1.2 6.8 
 Maximum 1.2 101.7 7.1 94.6 
 Minimum 0.050 2.1 0.72 0.90 
 -fold range 24 48 11 106 
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Table 5.10 - Biologically Relevant In-vivo Human PK Variables of NMB with ASN Scaffold 
 
Drug 
Vdssu 
[l/kg] 
CLtotu 
[ml/min/kg] 
CLrenu 
[ml/min/kg] 
CLnonrenu 
[ml/min/kg] 
A
S
N
 
Rocuronium  0.32 5.4 1.4 4.1 
Pipercuronium 0.33 2.7 1.1 1.6 
Pancuronium 0.29 2.1 1.2 0.90 
Vecuronium 0.42 10.3 0.72 9.6 
Org 7268  0.38 6.2 1.1 5.1 
Rapacuronium 0.84 21.9 2.0 19.9 
Org 9488  . . . . 
Org 9489 1.2 14.9 1.2 13.7 
Org 9453 0.64 24.6 1.2 23.4 
 N 8 8 8 8 
 Mean 
(95% CI) 
0.6 
(0.3, 0.8) 
11.0 
(3.8, 18.2) 
1.2 
(1.0, 1.5) 
9.8 
(2.7, 16.9) 
 Maximum 1.2 24.6 2.0 23.4 
 Minimum 0.3 2.1 0.7 0.9 
 -fold range 4 12 3 26 
 
 
 
Table 5.11 - Biologically Relevant In-vivo Human PK Variables of NMB with BIQ Scaffold 
 
Drug 
Vdssu 
[l/kg] 
CLtotu 
[ml/min/kg] 
CLrenu 
[ml/min/kg] 
CLnonrenu 
[ml/min/kg] 
B
IQ
 
Alcuronium . . . . 
Doxacurium 0.38 4.7 1.2 3.5 
Mivacurium 0.27 101.7 7.1 94.6 
Atracurium 0.26 11.1 0.77 10.4 
Cisatracurium 0.24 8.1 1.3 1.5 
 N 4 4 4 4 
 Mean 
(95% CI) 
0.3 
(0.2, 0.4) 
31.4 
(-43.3, 106.1) 
2.6 
(-2.3, 7.4) 
28.8 
(-41.1, 98.7) 
 Maximum 0.4 101.7 7.1 94.6 
 Minimum 0.2 4.7 0.7 1.5 
 -fold range 2 22 10 63 
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Table 5.12 - In-vivo Human PD Properties of NMB 
 
Drug 
keo 
(min-1) 
Cpss50  
(mM) 
γ 
A
S
N
 
Rocuronium  0.17 2.13 6.1 
Pipercuronium .  . 
Pancuronium 0.17 0.17 4.8 
Vecuronium 0.24 0.2 5.8 
Org 7268  0.26 0.25 . 
Rapacuronium .  . 
Org 9488  0.11 3.29 4.3 
Org 9489 .  . 
Org 9453 .  . 
B
IQ
 
Alcuronium . 0.82 5.0 
Doxacurium 0.05 0.05 5.5 
Mivacurium .  . 
Atracurium .  . 
Cisatracurium 0.05 0.16 6.9 
 Fazadinium . . . 
 Succinylcholine 0.06 2.62 19.3 
 N 8 9 9 
 Median 0.14 0.25 5.7 
 Maximum 0.26 3.29 19.3 
 Minimum 0.05 0.05 4.3 
 -fold range 5 68 4 
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Table 5.13 - In-vivo Human PD Properties of NMB with ASN Scaffold 
 
Drug 
keo 
(min-1) 
Cpss50  
(mM) 
γ 
A
S
N
 
Rocuronium  0.17 1.13 6.1 
Pipercuronium . . . 
Pancuronium 0.17 0.10 4.8 
Vecuronium 0.24 0.11 5.8 
Org 7268  0.26 0.13 . 
Rapacuronium . . . 
Org 9488  0.11 1.83 4.3 
Org 9489 . . . 
Org 9453 . . . 
 N 5 5 4 
 Mean 
(95% CI) 
0.19 
(0.11, 0.27) 
1.21 
(-0.57, 2.99) 
5.3 
(3.9, 6.6) 
 Maximum 0.26 3.29 6.1 
 Minimum 0.11 0.17 4.3 
 -fold range 2.4 19.4 1.4 
 
 
 
Table 5.14 - In-vivo Human PD Properties of NMB with BIQ Scaffold 
 
Drug 
keo 
(min-1) 
Cpss50  
(mM) 
γ 
B
IQ
 
Alcuronium . 0.82 5.0 
Doxacurium 0.05 0.05 5.5 
Mivacurium . . . 
Atracurium . . . 
Cisatracurium 0.05 0.16 6.9 
 N 2 3 2 
 Mean 
(95% CI) 
0.05 
(0.05, 0.05) 
0.34 
(-0.69, 1.38) 
5.8 
(3.4, 8.2) 
 Maximum 0.05 0.82 6.9 
 Minimum 0.05 0.05 5.0 
 -fold range  16 1.4 
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Table 5.15 - Descriptive Statistics of Human Systemic PK/PD Variables of NMB 
 N Mean SD 95% CI Minimum 10% 25% Median 75% 90% Maximum 
Vdss (L/kg) 16 0.2 0.09 0.2, 0.3 0.04 0.1 0.2 0.2 0.3 0.4 0.5 
CLtot (ml/min/kg) 16 10.3 18.6 0.4, 20.2 0.9 1.1 2.2 4.7 6.8 47.6 72.2 
CLren (ml/min/kg) 15 1.0 1.15 0.4, 1.6 0.4 0.4 0.5 0.8 0.9 2.7 5.1 
CLnonren (ml/min/kg) 15 7.6 16.65 -1.7, 16.7 0.3 0.4 1.1 3.5 5.9 31.4 67.2 
fu  14 0.6 0.19 0.5, 0.7 0.3 0.3 0.5 0.6 0.7 0.9 1.0 
Vdss
u (L/kg) 14 0.4 0.29 0.3, 0.6 0.1 0.2 0.3 0.4 0.5 1.0 1.2 
CLtot
u (ml/min/kg) 14 18.9 26.62 3.5, 34.3 2.1 2.4 4.6 9.2 22.5 74.0 101.7 
CLren
u (ml/min/kg) 13 1.7 1.67 0.7, 2.7 0.7 0.7 1.1 1.2 1.7 5.1 7.1 
CLnonren
u (ml/min/kg) 13 15.1 24.90 0.002, 30.095 0.9 1.2 2.8 6.8 16.8 66.1 94.6 
keo (min
-1)  8 0.1 0.08 0.07, 0.21 0.1 0.1 0.1 0.1 0.2 0.3 0.3 
Cpss
50 (mM) 9 1.1 1.26 0.1, 2.0 0.1 0.1 0.2 0.3 2.4 3.3 3.3 
γ (Sigmoidicity) 8 7.2 4.95 3.1, 11.4 4.3 4.3 4.9 5.7 6.7 19.3 19.3 
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Table 5.16 - Correlation Analysis of Human Systemic PK Variables of NMB 
 Vdss 
(L/kg) 
CLtot 
(ml/min/kg) 
CLren 
(ml/min/kg) 
CLnonren 
(ml/min/kg) 
fu 
(%) 
Vdssu 
(L/kg) 
CLtotu 
(ml/min/kg) 
CLrenu 
(ml/min/kg) 
CLnonrenu 
(ml/min/kg) 
Vdss (L/kg) 1.00         
CLtot (ml/min/kg) -0.51 1.00        
CLren (ml/min/kg) -0.67 0.77 1.00       
CLnonren (ml/min/kg) -0.14 0.91 0.59 1.00      
fu (%) -0.83 0.37 0.79 0.03 1.00     
Vdss
u (L/kg) 0.94 -0.42 -0.77 -0.06 -0.97 1.00    
CLtot
u (ml/min/kg) 0.07 0.77 0.26 0.92 -0.30 0.24 1.00   
CLren
u (ml/min/kg) -0.59 0.84 0.98 0.70 0.66 -0.66 0.41 1.00  
CLnonren
u (ml/min/kg) 0.64 0.26 -0.18 0.62 -0.72 0.72 0.78 -0.02 1.00 
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5.2.3. QSPKR Analysis, Model Building and Evaluation 
The results of the univariate regression of the in-vitro/(log-transformed) in-vivo biologically 
relevant and reported PK/PD variables as a function of the molecular/PC descriptors of NMB, 
namely, MW, logD7.4 and HBD, are shown in Table 5.17 - 5.22. MW shows significant 
univariate relationships (r2 ≥ 0.3, p < 0.05) with log (Cpss50) and logD7.4 with fu and log (Vdssu) 
(Figures 5.1 - 5.3). Please refer Table 5.1 in page 60 for the individual compounds representing 
the numbers shown in all the plots in this chapter. Although there are other relationships in 
which > 30% of the variability in certain in-vivo systemic and/or biologically relevant PK/PD 
variables could be explained, the slopes of none of them differed statistically from zero.  
In general, the model fits (i.e., r2) with respect to MW and HBD are comparatively better for 
both systemic and biologically relevant PK variables for NMB with BIQ than for those with 
ASN scaffold. This is mechanistically plausible because the former is relatively more 
heterogeneous than the latter in their molecular/PC and PK property space. During the final 
(multivariate) model building process (using MLLR with forward inclusion followed by 
backward elimination), logD7.4 was found to be the single most important determinant affecting 
biologically relevant systemic PK of NMB. The final models are summarized in Table 5.23. 
Overall, none of the final QSPKR models developed across all NMB for fu and Vdss
u gave 
acceptable predictions (q2 ≥ 0.40).  
5.2.3.1. Effect of LogD7.4 on Systemic and Biologically Relevant PK Variables of NMB 
There is a significant negative association between logD7.4 and fu, i.e., an increase in logD7.4 is 
associated with a decrease in fu (increase in PPB) of NMB (Slope = -0.04, r
2 = 0.42, n = 11, 
shown in Figure - 5.1), and a significant positive association is found with (log-transformed) 
Vdss
u (Slope = 0.13, r2 = 0.68, n = 11, shown in Figure 5.2). Due to the offsetting effects of 
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logD7.4 on fu and Vdss
u, its uncorrected counterpart, Vdss did not depend on logD7.4. None of the 
other relationships were statistically different. It can be seen from Figures 5.1 and 5.2, SCh 
(labeled as compound 16, most hydrophilic, highest fu and lowest Vdss
u) is pivotal in defining the 
slopes of these relationships. When stratified by structural class, it can be seen that the 
relationship shown with fu is significant for neither class of NMB, possibly because of the 
reduction in the diversity and/or sample size. Additionally, NMB with the ASN scaffold show a 
significant positive association between logD7.4 and log Vdss
u
 (Slope = 0.17, r
2 = 0.99, n = 5, 
Figure 5.4), log CLtot
u (Slope = 0.34, r2 = 0.84, n = 5, Figure 5.5) and log CLtot (Slope = 0.22, r
2 
= 0.79, n = 5, Figure 5.6), while NMB with BIQ scaffold show a significant positive association 
with log CLnonren (Slope = 0.55, r
2 = 0.84, n = 4, Figure 5.7) 
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Table 5.17 - Log-Linear Regression Between MW and Biologically Relevant PK Variables of NMB  
 
fu 
 
Log  
(Vdssu) 
[l/kg] 
Log  
(CLtotu) 
[ml/min/kg] 
Log  
(CLrenu) 
[ml/min/kg] 
Log  
(CLnonrenu) 
[ml/min/kg] 
NMB (All) N.S. N.S. N.S. N.S. N.S. 
NMB with ASN 
Scaffold  
N.S. N.S. N.S. N.S. N.S. 
NMB with BIQ 
Scaffold 
N.S. 
n = 4 
r2 = 0.49 
Slope =0.001 
N.S. 
N.S. 
n = 4 
r2 = 0.40 
Slope =0.005 
N.S. 
N.S. 
 
 
Table 5.18 - Log-Linear Regression Between MW and Reported PK/PD Variables of NMB  
 
Log  
(Vdss) 
[l/kg] 
Log  
(CLtot) 
[ml/min/kg] 
Log  
(CLren) 
[ml/min/kg] 
Log  
(CLnonren) 
[ml/min/kg] 
keo 
(min-1) 
Log  
(Cpss50)  
(mM) 
γ 
NMB 
(All) 
N.S. N.S. N.S. N.S N.S. 
n = 9 
r2 = 0.50 
Slope = -
0.002 
-0.004, -0.001 
N.S. 
NMB 
with 
ASN 
Scaffold  
N.S. N.S N.S. N.S. N.S. N.S. 
n = 4 
r2 = 0.41 
Slope =-
0.031 
N.S. 
NMB 
with 
BIQ 
Scaffold 
n = 5 
r2 = 0.48 
Slope =-
0.001 
N.S. 
n = 5 
r2 = 0.44 
Slope =0.003 
N.S. 
N.S. 
n = 5 
r2 = 0.58 
Slope 
=0.005 
N.S. 
N.S. 
n = 3 
r2 = 0.98 
Slope =-
0.003 
N.S. 
N.S. 
 
In red: r2 ≥ 0.30 and p<0.05; 
In italic and red: r2 ≥ 0.30 but p>0.05 or r2 < 0.30 but p<0.05; 
N.S = Not Significant (r2 < 0.30 and p>0.05); 
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Table 5.19 - Log-Linear Regression Between LogD7.4 and Biologically Relevant PK Variables of NMB  
 
fu 
 
Log  
(Vdssu) 
[l/kg] 
Log  
(CLtotu) 
[ml/min/kg] 
Log  
(CLrenu) 
[ml/min/kg] 
Log  
(CLnonrenu) 
[ml/min/kg] 
NMB (All) 
n = 11 
r2 = 0.42 
Slope = -0.044 
-0.083, -0.005 
n = 11 
r2 = 0.68 
Slope = 0.129 
0.062, 0.196 
N.S. N.S. N.S. 
NMB with 
ASN 
Scaffold  
n = 5 
r2 = 0.76 
Slope = -0.125 
N.S. 
n = 5 
r2 = 0.96 
Slope = 0.165 
0.103, 0.226 
n = 5 
r2 = 0.84 
Slope = 0.318 
0.064, 0.571 
n = 5 
r2 = 0.36 
Slope = 0.087 
N.S. 
n = 5 
r2 = 0.75 
Slope = 0.403 
N.S. 
NMB with 
BIQ 
Scaffold 
n = 4 
r2 = 0.70 
Slope =0.061 
N.S. 
n = 4 
r2 = 0.80 
Slope = -0.072 
N.S. 
n = 4 
r2 = 0.58 
Slope = 0.420 
N.S. 
N.S. 
n = 4 
r2 = 0.63 
Slope = 0.461 
N.S. 
 
Table 5.20 - Log-Linear Regression Between LogD7.4 and Reported PK/PD Variables of NMB 
 
Log  
(Vdss) 
[l/kg] 
Log  
(CLtot) 
[ml/min/kg] 
Log  
(CLren) 
[ml/min/kg] 
Log  
(CLnonren) 
[ml/min/kg] 
keo 
(min-1) 
Log  
(Cpss50)  
(mM) 
γ 
NMB 
(All) 
n = 12 
r2 = 0.33 
Slope = 
0.069 
N.S. 
N.S N.S. N.S. 
n = 7 
r2 = 0.31 
Slope = 
0.029 
N.S. 
N.S. 
n = 7 
r2 = 0.55 
Slope =-
2.170 
N.S. 
NMB 
with 
ASN 
Scaffold  
n = 5 
r2 = 0.64 
Slope = 
0.062 
N.S. 
n = 5 
r2 = 0.79 
Slope = 
0.215 
0.009, 0.421 
N.S. 
n = 5 
r2 = 0.67 
Slope = 
0.301 
N.S. 
n =4 
r2 = 0.38 
Slope = 
0.068 N.S. 
N.S. 
n = 3 
r2 = 0.87 
Slope =1.238 
N.S. 
NMB 
with 
BIQ 
Scaffold 
n = 5 
r2 = 0.67 
Slope =-
0.073 
N.S. 
n = 5 
r2 = 0.75 
Slope =0.422 
N.S. 
N.S. 
n = 5 
r2 = 0.84 
Slope = 
0.554 
0.108, 1.000 
N.S. N.S. 
n = 3 
r2 = 0.99 
Slope =0.690 
N.S. 
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Table 5.21 - Log-Linear Regression Between HBD and Biologically Relevant PK Variables of NMB  
 
fu 
 
Log  
(Vdssu) 
[l/kg] 
Log  
(CLtotu) 
[ml/min/kg] 
Log  
(CLrenu) 
[ml/min/kg] 
Log  
(CLnonrenu) 
[ml/min/kg] 
NMB (All) N.S. N.S. N.S. N.S. N.S. 
NMB with 
ASN 
Scaffold  
N.S. N.S. N.S. 
n = 4 
r2 = 0.30 
Slope = 0.112 
N.S. 
N.S. 
NMB with 
BIQ Scaffold 
N.S. N.S. N.S. N.S. N.S. 
 
 
 
Table 5.22 - Log-Linear Regression Between HBD and Reported PK/PD Variables of NMB  
 
Log  
(Vdss) 
[l/kg] 
Log  
(CLtot) 
[ml/min/kg] 
Log  
(CLren) 
[ml/min/kg] 
Log  
(CLnonren) 
[ml/min/kg] 
keo 
(min-1) 
Log  
(Cpss50)  
(mM) 
γ 
NMB 
(All) 
N.S. N.S. N.S. N.S. 
n = 7 
r2 = 0.30 
Slope = 0.101 
N.S. 
N.S. N.S. 
NMB 
with 
ASN 
Scaffold  
n =4 
r2 = 0.30 
Slope 
=0.047 
N.S. 
N.S. N.S. N.S. N.S. 
n =4 
r2 = 0.45 
Slope 
=0.597 
N.S. 
n = 3 
r2 = 0.46 
Slope =0.800 
N.S. 
NMB 
with 
BIQ 
Scaffold 
n = 5 
r2 = 0.80 
Slope = 
0.129 
0.011, 0.247 
n =5 
r2 = 0.39 
Slope =-
0.492 
N.S. 
N.S. 
n =4 
r2 = 0.56 
Slope =-
0.736 
N.S. 
N.S. 
n =3 
r2 = 0.83 
Slope 
=0.481 
N.S. 
n =3 
r2 = 0.50 
Slope =-
0.600 
N.S. 
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Table 5.23 - Final QSPKR Models for NMB 
Final QSPKR Model N Slope (95% CI) r2 q2 
fu = 0.583 - 0.044 * LogD7.4 11 - 0.044 (-0.083, -0.005) 0.42 0.21 
Log (Vdss
u) =  - 0.461 + 0.129 * LogD7.4 11   0.129 (0.062, 0.196) 0.68 0.21 
                               q2 ≥ 0.40: Acceptable 
Figure 5.3 - fu vs. logD7.4 for NMB   
 
Figure 5.4 - Vdssu vs. logD7.4 for NMB 
 
 
(Please refer Table 5.1 in Page 60, for the list of the individual compounds 
 labeled in the figures 5.3 and 5.4) 
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                    Figure 5.5 - Cpss50 vs. MW for NMB                            
   
(Please refer Table 5.1 in Page 60, for the list of the individual compounds labeled in figure 5.5) 
Figure 5.6 - Vdssu vs. logD7.4 for NMB with ASN Scaffold                  
      
(Please refer Table 5.2 in Page 61, for the list of the individual compounds labeled in figure 5.6) 
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Figure 5.7 - CLtotu vs. logD7.4 for NMB with ASN Scaffold             Figure 5.8 - CLtot vs. logD7.4 for NMB with ASN Scaffold 
                                   
(Please refer Table 5.2 in Page 61, for the list of the individual compounds labeled in the figures 5.7 and 5.8) 
Figure 5.9 - CLnonren vs. logD7.4 for NMB with BIQ Scaffold 
 
(Please refer Table 5.3 in Page 62, for the list of the individual compounds labeled in the 5.8) 
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5.3. Discussion 
Structurally, NMBs in the current dataset (n = 16) exhibit two common scaffolds - ASN (n = 9) 
and BIQ (n = 5), while fazadinium and SCh are classified under the miscellaneous category. 
Overall, the PC/molecular property space has fairly large diversity (2- to 8-fold, n = 11 - 16), and 
NMB with the BIQ scaffold seem to be relatively more heterogeneous than those with ASN 
scaffold. NMB have fairly large MW (ranging from 444 - 1035 Da, n = 15, except SCh), mostly 
hydrophilic, i.e., logD7.4 < 1.0 (n = 10, i.e., excluding rapacuronium and fazadinium), ranging 
from -5.00 to 2.08 (n = 12), bases with two positive charges. Roy et al79 determined the 
experimental values of (logarithm of) distribution coefficient for seven NMB, including SCh and 
they found that all of the values were negative, i.e., they are all hydrophilic. The ACD/Labs 
predicted logD7.4 values for mivacurium, atracurium and cisatracurium are lower than their 
corresponding experimental determined values, while for vecuronium, rocuronium and SCh, the 
ACD/Labs predicted values are comparable to their corresponding experimentally determined 
values. This suggests that the accuracy of ACD/Labs predicted logD7.4 is less reliable, especially 
for the relatively more polar compounds.   
Most NMB are not extensively plasma protein bound, and their Vdss
u values indicate little 
extravascular distribution (primarily into extra and/or intracellular water) - possibly due to their 
hydrophilic nature and/or large MW. Despite low PPB values in general, it seem to still offset the 
Vdss
u resulting in lower Vdss values, indicated binding-restricted distribution.  
The available CLren
u values suggest net tubular reabsorption, potentially involving transporters. 
Few compounds, i.e., atracurium, cisatracurium, mivacurium and SCh, show significant 
extrahepatic clearance pathways by enzymatic/chemical degradation, while the rest of NMB 
show (non-binding restricted) low to intermediate ERhep.  
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In-vivo PD properties suggested that NMB, in general, equilibrate with the biophase 
compartment fairly rapidly (equilibration half-lives ranging between 3 - 14 minutes). Overall, 
there is considerable to large diversity in the in-vitro/in-vivo systemic PK/PD properties of NMB 
in the current dataset with available information, ranging from 4- to 266-fold (n = 8 - 16), and 
NMB with BIQ scaffold seem to be relatively more heterogeneous than those with ASN scaffold.  
LogD7.4 is found to be the important determinant affecting biologically relevant systemic PK 
properties, namely, fu and Vdss
u. An increase in logD7.4 is associated with a decrease in fu (Figure 
5.3), suggesting that NMB bind to plasma proteins by hydrophobic interactions. These findings 
are consistent with binding of quaternary ammonium compounds in rats80, and a similar 
relationship was also found between in-vitro PPB of NMB in human plasma (fraction bound) and 
experimentally determined (log of) the partition coefficient (octanol/Krebs buffer) (Slope = 0.18, 
r2 = 0.75, n = 15)81.  
Obach et al29 investigated a diverse set of 554 drugs found that (non-specific) hydrophobic 
interactions with the plasma proteins drive the negative trend between fu and logD7.4. Vdss
u 
shows a positive association with logD7.4 (Figure 5.4), and this relationship is comparable to that 
obtained for sulfonamides in rats (Slope = 0.20, r2 = 0.69, n = 6)82, β-adrenergic ligands in 
humans (Slope = 0.33, r2 = 0.71, n = 13)39. Because of the offsetting effect of logD7.4 on fu and 
Vdss
u, Vdss did not show any relationship with logD7.4.  
None of the other PC variables show significant relationships with the other biologically relevant 
systemic PK variables (namely CLtot
u, CLren
u and CLnonren
u) across all the NMB and a plausible 
explanation may be the diverse clearance mechanisms that cannot be explained by (bulk) 
PC/molecular properties. However, when NMB are stratified based on their structural scaffold, 
NMB with the ASN scaffold show a significant positive association between Vdss
u and logD7.4 
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(Figure 5.6) but NMB with the BIQ scaffold do not (Table 5.19). Furthermore, significant 
positive associations are observed with CLtot
u (as well as CLtot) as a function of logD7.4 only for 
NMB with the ASN scaffold (Table 5.19 and Figures 5.7 and 5.8). Wierda et al83 reported a 
similar trend for NMB in humans (n = 5) both for CLtot
u and CLtot as a function of lipophilicity 
(despite the offsetting effects of lipophilicity on fu).  
None of the PD properties show significant relationships with the PC/molecular variables, except 
log Cpss
50
 with MW (Table 5.22 and Figure 5.5). Notably, an increase in MW is associated with a 
decrease in Cpss
50 (or increase in potency, when concentration is expressed in molar terms). A 
similar relationship was obtained by Roy et al79 who investigated NMB with ASN-, BIQ-
scaffolds and also SCh. Although the exact reason for such a relationship is not fully understood, 
MW has also been proposed to be an important determinant in the speed of onset of action 
(despite the presence of permanently positively charged nitrogens)84.  
Overall, nonspecific hydrophobic interactions with plasma proteins (and tissues) appear to be a 
plausible explanation for the observed significant relationships of logD7.4 with fu and Vdss
u for 
NMB seen in this study. Within the limitations of the study, none of the PC variables for NMB 
correlated with elimination clearances and PD (except molar Cpss
50 with MW) variables, 
suggesting high molecular selectivity of the various clearance mechanisms (i.e., 
chemical/enzymatic degradation, hepatobiliary excretion and/or renal tubular reabsorption) and 
drug - target interactions. Final QSPKR models did not give acceptable predictions for NMB.  
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4 CHAPTER 6. QSPKR of TRP 
6.1. Background 
TRP are used therapeutically to alleviate migraine pain. Although the underlying etiology of 
migraine is not fully understood, the role of serotonin (5-hydroxy-tryptamine, 5-HT) has been 
implicated in its pathogenesis57,58. TRP show high selectivity and potent agonist activity at the 
serotoninergic, G-protein coupled receptors and more specifically at 5-HT1B/1D subtypes
56. The 
distribution of these receptors and pharmacological action of TRP at these receptors is shown in 
Figure - 6.1 below85.  
Figure 6.1 - 5-HT1B/1D Receptors in CNS and Their Pharmacological Actions 
 
5-HT1B
Substantia nigra, basal ganglia, 
superior colliculus and       
frontal cortex
CNS: Presynaptic inhibition, 
behavioral effects including 
satiety
Vascular: Vasoconstriction
5-HT1D
Basal ganglia, substantia nigra, 
nucleus accumbens, 
hippocampus, locus coeruleus 
and dorsal raphe
CNS: Locomotion
Vascular: Cerebral 
Vasoconstriction
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Consistent with their 5-HT target receptors, structurally, TRP show a tryptamine nucleus:  
Figure 6.2 - Tryptamine nucleas 
 
 
The following structure activity relationships (SAR)86 were identified: 
1. Recognition of the ligand at 5-HT1B/1D requires the presence of an indole ring and linkage of 
the basic nitrogen to the 3-position (i.e., tryptamine nucleus), which is involved in hydrogen 
bonding interactions with the receptor.  
2. Substitution at R2 - position results in reduction of potency, owing to steric hindrance in 
receptor binding interactions 
3. Substituent at 6-position resulted with hydrogen bond accepting groups resulted in hydrogen 
bonding interactions with (hydrogen bond donating groups) in the receptors 
4. The quaternary nitrogen present either as a aliphatic/heterocyclic substituent is involved in 
ionic interactions with the receptor.   
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6.2. Results 
The final PC/molecular and human systemic PK/PD database consists of eight TRP. Based on 
the available information in the literature for TRP, four of them, namely, sumatriptan, 
almotriptan, rizatriptan and zolmitriptan are known to be substrates of monoamine oxidase 
(MAO), while there is sufficient evidence in the literature for the remaining three (i.e., non-MAO 
substrates), namely, naratriptan, frovatriptan and eletriptan. Further discussion of the property 
spaces for both PC/molecular and systemic PK/PD is presented comprehensively (i.e., all TRP) 
and also by MAO-substrate status.    
6.2.1. PC/Molecular Property Space of TRP  
The PC/molecular property space exhibited by TRP in the current dataset is presented in Table - 
6.1. Structurally, all TRP in the current dataset show a 5-hydroxy-tryptamine scaffold (but vary 
in the substituents attached to it, see Figure 6.2); thus, they exhibit fairly similar values for PSA, 
nRot, HBA and HBD, as is evident from low diversity (2- to 4- fold, n = 8) of these PC 
properties, except for avitriptan which has higher values. All TRP have relatively low MW, 
ranging from 243 to 459 Da, n = 8. Although all the TRP in the current dataset show both pKa1 
and pKa2, only pKa2, i.e., due to a weakly basic group (e.g., -NH2 group) is relevant at 
physiological pH of 7.4. Therefore, all of them are bases (n = 8) and, at pH 7.4, they are 
completely ionized (~99% for all TRP except avitriptan, which is 60% ionized), i.e., they carry a 
(single) positive charge on nitrogen present in secondary form either in an aliphatic/heterocyclic 
side chain.  
All the TRP in the current dataset are hydrophilic, i.e., logD7.4 < 1.0, and their (estimated logD7.4) 
values are consistently lower than their respective (SciFinder-predicted) logP values, which is a 
consequence of complete ionization (see above).   When they are further categorized based on 
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their known MAO-substrate status (shown in Tables 6.2 and 6.3), their respective molecular/PC 
property spaces overlap, suggesting that there are no meaningful differences in their PC 
properties due to MAO status. However, TRP that are MAO-substrates seem to be relatively 
more homogenous in their PC/molecular property space than the non-MOA substrates.  
The descriptive statistics of PC/molecular properties are shown in Table 6.4, and their mean 
values are comparable to the median values. Based on the acceptance criteria set a-priori for 
collinearity, i.e., r ≥ 0.80, MW is highly correlated with MV (r = 0.99, n = 8), MW with nRot (r 
= 0.84, n = 8), PSA with HBD (r = 0.84, n = 8), and nRot with MV (r = 0.84, n = 8) (shown in 
Table 6.5). Thus, logD7.4, MW, HBA and HBD were used for subsequent analysis (i.e., PSA, 
MV and nRot were excluded). 
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Table 6.1 - Molecular/PC Property Space of TRP 
 
 Drug 
MW 
(Da) 
logP pKa1 pKa  2 
LogD  
at pH 7.4 
% 
Ionized 
at pH 7.4 
Charge 
at pH 7.4 
PSA 
(A2) 
MV 
(cm3/  
mol) 
nRot HBD HBA 
M
A
O
  
S
u
b
st
ra
te
s 
1 Sumatriptan 295 0.44 11.31 9.49 -1.65 99% C 74 238 5 2 5 
2 Almotriptan 335 2.30 16.92 9.48 0.22 99% C 65 264 6 1 5 
3 Rizatriptan 269 1.20 16.98 9.49 -0.89 99% C 50 223 5 1 5 
4 Zolmitriptan 287 0.46 12.57 9.52 -1.66 99% C 57 236 5 2 5 
N
o
n
-M
A
O
 
S
u
b
st
ra
te
s 5 Naratriptan 335 1.15 11.52 9.30 -0.76 99% C 74 273 4 2 5 
6 Frovatriptan 243 0.93 16.39 10.38 -2.05 100% C 71 192 2 4 4 
7 Eletriptan 383 2.98 17.14 10.35 0.03 100% C 62 310 6 1 4 
 8 Avitriptan 459 0.09 11.32 7.57 -0.30 60% C 112 353 8 2 9 
  N 8 8   8   8 8 8 8 8 
  Mean 326 1.19   -0.88   71 261 5 2 5 
  Maximum 459 2.98   0.22   112 353 8 4 9 
  Minimum 243 0.09   -2.05   50 192 2 1 4 
  -fold range 2 33   2   2 2 4 4 2 
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Table 6.2 - Molecular/PC Property Space of TRP - MAO Substrates 
  Drug MW (Da) 
LogD   
at pH 7.4 
PSA 
(A2) 
MV  
(cm3/mol) 
nRot HBD HBA 
M
A
O
  
S
u
b
st
ra
te
s 
1 Sumatriptan 295 -1.65 74 238 5 2 5 
2 Almotriptan 335 0.22 65 264 6 1 5 
3 Rizatriptan 269 -0.89 50 223 5 1 5 
4 Zolmitriptan 287 -1.66 57 236 5 2 5 
  N 4 4 4 4 4 4 4 
 
 
Mean 
(95% CI) 
297 
(252, 341) 
-1.00 
(-2.41, 0.42) 
62 
(45, 78) 
240 
(213, 268) 
5 
(4, 6) 
1.5 
(0.6, 2.4) 
5 
  Maximum 335 0.22 74 264 6 2 5 
  Minimum 269 -1.66 50 223 5 1 5 
  -fold range 1.2 1.9 1.5 1.2 1.2 2 1 
 
Table 6.3 - Molecular/PC Property Space of TRP - Non-MAO Substrates 
  Drug MW (Da) 
LogD   
at pH 7.4 
PSA (A2) 
MV  
(cm3/mol) 
nRot HBD HBA 
N
o
n
-M
A
O
 
S
u
b
st
ra
te
s 1 Naratriptan 335 -0.76 74 273 4 2 5 
2 Frovatriptan 243 -2.05 71 192 2 4 4 
3 Eletriptan 383 0.03 62 310 6 1 4 
  N 3 3 3 3 3 3 3 
 
 
Mean 
(95% CI) 
320 
(144, 497) 
-0.93 
(-3.53, 1.68) 
69 
(53, 84) 
258 
(108, 408) 
4 
(-1, 9) 
2 
(-1, 6) 
4 
(3, 6) 
  Maximum 383 0.03 74 310 6 4 5 
  Minimum 243 -2.05 62 192 2 1 4 
  -fold range 1.6 2.1 1.2 1.6 3.0 4.0 1.3 
 94 
 
 
 
 
Table 6.4 - Descriptive Statistics of PC/Molecular Properties of TRP 
 
N Mean SD 95% CI Minimum 10% 25% Median 75% 90% Maximum 
MW (Da) 8 326 69 268, 384 243 243 274 315 371 459 459 
LogD7.4  8 -0.88 0.84 -1.6, -0.18 -2.1 -2.1 -1.7 -0.83 -0.053 0.22 0.22 
PSA (A2) 8 71 19 55, 86 50 50 58 68 74 112 112 
MV (cm3/mol) 8 261 51 218, 304 192 192 226 251 301 353 353 
nRot 8 5.1 1.7 3.7, 6.6 2.0 2.0 4.2 5.0 6.0 8.0 8.0 
HBA 8 5.3 1.6 3.9, 6.6 4.0 4.0 4.3 5.0 5.0 9.0 9.0 
HBD 8 1.9 0.99 1.0, 2.7 1.0 1.0 1.0 2.0 2.0 4.0 4.0 
 
 
 
Table 6.5 - Correlation Matrix for PC/Molecular Variables of TRP 
 
MW (Da) LogD7.4 PSA (A2) 
MV 
(cm3/mol) 
nRot HBD HBA 
MW (Da) 1.00       
LogD7.4  0.71 1.00      
PSA (A2) 0.72 0.16 1.00     
MV (cm3/mol) 0.99 0.73 0.66 1.00    
nRot 0.84 0.70 0.47 0.84 1.00   
HBA -0.36 -0.74 0.27 -0.43 -0.66 1.00  
HBD 0.73 0.28 0.84 0.68 0.72 -0.07 1.00 
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6.2.2. Humans Systemic PK/PD Property Space of TRP  
The final mean in-vitro and in-vivo human systemic PK and PD properties compiled from 
various studies in the literature are shown in Table - 6.6 and 6.12 respectively and the estimated 
biologically relevant PK properties are listed in Table 6.9. Appendix 3 contains all the 
supplemental information with respect to the in-vitro/in-vivo human systemic PK and ex-vivo/in-
vitro PD data compiled for each of the compound from the literature.  
Depending on the property, there is little to considerable diversity in the in-vitro/ in-vivo 
systemic and biologically relevant PK/PD properties of TRP in the current dataset, ranging from 
3- to 21-fold (n = 7-8). Therefore, the systemic PK variables (except fu, and PD variables) were 
log-transformed for further analysis. When classified based on MAO substrate status, it is 
observed that the diversity is reduced for the in-vitro/in-vivo systemic (shown in Tables 6.7 and 
6.8), biologically relevant PK (shown in Tables 6.10 and 6.11) and for the PD property space 
(shown in Tables 6.13 and 6.14). When TRP were categorized by MAO-substrate status, it is 
observed that property spaces shown by MAO-substrates is relatively more homogenous than the 
non-MOA substrates, however, overall, no meaningful differences are observed in these property 
spaces.  
The descriptive statistics for these PK/PD properties of all the TRP in the dataset 
(comprehensively) are shown in Table 6.15, and the mean values are comparable to the median 
values for the majority of them. Several correlations are observed between the in-vitro/in-vivo 
human systemic and biologically relevant PK variables of TRP (shown in Table 6.16). However, 
most of these correlations are mechanistically plausible, e.g., CLtot
 is highly correlated with 
CLnonren (r = 0.98, n = 8), and CLtot is also highly correlated with CLren
 (r = 0.80, n = 8) 
suggesting that a few TRP show significant renal and the rest have significant non-renal 
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clearance pathways. Furthermore, fu is highly negatively correlated with Vdss
u (r = -0.92, n = 7) 
and CLtot
u (r = -0.82, n = 7), possibly because of a common underlying factor (e.g., logD7.4 
and/or MW) causing, counteracting effects on PPB and distribution/non-renal clearance of the 
unbound drug.  
Overall, PPB varies 6-fold (n = 7), and the majority of TRP in the dataset are not extensively 
bound to plasma proteins, possibly because of their low lipophilicity and/or ionization. Most of 
the TRP show a low degree of PPB (median fu = 75%, n = 7) with the exception of eletriptan (fu 
= 15%). Furthermore, MAO substrates are fairly homogeneous in their fu values (1.3-fold, n = 4), 
while the non-MAO substrates are quite heterogeneous (5.7-fold, n = 3). Vdss
u varies 8-fold (n = 
7) compared to Vdss (6-fold, n = 7); after correcting for PPB, the mean value of Vdss
u (5.7 l/kg) is 
higher than the mean Vdss (2.3 l/kg). Therefore, it seems that the high Vdss
u values are offset by 
high PPB (i.e., low fu), which resulted in lower Vdss values, suggesting that the extravascular 
tissue distribution is restricted by PPB. The majority of TRP have Vdss
u values greater than BW 
(70 kg), suggesting they undergo moderate extravascular distribution into tissues and/or binding 
to plasma membranes etc. (with the exception of eletriptan, which has Vdss
u value of 15.7 l/kg 
suggesting that it undergoes extensive extravascular distribution). This is true for both MAO and 
non-MAO substrates; however, the range of Vdss
u for the former (2-fold, n  = 4) is relatively 
more homogeneous than for the latter (4-fold, n = 3).  
Most of the TRP show clearance by renal pathways (with fe ranging from 9% to 44%, n = 7); 
again, the range in CLren for MAO substrates is relatively more homogeneous (2-fold, n = 4) than 
for non-MAO substrates (5-fold, n = 3). CLren
u estimates for all the TRP (except frovatriptan) 
exceed GFR (1.7 ml/min/kg), suggesting they undergo net tubular secretion, potentially 
involving drug transporters (as they are all positively charged at physiological pH of 6.3 in urine 
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and 7.4 in the plasma). Naratriptan shows a CLren
u value (9 ml/min/kg) close to RPF (10 
ml/min/kg). Although the mean estimates for CLren
u between MAO and non-MAO substrate 
classes are comparable, the range for former is more homogeneous (2-fold, n = 4) than for the 
latter (6-fold, n = 3).  
Overall, CLnonren varies 21-fold (n = 8). The CLtot and CLnonren values of MAO substrates are, in 
general, (a) on an average are higher, and (b) more heterogeneous than non-MAO substrates. 
However, after correcting for PPB, on an average, the CLtot
u and CLnonren
u values for non-MAO 
substrates are higher and more heterogeneous than MAO-substrates. This suggests that the PPB 
offset the high values of CLtot
u and CLnonren
u for non-MAO substrates. The pathways that 
encompass CLnonren are known to include hepatic metabolism via enzymes e.g., CYP3A, 1A2 
(and 2D6) and is also mediated by MAO, which is present both hepatically and extrahepatically 
(see Appendix 3). CLnonren values (assuming a B:P ratio close to 1) for non-MAO substrates are 
lower than LBF (21 ml/min/kg), suggesting they are all low ERhep drugs either because of low 
hepatic CLint (e.g., frovatriptan) and/or (relatively) high PPB (e.g., eletriptan). Furthermore, 
owing to their positively charged nature, they may also be subject to hepato-biliary excretion, 
potentially involving transporters.  
Based on the available in-vivo drug - drug interaction studies (i.e., in the presence of 
moclobemide, a MAO inhibitor), oral bioavailability studies and mass balance studies, the rank 
order for the contribution of MAO-mediated metabolic clearance towards the CLnonren for MAO 
substrates is rizatriptan > almotriptan > zolmitriptan (see Appendix 3).  
There is considerable diversity (7- to 11-fold, n = 7) in the in-vitro/ex-vivo PD properties, 
namely, receptor binding affinities at 5-HT1B/1D relative to [
3H] eletriptan and [3H] sumatriptan. 
When they are classified based on MAO-substrate status, (a) in general, on an average, MAO-
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substrates show high Ki (low affinity) values compared to non-MAO substrates, which show low 
Ki (high affinity) values, and (b) MAO-substrates, in general, show relatively larger diversity 
than non-MAO substrates. 
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Table 6.6 - In-vitro and In-vivo Human PK Systemic Properties of TRP 
 
 
In-vitro 
PK 
Variable 
In-vivo PK Variables 
 
Drug 
fu 
[%] 
Vdss 
[l/kg] 
CLtot 
[ml/min/kg] 
fe  
[%] 
CLren 
[ml/min/kg] 
CLnonren 
[ml/min/kg] 
M
A
O
 
S
u
b
st
ra
te
s 
Sumatriptan 84% 2.6 16 23% 3.7 12 
Almotriptan 65% 2.3 9.0 42% 3.8 5.2 
Rizatriptan 86% 1.7 15 25% 3.7 11 
Zolmitriptan 75% 2.1 11 28% 3.0 7.5 
N
o
n
-M
A
O
 
S
u
b
st
ra
te
s Naratriptan 28% 2.4 6.6 36% 2.4 4.2 
Frovatriptan 85% 3.6 2.8 44% 1.3 1.5 
Eletriptan 15% 2.4 6.3 9.0% 0.57 5.7 
 Avitriptan - 1.1 7.4 - - - 
 N 7 8 8 7 7 7 
 Mean 63% 2.3 9.2 30% 2.6 6.9 
 Maximum 86% 3.6 16 44% 3.8 12 
 Minimum 15% 1.1 2.8 9.0% 0.57 1.5 
 -fold range 6 3 6 5 7 8 
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Table 6.7 - In-vitro and In-vivo Human PK Systemic Properties of TRP - MAO Substrates 
 
 
In-vitro PK 
Variable 
In-vivo PK Variables 
 
Drug 
fu 
[%] 
Vdss 
[l/kg] 
CLtot 
[ml/min/kg] 
fe  
[%] 
CLren 
[ml/min/kg] 
CLnonren 
[ml/min/kg] 
M
A
O
 
S
u
b
st
ra
te
s 
Sumatriptan 84% 2.6 16.1 23% 3.7 12.4 
Almotriptan 65% 2.3 9.0 42% 3.8 5.2 
Rizatriptan 86% 1.7 15.2 25% 3.7 11.4 
Zolmitriptan 75% 2.1 10.5 28% 3.0 7.5 
 N 4 4 4 4 4 4 
 Mean 
(95% CI) 
77% 
(62%, 93%) 
2.1 
(1.6, 2.8) 
12.7 
(7.2, 18.2) 
30% 
(16%, 43%) 
3.6 
(3.0, 4.1) 
9.2 
(3.8, 14.5) 
 Maximum 86% 2.6 16.1 42% 3.8 12.4 
 Minimum 65% 1.7 9.0 23% 3.0 5.2 
 -fold range 1.3 1.5 1.8 1.8 1.3 2.4 
 
 
Table 6.8 - In-vitro and In-vivo Human PK Systemic Properties of TRP - Non-MAO Substrates 
 
 
In-vitro PK 
Variable 
In-vivo PK Variables 
 
Drug 
fu 
[%] 
Vdss 
[l/kg] 
CLtot 
[ml/min/kg] 
fe  
[%] 
CLren 
[ml/min/kg] 
CLnonren 
[ml/min/kg] 
N
o
n
-M
A
O
 
S
u
b
st
ra
te
s Naratriptan 28% 2.4 6.6 36% 2.4 4.2 
Frovatriptan 85% 3.6 2.8 44% 1.3 1.5 
Eletriptan 15% 2.4 6.3 9.0% 0.57 5.7 
 N 3 3 3 3 3 3 
 Mean 
(95% CI) 
43% 
(-50%, 135%) 
2.8 
(1.0, 4.5) 
5.2 
(-0.01, 10.5) 
30% 
(-15%, 75%) 
1.4 
(-0.9, 3.7) 
3.9 
(-1.3, 9.0) 
 Maximum 85% 3.6 6.6 44% 2.4 5.7 
 Minimum 15% 2.4 2.8 9.0% 0.57 1.6 
 -fold range 5.7 1.5 2.4 4.9 3.0 3.6 
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Table 6.9 - Biologically Relevant In-vivo Human PK Properties of TRP 
 
Drug 
Vdssu 
[l/kg] 
CLtotu 
[ml/min/kg] 
CLrenu 
[ml/min/kg] 
CLnonrenu 
[ml/min/kg] 
M
A
O
 
S
u
b
st
ra
te
s 
Sumatriptan 3.1 19.2 4.4 14.8 
Almotriptan 3.5 13.8 5.8 8.0 
Rizatriptan 2.0 17.6 4.3 13.3 
Zolmitriptan 2.8 14.0 4.0 10.0 
N
o
n
-M
A
O
 
S
u
b
st
ra
te
s Naratriptan 8.6 23.6 8.6 15.0 
Frovatriptan 4.2 3.2 1.4 1.8 
Eletriptan 15.7 42.0 3.8 38.2 
 N 7 7 7 7 
 Mean 5.7 19.2 4.6 14.4 
 Maximum 15.7 42.0 8.6 38.2 
 Minimum 2.0 3.2 1.4 1.8 
 -fold range 8 13 6 21 
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Table 6.10 - Biologically Relevant In-vivo Human PK Properties of TRP - MAO Substrates 
 
Drug 
Vdssu 
[l/kg] 
CLtotu 
[ml/min/kg] 
CLrenu 
[ml/min/kg] 
CLnonrenu 
[ml/min/kg] 
M
A
O
 
S
u
b
st
ra
te
s 
Sumatriptan 3.1 19.2 4.4 14.8 
Almotriptan 3.5 13.8 5.8 8.0 
Rizatriptan 2.0 17.6 4.3 13.3 
Zolmitriptan 2.8 14.0 4.0 10.0 
 N 4 4 4 4 
 Mean 
(95% CI) 
2.9 
(1.8, 3.9) 
16.2 
(11.9, 20.4) 
4.6 
(3.3, 5.9) 
11.5 
(6.6, 16.5) 
 Maximum 3.5 19.2 5.8 14.8 
 Minimum 2.0 13.8 4.0 8.0 
 -fold range 1.8 1.4 1.5 1.9 
 
 
 
Table 6.11 - Biologically Relevant In-vivo Human PK Properties of TRP - Non-MAO Substrates 
 
Drug 
Vdssu 
[l/kg] 
CLtotu 
[ml/min/kg] 
CLrenu 
[ml/min/kg] 
CLnonrenu 
[ml/min/kg] 
N
o
n
-M
A
O
 
S
u
b
st
ra
te
s Naratriptan 8.6 23.6 8.6 15.0 
Frovatriptan 4.2 3.2 1.4 1.8 
Eletriptan 15.7 42.0 3.8 38.2 
 N 3 3 3 3 
 Mean 
(95% CI) 
9.5 
(-4.8, 23.8) 
23.0 
(-25.1, 71.0) 
4.7 
(-4.3, 13.7) 
18.3 
(-27.1, 63.7) 
 Maximum 15.7 42.0 8.6 38.2 
 Minimum 4.2 3.2 1.4 1.8 
 -fold range 3.7 13.2 6.2 21.2 
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Table 6.12 - In-vitro/Ex-vivo Relative Receptor Binding Affinities of TRP at 5-HT1B/1D 
 
Drug 
5-HT1B 5-HT1D 
[3H]  
Eletriptan 
[3H]  
Sumatriptan 
[3H] 
Eletriptan 
[3H] 
Sumatriptan 
M
A
O
 
S
u
b
st
ra
te
s 
Sumatriptan 22.4 8.7 10.0 10.2 
Almotriptan 10.0 10.0 10.0 10.0 
Rizatriptan 27.5 13.8 18.6 11.5 
Zolmitriptan 7.1 2.8 2.1 1.2 
N
o
n
-M
A
O
 
S
u
b
st
ra
te
s Naratriptan 4.3 1.9 5.1 4.6 
Frovatriptan 2.5 2.5 4.0 4.0 
Eletriptan 4.5 3.2 1.6 1.7 
 N 7 7 7 7 
 Mean 11.2 6.1 7.4 6.2 
 Maximum 27.5 13.8 18.6 11.5 
 Minimum 2.5 1.9 1.6 1.2 
 -fold range 11 7 11 9 
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Table 6.13 - In-vitro/Ex-vivo RRA of TRP - MAO Substrates 
 
Drug 
5-HT1B 5-HT1D 
[3H]  
Eletriptan 
[3H]  
Sumatriptan 
[3H] 
Eletriptan 
[3H] 
Sumatriptan 
M
A
O
 
S
u
b
st
ra
te
s 
Sumatriptan 22.4 8.7 10.0 10.2 
Almotriptan 10.0 10.0 10.0 10.0 
Rizatriptan 27.5 13.8 18.6 11.5 
Zolmitriptan 7.1 2.8 2.1 1.2 
 N 4 4 4 4 
 Mean 
(95% CI) 
16.7 
(1.2, 32.3) 
8.8 
(1.6, 16.1) 
10.2 
(-0.52, 20.9) 
8.2 
(0.70, 15.8) 
 Maximum 22.4 13.8 18.6 11.5 
 Minimum 7.1 2.8 2.1 1.2 
 -fold range 3 5 9 9 
 
 
 
 
Table 6.14 - In-vitro/Ex-vivo RRA of TRP - Non-MAO Substrates 
 
Drug 
5-HT1B 5-HT1D 
[3H]  
Eletriptan 
[3H]  
Sumatriptan 
[3H] 
Eletriptan 
[3H] 
Sumatriptan 
N
o
n
-M
A
O
 
S
u
b
st
ra
te
s Naratriptan 4.3 1.9 5.1 4.6 
Frovatriptan 2.5 2.5 4.0 4.0 
Eletriptan 4.5 3.2 1.6 1.7 
 N 3 3 3 3 
 Mean 
(95% CI) 
3.8 
(1.1, 6.4) 
2.5 
(0.82, 4.3) 
7.5 
(-0.87, 8.0) 
5.8 
(-0.37, 7.2) 
 Maximum 4.5 3.2 5.1 4.6 
 Minimum 2.5 1.9 1.6 1.7 
 -fold range 2 2 3 3 
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Table 6.15 - Descriptive Statistics of Human Systemic PK/PD Variables of TRP 
 N Mean SD 95% CI Minimum 10% 25% Median 75% 90% Maximum 
Vdss (L/kg) 8 2.3 0.71 1.7, 2.9 1.1 1.1 1.8 2.3 2.6 3.6 3.6 
CLtot (ml/min/kg) 8 9.2 4.5 5.4, 13.0 2.8 2.8 6.4 8.2 14.0 16.1 16.1 
CLren (ml/min/kg) 7 2.6 1.3 1.4, 3.8 0.60 0.60 1.2 3.0 3.7 3.8 3.8 
CLnonren (ml/min/kg) 7 6.9 3.9 3.2, 10.5 1.6 1.6 4.2 5.7 11.5 12.4 12.4 
fu  7 0.63 0.29 0.36, 0.90 0.15 0.15 0.28 0.75 0.85 0.86 0.86 
Vdss
u (L/kg) 7 5.7 4.9 1.2, 10.2 2.0 2.0 2.8 3.5 8.6 15.7 15.7 
CLtot
u (ml/min/kg) 7 19.1 11.90 8.1, 30.1 3.3 3.3 13.9 17.7 23.6 42.0 42.0 
CLren
u (ml/min/kg) 7 4.7 2.17 2.6, 6.7 1.4 1.4 4.0 4.3 5.8 8.6 8.6 
CLnonren
u (ml/min/kg) 7 14.4 11.4 3.9, 24.9 1.9 1.9 8.0 13.4 15.0 38.0 38.0 
5-HT1B - RRA [
3H] Eletriptan 7 11.2 9.8 2.1, 20.3 2.5 2.5 4.3 7.1 22.4 27.5 27.5 
5-HT1B - RRA [
3H] Sumatriptan 7 6.1 4.7 1.8, 10.5 1.9 1.9 2.5 3.2 10.0 13.8 13.8 
5-HT1D - RRA [
3H] Eletriptan 7 7.4 6.0 1.8, 12.9 1.6 1.6 2.1 5.1 10.0 18.6 18.6 
5-HT1D - RRA [
3H] Sumatriptan 8 6.7 4.2 3.1, 10.2 1.2 1.2 2.3 7.3 10.2 11.5 11.5 
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Table 6.16 - Correlation Analysis of Human Systemic PK Variables of TRP 
 Vdss 
(L/kg) 
CLtot 
(ml/min/kg) 
CLren 
(ml/min/kg) 
CLnonren 
(ml/min/kg) 
fu 
Vdssu 
(L/kg) 
CLtotu 
(ml/min/kg) 
CLrenu 
(ml/min/kg) 
CLnonrenu 
(ml/min/kg) 
Vdss (L/kg) 1.00         
CLtot (ml/min/kg) -0.37 1.00        
CLren (ml/min/kg) -0.52 0.79 1.00       
CLnonren (ml/min/kg) -0.62 0.98 0.65 1.00      
fu  0.13 0.46 0.56 0.38 1.00     
Vdss
u (L/kg) 0.05 -0.50 -0.77 -0.36 -0.92 1.00    
CLtot
u (ml/min/kg) -0.41 0.03 -0.37 0.16 -0.82 0.85 1.00   
CLren
u (ml/min/kg) -0.47 0.12 0.33 0.04 -0.51 0.17 0.33 1.00  
CLnonren
u (ml/min/kg) -0.34 0.01 -0.45 0.16 -0.76 0.85 0.98 0.15 1.00 
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6.2.3. QSPKR Analysis, Model Building and Evaluation 
The results of the univariate regression of the in-vitro/(log-transformed) in-vivo biologically 
relevant and reported PK/PD variables as a function of the molecular/PC variables of TRP, 
namely, MW, logD7.4, HBD and HBA are shown in Table 6.17 to 6.24. MW shows significant 
univariate relationships (r2 ≥ 0.3, p < 0.05) with fu, log (Vdssu), log (CLtotu) and log (CLnonrenu), 
HBD with log (CLtot
u) and log (CLnonren
u), and HBA with log (Vdss) and log (CLren). 
Lipophilicity (logD7.4) did not show significant relationship (p < 0.05), although it explains ~ 
35% of variability in the in-vitro/in-vivo systemic and/or biologically relevant PK variables. 
Similarly, HBA and HBD explain more than 30% of the variability in certain in-vivo and/or 
biologically relevant, but none of these relationships were significant. None of the PC/molecular 
variables show significant relationship with the PD variables of TRP; however, MAO substrates 
alone show significant relationships with HBA, potentially due to large range and/or limited 
sample size. During the final (multivariate) model building process (using MLLR with forward 
inclusion followed by backward elimination), MW was found to be the single most important 
determinant affecting biologically relevant systemic PK variable of TRP, and the final models 
are summarized in Table - 6.25. Overall, the final QSPKR models developed for TRP gave 
acceptable predictions (q2 ≥ 0.40) only for fu only.   
6.2.3.1.   Effect of MW on Systemic and Biologically Relevant PK Variables of TRP 
There is a significant negative association between MW and fu, i.e., an increase in MW is 
associated with decrease in fu (increase in PPB) for TRP (Slope = -0.0055, r
2 = 0.78, n = 7, 
shown in Figure - 6.1). A significant positive association is found with (each of log-transformed) 
Vdss
u (Slope = 0.0050, r2 = 0.58, n = 7), CLtot
u (Slope = 0.0057, r2 = 0.65, n = 7), CLnonren
u (Slope 
= 0.0064, r2 = 0.58, n = 7) and MW of TRP (Figures - 6.2, 6.3 and 6.4 respectively). Due to the 
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offsetting effects of MW on fu and Vdss
u, fu and CLtot
u, and fu and CLnonren
u, their uncorrected 
counterparts, Vdss, CLtot and CLnonren, respectively, did not depend on MW. Lastly, MW did not 
show a significant relationship with log-transformed CLren
u, probably because of the limited 
range in the MW and/or CLren
u estimates of triptans in the current dataset. Therefore, it seems 
that the (significant) relationship of MW on CLnonren
u drive that of CLtot
u. When the TRP are 
classified based on their MAO substrate status: (a) none of the relationships with MW are 
significant (except for the MW relationship with log CLnonren
u), potentially because of reduction 
in the sample size and/or -fold range in the property space (e.g., Vdss
u); (b) a significant positive 
association between log (CLnonren
u) and MW for non-MAO substrates (Slope = 0.009, r2 = 0.99, n 
= 3) is observed and this seems to drive the overall TRP (comprehensive) relationship with MW 
(as their slopes are comparable) and (c) in general, the model fits with respect to MW (i.e., r2) are 
comparatively better for both systemic and biologically relevant PK variables for the non-MAO 
substrates than MAO substrates and this is mechanistically plausible because the former is 
relatively more heterogeneous than the latter both in their molecular/PC as well as their PK 
property space.  
6.2.3.2. Effect of Other PC/Molecular Variables on Systemic/Biologically Relevant PK 
Variables of TRP 
 
None of systemic/biologically relevant PK/PD variables show significant relationship (r2 ≥ 0.3, p 
< 0.05) with logD7.4, (for all TRP) or by MAO-substrate status. There is a significant negative 
association between HBD and log (CLtot
u) (Slope = -0.26, r2 = 0.68, n = 4), and also with log 
(CLnonren
u) (Slope = -0.30, r2 = 0.64, n = 7) comprehensively, and when classified there is a 
significant negative association with log (CLnonren
u) (Slope = -0.44, r2 = 0.99, n = 3) for non-
MAO substrates. Frovatriptan (a non-MAO substrate) has the highest HBD (n = 4, while the rest 
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of TRP in the dataset have either n = 1 or 2) and it shows the lowest CLtot
u and CLnonren
u values 
and it seems to drive these relationships. There is a significant negative association between 
HBA and log (Vdss) (Slope = -0.08, r
2 = 0.73, n = 8) and significant positive association with log 
(CLren) (Slope = 0.59, r
2 = 0.87, n = 7) comprehensively. Although there are several relationships 
in which logD7.4, HBD and HBA explained ≥ 30% variability in PK variables both 
comprehensively for all TRP and also when categorized based on MAO substrate status, none of 
the slopes for these relationships are different from zero. However, it is observed that, in general, 
the model fits (i.e., r2) relative to these PC variables (as seen with MW) are comparatively better 
for both systemic and biologically relevant PK variables for the non-MAO substrates than MAO 
substrates and this is mechanistically plausible because the former is relatively more 
heterogeneous than the latter both in molecular/PC as well as PK property space. 
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Table 6.17 - Log-Linear Regression Between MW and Biologically Relevant/Systemic PK Variables of TRP  
 
fu 
 
Log  
(Vdssu) 
[l/kg] 
Log  
(CLtotu) 
[ml/min/kg] 
Log  
(CLrenu) 
[ml/min/kg] 
Log 
(CLnonrenu) 
[ml/min/kg] 
Log  
(Vdss) 
[l/kg] 
Log  
(CLtot) 
[ml/min/kg] 
Log  
(CLren) 
[ml/min/kg] 
Log  
(CLnonren) 
[ml/min/kg] 
All TRP 
n = 7 
r2 = 0.78 
Slope =  
-0.0055 
-0.0088,  
-0.0022 
n = 7 
r2 = 0.58 
Slope = 
0.0050 
0.00015, 
0.0010 
n = 7 
r2 = 0.65 
Slope = 
0.0057 
0.00085, 
0.011 
n = 7 
r2 = 0.37 
Slope = 
0.0031 
N.S. 
n = 7 
r2 = 0.58 
Slope = 
0.0064 
0.00021, 
0.013 
n = 8 
r2 = 0.48 
Slope =-
0.0015 
N.S. 
N.S. N.S. N.S. 
MAO 
Substrates 
n = 4 
r2 = 0.76 
Slope = 
-0.0030 
N.S. 
n = 4 
r2 = 0.77 
Slope 
=0.0034 
N.S. 
N.S. 
n = 4 
r2 = 0.80 
Slope 
=0.0023 
N.S. 
n = 4 
r2 = 0.54 
Slope = 
-0.0032 
N.S. 
n = 4 
r2 = 0.35 
Slope 
=0.0017 
N.S. 
n = 4 
r2 = 0.50 
Slope =-
0.0031 
N.S. 
N.S. 
n = 4 
r2 = 0.62 
Slope = 
-0.0049 
N.S. 
Non-MAO 
Substrates 
n = 3 
r2 = 0.97 
Slope = 
-0.0051 
N.S. 
n = 3 
r2 = 0.98 
Slope 
=0.0039 
N.S. 
n = 3 
r2 = 0.98 
 Slope 
=0.0080 
N.S. 
n = 3 
r2 = 0.51 
 Slope 
=0.0039 
N.S. 
n = 4 
r2 = 0.99 
Slope = 
0.0094 
0.0049, 0.014 
n = 3 
r2 = 0.91 
Slope = 
-0.0014 
N.S 
n = 3 
r2 = 0.85 
 Slope 
=0.0027 
N.S 
N.S. 
n = 3 
r2 = 0.99 
 Slope 
=0.0040 
N.S. 
 
In red: r2 ≥ 0.30 and p<0.05; 
In italic and red: r2 ≥ 0.30 but p>0.05 or r2 < 0.30 but p<0.05; 
N.S = Not Significant (r2 < 0.30 and p>0.05); 
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Table 6.18 - Log-Linear Regression Between LogD7.4 and Biologically Relevant/Systemic PK Variables of TRP 
 
fu 
 
Log  
(Vdssu) 
[l/kg] 
Log  
(CLtotu) 
[ml/min/kg] 
Log  
(CLrenu) 
[ml/min/kg] 
Log 
(CLnonrenu) 
[ml/min/kg] 
Log  
(Vdss) 
[l/kg] 
Log  
(CLtot) 
[ml/min/kg] 
Log  
(CLren) 
[ml/min/kg] 
Log  
(CLnonren) 
[ml/min/kg] 
All TRP 
n = 7 
r2 = 0.41 
Slope = -0.23 
N.S 
N.S 
n = 7 
r2 = 0.39 
Slope = 0.24 
N.S 
n = 7 
r2 = 0.34 
Slope = 0.16 
N.S 
n = 7 
r2 = 0.32 
Slope = 0.26 
N.S 
N.S N.S N.S N.S 
Only  
MAO 
Substrates 
n = 4 
r2 = 0.44 
Slope = -
0.072 
N.S 
N.S. N.S. 
n = 4 
r2 = 0.84 
Slope = 
0.075 
N.S 
n = 4 
r2 = 0.45 
Slope =-
0.091 
N.S 
N.S. 
n = 4 
r2 = 0.32 
Slope =-
0.079 
N.S 
n = 4 
r2 = 0.35 
Slope =0.032 
N.S 
n = 4 
r2 = 0.46 
Slope =-0.13 
N.S 
Only 
Non-MAO 
Substrates 
n = 3 
r2 = 0.96 
Slope =-0.35 
N.S 
n = 3 
r2 = 0.99 
Slope =0.27 
N.S 
n = 3 
r2 = 0.97 
Slope =0.54 
N.S 
n = 3 
r2 = 0.47 
Slope =0.26 
N.S 
n = 3 
r2 = 0.99 
Slope =0.63 
N.S 
n = 3 
r2 = 0.89 
Slope =-
0.094 
N.S 
n = 3 
r2 = 0.82 
Slope =0.18 
N.S 
N.S. 
n = 3 
r2 = 0.98 
Slope =0.27 
N.S 
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Table 6.19 - Log-Linear Regression Between HBD and Biologically Relevant/Systemic PK Variables of TRP 
 
fu 
 
Log  
(Vdssu) 
[l/kg] 
Log  
(CLtotu) 
[ml/min/kg] 
Log  
(CLrenu) 
[ml/min/kg] 
Log 
(CLnonrenu) 
[ml/min/kg] 
Log  
(Vdss) 
[l/kg] 
Log  
(CLtot) 
[ml/min/kg] 
Log  
(CLren) 
[ml/min/kg] 
Log  
(CLnonren) 
[ml/min/kg] 
All TRP N.S N.S 
n = 7 
r2 = 0.68 
Slope = -0.26 
-0.47, -0.053 
n = 7 
r2 = 0.50 
Slope =-0.16 
N.S 
n = 7 
r2 = 0.64 
Slope = -0.30 
-0.55, -0.039 
N.S 
n = 7 
r2 = 0.45 
Slope =-0.16 
N.S 
N.S 
n = 7 
r2 = 0.50 
Slope =-0.20 
N.S 
Only  
MAO 
Substrates 
N.S. N.S. N.S. 
n = 4 
r2 = 0.38 
Slope =-0.077 
N.S 
N.S. 
n = 4 
r2 = 0.32 
Slope =0.077 
N.S. 
N.S. 
n = 4 
r2 = 0.38 
Slope =-0.051 
N.S. 
N.S. 
Only 
Non-MAO 
Substrates 
n = 3 
r2 = 0.98 
Slope =0.24 
N.S 
n = 3 
r2 = 0.98 
Slope =-0.18 
N.S 
n = 3 
r2 = 0.99 
Slope =-0.38 
N.S 
n = 3 
r2 = 0.52 
Slope =-0.185 
N.S 
n = 3 
r2 = 0.99 
Slope = -0.44 
-0.59, -0.29 
n = 3 
r2 = 0.92 
Slope =0.065 
N.S 
n = 3 
r2 = 0.86 
Slope =-0.13 
N.S 
N.S. 
n = 3 
r2 = 0.99 
Slope =-0.19 
N.S 
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Table 6.20 - Log-Linear Regression Between HBA and Biologically Relevant/Systemic PK Variables of TRP 
 
fu 
 
Log  
(Vdssu) 
[l/kg] 
Log  
(CLtotu) 
[ml/min/kg] 
Log  
(CLrenu) 
[ml/min/kg] 
Log 
(CLnonrenu) 
[ml/min/kg] 
Log  
(Vdss) 
[l/kg] 
Log  
(CLtot) 
[ml/min/kg] 
Log  
(CLren) 
[ml/min/kg] 
Log  
(CLnonren) 
[ml/min/kg] 
All TRP N.S. 
n = 7 
r2 = 0.33 
Slope = -0.37 
N.S 
N.S 
n = 7 
r2 = 0.48 
Slope = 0.34 
N.S 
N.S 
n = 8 
r2 = 0.73 
Slope = -0.079 
-0.13, -0.031 
N.S 
n = 7 
r2 = 0.87 
Slope = 0.59 
0.32, 0.85 
n = 7 
r2 = 0.41 
Slope = 0.39 
N.S 
Only  
MAO 
Substrates 
N.S. N.S N.S N.S N.S N.S N.S N.S N.S 
Only 
Non-MAO 
Substrates 
N.S. N.S N.S 
n = 3 
r2 = 0.67 
Slope = 0.56 
N.S 
N.S N.S N.S 
n = 3 
r2 = 0.75 
Slope = 0.45 
N.S 
N.S. 
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Table 6.21 - Linear Regression Between MW and PD Variables of TRP  
 
 [3H]  
Eletriptan 
[3H]  
Sumatriptan 
[3H]  
Eletriptan 
[3H]  
Sumatriptan 
All TRP N.S. N.S. N.S. N.S. 
Only  
MAO 
Substrates 
N.S. 
n = 4 
r2 = 0.72 
Slope = 0.13 
N.S. 
n = 4 
r2 = 0.52 
Slope = 0.082 
N.S. 
n = 4 
r2 = 0.53 
Slope = 0.088 
N.S. 
Only 
Non-MAO 
Substrates 
N.S. N.S. N.S. N.S. 
 
 
 
 
Table 6.22 - Linear Regression Between LogD7.4 and PD Variables of TRP 
 
 [3H]  
Eletriptan 
[3H]  
Sumatriptan 
[3H]  
Eletriptan 
[3H]  
Sumatriptan 
All TRP N.S. N.S. N.S. N.S. 
Only  
MAO 
Substrates 
N.S. N.S. N.S. N.S. 
Only 
Non-MAO 
Substrates 
N.S. N.S. N.S. N.S. 
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Table 6.23 - Linear Regression Between HBD and PD Variables of TRP  
 
 [3H]  
Eletriptan 
[3H]  
Sumatriptan 
[3H]  
Eletriptan 
[3H]  
Sumatriptan 
All TRP N.S. N.S. N.S. N.S. 
Only  
MAO 
Substrates 
N.S. N.S. N.S. N.S. 
Only 
Non-MAO 
Substrates 
N.S. N.S. N.S. N.S. 
 
 
 
Table 6.24 - Linear Regression Between HBA and PD Variables of TRP 
 
 [3H]  
Eletriptan 
[3H]  
Sumatriptan 
[3H]  
Eletriptan 
[3H]  
Sumatriptan 
All TRP N.S. N.S. 
n = 7 
r2 = 0.39 
Slope = 7.7 
N.S. 
N.S. 
Only  
MAO 
Substrates 
N.S. N.S. N.S. N.S. 
Only 
Non-MAO 
Substrates 
n = 3 
r2 = 0.99 
Slope = 21.8 
N.S. 
n = 3 
r2 = 0.99 
Slope = 10.7 
6.8, 14.7 
n = 3 
r2 = 0.99 
Slope = 16.7 
11.0, 22.5 
n = 3 
r2 = 0.99 
Slope = 10.1 
4.6, 15.6 
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Table 6.25 - Final QSPKR Models for TRP 
Final QSPKR Model N Slope (95% CI) r2 q2 
fu = 2.3 - 0.0054 * MW 7 -0.0054 (-0.0088, -0.0022) 0.78 0.59 
Log (Vdss
u) =  - 0.89 + 0.0050 * MW 7 0.0050 (0.00015, 0.0010) 0.58 -0.11 
Log (CLtot
u) =  - 0.58 + 0.0058 * MW 7 0.0058 (0.00085, 0.010) 0.65 0.18 
Log (CLnonren
u) =  - 0.93 + 0.0064 * MW 7 0.0064 (0.00021, 0.013) 0.58 0.11 
                               q2 ≥ 0.40: Acceptable 
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                                   Figure 6.3 - fu vs. MW for TRP        Figure 6.4 - Vdssu vs. MW for TRP 
                                                    
 
            Figure 6.5 - CLtotu vs. MW for TRP                       Figure 6.6 - CLnonrenu vs. MW for TRP 
                                                  
(Please refer Table 6.1 in Page 91, for the list of the individual compounds labeled in the figures 6.3 - 6.6) 
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     Figure 6.7 -  CLtotu vs. HBD for TRP        Figure 6.8 - CLtotu vs. HBD for TRP 
                                                      
(Please refer Table 6.1 in Page 91, for the list of the individual compounds labeled in the figures 6.7 and 6.8) 
          Figure 6.9- CLnonrenu vs. MW for TRP - MAO Substrates           Figure 6.10 -  CLnonrenu vs. HBD for TRP - MAO Substrates 
                                                      
(Please refer Table 6.2 in Page 92, for the list of the individual compounds labeled in the figures 6.9 and 6.10) 
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6.3. Discussion 
Structurally, TRP in the dataset show 5-hydroxy-tryptamine scaffold and exhibit low diversity 
(2- to 4- fold, n = 8) in their PC/molecular property space. They are relatively low MW (ranging 
from 243 to 459 Da, n = 8) hydrophilic bases, i.e., logD7.4 < 1.0 (ranging from 0.22 to -2.08, n = 
8) and are (single) positively charged (~99% ionized for all TRP except avitriptan, which is 60% 
ionized). When they are classified based on MAO substrate status, although their respective 
PC/molecular property spaces overlap, MAO-substrates seem to be relatively more homogenous 
than the non-MOA substrates.  
Most of the TRP in the dataset are not extensively PPB, and Vdss
u estimates suggest moderate 
extravascular distribution into tissues and/or binding to plasma membranes etc. High Vdss
u 
values are offset by high PPB resulting in lower Vdss values, suggesting that their distribution is 
restricted by PPB. CLren
u values for the available TRP in the dataset (except frovatriptan) suggest 
net tubular secretion, potentially involving drug transporters. Known pathways that encompass 
CLnonren include hepatobiliary excretion and metabolism via enzymes e.g., CYP3A, 1A2 (and 
2D6) and by MAO, which is present both hepatically and extra-hepatically. When they are 
classified based on MAO substrate status, although their respective PK/PD property spaces 
overlap, TRP that are MAO-substrates seem to be relatively more homogenous than the non-
MOA substrates (except for CLnonren). Based on the available in-vivo drug - drug interaction 
studies (i.e., in the presence of moclobemide, a MAO inhibitor), oral bioavailability studies and 
mass balance studies, the rank order for the contribution of MAO-mediated metabolic clearance 
towards the CLnonren for MAO substrates is rizatriptan > almotriptan > zolmitriptan.  
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Overall, there is low to considerable diversity in the in-vitro/in-vivo systemic and biologically 
relevant PK/PD properties of TRP in the current dataset with available information, ranges from 
3- to 21-fold (n = 7-8). 
MW (which is highly correlated with logD7.4) is found to be the important determinant affecting 
biologically relevant systemic PK properties, namely fu, Vdss
u, CLtot
u and CLnonren
u. A significant 
negative association is observed between fu and MW for TRP in the current dataset.  A similar 
trend was observed between in-vitro PPB of diverse set of 2939 molecules in the GSK 
database22. Vdss
u of TRP in the current dataset show a significant positive association with MW. 
Similar positive trends were observed between Vdss
u and MV for cephalosporins87. Owing to the 
offsetting effects of MW on fu and Vdss
u, Vdss did not show any relationship with MW. CLtot
u and 
CLnonren
u show a significant association with MW for TRP (comprehensively), and the slopes are 
quite similar, suggesting that the latter non-renal clearance drives the relationship for the total 
clearance. Furthermore, the slope of CLnonren
u of non-MAO substrates with MW is comparable 
and seems to drive the comprehensive TRP CLnonren
u relationship.  
Cheng et al88 carried out in-vitro OATP1A2-mediated uptake studies using six TRP, four of 
which are MAO substrates and the other two are not. In order to assess if hepatic excretion of 
TRP is dependent on OATP1A2-mediated uptake, CLnonren
u values from the present work 
showed no (statistically significant, p < 0.05) relationship with the experimentally determined in-
vitro OATP1A2-mediated uptake rates. This suggests that OATP1A2 may not be the primary 
route for cellular uptake for TRP. 
So overall, MW (which is highly correlated with lipophilicity) is found to be the major 
determinant affecting the systemic disposition of (small MW, hydrophilic) TRP suggesting that 
they may be involved in more specific interactions with biological membranes, tissues, drug 
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metabolizing enzymes, both hepatic (e.g., CYP3A and extrahepatically (e.g., MAO), potentially 
involving drug transporters. Final QSPKR models gave acceptable predictions for fu.  
On the contrary, as evident from SAR studies, the receptor binding (PD) interactions encompass 
diverse interactions ranging from non-specific hydrogen bonding, ionic to more specific steric 
forces.  
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5 CHAPTER 7. QSPKR of Class III Anti-Arrhythmic Agents 
 
7.1. Background 
 
Cardiac arrhythmias result from abnormalities in the generation and/or conduction of impulses in 
the myocardium or pacemakers/conducting tissue and if untreated can prove to be fatal. AAR are 
classified broadly into four classes based on the mechanism of action89,90: 
1. Class I AAR act by blocking voltage-sensitive sodium (Na+) channels. They are further 
categorized depending on their effect on the cardiac action potential duration (APD) and the 
kinetics of Na+ channel blockade: 
A. Class IA AAR prolong the APD by slowing phase 0 depolarization and dissociate from 
the channels with intermediate kinetics. 
B. Class IB AAR shorten the APD by shortening phase 3 repolarization and dissociate from 
the channels with rapid kinetics. 
C. Class IC AAR slow the phase 0 depolarization markedly but have minimal effects on the 
APD and dissociate from the channels with slow kinetics. 
2. Class II AAR act by blocking β-adrenergic receptors and inhibiting the phase 4 
depolarization in the SA and AV nodes. 
3. Class III AAR act by blocking (delayed rectifier) potassium (K+) channels and prolonging 
phase 3 repolarization (and thus APD, too). 
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4. Class IV AAR act by blocking calcium (Ca+) channels and inhibiting the action potentials in 
SA and AV nodes.  
Structure activity studies on the molecules of class III AAR91,92 indicate that binding to K+ 
channels is characterized by the presence of a protonated nitrogen linked with two or three 
hydrophobic and/or aromatic moieties (with hydrogen bonding abilities). The charge of the N-
atom is known to have a strong influence on the potency of the binding and is involved in 
hydrogen-bonding interaction93.  The para-substituents of phenyl rings are involved in polar 
interactions, and the rank order of potency (of binding) was found to be nitro < chlorine < amine 
< amide. The ethyl group(s) attached to protonated N-atom are involved in hydrophobic 
interactions in the central cavity of K+ channels94. By study analogues of dofetilide, it was also 
found that the methanesulfonamide moieties (which are also present in ibutilide and sotalol) are 
involved in hydrogen bonding interactions95.  
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7.2. Results 
 
7.2.1. PC/Molecular and Humans Systemic PK Property Space of Class III AAR  
 
   The final PC/molecular and human systemic PK database consisted of seven drugs that 
are/have been used clinically for treating arrhythmias. While bretylium96 and sotalol97 show both 
class II and III activity, dofetilide98 and ibutilide99 are selective class III drugs. Amiodarone100 
and dronedarone101 (a derivative of desethyl metabolite of amiodarone) show broad spectrum 
(class I - IV) antiarrhythmic properties. The drugs included in the final database have been 
approved by US FDA for therapeutic use in the US and have also widely used over the past 
several decades. 
   The class III AAR in the final database represent quite a heterogeneous molecular/PC property 
space (Table - 7.1). Sotalol, dofetilide and ibutilide share a similar structural scaffold, while 
dronedarone is structurally related to amiodarone. Overall, they show relatively low to 
intermediate MW (243 - 645 Da). Sotalol has a low MW (272 Da) and is the least lipophilic 
(logD7.4 = -1.7), while amiodarone and dronedarone have high MW (645, 559 Da respectively) 
and are the most lipophilic drugs in the final database (logD7.4 = 5.9 and 5.8 respectively).  
Although few of the drugs in the current dataset have two pKas, pKa2, i.e., due to a basic (e.g., -
NH2) group, is the only relevant one for all the drugs in the database at the physiological pH of 
7.4.  Consequently, all the drugs in the database are almost entirely ionized, i.e., positively 
charged at physiologically relevant pH of 7.4. Ibutilide, azimilide, amiodarone and dronedarone 
exist at ≥ 70% as cationic species at pH of 7.4; however, all of them are lipophilic with logD7.4 > 
1.0, possibly owing to the presence of large aromatic and/or aliphatic functional groups (as 
evident from their higher MW relative to the more hydrophilic drugs in the database). 
Furthermore, the impact of the ionization on the estimated logD7.4 is evident from their 
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(consistently) low values relative to the SciFinder-predicted logP, and this is more pronounced 
for hydrophilic drugs in the database. SciFinder-reported values for all the PC properties of 
Bretylium, except PSA and MV.  
Descriptive statistics (Table 7.2) show that, for most of the molecular/PC properties, except 
logD7.4, mean and median values were comparable. The wide dispersion (high standard 
deviations) is indicative of their diverse molecular/PC property space. Based on the acceptance 
criteria set a-priori for collinearity, (i.e., r ≥ 0.80), MW is highly correlated with logD7.4, MV 
and HBD; logD7.4 with MV and HBD; PSA with MV and HBA; and MV with HBD (shown in 
Table 7.3). Thus, only logD7.4 (and MW, just for the purpose of comparison), nRot and HBA 
were used for subsequent analysis.  
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Table 7.1 - Molecular/PC Properties of Class III AAR 
 Drug 
MW 
(Da) 
logP pKa1 pKa2 LogD7.4 
% 
Ionized 
at pH 
7.4 
Charge 
at pH 
7.4 
% 
Ionized 
at pH 
6.3 
Charge 
at pH 
6.3 
PSA 
(A2) 
MV 
(cm3/
mol) 
nRot HBD HBA 
1 Sotalol 272 0.24 8.3 9.3 -1.68 99% C 100% C 87 220 6 3 5 
2 Dofetilide 442 1.38 9.0 8.3 0.45 88% C 99% C 122 328 9 2 8 
3 Ibutilide 385 3.72 8.5 9.9 1.17 100% C 100% C 78 350 14 2 5 
4 Azimilide 458 3.33  7.7 2.84 68% C 96% C 73 346 8 0 8 
5 Amiodarone 645 7.82  9.4 5.85 99% C 100% C 43 408 11 0 4 
6 Dronedarone 557 7.98 7.4 9.4 5.94 99% C 100% C 97 487 17 1 7 
7 Bretylium 243 -1.17   -1.17 100% C 100% C   3 0 1 
 N 7 7 4 6 7     6 6 7 7 7 
 Mean 429 3.3 8.3 9.0 1.9     83 357 10 1 5 
 Maximum 645 8.0 9.0 10.0 5.9     122 487 17 3 8 
 Minimum 243 -1.2 7.4 7.7 -1.7     43 220 3 0 1 
 -fold range 3 9 1 1 8     3 2 6  8 
 
**C - Cationic 
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Table 7.2 - Descriptive Statistics of PC/Molecular Properties of Class III AAR 
 
N Mean SD 95% CI Minimum 10% 25% Median 75% 90% Maximum 
MW (Da) 7 429 145 295, 563 243 243 272 442 557 645 645 
LogD7.4 7 1.9 3.1 -1.0, 4.8 -1.7 -1.7 -1.2 -1.2 5.9 5.9 5.9 
PSA (A2) 6 83 26 56, 111 43 43 66 83 103 122 122 
MV (cm3/mol) 6 357 89 263, 450 220 220 301 348 428 487 487 
nRot 7 10 5 5.3, 14.1 3 3 3 9 14 17 17 
HBA 7 5 2.5 3.1, 7.7 1 1 4 5 8 8 8 
HBD 7 1 1.2 0.020, 2.3 0 0 0 1 2 3 3 
 
 
 
Table 7.3 - Correlation Matrix of PC/Molecular Variables of Class III AAR 
 
MW (Da) LogD7.4  PSA (A2) 
MV 
(cm3/mol) 
nRot HBD HBA 
MW (Da) 1.00       
LogD7.4  0.98 1.00      
PSA (A2) 0.70 0.71 1.00     
MV (cm3/mol) 0.92 0.95 0.88 1.00    
nRot -0.25 -0.24 -0.49 -0.38 1.00   
HBD -0.90 -0.93 -0.76 -0.94 0.54 1.00  
HBA 0.62 0.63 0.86 0.74 -0.33 -0.66 1.00 
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     The final in-vitro fu and in-vivo human systemic PK variables compiled from various studies 
in the literature are shown in Table - 7.4 and the corresponding estimated biologically relevant 
PK variables are shown in Table 7.5. There was considerable to large diversity in the in-vitro fu 
(99-fold), in-vivo PK variables, namely, Vdss (50-fold), CLtot (15-fold), CLren (351-fold) and 
CLnonren (66-fold). After correcting for PPB, the biologically relevant PK variables showed 
relatively higher mean values and larger diversity (except CLren
u) compared to their respective 
uncorrected counterparts, e.g., Vdss
u (1650-fold), CLtot
u (1500-fold) and CLnonren
u (6522-fold) 
suggesting that class III ARR, on an average, show PPB-restricted distribution and clearance 
pathways (both total and nonrenal). 
    PPB of class III AAR in the current dataset varied from 1% to 99%, with the lipophilic drugs 
showing low fu values, e.g., dronedarone (fu = 1%, logD7.4 = 5.9), amiodarone (fu = 3%, logD7.4 = 
5.8) and azimilide (fu = 6%, logD7.4 = 2.8), while the hydrophilic drugs show high fu values, e.g., 
sotalol (fu = 99%, logD7.4 = -1.7) and bretylium (fu = 97%, logD7.4 = -1.2). Vdss
u estimates for all 
the drugs in the database exceeded the BW, indicating moderate to extensive extravascular tissue 
distribution, potential binding to cell surface membranes etc., with the lipophilic drugs 
(dronedarone Vdss
u
 = 2000 L/kg) showing several fold higher values compared to the hydrophilic 
ones (sotalol Vdss
u = 1.2 L/kg). Also, the lipophilic drugs in the final database (with logD7.4 > 
1.0) showed fe values ≤ 10%, suggesting they are highly metabolized, while renal clearance 
seems to be the major pathway (fe ≥ 50%) of elimination for the more hydrophilic drugs (logD7.4 
< 1.0). The CLren
u value for amiodarone was less than GFR suggesting (a) it may have low 
glomerular filtration, potentially due to its large MW and/or high PPB or (b) it may undergo net 
tubular reabsorption potentially due to its lipophilic nature. Sotalol shows CLren
u value that is 
comparable to GFR suggesting that is excreted by net glomerular filtration. Dofetilide and 
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bretylium have CLren
u values that approach RPF, indicating that they undergo significant net 
renal tubular secretion. Both these drugs are hydrophilic, and are ≥ 90% positively charged at 
physiological pH of 7.4 (plasma) and 6.3 (urine), suggesting a potential role of the organic 
cationic transport (OCT) system. While dofetilide102,103 is known to be a substrate for OCTs and 
is contraindicated with OCT inhibitors such as cimetidine, ketoconazole, trimethoprim, 
megestrol etc., there is no literature on the renal disposition of bretylium. Ibutilide and azimilide 
have CLren
u values greater than GFR, indicating that they are excreted by net tubular secretion, 
potentially involving OCTs.  
Except for ibutilide and dronedarone, the rest of the drugs in the database have CLnonren values 
lower than LBF, suggesting they are all low ERhep drugs. For the hydrophilic drugs, e.g., sotalol 
and bretylium, the PPB is negligible and; therefore, they are low ERhep drugs owing to low 
hepatic CLint, while the lipophilic drugs e.g., azimilide and amiodarone, show low ERhep because 
they undergo PPB-restricted hepatic metabolism.  CLnonren values for ibutilide and dronedarone 
are greater than LBF, suggesting they undergo extra-hepatic clearance pathways. Ibutilide104 is 
metabolized primarily by ω-oxidation and sequential β-oxidation of the hepatyl side chain, but 
no further metabolic mechanisms have been reported in the literature. Dronedarone105,106 is 
reported to undergo extensive metabolism, mainly by CYP3A, but exact mechanism of the extra-
hepatic pathways is not known.  
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Table 7.4 - In-vitro and In-vivo Human PK Systemic Properties of Class III AAR 
 
In-vitro 
PK Variable 
 
In-vivo PK Variable 
Drug 
fu 
[%] 
Vdss 
[l/kg] 
CLtot 
[ml/min/kg] 
fe  
[%] 
CLren 
[ml/min/kg] 
CLnonren 
[ml/min/kg] 
Sotalol 99% 1.2 2.2 77% 1.7 0.51 
Dofetilide 36% 3.4 5.3 52% 2.7 2.5 
Ibutilide 60% 12 29 6% 1.7 27.3 
Azimilide 6% 12 2.2 10% 0.21 2.0 
Amiodarone 3% 59 2.5 1.0% 0.025 2.4 
Dronedarone 1.0% 20 33 . . 33.3 
Bretylium 97% 7.2 11.3 76% 8.6 2.7 
N 7 7 7 6 6 7 
Mean 43% 16.4 12.3 37% 2.5 10.1 
Maximum 99% 59.5 33 77% 8.6 33 
Minimum 1.0% 1.2 2.2 1.0% 0.025 0.51 
-fold range 99 50 15 77 351 66 
 
 
 
Table 7.5 - Biologically Relevant In-vivo Human PK Variables of Class III AAR 
Drug 
Vdssu 
[l/kg] 
CLtotu 
[ml/min/kg] 
CLrenu 
[ml/min/kg] 
CLnonrenu 
[ml/min/kg] 
Sotalol 1.2 2.2 1.7 0.51 
Dofetilide 9.4 15 7.6 7.0 
Ibutilide 20 48 2.9 45 
Azimilide 193 37 3.5 33 
Amiodarone 1725 71 0.71 70 
Dronedarone 2000 3333  3333 
Bretylium 7.4 12 8.9 2.8 
N 7 7 6 7 
Mean 565.1 502.6 4.1 498.8 
Maximum 2000.0 3333.3 8.9 3333.3 
Minimum 1.2 2.2 0.71 0.51 
-fold range 1650 1500 13 6522 
 
 133 
Table 7.6 - Descriptive Statistics of Human Systemic PK Variables of Class III AAR 
 N Mean SD 95% CI Minimum 10% 25% Median 75% 90% Maximum 
Vdss (L/kg) 7 16 20 -2.1, 35 1.2 1.2 3.4 11.6 20 59 59 
CLtot (ml/min/kg) 7 12 13 -0.093, 25 2.2 2.2 2.2 5.3 29 33 33 
CLren (ml/min/kg) 6 2.5 3.2 -0.83, 5.8 0.020 0.020 0.15 1.7 4.2 8.6 8.6 
CLnonren (ml/min/kg) 7 10 14 -2.7, 23 0.50 0.50 2.0 2.6 27 33 33 
fu  7 0.43 0.43 0.034, 0.83 0.010 0.010 0.035 0.36 0.97 0.99 0.99 
Vdss
u (L/kg) 7 565 892 -260, 1390 1.2 1.2 7.4 20 1725 2000 2000 
CLtot
u (ml/min/kg) 7 502 1247 -651, 1656 2.2 2.2 11.7 36 73 3333.3 3333 
CLren
u (ml/min/kg) 6 4.1 3.3 0.67, 7.6 0.58 0.58 1.4 3.1 7.8 8.9 8.9 
CLnonren
u (ml/min/kg) 7 499 1249 -656, 1654 0.51 0.51 2.9 33 73 3333 3333 
 
 
 
Table 7.7 - Correlation Analysis of Human Systemic PK Variables of Class III AAR 
 Vdss 
(L/kg) 
CLtot 
(ml/min/kg) 
CLren 
(ml/min/kg) 
CLnonren 
(ml/min/kg) 
fu Vdssu 
(L/kg) 
CLtotu 
(ml/min/kg) 
CLrenu 
(ml/min/kg) 
CLnonrenu 
(ml/min/kg) 
Vdss (L/kg) 1.00         
CLtot (ml/min/kg) -0.07 1.00        
CLren (ml/min/kg) -0.40 0.21 1.00       
CLnonren (ml/min/kg) 0.02 0.98 -0.09 1.00      
fu  -0.58 -0.12 0.68 -0.27 1.00     
Vdss
u (L/kg) 0.75 0.33 -0.43 0.43 -0.69 1.00    
CLtot
u (ml/min/kg) 0.10 0.70 -0.54 0.74 -0.45 0.72 1.00   
CLren
u (ml/min/kg) -0.54 0.10 0.83 -0.15 0.35 -0.55 -0.57 1.00  
CLnonren
u (ml/min/kg) 0.10 0.70 -0.60 0.74 -0.45 0.72 1.00 -0.65 1.00 
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7.2.2. QSPKR Analysis, Model Building and Evaluation 
The results of the univariate regression of the log-transformed in-vivo systemic and biologically 
relevant PK variables as a function of the molecular/PC descriptors are shown in Table 7.8. MW 
shows significant univariate relationship (r2 ≥ 0.30 and p < 0.05) with fu, log (Vdssu),                
log (CLnonren
u), log (Vdss) and log (CLren) (Figures 7.1 - 7.5 respectively); while logD7.4 is related 
with fu, log (Vdss
u), log (CLtot
u), log (CLnonren
u), log (Vdss) and log (CLren) (Figures 7.6 - 7.11 
respectively). Although MW and logD7.4 are highly correlated (r = 0.98), univariate relationships 
for both these descriptors were presented for the purpose of comparing them with those obtained 
for other pharmacological classes (see Chapter 8). Only logD7.4 was considered for further model 
building because it described greater variability in the biologically relevant as well as systemic 
PK variables. nRot shows significant univariate relationship with log (CLtot
u), log (CLnonren
u) and 
log (CLnonren) (Figures 7.12 - 7.14, respectively). During the final (multivariate) model building 
process (using MLLR with forward inclusion followed by backward elimination), logD7.4 was 
found to be the single most important determinant affecting biologically relevant systemic PK of 
Class III AAR, and the final models are summarized in Table 7.9. Overall, the final QSPKR 
models developed for Class III AAR gave acceptable predictions (q2 ≥ 0.40) for fu, Vdssu and 
CLnonren
u 
7.2.2.1.   Effect of LogD7.4  
LogD7.4 shows a significant positive association with fu,, log (Vdss
u), log (CLtot
u), log (CLnonren
u), 
log (Vdss), i.e., an increase in logD7.4 is associated with increase in those PK variables; while a 
negative association is observed with log (CLren
u). Furthermore, it explains ≥ 70% variability in 
the biologically relevant PK variables (range: 70% for log CLtot
u, n = 7 to 97% for log Vdss
u, n = 
7) and ≥ 75% variability in the systemic PK. Despite the offsetting effects of logD7.4 on fu and 
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log (Vdss
u), there was still a positive association with uncorrected counterpart - log (Vdss). This 
might be due to the predominant effects of logD7.4 on Vdss
u (especially for the lipophilic 
compounds, namely, azimilide, amiodarone and dronedarone) that drive the relationship with 
Vdss than that on fu (although it offsets the trend, evident from statistically significant shallower 
slope relative to that obtained with log Vdss
u). On the other hand, due to the offsetting effects of 
logD7.4 on fu and CLtot
u, and fu and CLnonren
u, their uncorrected counterparts, CLtot
 and CLnonren, 
respectively, did not depend on logD7.4. Lastly, for the compounds in the final dataset, logD7.4 
did not show a significant relationship with log (CLren
u), but showed a negative association with 
log (CLren). Therefore, the (significant) relationship of logD7.4 on log (CLnonren
u) seem to drive 
those on log (CLtot
u), as also evident from the high correlation (r = 1.00) between CLnonren
u and 
CLtot
u. 
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Table 7.8 - Log-Linear Regression Between PC/Molecular Descriptors and PK Variables of Class III AAR 
 
fu 
 
Log  
(Vdssu) 
[l/kg] 
Log  
(CLtotu) 
[ml/min/kg] 
Log  
(CLrenu) 
[ml/min/kg] 
Log 
(CLnonrenu) 
[ml/min/kg] 
Log  
(Vdss) 
[l/kg] 
Log  
(CLtot) 
[ml/min/kg] 
Log  
(CLren) 
[ml/min/kg] 
Log  
(CLnonren) 
[ml/min/kg] 
MW  
(Da) 
n = 7 
r2 = 0.87 
Slope = -0.0028 
-0.0040, -0.0015 
n = 7 
r2 = 0.81 
Slope = 
0.00078 
0.0034, 
0.012 
n =7 
r2 = 0.47 
Slope = 
0.0047 
N.S 
n =6 
r2 = 0.39 
Slope = -
0.019 
N.S 
n = 7 
r2 = 0.57 
Slope = 
0.0064 
0.000060, 
0.013 
n = 7 
r2 = 0.62 
Slope = 
0.0029 
0.00027, 
0.0056 
N.S 
n = 6 
r2 = 0.79 
Slope =  
-0.0058 
-0.010, 
 -0.0017 
N.S 
LogD7.4  
n = 7 
r2 = 0.83 
Slope = -0.13 
-0.19, -0.061 
n = 7 
r2 = 0.97 
Slope = 0.39 
0.32, 0.47 
n = 7 
r2 = 0.71 
Slope = 0.27 
0.070, 0.46 
n =6 
r2 = 0.43 
Slope = -0.10 
N.S 
n = 7 
r2 = 0.79 
Slope = 0.35 
0.14, 0.56 
n = 7 
r2 = 0.74 
Slope = 0.15 
0.048, 0.25 
N.S 
n = 6 
r2 = 0.86 
Slope = -0.32 
-0.49, -0.14 
N.S 
nRot 
n = 7 
r2 = 0.41 
Slope =-0.058 
N.S. 
n = 7 
r2 = 0.42 
Slope = 0.17 
N.S. 
n = 7 
r2 = 0.69 
Slope = 0.17 
0.040, 0.30 
N.S. 
n = 7 
r2 = 0.74 
Slope = 0.22 
0.074, 0.37 
N.S. 
n = 7 
r2 = 0.33 
Slope =0.062 
N.S. 
N.S. 
n = 7 
r2 = 0.66 
Slope = 0.11 
0.018, 0.20 
HBA 
n = 7 
r2 = 0.37 
Slope =-0.10 
N.S. 
N.S. N.S. N.S. N.S N.S N.S N.S N.S 
In red: p<0.05 and r2 ≥ 0.30; In italic and red: r2 ≥ 0.30 but p>0.05; N.S = Not Significant (p>0.05 and r2 < 0.30); 
 
 
  
 137 
 
Table 7.9: Final QSPKR Models for Class III AAR 
Final QSPKR Model N  Slope (95% CI) r2 q2 
fu = 0.67 - 0.13 * LogD7.4 7  - 0.13 (-0.19, -0.061) 0.83 0.71 
Log (Vdss
u) = 0.97 + 0.39 * LogD7.4 7    0.39 (0.32, 0.47) 0.97 0.94 
Log (CLtot
u) = 1.1 + 0.27 * LogD7.4 7    0.27 (0.070, 0.46) 0.71 0.21 
Log (CLnonren
u) = 0.70 + 0.35 * LogD7.4 7    0.35 (0.14, 0.56) 0.79 0.45 
                                  q2 ≥ 0.40: Acceptable 
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                             Figure 7.1 -  fu vs. MW for Class III AAR        Figure 7.2 - Vdssu vs. MW for Class III AAR 
                                            
 
                                                                            Figure 7.3 - CLnonrenu vs. MW for Class III AAR 
                  
(Please refer Table 7.1 in Page 128, for the list of the individual compounds labeled in the figures 7.1 to 7.3) 
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Figure 7.4 - Vdss vs. MW for Class III AAR 
 
 
Figure 7.5 - CLren vs. MW for Class III AAR 
 
(Please refer Table 7.1 in Page 128, for the list of the individual compounds labeled in the figures 7.4 and 7.5) 
 140 
                                Figure 7.6 - fu vs. logD7.4 for Class III AAR    Figure 7.7 - Vdssu vs. logD7.4 for Class III AAR 
                                          
 
   Figure 7.8 - CLtotu vs. logD7.4 for Class III AAR                 Figure 7.9 - CLnonrenu vs. logD7.4 for Class III AAR 
                                           
(Please refer Table 7.1 in Page 128, for the list of the individual compounds labeled in the figures 7.6 to 7.9) 
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Figure 7.10 - Vdssu vs. logD7.4 for Class III AAR 
 
 
Figure 7.11 - CLren vs. logD7.4 for Class III AAR 
 
(Please refer Table 7.1 in Page 128, for the list of the individual compounds labeled in the figures 7.10 and 7.11) 
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                         Figure 7.12 - CLtotu vs. nRot for Class III AAR               Figure 7.13 - CLnonrenu vs. nRot for Class III AAR 
                      
 
Figure 7.14 - CLnonren vs. nRot for Class III AAR 
 
(Please refer Table 7.1 in Page 128, for the list of the individual compounds labeled in the figures 7.12 to 7.14) 
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7.3. Discussion 
Few of the class III AAR in the final database share a similar structural scaffold (e.g., sotalol, 
dofetilide and ibutilide; amiodarone and dronedarone); however, they show very large diversity 
in the molecular/PC property space, e.g., MW ranged between 243 - 645 Da (3-fold, n = 7) and 
logD7.4 ranged between -1.7 to 5.9 (8-fold, n = 7). All compounds in the final dataset are bases 
and predominantly (>70%) positively charged at physiological pH. They show an even larger 
diversity in the systemic PK (15- to 351-fold) and biologically relevant PK (13- to 6522-fold) 
variables. Vdss varies 50-fold, while fu varies 99-fold across the compounds in the database. Vdss
u 
values (varies 1650-fold) were greater than BW, suggesting extensive extravascular distribution, 
which was counteracted by high PPB that led to lower values of Vdss. Except for ibutilide and 
dronedarone, the rest of the compounds in the database show CLnonren values much lower LBF, 
suggesting that they are all low ERhep drugs. Ibutilide
104 and dronedarone105,106, on the other hand 
show CLnonren values exceeding LBF suggesting they are subject to (not fully understood) extra-
hepatic clearance pathways. The CLren
u values of compounds are also heterogeneous with values 
lower than GFR (e.g., amiodarone), suggesting (binding-) restricted filtration and/or net tubular 
reabsorption; approximating GFR suggesting net filtration (e.g., sotalol) and values greater than 
GFR suggesting net tubular reabsorption (dofetilide and bretylium approaching RPF, the former 
involving OCTs).  
To characterize the large variability in the systemic and biologically relevant PK variables, the 
effect of molecular/PC descriptors were explored. Overall, logD7.4 was found to be the most 
important determinant affecting biologically relevant PK properties, namely, fu, Vdss
u, CLtot
u and 
CLnonren
u. Since, logD7.4 is found to be highly correlated with MW, the trends observed by each 
of them cannot be distinguished. Non-specific hydrophobic interactions with plasma proteins 
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(potentially with α-acid glycoprotein, since they are all positively charged bases), seems to be a 
plausible explanation for the (significant) negative association of logD7.4 with fu. These findings 
are consistent with barbiturates in rats68, β-adrenergic blockers in man39,107, corticosteroids in 
man (in addition to polarizability)40. Obach et al29 studied a heterogeneous dataset comprising of 
554 drugs, and concluded that (non-specific) hydrophobic interactions with albumin and α-acid 
glycoprotein drive the negative trend of fu as a function of logD7.4.  
Non-specific hydrophobic interactions with extravascular tissues/plasma membranes seem to be 
the plausible explanation for the (significant) positive association - of logD7.4 with Vdss
u. PPB-
restriction seems to lessen the Vdss values, and this is even more pronounced for highly PPB, 
lipophilic compounds. Furthermore, correction for the free fraction (i.e., PPB), increased the 
slope estimate for effect of logD7.4 on Vdss
u.  Although there was a reduction in that trend, there 
is still a positive association observed between logD7.4 and Vdss, suggesting the predominant 
hydrophobic interactions with Vdss
u drive the relationships with Vdss as well. Similar trends were 
observed with Vdss
u of sulfonamides in rat82 and β-adrenergic blockers in man39 and 
heterogeneous dataset of 670 drugs (159 acids, 267 bases, 173 neutrals and 68 zwitterions).  
Non-specific hydrophobic interactions with hepatic and possibly extrahepatic drug-metabolizing-
enzymes seem to be plausible explanation for effect of logD7.4 on CLnonren
u. Ibutilide and 
dronedarone seem to have extra-hepatic clearance pathways and even with the exclusion of these 
drugs, the relationships of logD7.4 with biologically relevant PK variables log CLtot
u and log 
CLnonren
u still hold true, with a slight improvement in the goodness of fit (r2) but without any 
effect on the slope, suggesting that logD7.4 is still the important determinant affecting the 
(unknown) extra-hepatic clearance pathways of those drugs in the same way as seen with hepatic 
clearance pathways.  
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A (significant) negative association is observed for CLren with logD7.4 but there was no effect on 
CLren
u. This may be due to (a) large diversity in CLren (351-fold) vs. CLren
u (15-fold) and/or (b) 
from a mechanistic standpoint, all the drugs in the current dataset are positively charged at 
physiological pH of 7.4 and 6.3 - the hydrophilic compounds, e.g., dofetilide (for which CLren
u 
approaches RPF) undergo net tubular secretion possibly involving on the OCT system that don’t 
depend on logD7.4 but may rely on more specific molecular properties. On the other hand, the 
more lipophilic compounds, e.g., amiodarone show CLren
u values lower than GFR suggesting 
they undergo net tubular reabsorption, possibly by passive tubular reabsorption owing to their 
high degree of lipophilicity. Varma et al23 reported a negative association of CLren with logD7.4 
for set of 391 compounds, while Hinderling et al39 found a similar trend with β-adrenergic 
blockers in humans. Furthermore, van de Waterbeemd et al108 found the relationship of CLren
u as 
a function of lipophilicity to be insignificant for β-adrenergic blockers in humans.  
Overall, logD7.4 was found to be the most important descriptor for predicting the biologically 
relevant PK variables of Class III AAR based on the compounds within the dataset. Thus, the 
disposition of these drugs depends on the hydrophobic interactions to pass through 
tissues/plasma membranes, hepatocytes and binding to drug metabolizing enzymes. The final 
QSPKR models gave acceptable predictions for fu, Vdss
u and CLnonren
u.  
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CHAPTER 8. OVERALL QSPKR DISCUSSION 
 
8.1. Molecular/PC Property Space 
  
8.1.1. BZD, NMB, TRP and Class III AAR 
 The distribution of the molecular/PC variables for BZD, NMB, TRP and Class III AAR is 
shown in Figures 8.1 - 8.7, and the ranges in these respective properties in Table - 8.1. BZD with 
their 5-aryl, 1, 4-benzodiazepine structural scaffold and TRP with 5-hydroxy-tryptamine 
scaffold, based on the substituents attached to the scaffold, show relatively small values in nRot, 
HBA, PSA and MV and little diversity. On the other hand, although, there are missing values for 
few compounds, NMB, are structurally diverse compounds with either an aminosteroid (ASN) 
nucleus, (n = 9) or with a benzylisoquinolinium (BIQ) nucleus, consisting of large, fused 
aromatic rings and, therefore, show higher values for nRot, HBA PSA and MV and greater 
diversity. Likewise, Class III AAR compounds are heterogeneous with large diversity in their 
molecular/PC properties. While BZD (271 - 412 Da, n = 20) and TRP (243 - 459 Da, n = 8) are 
relatively low MW compounds, Class III AAR (243 - 645 Da, n = 7) seem to be skewed towards 
intermediate - high MW, and a majority of NMB - with the exception of succinylcholine - are 
high MW compounds (290 - 1035 Da, n = 16). Similar trends, i.e., lower values for BZD and 
TRP (in general), while Class III AAR and NMB have higher values for MV, PSA and nRot, 
which is also evident from their high correlations with MW.  
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BZD in the database consist of both weakly acidic (n = 7) and weakly basic (n = 16), lipophilic 
compounds (logD7.4 > 1.0, n = 19, except N-DMAD whose logD7.4 is 0.75), and all of them are 
unionized at physiological pH of 7.4. In contrast, NMB (n = 16), TRP (n = 8) and Class III AAR 
(n = 7) are all weakly basic compounds, charged with either one (e.g., TRP, and Class III AAR) 
or two positive charges (e.g., NMB) at pH of 7.4. Furthermore, while TRP are hydrophilic 
(logD7.4 < 1.0, n = 8); NMB (logD7.4 ranges from -5.0 to 2.1, n = 16) and Class III AAR (logD7.4 
ranges from -1.7 to 5.9, n = 7) show a wide dispersion in the logD7.4 values, consisting of a 
combination of hydrophilic as well as lipophilic compounds (despite being positively charged, 
possibly because of their large aromatic functional groups).   
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  Figure 8.1 - MW Distribution By Pharmacological Class        Figure 8.2 - LogD7.4 Distribution By Pharmacological Class 
     
1 - BZD (X); 2 - NMB (); 3 - TRP () and 4 - Class III AAR (☐) 
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 Figure 8.3 - PSA Distribution By Pharmacological Class         Figure 8.4 - nRot Distribution By Pharmacological 
Class  
     
1 - BZD (X); 2 - NMB (); 3 - TRP () and 4 - Class III AAR (☐) 
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        Figure 8.5 - HBA Distribution By Pharmacological Class            Figure 8.6 - HBD - Distribution By Pharmacological Class  
     
1 - BZD (X); 2 - NMB (); 3 - TRP () and 4 - Class III AAR (☐) 
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Figure 8.7 - MV Distribution by Pharmacological Class 
 
1 - BZD (X); 3 - TRP () and 4 - Class III AAR (☐) 
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Table 8.1 - Molecular/PC Property Space of BZD, NMB, TRP and Class III AAR 
PC Property BZD (n) NMB (n) TRP (n) Class III AAR (n) 
MW (Da) 271 - 412 (20) 290 - 1035 (16) 243 - 459 (8) 243 - 645 (7) 
LogD7.4 0.75 to 3.8 (20) -5.0 to 2.1 (12) -2.1 to 0.22 (8) -1.7 to 5.9 (7) 
nRot 1.0 - 7.0 (20) 4.0 - 30 (11) 2.0 - 8.0 (8) 3.0 - 17 (7) 
HBA 3.0 - 8.0 (20) 5.0 - 18 (11) 4.0 - 9.0 (8) 1.0 - 8.0 (7) 
HBD 0 - 2.0 (20) 0 - 2.0 (11) 1.0 - 4.0 (8) 0 - 3.0 (7) 
PSA (A2) 30 - 87 (20)  43 - 163 (11) 50 - 112 (8) 43 - 122 (6) 
MV (cm3/mol) 201 - 318 (20) - 192 - 353 (8) 220 - 487 (6) 
 
Table 8.2 - Molecular/PC Property Space of Opioids, β-ARLs, β-LAs and CCB 
PC Property Opioids (n) β-ARLs (n) β-LAs (n) CCB (n) 
MW (Da) 221 - 496 (38) 225 - 510 (48) 199 - 672 (60) 315 - 496 (14) 
LogD7.4 -4.1 to 3.7 (38) -2.9 to 3.1 (48)  -7.3 to 2.5 (60) 1.5 to 5.1 (14) 
nRot 1.0 - 9.0 (38) 6.0 - 15 (48) 1.0 - 12.0 (60)  6.0 - 13 (14) 
HBA 0 - 10.0 (38) 3.0 - 11 (48) 6.0 - 17 (60) 1.0 - 9.0 (14) 
HBD 0 - 7.0 (38) 2.0 - 5.0 (48) 1.0 - 6.0 (60) 0 - 3.0 (14) 
PSA (A2) 5.8 - 248 (38) 45 - 228 (48) 118 - 447 (60) 12 - 120 (14) 
MV (cm3/mol) 198 - 467 (37) 192 - 424 (48) 120 - 364 (54) 272 - 429 (14) 
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8.1.2.  Comparison with Opioids, β-ARLs, β-LAs and CCB 
The ranges of the molecular/PC variables for available datasets of opioids109, β-ARLs109, β-
LAs109 and CCB110 are shown in Table 8.2. CCB have a similar molecular/PC property space to 
BZD, i.e., they are relatively low MW, weakly basic, lipophilic compounds and also show 
relatively low diversity. Both opioids and β-ARLs are weakly basic compounds with MW 
ranging between 221 and 510 Da (n = 38 - 48), comparable to that observed for weakly 
acidic/basic BZD (271 - 412 Da, n = 20), weakly basic TRP (243 - 549 Da, n = 8) and weakly 
basic CCB (315 - 496 Da, n = 14). β-LAs (are weakly acidic) show diverse MW range that is 
comparable (199 - 672 Da, n = 60) to that of weakly basic Class III AAR (243 - 645 Da), while 
NMB show the most diverse range (290 - 1035 Da, n = 16) and the largest MW amongst all the 
eight classes.  
The opioids dataset, in general, is relatively skewed towards lipophilic compounds, comparable 
to BZD and CCB; however, the overall range in the logD7.4 values (-4.1 to 3.7, n = 38) suggests 
that it is quite heterogeneous. LogD7.4 values of β-ARLs are also heterogeneous (ranging from -
2.9 to 3.1, n = 48), consisting a combination of hydrophilic as well as lipophilic compounds, 
which is comparable to the (smaller) heterogeneous dataset of Class III AAR (ranging from -1.7 
to 5.9, n = 7). TRP (-2.1 to 0.22, n = 8), NMB (-5.0 to 2.1, n = 12) and β-LAs (-7.3 to 2.5, n = 
60) are all predominantly hydrophilic compounds in increasing order of diversity in LogD7.4 
values. Except for TRP, none of the other classes show high correlations between MW and 
logD7.4. In general, there are several other correlations that are consistent across pharmacological 
classes, e.g., MW with MV, PSA, nRot, HBA, which is mechanistically plausible, owing to 
addition of substituents that not only add to the molecular size but also affect the increase 
hydrogen bonding ability (HBA, HBD), flexibility of bond rotation etc. 
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8.1.3. Discussion 
Lipinski et al27 investigated the in-vitro gastrointestinal solubility and permeability for a 2245 
compounds in a United States Adopted Database (USAN) and proposed the “rule of five” cutoffs 
for log (P), MW, HBA and HBD. The rule states that a compound is likely to have poor oral 
absorption if (a) MW > 500 Da, (b) log (P) > 5, (c) HBD > 5.0 and HBA > 10.0. The majority of 
the compounds belonging to BZD, TRP and Class III AAR concur with the “rule of five”, 
suggesting that, in general, they are less likely to show poor oral bioavailability due to poor 
solubility and/or permeability if administered by oral routes, as they are in clinical practice. 
However, the majority of NMB are exception to the Lipinski’s “rule of five”. In general, few 
NMB, especially the newer generations, show high MW and they show significant extrahepatic 
metabolism via chemical degradation. This is mechanistically plausible, because they are 
designed with the intent of having a short plasma half-life, facilitating quicker recovery from the 
neuromuscular blockade. Since, the intent of (exclusive) administration of NMB by I.V. route is 
to facilitate quick onset of neuromuscular blockade during surgical procedures, and they have 
been approved for clinical use, adequate oral bioavailability (and Lipinski’s rule) is considered 
irrelevant.   
 Veber et al28 studied oral bioavailability in rats of 1100 drug candidates in GSK database 
and suggested that there is high probability of acceptable oral bioavailability in rats if (a) nRot is 
≤ 10, (b) PSA ≤140 A2, and (c) sum of HBA and HBD is ≤ 12. The majority of the compounds 
belonging to BZD, TRP and Class III AAR meet these criteria, suggesting that they are likely to 
show acceptable oral bioavailability in rats, while NMB seem to have values that are outside of 
these criteria.  
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Obach et al29 investigated the trend analysis of human systemic PK for 670 drugs (159 acids, 271 
bases, 173 neutrals and 67 zwitterions) following I.V. administration, and is the only study that 
looked at human systemic and biologically relevant PK properties. They found that the typical 
‘drug-like’ space for MW lies between 200 to 600 Da and is represented by 80% of the 
compounds in the dataset with a median value of 342 Da. Furthermore, they reported median 
value for logD (at pH = 7.0) of 0.42, PSA is 87 A2, nRot is 5.0, HBA is 6.0 and HBD is 2.0. The 
database in the present work consists primarily of bases (n = 43), the majority of which are 
predominantly positively charged (Class III AAR show two positive charges) at physiological 
pH of 7.4, and only a few (n = 7) acids (all BZD). The median values of these molecular/PC 
properties for the compounds in the database of the present work, in general, are comparable to 
those shown in Obach et al.’s database, namely MW (352 Da), PSA (62 A2), nRot (5.0), HBA 
(5.0) and HBD (1.0). However, in case of logD, in the present work, it was estimated at pH of 
7.4 unlike at 7.0 and it tends to be skewed towards lipophilic side (median = 1.4) compared to 
Obach et al’s database, in which it tends to be skewed towards hydrophilic side (median = 0.46). 
Overall, the molecular/PC property space in the present work is relatively less diverse compared 
to that of Obach et al. 
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8.2. Systemic and Biologically Relevant PK Property Space 
8.2.1. BZD, NMB, TRP and Class III AAR 
The statistical distribution of the in-vivo systemic and biologically relevant PK variables for 
BZD, NMB, TRP and Class III AAR are shown in Figures 8.8 - 8.16, and the ranges in these 
respective properties are listed in Table 8.3. There are missing values for several compounds in 
each class and therefore, the results should be interpreted with caution. On average, the majority 
of BZD show high PPB (i.e., low fu values), owing to their lipophilic nature and low diversity in 
lipophilicity. The remaining three classes, in general, show greater diversity in the PPB values, 
possibly due to their relatively higher dispersion in lipophilicity.  
In general, NMB and TRP show higher fu values (i.e., skewed towards lower PPB) possibly 
owing to their predominantly hydrophilic nature, while Class III AAR show a wide dispersion in 
fu values, due to the heterogeneous dataset of hydrophilic and lipophilic compounds with the 
latter showing a greater impact and thus skewing the distribution towards smaller fu values (i.e., 
higher PPB). As a result of the (relatively) high PPB of (lipophilic) BZD, the impact of fu 
correction of in-vivo systemic PK is more pronounced (i.e., in general, higher values for 
biologically relevant PK properties suggesting they are subject to binding - restricted distribution 
and clearance mechanisms) for BZD than for (hydrophilic) NMB and TRP. However, since 
Class III AAR are a heterogeneous dataset, there are no obvious conclusions, although, in 
general, the fu correction increases the diversity of biologically relevant PK properties. The Vdss
u 
values for the lipophilic BZD (1.0 - 124 L/kg, n = 16) suggest moderate to extensive 
extravascular distribution and/or sequestration to tissues/membranes, low MW, hydrophilic TRP 
(2.0 - 16 L/kg, n = 7) also show moderate to extensive extravascular distribution. In contrast, the 
majority of the Vdss
u values for NMB (0.10 - 1.2 L/kg, n = 14) suggest that their distribution is 
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restricted to the intracellular/extracellular (0.26/0.34 L/kg) and total body water (0.60 L/kg) 
spaces owing to their large, charged and hydrophilic nature.  
Except for the (most hydrophilic) N-DMAD and clorazepate, the remaining seven compounds in 
BZD dataset with available information show negligible contribution of renal clearance (fe < 
1%), i.e., they are all subject to extensive hepatic metabolism (with no obvious extra-hepatic 
pathways reported in literature); their high degree of lipophilicity is a plausible explanation for 
this finding. CYP3A, CYP2C19 and UGTs are the major known phase I and phase II metabolic 
pathways involved in the metabolism of BZD.  
The compounds in NMB and TRP datasets with available information show considerable 
diversity in fe and relatively higher values ranging from 5% - 58% (n = 12) and 9% - 44% (n = 
5), respectively, compared to BZD. Although compounds belonging to these two classes are 
predominantly hydrophilic, their renal handling o is quite different. With the exception of 
mivacurium, CLren
u values of the remaining NMB with available information are lower than 
GFR (1.7 ml/min/kg) suggesting (a) they are potentially poorly filtered, due to their large size 
and/or (b) they undergo net tubular reabsorption, possibly involving transporters. On the other 
hand, with the exception of frovatriptan, CLren
u values for TRP exceed GFR, suggesting they 
undergo net tubular secretion, potentially involving drug transporters owing to the positive 
charge they show at physiological pH. Finally, Class III AAR show the highest diversity in fe 
values (ranging from 1% to 77%, n = 6) amongst the four pharmacological classes. Within the 
Class III AAR, relatively hydrophilic ones show CLren
u values comparable to GFR suggesting 
filtration, potentially involving drug transporters, while the lipophilic ones have CLren
u < GFR, 
suggesting net renal tubular reabsorption. The compounds in NMB, TRP and Class III AAR 
datasets are known to undergo diverse nonrenal clearance mechanisms: A few NMB show 
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CLnonren values exceeding the cardiac output, suggesting the presence of extra-hepatic pathways 
such as chemical (e.g., cisatracurirum and atracurium) and enzymatic degradation (e.g., 
mivacurium and succinylcholine) in plasma and/or tissues. A few others have CLnonren values 
lower than LBF, suggesting they are low ERhep drugs and may subject to hepato-biliary clearance 
mechanisms. Likewise, a few compounds in the TRP dataset are metabolized by mono amine 
oxidase (MAO) which is present both hepatically as well as extra-hepatically, while the 
remaining ones may be subject to hepato-biliary excretion, potentially involving drug 
transporters, owing to their positive charge and hydrophobicity. Except for ibutilide and 
dronedarone, the rest of the drugs in the Class III AAR dataset have CLnonren values lower than 
the LBF, suggesting they are all low ERhep ratio drugs. For the hydrophilic ones, e.g., sotalol and 
bretylium, PPB is negligible and they are low ERhep drugs, owing to their low hepatic CLint, 
while the lipophilic drugs e.g., azimilide and amiodarone, show low ERhep because they undergo 
PPB-restricted hepatic metabolism.  CLnonren values for ibutilide and dronedarone are greater than 
LBF suggesting that they exhibit extra-hepatic clearance pathways.  
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Figure 8.8 - fu Distribution by Pharmacological Class 
 
1 - BZD (X); 2 - NMB (); 3 - TRP () and 4 - Class III AAR (☐) 
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  Figure 8.9 - Vdssu Distribution by Pharmacological Class        Figure 8.10 - Vdss Distribution by Pharmacological 
Class  
     
1 - BZD (X); 2 - NMB (); 3 - TRP () and 4 - Class III AAR (☐) 
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    Figure 8.11 - CLtotu Distribution by Pharmacological Class               Figure 8.12 - CLtot Distribution by Pharmacological Class   
     
1 - BZD (X); 2 - NMB (); 3 - TRP () and 4 - Class III AAR (☐) 
  
 162 
 
 
     Figure 8.13 - CLrenu Distribution by Pharmacological Class           Figure 8.14 - CLren Distribution by Pharmacological Class 
     
1 - BZD (X); 2 - NMB (); 3 - TRP () and 4 - Class III AAR (☐) 
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   Figure 8.15- CLnonrenu Distribution by Pharmacological Class       Figure 8.16 - CLnonren Distribution by Pharmacological Class 
     
1 - BZD (X); 2 - NMB (); 3 - TRP () and 4 - Class III AAR (☐) 
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Table 8.3 - Systemic and Biologically Relevant Property Space of BZD, NMB, TRP and Class III AAR 
PK Property BZD (n) NMB (n) TRP (n) Class III AAR (n) 
fu  (%) 2.0 - 65 (17) 28 - 98 (14) 15 - 86 (7) 1.0 - 99 (7) 
Vdss
u (L/kg) 1.0 - 124 (16) 0.10 - 1.2 (14) 2.0 - 16 (7) 1.2 - 2000 (7) 
CLren
u (ml/min/kg) 0.030 - 3.2 (8) 0.70 - 7.1 (13) 1.4 - 8.6 (7) 0.70 - 8.9 (6) 
CLnonren
u
 (ml/min/kg) 1.3 - 189 (8) 0.90 - 95 (13) 1.9 - 38 (7) 0.50 - 3333 (7) 
Vdss (L/kg) 0.20 - 4.3 (19) 0.040 - 0.50 (16) 1.1 - 3.6 (8) 1.2 - 60 (7) 
CLren (ml/min/kg) 0.0010 - 2.1 (9) 0.36 - 5.1 (15) 0.60 - 3.8 (7) 0.020 - 8.6 (6) 
CLnonren (ml/min/kg) 0.020 - 15 (9) 0.38 - 67 (15) 1.6 - 12 (7) 0.56 - 33 (7) 
 
Table 8.4 - Systemic and Biologically Relevant Property Space of Opioids, β-ARLs, β-LAs and CCB 
PK Property Opioids (n) β-ARLs (n) β-LAs (n) CCB (n) 
fu (%) 4.0 - 92 (29) 2.0 - 99 (34) 3.0 - 96 (57) 0.20 - 20 (13) 
Vdss
u (L/kg) 0.10 - 96 (28) 0.30 - 590 (34) 0.13 - 4.5 (57) 14 - 4391 (13) 
CLren
u (ml/min/kg) 0.40 - 4.4 (18) 0.20 - 13 (29) 0.18 - 12 (57) 0.30 - 14 (4) 
CLnonren
u
 (ml/min/kg) 0.80 - 283 (18) 0.18 - 462 (29) 0.080 - 26 (57) 51 - 41904 (13) 
Vdss (L/kg) 0.010 - 13 (36) 0.30 - 14 (46) 0.11 - 0.46 (60) 0.60 - 20 (14) 
CLren (ml/min/kg) 0.090 - 11 (21) 0.020 - 12 (38) 0.090 - 4.5 (60) 0.0030 - 0.72 (4) 
CLnonren (ml/min/kg) 0.70 - 198 (21) 0.18 - 284 (38) 0.080 - 4.8 (60) 6.7 - 132 (9) 
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8.2.2. Comparison with Opioids, β-ARLs, β-LAs and CCB  
The ranges of the in-vivo systemic and biologically relevant PK variables for opioids, β-ARLs, 
β-LAs109 and CCB110 are shown in Table 8.3. On average, the BZD, CCB and opioids datasets 
consist of lipophilic compounds, and as a result, they show high PPB (i.e., low fu), high Vdss
u 
suggesting extensive extravascular distribution and sequestration to body tissues/membranes etc.; 
(in general) the majority of them are cleared by nonrenal pathways, i.e., hepatic and extrahepatic 
pathways with little/negligible renal contribution (fe < 10%) for BZD and CCB, while slightly 
higher for opioids (but the majority of them show fe < 50%).  
Except clevidine (whose CLnonren values exceeds LBF, due to known extra-hepatic plasma/tissue 
ester hydrolysis) and amlodipine (whose CLnonren is below LBF, suggesting low ERhep), the rest 
of CCB in the dataset with available information are moderate to high ERhep compounds with 
CLnonren values approaching LBF. Furthermore, oxidative metabolism via phase I pathways, e.g., 
CYP3A, seem to be the major hepatic route for CCB.  
In general, CLnonren values of majority of opioids approach LBF, suggesting they are high ERhep 
drugs. Glucuronidation via UGT2B7 and phase I pathways mediated by CYP2D6, CYP3A, 
CYP2C9, and CY2C19 are known to be involved in opioid metabolism. β-ARLs are 
heterogeneous dataset, consisting of both hydrophilic as well as lipophilic compounds; as a result 
they show diverse PK property space, i.e., low to extensive extravascular tissue distribution 
(skewed towards higher values) and the majority of them have fe values less than 50% (35 out of 
47), suggesting CLtot is primarily due to elimination by nonrenal pathways, i.e., hepatic and 
extrahepatic clearance. CLren
u values exceed the GFR suggesting that they undergo net tubular 
secretion involving drug transporters; P-gp, OCTs and MRP2 are knownto be involved in 
transport of (positively) charged β-ARLs111,112. 
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On the other hand, β-LAs are, in general, hydrophilic compounds like TRP and NMB, but differ 
from TRP in being intermediate to high MW (unlike NMB that are higher MW). Their Vdss
u 
values are low, suggesting little extravascular distribution, possibly owing to their molecular size 
and/or charged hydrophilic nature. Owing to their hydrophilicity, the contribution of renal 
pathways for β-LAs is significant (fe exceeds 50%) for a large number of compounds. CLrenu 
values exceed GFR, suggesting that they undergo net tubular secretion; interactions of 
cephalosporins with hOATs is documented in the literature113,114. The majority of them show 
CLnonren values less than LBF, suggesting that they are low ERhep drugs subject to hepatobiliary, 
which may be excretion potentially mediated by hepatic drug transporters owing to their 
molecular size and (positive) charge.  
 
8.2.3. Discussion 
In the database that was used for investigating the trend analysis of human systemic PK for 670 
drugs following I.V. administration, Obach et al29 reported that (a) two-thirds of the compounds 
in their dataset are less than 90% PPB, with median fu  of 26%, (b) Vdss values ranged between 
0.035 and 700 L/kg, with a median value of 0.96 L/kg, and the vast majority (90%) of the 
compounds lying between 0.10 and 10 L/kg (biologically relevant Vdss
u is not reported), and (c) 
CLtot values ranged from 0.0037 ml/min/kg to 1070 ml/min/kg, with a median value of 4.0 
ml/min/kg, and three-fifths of the compounds having values within the range 1.0 to 10 ml/min/kg 
and about fifty six (8.4% of the total number of the) compounds potentially cleared by 
extrahepatic pathways (i.e., based on the clearance values exceeding the LBF).  
 In the present work, the median values for the reported systemic PK variables are 
comparable, in general, e.g., (a) median fu = 38% (ranging from 1% to 99%, n = 45), (b) median 
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Vdss = 0.98 L/kg (ranging from 0.04 to 59.5 L/kg, n = 50), while Vdss
u = 3.5 L/kg (ranging from 
0.05 to 2000 L/kg, n = 44), suggesting that, on an average, the compounds in the current dataset 
show binding-restricted extravascular distribution, and this trend seem to be driven by more 
lipophilic compounds in the current dataset (concurrent with the median lipophilic logD7.4 of 1.4) 
and, (d) median CLtot of 3.5 ml/min/kg (ranging from 0.02 and 72.2 ml/min/kg, n = 51). Overall, 
the in-vitro PPB/in-vivo systemic PK property space in the present work is relatively less diverse 
compared to that of Obach et al29.  
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CHAPTER 9. INTERSPECIES PHARMACOKINETIC 
ALLOMETRIC SCALING 
 
Using the publicly available PK information on the drugs/compounds belonging to BZD and 
NMB: 
9.1. Research Hypothesis II 
Human systemic PK properties can be quantitatively predicted by scaling from available in-vivo 
animal systemic PK properties using interspecies PK-AS approaches. In order to test this 
hypothesis, the following specific aims were pursued: 
e. Pertinent animal in-vivo systemic PK properties of the BZD and NMB were collected from 
the biomedical literature, and, subsequently, their biologically relevant animal PK properties 
were estimated. 
f. PK properties of BZD were compared across different animal species  
g. Allometric relationships were explored statistically using systemic and biologically relevant 
animal PK for BZD and NMB. 
h. Different allometric-based prediction methods were assessed and validated based on their 
predictive performance.  
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9.2. Methods 
9.2.1. Data Collection - Animal PK Studies 
A comprehensive and exhaustive search was carried out for original research and/or review 
articles on animal systemic PK properties of BZD and NMB, in which the compounds of interest 
are administered exclusively by the I.V. route. Furthermore, urinary excretion studies, subject to 
availability were also compiled. The in-vitro PPB and in-vivo systemic and biologically relevant 
PK properties were compiled as described in detail in Chapter - 3.  
Using these methods, the final BZD database consists of up to ten BZD including one 
metabolite, N-DMD and flumazenil, a GABAA antagonist in up to six species (i.e., including 
humans); the final NMB database consists of six NMB, including one metabolite, Org 7268 
(vecuronium metabolite), all having aminosteroid structural scaffold, mostly in cats (and dogs for 
pipercuronium).  
9.2.2. Descriptive PK Across Species 
Interspecies comparison: The in-vitro PPB and in-vivo systemic and biologically relevant PK 
properties for each compound were compared across the different animal. Furthermore, the -fold 
range across all available the species was calculated to assess variation across all available 
species for each PK variable. Since the majority of BZD undergo hepatic extraction (and show 
negligible renal clearance), they were stratified as low, intermediate and high clearance drugs 
based on the LBF in the respective animal species and see Table 3.2 for the criteria. 
Since NMB show significant renal clearance pathways, no such stratification was performed.   
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9.2.3.  Simple Allometry 
Simple PK-AS uses power functions to explore the relationship of PK variables (e.g., CLtot, Vdss; 
their biologically relevant counterparts, CLtot
u, Vdss
u) as a function of BW (in kg) across the 
animal species with available information.  
 
Table 9.1 - Concentration of Plasma Proteins in Various Animal Species55 
 Variable Mouse Rat Rabbit Dog Human 
 Weight (kg) 0.02 0.25 2.5 10 70 
 Plasma Albumin (μM) 495 479 586 398 633 
 Plasma α-Acid Glycoprotein (μM) 313 453 33 93 45 
 
 
From Table 9.1, it can be observed that plasma albumin (which, in general, binds weak acids) 
concentrations are fairly similar across the various animal species. However, there are significant 
interspecies differences in the concentrations of plasma α-acid glycoprotein (which, in general, 
binds weak bases), with the smaller animal species (e.g., mice and rats) higher concentrations 
than bigger animal species (e.g., dogs and humans). Since most of the BZD and NMB are weak 
bases that (potentially) bind to α-acid glycoprotein, indicating that the PPB-correction could 
potentially account (at least in part) for interspecies differences in the systemic PK properties.   
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9.2.4. Prediction Methods 
Single-species methods: 
 BW-Based Scaling: Human PK variables (PKV), namely, Vdss (and Vdss
u), CLtot (and CLtot
u), 
were predicted from the available (corresponding) single animal species PK based on BW, for 
BZD and NMB. The following equation was used:     
 …. Eq 9.1 
Where, the units of Vdss and Vdss
u, are in l; and, CLtot and CLtot
u are in ml/min 
 
LBF-Based Scaling: Selected human PK variables, namely, CLtot (and CLtot
u) were predicted 
from the available (corresponding) single animal species PK based on LBF for BZD and NMB. 
This prediction method is based on the assumption that renal elimination is negligible, and CLtot 
(in plasma) approaches CLhepatic
blood. The following equation was used11: 
…Eq 9.2 
 
GFR-Based Scaling: For compounds that are eliminated primarily by the kidneys, selected 
human PK variables, namely, CLren (and CLren
u), were predicted from the available single animal 
species (corresponding) PK based on GFR. The important underlying assumption (in this GFR-
based prediction of CLren) is that the drugs are renally cleared by net glomerular filtration, 
without differences in tubular handling across the species.  The following equation was used115: 
… Eq 9.3 
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Two-species methods:  
Log-log regression of PKV from at least two animal species (other than humans) were used to 
develop the PK-AS relationship (AS exponent and intercept), and the corresponding human PKV 
was predicted using the equation:    
Log (PKV) = b*Log (BW) + Log a; …. Eq 9.4 
where a the intercept and b is the AS exponent obtained from the PK-AS relationship based on at 
least two animal species. 
 
9.2.5. Validation of the Predictive Performance of Different Prediction Methods 
The predictive performance of the different PK-AS methods was assessed using % mean 
prediction error (%MPE) for bias and % root mean square error (%RMSE) for imprecision.  
The respective equations that were used116: 
   … Eq 9.5 
 … Eq 9.6 
Furthermore, MPE values between -50% and 100% (i.e., a 0.5- to 2.0-fold prediction error) was 
considered as an acceptable range of prediction11. The number (or percentage) of compounds 
whose predicted values fall within this range were considered acceptable predictions, which were 
then used to compare the accuracy of the predictions based on the different methods.   
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CHAPTER 10. INTERSPECIES SCALING OF BZD 
 
10.1. Results 
10.1.1.   Comparative PK of BZD Across Different Species 
The final animal systemic PK database consists of ten BZD, including one metabolite, N-DMD 
and flumazenil, a GABAA antagonist. There are several missing values, i.e., for most of the BZD 
in the database, there is limited information available in a few preclinical species.  
Overall, there are large interspecies differences in the BW-corrected in-vivo systemic animal PK 
properties, namely, CLtot (mean values across the available animal species ranges from 1.7 
ml/min/kg for N-DMD to 36.7 ml/min/kg for midazolam with an overall 1 to 200-fold range) and 
Vdss
 (mean values across the available animal species ranges from 0.5 l/kg for chlordiazepoxide 
to 4.7 l/kg for clonazepam and a 1 to 17-fold overall range) as represented in Table - 10.1. There 
are even larger interspecies differences in BW-corrected unbound in-vivo systemic PK animal 
properties, namely, CLtot
u (mean values across the available animal species ranges from 18.2 
ml/min/kg for N-DMD to 973.4 ml/min/kg for midazolam and a 1 to 272-fold overall range) and 
Vdss
u (mean values across the available animal species ranges from 4.8 l/kg for triazolam to 39.4 
l/kg for diazepam and a 1 to 18-fold overall range) as represented in Table 10.1. In-vitro fu 
values for most BZD with available information also show interspecies differences, i.e., in 
general, larger animal species showing lower fu, e.g., diazepam and N-DMD showed highest 
PPB in humans and (see Table 10.2 and Figure 10.1 & 10.2 for diazepam, and N-DMD 
respectively).  
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Further, BZD in the dataset are categorized (Table 10.3) as low, intermediate and high ERhep 
drugs in each animal species with available information by comparing the reported systemic 
CLtot in plasma to the LBF in the respective animal species (shown in Table 10.3). However, two 
important assumptions in the estimation of ERhep include (a) renal elimination is considered 
negligible, and (b) systemic CLtot in plasma is considered equivalent to CLnonren
blood (i.e., B:P 
ratio is assumed to be close to 1.0 across the species). Certain BZD, e.g., temazepam, diazepam, 
midazolam, triazolam, etc., show higher ERhep in smaller animal species and lower ERhep in 
larger animal species. This is a plausible explanation for (plasma protein) binding-restricted 
hepatic extraction (low ERhep) in larger animal species, e.g., humans, for certain BZD, e.g., 
diazepam. 
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Table 10.1 - In-vitro and In-vivo Systemic and Biologically Relevant PK Variables Across Different Animal Species 
Compound Species 
BW 
(kg) 
Mean 
Dose 
(mg/kg) 
CLtot 
(ml/min/kg) 
CLtot 
(ml/min) 
Vdss  
(L/kg) 
Vdss  
(L) 
fu  
(%) 
CLtotu 
(ml/min/kg) 
Vdssu 
(L/kg) 
Alprazolam Dogs 10 8.9     43   
 Humans 70 0.50     32   
Chlordiazepoxide Dogs 12 8.9 4.4 52 0.52 6.2    
 Humans 70 0.50 0.44 31 0.39 27    
Clonazepam Mice 0.020 2.0 32 0.65 6.4 0.13    
 Humans 70 0.030 0.90 63 3.0 210    
Diazepam Rats 0.25 5.0 82 20 1.7 0.43 14 582 12 
 
Guinea 
Pigs 
0.85 2.5 19 16 1.6 1.4 9.0 211 18 
 Cats 4.0 12.5 3.4 14 1.6 6.4 - - - 
 Rabbits 2.5 1.8 24 60 4.1 10 11 218 37 
 Dogs 10 1.0 19 190 3.0 30 4.0 475 75 
 Humans 70 0.20 0.40 28 1.1 77 2.0 20 55 
Minimum  0.25 0.20 0.40 14 1.1 0.43 2.0 20 12 
Maximum  70 12.5 82 190 4.1 77 14 582 75 
Mean  15 3.8 25 55 2.2 21 8.0 251 33 
SD  27 4.6 29 68 1.1 29 4.9 236 28 
Fold-range  280 63 205 14 3.7 179 7.0 29 6.3 
COV  187% 119% 120% 125% 52% 141% 62% 94% 86% 
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N-DMD Cats 4.0 7.5 0.50 2.0 1.0 4.0 14 3.6 7.1 
 Dogs 8.3 1.5 4.5 37 1.2 10 10 45 12 
 Humans 70 0.10 0.24 14 1.2 84 3.0 6.7 40 
Minimum  4.0 0.10 0.24 2.0 1.0 4.0 3.0 3.6 7.1 
Maximum  70 7.5 4.5 37 1.2 84 14 45 40 
Mean  27 3.0 1.7 18 1.1 33 10 18 20 
SD  37 3.9 2.4 18 0.12 45 5.6 23 18 
Fold-range  17 75 19 19 1.2 21 4.7 13 5.6 
COV  135% 130% 139% 101% 10% 136% 62% 125% 90% 
Lorazepam Cats 4.0 0.50 -  -  12   
 Rabbits 2.5 0.20 22  1.7  -   
 Humans 70 0.040 1.2  1.3  10   
Midazolam Rats 0.25 7.5 72 18 1.8 0.45 3.0 2410 60 
 Cats 4.0 10 30 121 2.4 9.6 9.0 336 27 
 Humans 70 0.15 7.0 490 1.0 70 4.0 175 25 
Minimum  0.25 0.15 7.0 18 1.0 0.45 3.0 175 25 
Maximum  4.0 10 72 490 2.4 70 9.0 2410 60 
Mean  25 5.9 37 210 1.7 27 5.3 974 37 
SD  39 5.1 33 248 0.70 38 3.2 1247 20 
Fold-range  16 67 10 27 2.4 156 3.0 14 2.4 
COV  159% 87% 91% 118% 41% 142% 60% 128% 3% 
Triazolam Rats 0.25 9.3 50 13 2.5 0.63 -   
 Cats 4.0 0.30 15 60 1.4 5.6 33 45 4.2 
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 Humans 70 0.0030 2.8 196 0.60 42 11 25 5.4 
Minimum  0.25 0.0030 2.8 13 0.60 0.63    
Maximum  4.0 9.3 50 196 2.5 42    
Mean  25 3.2 23 90 1.5 16    
SD  39 5.3 25 95 1.0 23    
Fold-range  16 3100 18 15 4.2 67    
COV  159% 165% 108% 106% 64% 141%    
Flunitrazepam Rats 0.25 2.5     15   
 Cats 4.0 0.30     32   
 Humans 70 0.020     23   
Minimum  0.25 0.020     15   
Maximum  4.0 2.5     32   
Mean  25 0.94     23   
SD  39 1.4     8.5   
Fold-range  16 125     2.1   
COV  159% 144%     36%   
Oxazepam Rats 0.25 7.5 24 6.0 1.9 0.48 9.0 267 21 
 Dogs 10 1.3 5.1 51 1.4 14 10 51 14 
 Humans 70 0.20 1.1 77 0.60 42 5.0 22 12 
Minimum  0.25 0.20 1.1 6.0 0.60 0.48 5.0 22 12 
Maximum  10 7.5 5.1 77 1.9 42 10 267 21 
Mean  27 3.0 10 45 1.3 19 8.0 113 16 
SD  38 4.0 12 36 0.66 21 2.6 134 4.8 
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Fold-range  40 38 4.6 13 3.2 29 2.0 12 1.8 
COV  141% 132% 122% 80% 50% 113% 33% 118% 30% 
Temazepam Cats 6.0 5.0 6.5  1.7     
 Humans 70 0.40 1.4  -     
Flumazenil Dogs 10 0.010 37  2.5     
 Humans 70 
0.030 - 
0.54 
15  0.90     
 
 
 179 
Table 10.2 - Plasma Protein Binding (fu %) of BZD in Most Common Animal Species 
Compound 
Species 
Rat Cat Dog Human 
Alprazolam 
  
43% 32% 
Diazepam 14% 
 
4% 2% 
N-DMD 
 
14% 10% 3% 
Lorazepam 
 
12% 
 
10% 
Midazolam 3% 9% 
 
4% 
Triazolam 
 
33% 
 
11% 
Flunitrazepam 15% 32% 
 
23% 
Oxazepam 9% 
 
10% 5% 
 
Figure 10.1 - Diazepam: fu (%) vs. BW (kg) in log scale in Various Animal Species 
 
 
Figure 10.2 - N-DMD: fu (%) vs. BW (kg) in log scale in Various Animal Species 
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Table 10.3 - Categorization of BZD Into Low/Intermediate/High ERhep in Various Animal Species 
Compound 
Rats Rabbits Cats Dogs 
Humans 
CLtot 
(ml/min/kg) 
ERhep 
CLtot 
(ml/min/kg) 
ERhep 
CLtot 
(ml/min/kg) 
ERhep 
CLtot 
(ml/min/kg) 
ERhep 
CLtot 
(ml/min/kg) 
ERhep 
Temazepam 
  
  6.5 Intermediate 
  
1.7 Low 
Diazepam 81.6 High 24 Low 3.4 Low 19 Intermediate 0.4 Low 
N-DMD 
  
  0.5 Low 4.5 Low 0.2 Low 
Midazolam 72.3 High   30.2 High 
  
7.0 Intermediate 
Triazolam 50 High   15 High 
  
2.7 Low 
Oxazepam 24 Low   
  
5.1 Low 1.1 Low 
Chlordiazepoxide 
  
  
  
4.4 Low 0.4 Low 
Flumazenil 
  
  
  
37.4 High 14.8 Intermediate 
Lorazepam 
  
21.7 Low 
    
1.2 Low 
 
 
 10.1.2.    Simple PK Allometry 
Allometric relationships were studied for ten BZD, using information available in various animal 
species including humans. The exponents of these allometric relationships i.e., logarithm of each 
of Vdss (L), Vdss
u (L), CLtot (ml/min), CLtot
u (ml/min) plotted as a function of logarithm of BW (in 
kg) in various animal species are shown in Tables 10.4 - 10.7 respectively. They were compared 
with widely reported PK scaling factors in literature117 - 0.75 for CLtot (and CLtot 
u) and 1.0 for 
Vdss (and Vdss
u). Figures 10.3 - 10.6 show the interspecies PK-AS plots of Vdss, Vdss
u, CLtot and 
CLtot
u respectively, for a prototypical BZD, namely diazepam. The mean (range, n) AS 
coefficients for Vdss and Vdss
u are found to be 0.84 (0.48 - 1.1, n = 9) and 1.1 (0.90 - 1.6, n = 5), 
respectively; and (log - log) correlation coefficients are high (r2>0.93), suggesting a good fit of 
the allometric relationships. The physiological body compartments, namely, total body water, 
intracellular and extracellular water, plasma and blood volumes have been shown55 to scale with 
an AS coefficient of around 1.0 across the animal species (see Chapter 9); and the obtained mean 
AS coefficient for Vdss
u close to 1.0, suggests that distribution volumes for BZD scale well with 
physiological body compartments across the animal species. Mean (range, n) AS coefficients for 
CLtot and CLtot
u for BZD with available information in various animal species are 0.42 (0.13-
0.60, n = 9) and 0.68 (0.53-0.97, n = 5), respectively; and goodness of fit (r2) ranges from 0.11-
0.99. Chlordiazepoxide was excluded from estimation of the mean slope, since it scales with an 
AS of -0.3, i.e., it shows a value higher CLtot (in ml/min/kg) in smaller animal species (dogs) 
than larger animal species (humans) - potentially due to intrinsic species differences in clearance 
pathways. CLtot
u scaling for BZD is less than the (expected41,118) AS coefficient of 0.7 to 0.8 
(depending on the organ flow rates, e.g., LBF, RPF, GFR etc., as shown in Chapter 9), which 
suggests that even after accounting for the interspecies differences in PPB, qualitative and/or 
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quantitative interspecies differences in intrinsic (hepatic/metabolic) clearance seem to exist, i.e., 
smaller species showing higher metabolic clearance than larger species, especially humans. 
Furthermore, the biologically relevant PK properties, Vdss
u and CLtot
u, for most of the BZD in the 
dataset with available information show higher AS coefficients (1.14 and 0.53) than those 
obtained for uncorrected counterparts (0.84 and 0.42 respectively). A plausible explanation is the 
(plasma protein) binding-restricted tissue distribution and hepatic extraction, which seem to 
affect the PK-AS relationships and lower the allometric coefficients for uncorrected Vdss and 
CLtot. 
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Table 10.4 - Allometric PK Scaling of BZD - Log Vdss vs. Log BW 
Compound n BW range (kg) r2 Slope ± SE 
Chlordiazepoxide 2 12 - 70 . 0.84 
Clonazepam 2 0.02 - 70 . 0.91 
Diazepam 6 0.25 - 70 0.93 0.94 ± 0.13 
N-DMD 3 4 - 70 0.99 1.05 ± 0.05 
Lorazepam 2 2.5 - 70 . 0.92 
Midazolam 3 0.25 - 70 0.98 0.90 ± 0.12 
Triazolam 3 0.25 - 70 0.99 0.75 ± 0.03 
Oxazepam 3 0.25 - 70 0.99 0.81 ± 0.09 
Flumazenil 2 10 - 70 . 0.48 
  
Mean Slope ± SD (n = 9) 0.84 ± 0.16 
 
 
 
Figure 10.3 - Diazepam: log (Vdss in l) vs. log (BW in kg) in Various Animal Species 
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Table 10.5 - Allometric PK Scaling of BZD - log Vdssu vs. Log BW 
Compound n BW range (kg) r2 Slope ± SE 
Diazepam 5 0.25 - 70 0.99 1.3 ± 0.03 
N-DMD 3 4 - 70 0.99 1.6 ± 0.03 
Midazolam 3 0.25 - 70 0.99 0.84 ± 0.08 
Triazolam 2 0.25 - 70 . 1.1 
Oxazepam 3 0.25 - 70 0.99 0.90 ± 0.08 
  
Mean Slope ± SD (n=5) 1.1 ± 0.32 
 
 
 
 
 
Figure 10.4 - Diazepam: log (Vdssu in l) vs. log (BW in kg) in Various Animal Species 
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Table 10.6 - Allometric PK Scaling of BZD - log CLtot vs. log BW 
Compound n BW range (kg) r2 Slope ± SE 
Chlordiazepoxide 2 12 - 70 . -0.30 
Clonazepam 2 0.02 - 70 . 0.56 
Diazepam 6 0.25 - 70 0.11 0.17 ± 0.24 
N-DMD 3 4 - 70 0.18 0.42 ± 0.90 
Lorazepam 2 2.5 - 70 . 0.13 
Midazolam 3 0.25 - 70 0.99 0.60 ± 0.06 
Triazolam 3 0.25 - 70 0.99 0.49 ± 0.05 
Oxazepam 3 0.25 - 70 0.96 0.47 ± 0.06 
Temazepam 2 6 - 70 . 0.36 
Flumazenil 2 10 - 70 . 0.52 
 
 Mean Slope* ± SD (n = 9) 0.42 ± 0.17 
       *Excluding Chlordiazepoxide 
 
 
Figure 10.5 - Diazepam: log (CLtot in ml/min) vs. log (BW in kg) in Various Animal Species 
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Table 10.7 - Allometric PK Scaling of BZD - log CLtotu vs. log BW 
Compound n BW range (kg) r2 Slope ± SE 
Diazepam 5 0.25 - 70 0.64 0.53 ± 0.23 
N-DMD 3 4 - 70 0.54 0.97 ± 0.88 
Midazolam 3 0.25 - 70 0.93 0.54 ± 0.14 
Triazolam 2 0.25 - 70 . 0.80 
Oxazepam 3 0.25 - 70 0.99 0.56 ± 0.14 
 
 Mean Slope ± SD (n = 5) 0.68 ± 0.20 
 
 
 
 
Figure 10.6 - Diazepam: log (CLtotu in ml/min) vs. log (BW in kg) in Various Animal Species 
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10.1.3.   Prediction Methods 
Single-species methods: 
BW-Based Scaling:  
This method assumes an AS exponent of 1.0 for both Vdss (and Vdss
u) as well as CLtot (and 
CLtot
u). However, as discussed above, although the mean AS exponents for Vdss and Vdss
u are 
comparable to 1.0, the mean AS exponents for CLtot and CLtot
u are lower than 1.0, suggesting 
that the CLtot and CLtot
u predictions will be prone to errors. Single-species BW-based predictions 
(and % prediction errors, %PE) of Vdss, Vdss
u, CLtot and CLtot
u for individual BZD in the 
common preclinical species with available information are shown in Tables 10.8, 10.10, 10.12 
and 10.14 respectively. Additionally, bias (measured by % mean prediction error, MPE) and 
imprecision (measured by % root mean square error, RMSE) and number of compounds (and 
percentage of predictions) within ‘acceptable’ range of -50% to 100% are summarized in Tables 
10.9, 10.11, 10.13 and 10.15 for Vdss, Vdss
u, CLtot and CLtot
u, respectively.  
BW-based scaling of Vdss for BZD shows systematic positive bias, i.e., consistent over-
prediction, regardless of the species used. However, after correcting for fu, Vdss
u for BZD shows 
significant improvement in the MPE in all the species, and a slightly higher percentage of the 
compounds within the acceptable range of MPE - if cat and dog PK is used for the prediction of 
Vdss
u, compared to the Vdss predictions (although this is based on a limited sample size). This 
suggests that the prediction of Vdss
u is improved after accounting for interspecies differences in 
PPB. BW-based scaling of CLtot for BZD also shows a systemic bias (much higher than for Vdss) 
regardless of the species used. Likewise, after correcting for fu, CLtot
u for BZD shows significant 
improvement in MPE in all species, but still, consistently overpredicting from rats and dogs.  
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The plausible explanation for this can be because (a) the underlying assumption of AS exponent 
for single-species based approaches is equal to 1.0, which is not the case for BZD as discussed 
above; and (b) even after correcting for species differences in PPB, there are 
qualitative/quantitative species differences in clearance mechanisms, independent of body size. 
CLtot
u predictions from cats, however, are acceptable for all the three compounds with available 
information in the current dataset.  
     
LBF-Based Scaling:  
The results CLtot and CLtot
u predictions for individual compounds based on LBF scaling are 
shown in Table 10.16 and 10.18, respectively, while prediction errors, bias and imprecision are 
summarized in Table 10.17 and 10.19, respectively.  
The AS exponent for LBF across different species is 0.85 (see Chapter 9), which is lower than 
that assumed for BW-based scaling (1.0). Therefore, in general, the prediction errors obtained 
from LBF-based scaling are relatively lower than those obtained from BW-based scaling but still 
were unacceptable.  
 
Two-species methods:  
Due the limited availability of in-vivo systemic PK data in a sufficient number of animal species 
for most of the BZD in the database (only five BZD), the results for the two-species PK-AS 
approaches could not be interpreted adequately. 
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Table 10.8 - Prediction of Human Vdss - BW based Scaling 
Compound 
From Rats PK From Cats PK From Dogs PK 
Obs. Pred. %PE Obs. Pred. %PE Obs. Pred. %PE 
Diazepam 77 119 55% 77 112 45% 77 1330 1627% 
NDMD    84 70 -17% 84 84 0% 
Midazolam 70 126 80% 70 168 140%    
Triazolam 42 175 317% 42 98 133%    
Chlordiazepoxide       27 36 33% 
Flumazenil       63 175 178% 
Oxazepam 42 133 217%    42 98 133% 
 
 
 
 
Table 10.9 - Summary of Predictions of Human Vdss - BW based Scaling 
Species 
 
n 
 
Prediction Error 
No. of 
Compounds in  
-50% to 100% 
error range 
Bias Imprecision 
%MPE %RMSE 
Rats PK 4 167 (± 61%) 198 2/4 (50%) 
Cats PK 4 75 (± 38%) 100 2/4 (50%) 
Dogs PK 5 394 (± 310%) 735 2/5 (40%) 
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Table 10.10 - Prediction of Human Vdssu - BW based Scaling 
Compound 
From Rats PK From Cats PK From Dogs PK 
Obs. Pred. %PE Obs. Pred. %PE Obs. Pred. %PE 
Diazepam 3850 850 -78%    3850 5250 36% 
NDMD    2800 500 -82% 2800 840 -70% 
Midazolam 1750 4200 140% 1750 1867 7%    
Triazolam    3812 297 -22%    
Oxazepam 840 1478 76%    840 980 17% 
 
 
 
 
Table 10.11 - Summary of Predictions of Human Vdssu - BW based Scaling 
Species 
 
n 
 
Prediction Errors 
No. of 
Compounds in  
-50% to 100% 
error range 
Bias Imprecision 
%MPE %RMSE 
Rats PK 3 46 (± 65%) 103 1/3 (33%) 
Cats PK 3 -32 (± 26%) 49 2/3 (66%) 
Dogs PK 3 -10 (± 33%) 53 2/3 (66%) 
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Table 10.12 - Prediction of Human CLtot - BW based Scaling 
Compound 
From Rats PK From Cats PK From Dogs PK 
Obs. Pred. %PE Obs. Pred. %PE Obs. Pred. %PE 
Temazepam    98 455 364%    
Diazepam 28 5712 20300% 28 238 750% 28 1330 4650% 
NDMD    14 35 150% 14 35 150% 
Midazolam 490 5061 933% 490 2114 331%    
Triazolam 196 3500 1686% 196 1050 436%    
Chlordiazepoxide       31 306 893% 
Flumazenil       1036 2618 153% 
Oxazepam 77 1680 2082%    77 357 364% 
 
 
 
 
Table 10.13 - Summary of Predictions of Human CLtot - BW based Scaling 
Species 
 
n 
 
Prediction Errors 
No. of Compounds 
in -50% to 100% 
error range 
Bias Imprecision 
%MPE %RMSE 
Rats PK 4 6250 (± 4689%) 10249 0/4 (0%) 
Cats PK 5 406 (± 98%) 451 0/5 (0%) 
Dogs PK 5 1242 (± 828%) 2126 0/5 (0%) 
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Table 10.14 - Prediction of Human CLtotu - BW based Scaling 
Compound 
From Rats PK From Cats PK From Dogs PK 
Obs. Pred. %PE Obs. Pred. %PE Obs. Pred. %PE 
Diazepam 1400 40800 2814%    1400 33250 2275% 
NDMD    467 250 -46% 466.7 3150 575% 
Midazolam 12250 168700 1277% 12250 23500 92%    
Triazolam    1782 3182 79%    
Oxazepam 1540 18667 1112%    1540 3570 132% 
 
 
 
 
Table 10.15 - Summary of Predictions of Human CLtotu - BW based Scaling 
Species 
 
n 
 
Prediction Errors 
No. of Compounds 
in -50% to 100% 
error range 
Bias Imprecision 
%MPE %RMSE 
Rats PK 3 1734 (± 542%) 1896 0/3 (0%) 
Cats PK 3 42 (± 44%) 75 3/3 (100%) 
Dogs PK 3 994 (± 653%) 1357 0/3 (0%) 
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Table 10.16 - Prediction of Human CLtot - LBF based Scaling 
Compound 
From Rats PK From Cats PK From Dogs PK 
Obs. Pred. %PE Obs. Pred. %PE Obs. Pred. %PE 
Diazepam 28 9 -69% 28 122 335% 28 133 375% 
NDMD    14 18 28% 14 26 87% 
Midazolam 490 8 -98% 490 1083 121%    
Triazolam 196 5 -97% 196 538 174%    
Chlordiazepoxide       31 37 19% 
Flumazenil       1036 262 -75% 
Oxazepam 77 2 -97%    77 36 -54% 
Temazepam    98 233 138%    
 
 
 
 
Table 10.17 - Summary of Predictions of Human CLtot - LBF based Scaling 
Species 
 
n 
 
Prediction Errors 
No. of Compounds 
in -50% to 100% 
error range 
Bias Imprecision 
%MPE %RMSE 
Rats PK 4 -90 (± 7%) 91 0/4 (0%) 
Cats PK 5 159 (± 206%) 188 1/5 (20%) 
Dogs PK 5 70 (± 81%) 177 2/5 (40%) 
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Table 10.18 - Prediction of Human CLtotu - LBF based Scaling 
Compound 
From Rats PK From Cats PK From Dogs PK 
Obs. Pred. %PE Obs. Pred. %PE Obs. Pred. %PE 
Diazepam 1400 61 -96%    1400 3325 138% 
NDMD    467 128 -73% 467 261 -44% 
Midazolam 12250 253 -98% 12250 12031 -2%    
Triazolam    1782 1630 -9%    
Oxazepam 1540 28 -98%    1540 357 -77% 
 
 
 
 
Table 10.19 - Summary of Predictions of Human CLtotu - LBF based Scaling 
Species 
 
n 
 
Prediction Errors 
No. of Compounds 
in -50% to 100% 
error range 
Bias Imprecision 
%MPE %RMSE 
Rats PK 3 -97 (± 1%) 97 0/3 (0%) 
Cats PK 3 -28 (± 92%) 42 2/3 (66%) 
Dogs PK 3 6 (± 67%) 95 1/3 (33%) 
 
 
 
 
Table 10.20 - Predictions based Two Species Method - Cats and Dogs 
Compound 
Human CLtot (ml/min) Human CLtotu (ml/min) Human Vdss (L) Human Vdssu (L) 
Obs. Pred. %PE Obs. Pred. %PE Obs. Pred. %PE Obs. Pred. %PE 
Diazepam 
28 51393 183448% 
   
77 798 936% 
   
N-DMD 
14 192994 1378426% 467 5158616 1105318% 84 143 70% 2800 3823 37% 
 
 
Table 10.21 - Prediction based on Two Species Method - Cats and Rats 
Compound 
Human CLtot (ml/min) Human CLtotu (ml/min) Human Vdss (L) Human Vdssu (L) 
Obs. Pred. %PE Obs. Pred. %PE Obs. Pred. %PE Obs. Pred. %PE 
Diazepam 28 9 -68% 
   
77 105 37% 
   
Midazolam 490 858 75% 12250 3070 -75% 70 226 223% 1750 808 -54% 
Triazolam 196 303 55% 
   
42 54 28% 
   
 
 
Table 10.22 - Prediction based on Two Species Method - Rats and Dogs 
Compound 
Human CLtot (ml/min) Human CLtotu (ml/min) Human Vdss (L) Human Vdssu (L) 
Obs. Pred. %PE Obs. Pred. %PE Obs. Pred. %PE Obs. Pred. %PE 
Diazepam 28 616 2101% 1400 29833 2031% 77 283 268% 3850 13719 256% 
Oxazepam 
77 158 105% 1540 1492 -3% 42 83 99% 840 789 -6% 
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10.2. Discussion 
There are large differences in the reported, BW-corrected, CLtot and Vdss values across various 
preclinical species with available information (range 1 - 200 fold and 1 - 17 fold respectively). 
Furthermore, in-vitro fu values for most BZD with available information also show interspecies 
differences in PPB, i.e., in general, larger animal species showing lower fu; e.g., diazepam shows 
a negative allometric relationship with BW (shown in Figure 10.1).  
In general, BZD are relatively small MW acids and bases, which are mostly lipophilic (logD7.4 > 
1.0, except for N-DMAD) and unionized at physiological pH. The two main plasma proteins to 
which the drugs bind are α-acid glycoprotein (AAG, which binds with weakly basic drugs), and 
albumin (which binds with weakly acidic and neutral drugs). The concentrations of these plasma 
proteins is known to be different across the animal species55 (see Chapter 9). Age and gender are 
important covariates that could potentially affect PPB, especially the concentration of plasma 
proteins119,120. Therefore, these factors may contribute to the observed interspecies differences in 
PPB, if the life-span expectancy (and/or gender) is not considered while AS. Lastly, the observed 
species differences in PPB may also reflect qualitative differences121 in binding affinity and/or 
the number of binding sites on the protein molecule. Sawada et al122 studied PPB of ten basic 
drugs across various preclinical species and reported that the interspecies differences in 
distribution may be attributed to differences in fu.  
Categorization of BZD based on their hepatic extraction suggests that certain BZD, e.g., 
temazepam, diazepam, midazolam, triazolam, etc., show higher ERhep in smaller animal species 
and lower ERhep in larger animal species. A plausible explanation for this finding is (plasma 
protein) binding-restricted hepatic extraction (low ERhep) in larger animal species, e.g., humans, 
for certain BZD, e.g., diazepam. Furthermore, the underlying assumptions in the estimation of 
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(and categorization of compounds based on) hepatic extraction ratio are (a) the renal elimination 
is considered negligible, and (b) systemic CLtot in plasma is considered to be equivalent to 
CLnonren
blood, that is, there are no interspecies differences B:P ratio and also that there is/are no 
extrahepatic clearance pathway(s). Diazepam has been extensively studied across various 
preclinical species and it is reported to show123 (a) different values of B:P in different species and 
(b) the systemic CLtot exceeds the LBF in rats, suggesting there are extrahepatic pathways unlike 
other species. Similarly, systemic CLtot exceeds LBF in dogs for flumazenil
124, suggesting 
extrahepatic clearance pathway(s). Boxenbaum et al125 investigated PK of BZD (n = 12)  in 
humans and dogs and reported that, in general, they exhibit greater tissue distribution and are 
metabolized more rapidly in dog than in man. Most of BZD are subject to phase I metabolism 
e.g., CYP3A, CYP2D isoforms while lorazepam undergoes phase II metabolism by 
glucuronidation via UGTs. Both qualitative (e.g., genetic polymorphisms, substrate specificity, 
catalytic activity, etc.) as well as quantitative differences (expression levels of the enzyme, etc.) 
in CYP isoforms45–47 and UGTs126 has been widely documented in literature.  
The mean (range, n) AS coefficients for Vdss and Vdss
u are found to be 0.84 (0.48 - 1.1, 9) and 
1.1 (0.90 - 1.6, 5), respectively, and both of them are comparable to 1.0, which the various 
physiological body compartments, namely, total body water, intracellular and extracellular water, 
plasma and blood volumes across the animal species (see Chapter 9). The plausible explanation 
for such an occurrence may be attributed to the lipophilic nature of most of BZD, because of 
which they undergo moderate to extensive extravascular distribution/binding to 
membranes/tissues across the various preclinical species.  
Mean (range, n) AS coefficients for CLtot and CLtot
u for BZD with available information in 
various animal species scales with exponents 0.42 (0.13-0.60, n = 9) and 0.68 (0.53-0.97, n = 5), 
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suggesting there are qualitative and/or quantitative interspecies differences in intrinsic 
(hepatic/metabolic) clearance that are independent of body size even after accounting for the 
interspecies differences in PPB. Mahmood et al117 reported AS exponents for systemic CLtot 
ranging between 0.42 to 1.2 for heterogeneous dataset of fifty compounds that were administered 
by I.V route to various animal species including humans.  
BW-based scaling of Vdss for BZD shows systematic positive bias, i.e., consistent over-
prediction, compared to Vdss predictions, regardless of the species used. However, after 
correcting for fu, Vdss
u prediction shows significant improvement in accuracy and precision of 
the predictions from all species as well as higher r2, indicating better goodness of fit and a 
slightly higher percentage of the compounds within the acceptable range of MPE - if cat and dog 
PK was used for prediction of Vdss
u,. BW-based scaling for CLtot for BZD also shows a systemic 
bias (much higher than for Vdss) regardless of the species used. Likewise, after correcting for fu, 
CLtot
u for BZD shows significant improvement in the accuracy and precision of prediction from 
all species, higher r2 but still consistently overpredicting from rats and dogs. Overall, the number 
of  acceptable predictions for Vdss and Vdss
u seem to be relatively higher than those compared to 
CLtot and CLtot
u for BW-based scaling (which is expected because of implicit assumption of 1.0 
that is not true with BZD in the current dataset).  
LBF has been shown to scale across several species (n = 11), including humans with AS 
exponent of 0.85127. Because of the limited sample size, adequate interpretation could not made 
for LBF-based predictions. However, within the limitation of a small sample size, in general, (a) 
the prediction errors in CLtot and CLtot
u seem to be lower for LBF-based scaling compared to 
BW-based scaling, possibly owing relatively higher AS exponent (implicit) assumption of 0.85 
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compared to 1.0 respectively; and (b) PPB correction seem to improve the prediction errors and 
also higher number of acceptable predictions.  
LBF-based predictions are more likely to be accurate if the drugs show high ERhep (i.e., flow-
limited hepatic clearance127) across all animal species. However, intrinsic species differences in 
PPB and/or ERhep are particularly evident for BZD. Thus, overall, neither CLtot nor CLtot
u was 
predicted adequately for BZD based on BW- or LBF-based scaling, suggesting intrinsic 
quantitative and/or qualitative species differences in hepatic metabolism and/or B:P ratios that 
are independent of size.  
Ward et al10 investigated the BW-based prediction of human systemic Vdss from respective 
values in preclinical species (i.e., I.V administration in all animal species including humans), for 
a heterogeneous dataset of 103 compounds; they found that predictions across the compounds 
were within 1.4, 1.3 and 1.0-fold error range when rats, dogs and monkeys’ systemic Vdss values 
were used for prediction, respectively. In a study carried out by Obach et al3, human systemic 
Vdss was predicted from dog systemic Vdss (collected after I.V administration in both the 
species) for 16 compounds from Pfizer’s proprietary database by BW-based scaling methods, 
i.e., assuming AS exponent of 1.0. They reported that 81% of the compounds (13 of 16) were 
within the 2-fold error range and concluded that human systemic Vdss can be predicted 
reasonably well from systemic dog Vdss. Tang et al
128 investigated using a heterogeneous 
database of 102 compounds (57 metabolized by liver - 29 low, 17 intermediate and 11 high 
ERhep; 33 excreted by kidneys; and 11 by both renal and metabolism), for the prediction of 
human systemic CLtot from rats and they reported two potential rules for the occurrence of large 
overprediction, (1) ratio of unbound fraction of drug in plasma (fu) between rats and humans 
greater than 5; and (2) (predicted) logP greater than 2. They also concluded that metabolic 
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elimination could also serve as an additional indicator for expecting large vertical allometry. 
BZD within the dataset with available information on fu in rats and humans, diazepam shows 
large vertical allometry and meets both these criteria. Tang et al129 investigated the role of the 
selection of “best” or optimal combination of preclinical species by carrying out Monte Carlo 
simulations for different combinations and found that the predicted values were heavily 
dependent on certain species like dog, whereas, parameter values from rat made no contribution 
to the predicted human values, as long as the rat was not the smallest species used. In the 
prediction of human systemic Vdss, Vdss
u, CLtot and CLtot
u of BZD within the dataset with 
available information, cats, in general, seems to show better (acceptable) predictions compared 
to other preclinical species.    
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CHAPTER 11. INTERSPECIES SCALING OF NMB 
 
11.1. Results 
11.1.1.   Comparative PK of NMB 
 The final preclinical systemic PK database consists of six NMB, including one metabolite, Org 
7268 (Vecuronium metabolite), all having the aminosteroid structural scaffold, mostly in cats 
(and dogs for Pipercuronium). For these six NMB, there was information on urinary excretion 
data but PPB values were not found in the literature. There are considerable interspecies 
differences in the reported BW-corrected in-vivo systemic animal PK properties (shown in Table 
11.1), namely, CLtot (2 to 10 fold) while Vdss and CLren were comparable (except for CLren of 
pipercuronium) to respective in-vivo human systemic PK. 
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Table 11.1 - Summary of In-vivo Systemic PK of NMB Cats (&Dogs) 
 
Species 
Vdss 
(L/kg) 
CLtot 
(ml/min/kg) 
fe (%) 
CLren 
(ml/min/kg) 
CLnonren 
(ml/min/kg) 
ERhep** 
Rocuronium 
Cats 0.25 31 2.0% 0.56 30 High 
Humans 0.21 3.5 25% 0.88 2.6  
Org 9489 
Cats 0.19 33 5.0% 1.8 31 High 
Humans 0.46 5.8 8.0% 0.46 5.3  
Org 9453 
Cats 0.14 35 3.0% 1.1 34 High 
Humans 0.18 6.9 5.0% 0.35 6.6  
Org 7268 
Cats 0.22 58 4.0% 2.1 56 Extrahepatic? 
Humans 0.26 4.3 18% 0.77 3.5  
Vecuronium 
Cats 0.23 12 14% 1.7 10 Low 
Humans 0.20 5.0 7.0% 0.35 4.7  
Pipercuronium 
Cats 0.36 5.0 54% 2.7 2.3 Low  
Dogs 0.30 6.0 78% 4.7 1.3 Low  
Humans 0.32 2.6 41% 1.1 1.5  
**ERhep is estimated as CLnonren/LBF, and the cut-off are discussed in Table 3.2; LBF in cats is 41 ml/min/kg 
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11.1.2.   Prediction Methods 
Single-species methods: 
BW-Based Scaling:  
The results of BW-based scaling of human systemic Vdss and CLtot from the respective cat PK 
variables are shown in Table - 11.1 and summarized in Table - 11.2. Except for Org 9489, all 
Vdss predictions for the remaining NMB in the dataset are within the acceptable range. The 
plausible mechanistic explanation for such a high percentage (83%) of acceptable BW-based 
prediction of Vdss of the compounds within the dataset could be due to the limited extravascular 
distribution of NMB both in humans as well as preclinical species, potentially due to their large 
MW and/or (positively charged) hydrophilic nature. Further, the systematic bias is found to be 
insignificant and the imprecision in predictions for Vdss is quite low (< 30%).  
On the other hand, none of the CLtot predictions for NMB in the current dataset, except 
Pipercuronium, are within the acceptable range. Also, there is a significant positive systematic 
bias (i.e., consistent over-prediction) and high imprecision in the CLtot predictions. This suggests 
that even after correcting for BW, there are interspecies differences in CLtot. After accounting for 
the individual clearance pathways, i.e., renal and nonrenal, it is evident from Table - 11.1 that, 
the interspecies differences are more likely to exist in the nonrenal pathways, since the BW-
corrected CLren are comparable between cats/dogs and humans for most of the NMB within the 
dataset. Mechanistically, apart from potential species differences in hepatobiliary clearance 
pathways, cats may also show certain extrahepatic clearance pathways (unlike humans), evident 
from CLnonren values for certain NMB, which exceed the LBF. Also, BW-based scaling implies 
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an AS exponent of 1.0, which may or may not hold true for NMB (with the available information 
for limited number of NMB and only in cats, it is difficult to estimate the AS exponent for CLtot). 
 
LBF-Based Scaling:  
The results for LBF-based human systemic CLtot predictions from cats are shown in Table - 11.3 
and summarized in Table - 11.4 below. There is a significant positive systematic bias (i.e., 
consistent over-prediction) and high imprecision in the CLtot predictions. It is observed that most 
of the NMB in the current dataset (except pipercuronium) are primarily cleared by nonrenal 
pathways (i.e., relatively low CLren) in cats (which is the underlying assumption for the LBF-
based prediction method). The plausible mechanistic explanation for unacceptable, consistent 
(positively) biased and imprecise LBF-based predictions for CLtot could be due to the significant 
qualitative and/or quantitative interspecies differences in CLtot, more specifically in CLnonren.  
The results of LBF-based human CLnonren predictions from cats are shown in Table - 11.5 and 
summarized in Table - 11.6 below. There is a significant positive systematic bias (i.e., consistent 
over-prediction) and high imprecision in CLnonren predictions. The imprecision in the CLnonren 
predictions is higher than those obtained for CLtot predictions, suggesting that there are potential 
qualitative and/or quantitative interspecies differences. The CLnonren value for Org 7268 in cats 
exceed the LBF, suggesting it may be subject to extrahepatic pathways. Assuming that there are 
no significant extrahepatic clearance pathways, the CLnonren values for the rest of NMB in cats, 
rocuronium, Org 9489 and Org 9453 approach the LBF, suggesting that they are likely to be 
intermediate - high ERhep drugs, while vecuronium and pipercuronium are low ERhep drugs in 
cats. On the other hand, CLnonren values for all the NMB in the current dataset are lower than 
LBF, suggesting that they are likely to be low ERhep drugs.  
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GFR-Based Scaling:  
The results for GFR-based human systemic CLren predictions from cats are shown in Table - 11.7 
and summarized in Table - 11.8 below. The majority (67%) of GFR-based CLren predictions for 
NMB in the current dataset are within the acceptable range. Additionally, there was significant 
positive bias, i.e., consistent overprediction and high imprecision. The plausible mechanistic 
explanation is the 1.5- to 3.4- fold difference with respect to cats and dogs in the GFR relative to 
that in humans (more specifically, species differences55,130 in the number of nephrons per kg of 
BW). 
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Table 11.2 - Prediction of Human Systemic PK - BW-Based Scaling From Cat PK 
Compound 
CLtot  Vdss  
Obs. Pred. %PE Obs. Pred. %PE 
Rocuronium 245 2170 786% 15 18 19% 
Org 9489 406 2310 469% 32 13 -59% 
Org 9453 483 2450 407% 13 10 -22% 
Org 7268 301 4060 1249% 18 15 -15% 
Vecuronium 350 826 136% 14 16 15% 
Pipercuronium 182 350 92% 22 25 13% 
** In Dogs 182 413 127% 22 21 -6% 
 
 
 
Table 11.3 - Summary of BW - Based Predictions of Human Systemic PK Variables 
PK Variable 
 
n 
 
Prediction Errors 
No. of Compounds  
in -50% to 100% error 
range 
Bias Imprecision 
%MPE %RMSE 
CLtot 6 523 (± 178%) 657 1/6 (17%) 
Vdss 6 -8 (± 12%) 29 5/6 (83%) 
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Table 11.4 - Prediction of Human CLtot - LBF-Based Scaling 
Compound Obs. Pred. %PE 
Rocuronium 3.5 16 354% 
Org 9489 5.8 17 191% 
Org 9453 6.9 18 160% 
Org 7268 4.3 30 591% 
Vecuronium 5.0 6.2 23% 
Pipercuronium 2.6 2.6 -2% 
**In Dogs 2.6 4.2 62% 
 
 
 
Table 11.5 - Summary of CLtot Predictions - LBF-Based Scaling From Cat PK 
PK Variable 
 
n 
 
Prediction Errors 
No. of Compounds  
in -50% to 100% 
error range 
Bias Imprecision 
%MPE (± SE) %RMSE 
CLtot 6 220 (± 91%) 299 2/6 (33%) 
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Table 11.6 - Prediction of Human CLnonren - LBF-Based Scaling 
Compound Obs. Pred. %PE 
Rocuronium 2.62 15.59 495% 
Org 9489 5.34 15.99 199% 
Org 9453 6.55 17.39 165% 
Org 7268 3.53 28.63 711% 
Vecuronium 4.65 5.30 14% 
Pipercuronium 1.53 1.19 -22% 
**In Dogs 1.53 0.92 -40% 
 
 
 
Table 11.7 - Summary of CLnonren Predictions - LBF-Based Scaling From Cat PK 
PK Variable 
 
n 
 
Prediction Errors 
No. of Compounds  
in -50% to 100% 
error range 
Bias Imprecision 
%MPE (± SE) %RMSE 
CLtot 6 260 (± 117%) 369 2/6 (33%) 
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Table 11.8 - Prediction of Human CLren - GFR-Based Scaling 
Compound Obs. Pred. %PE 
Rocuronium 0.88 0.25 -72% 
Org 9489 0.46 0.80 74% 
Org 9453 0.35 0.47 34% 
Org 7268 0.77 0.95 23% 
Vecuronium 0.35 0.74 111% 
Pipercuronium 1.1 1.2 13% 
**In Dogs 1.1 1.2 31% 
 
 
 
 
Table 11.9 - Summary of CLren Predictions - GFR - Based Scaling From Cat PK 
PK Variable 
 
n 
 
Prediction Errors 
No. of Compounds  
in -50% to 100% 
error range 
Bias Imprecision 
%MPE (± SE) %RMSE 
CLren 6 31 (± 25%) 64 4/6 (67%) 
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 11.2. Discussion 
Overall, the prediction of human systemic Vdss of NMB from respective cat PK seem to be the 
most accurate (i.e., lowest bias and imprecision) compared to (BW-based and LBF-based) CLtot 
and (GFR-based) CLren predictions. The plausible explanation could be due to the limited 
extravascular distribution of NMB both in humans as well as preclinical species, owing to large 
size and (positively charged) hydrophilic nature at physiological pH.  
The bias and imprecision of CLtot predictions were lower for LBF-based scaling relative to BW-
based scaling, suggesting that hepato(biliary) route(s) could be the major clearance pathways 
while the contribution of renal clearance be low. However, the predictions are still biased and 
imprecise, suggesting likely qualitative and/or quantitative differences in the clearance 
mechanisms, e.g., few NMB show extra-hepatic pathways (as evident from plasma CLnonren 
values exceeding the LBF, assuming B:P ratio close to 1.0) in cats.  
Within the limitation of a small sample size, majority of the GFR-based CLren predictions were 
acceptable, possibly because they are all subject to net tubular reabsorption (CLren values lower 
than the respective GFR values, assuming that NMB show negligible PPB), but they are biased 
and imprecise, potentially due to differences in the GFR.   
 
11.3. Summary of AS-PK Findings - Comparison with BZD 
NMB and BZD differ dramatically in their respective PC/molecular and human systemic PK 
property spaces (see chapter 8). In general, BZD, are relatively small MW, weakly acidic or 
basic, unionized (at physiological pH of 7.4) lipophilic compounds, while, NMB, are relatively 
large MW, weakly basic, positively charged (at physiological pH of 7.4) hydrophilic compounds. 
For both classes the prediction of human systemic PK from preclinical species seem to be 
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relatively better for Vdss (using BW-based scaling) compared to the CLtot (BW-based or LBF-
based scaling). NMB show higher percentage of predictions within the acceptable range for BW-
based scaling of Vdss (using cats), which is mechanistically plausible because of their limited 
extravascular distribution owing to the PC/molecular properties discussed above, unlike BZD, 
which undergo moderate to extravascular tissue distribution/binding to membranes possibly 
because of their PC molecular property space discussed above.  
For NMB with available information in total systemic clearance in cats encompasses renal and 
hepatobiliary pathways, while for BZD there is inadequate information in the literature about the 
detailed mechanisms involved in the systemic CLtot. Overall, majority of the BW-based systemic 
CLtot (or CLtot
u) predictions from preclinical species were systematically (positively) biased and 
unacceptable (except from cats) suggesting even after correcting for species differences in PPB, 
there are qualitative/quantitative species differences in clearance mechanisms, independent of 
body size. Similar results were obtained for NMB, suggesting the positively biased and 
imprecise BW-based systemic CLtot predictions could be due to the significant qualitative and/or 
quantitative interspecies differences in CLtot, more specifically in CLnonren as the CLren values 
were comparable for majority of them between cats and humans.  
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CHAPTER 12. COMPARATIVE ANALYSIS ACROSS 
PHARMACOLOGICAL CLASSES OF COMPOUNDS 
 
12.1. Comparison of the QSPKR Relationships Across Pharmacological Classes 
 Overall, QSPKR of a total of eight pharmacological classes of compounds, namely, BZD, NMB, 
TRP and Class III AAR (in this research project); opioids, β-ARLs and β-LAs; and CCB have 
been investigated so far in this and previous research109,110. For the purpose of comparison of 
these relationships across classes, they are first grouped based on the molecular/PC property 
space as follows:  
a) Group I: consisting of BZD and CCB, the majority of which are of relatively low MW and 
lipophilic;  
b) Group II: consisting of heterogeneous pharmacological classes of Class III AAR, opioids and 
β-ARLs, which are of low to intermediate MW and include both hydrophilic as well as 
lipophilic compounds (although the former two classes are slightly skewed towards more 
lipophilic ones), and  
c) Group III: consisting of TRP, NMB and β-LAs, the majority of which are hydrophilic 
compounds, but vary in MW ranging from low (TRP) - intermediate/high (β-LAs and NMB). 
Next, the slope (or sensitivity) of the QSPKR relationships, i.e., in-vivo systemic as well as 
biologically relevant PK variables as a function of the molecular/PC variables is compared 
across these eight pharmacological classes, primarily focusing on the effects of logD7.4 and MW 
(as they were found to be the major determinants affecting the systemic disposition across 
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classes). Additionally, mechanistic plausibility and the potential significance of these 
relationships is also discussed.  
12.1.1.  Effect of Molecular/PC Variables on fu Across Pharmacological Classes 
 The effect of molecular/PC variables, namely, logD7.4 and MW on PPB (i.e., fu) across 
the eight pharmacological classes of compounds, which are categorized by different groups I - III 
is shown in Table 12.1.  
 Within group I, the trend is similar (i.e., negative) in direction, suggesting that for small 
MW, lipophilic compounds such as BZD and CCB, an increase in logD7.4 is associated with 
increase in PPB (or decrease in fu). However, the slope (or the sensitivity) of this relationship 
seems to be (relatively) steeper for CCB than BZD, potentially because CCB in general, are (a) 
relatively more lipophilic (logD7.4 ranges from 1.5 to 5.1, n = 14 compared to 0.75 to 3.8, n = 20 
for BZD) and/or (b) on an average, they are highly PPB and also show limited range (fu ranges 
from 0.20 to 20%, n = 13 compared to 2.0 to 65%, n = 17 for BZD) compared to BZD (and also 
to compounds belonging to other groups II and III).   
 Within group II, the trend seems to be consistent both in direction and magnitude. This is 
mechanistically plausible because of the heterogeneous nature of the molecular/PC as well as in-
vitro PPB property space for these three classes of compounds, namely, Class III AAR (fu ranges 
between 1.0 - 99%, n = 7), opioids (fu ranges between 4.0 - 92%, n = 29) and β-ARLs (fu ranges 
between 3.0 - 96%, n = 57).  
 Class III AAR within group II shows a significant negative association between fu and 
MW; the likely explanation for this trend is the high correlation between logD7.4 and MW (r = 
0.98, n = 7). Furthermore, it is observed that the slope is (significantly) steeper for the trend with 
logD7.4 than with MW; the potential reason for such a finding is the larger diversity in logD7.4 
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values (-1.7 to 5.9, n = 7) than MW values (243 - 645 Da, n = 7). Within group III - consisting of 
relatively hydrophilic compounds; namely TRP and β-LAs, fu shows a significant negative 
association with MW (rather than logD7.4), and slopes are comparable; however, for β-LAs, the 
variability explained by MW is lower than the criteria set a-priori (r2 > 0.3). For relatively large 
MW and hydrophilic NMB, fu shows a significant negative association with logD7.4 (and not 
with MW). The possible reasons for such a trend are (a) a large range in PPB (fu ranging between 
28 and 98%, n = 14), (b) despite a few missing values in logD7.4, NMB show larger range 
(ranging between -5.0 and 2.1, n = 12) than in MW (ranging between 290 and 1035 Da, n = 16).    
 The majority of the compounds in the database of the present work are bases that are, in 
general, skewed towards the relatively lipophilic side, although the majority of them are 
positively charged at physiological pH. Albumin is the major drug-binding protein in adult 
humans, and, in general, it binds weakly acidic drugs, while weakly basic drugs (in general) bind 
to alpha-1 acid glycoprotein (AAG)131. The trends observed in fu as a function of logD7.4 for 
compounds within group I and II in the present work, were comparable to those reported by 
Obach et al29 in their trend analysis of human systemic PK database of 670 compounds, where 
they expressed PPB as the logarithm of the apparent affinity constant, logK (or log[bound/free]) 
as a function of logP and it was consistent across all the charge types, acids, bases, neutral and 
zwitterions.  
 In another study by Valko et al132, logP was found to predict the drug binding to serum 
albumin for neutrals and ionized molecules, with the similar affinity133. A plausible explanation 
for higher PPB with higher lipophilicity is hydrophobic interactions with plasma proteins. 
Furthermore, based on in-vitro studies, acids are reported to show relatively higher PPB relative 
to bases and neutrals, due to an ion-pair interaction with basic residue within albumin; while 
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electrostatic interactions seem to drive the high affinity interactions between bases and acidic 
residues within AAG2,29,134. 
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Table 12.1 - Effect of LogD7.4 and MW on fu by Group  
Group 
 
LogD7.4 MW 
I 
BZD 
n = 17 
r2 = 0.51 
Slope = - 0.20 
N.S. 
CCB 
n = 12 
r2 = 0.40 
Slope = - 0.04 
N.S. 
II 
Class III AAR 
n = 7 
r2 = 0.83 
Slope = - 0.13 
n = 7 
r2 = 0.87 
Slope = -0.0028 
Opioids 
n = 29 
r2 = 0.42 
Slope = - 0.13 
N.S. 
β - ARLs 
n = 34 
r2 = 0.63 
Slope = - 0.23 
N.S. 
III 
TRP 
n = 7 
r2 = 0.41 
Slope = -0.21 
N.S 
n = 7 
r2 = 0.78 
Slope = -0.0055 
NMB 
n = 11 
r2 = 0.42 
Slope = - 0.044 
N.S. 
β - LAs N.S. 
n = 57 
r2 = 0.24 
Slope = -0.0020 
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12.1.2. Effect of Molecular/PC Variables on Vdssu (and Vdss) 
The effect of molecular/PC variables, namely, logD7.4 and MW on Vdss
u and Vdss across the 
eight pharmacological classes of compounds categorized by groups I - III is shown in Table 12.2. 
Within group I, Vdss
u (but not Vdss) values of BZD shows a significant positive association with 
logD7.4. CCB, on the other hand, do not show significant trends with Vdss
u or Vdss.  
Within group II, the trends for Vdss
u as a function of logD7.4 for Class III AAR, opioids and β-
ARLs seem to be consistent both in direction and magnitude, and also comparable with BZD 
(from group I). This is mechanistically plausible because of the heterogeneous nature of the 
molecular/PC as well as Vdss
u property space (although the rank order of diversity is Class III 
AAR > β-ARLs  > opioids) shown by these three classes of compounds, namely, Class III AAR 
(Vdss
u ranges between 1.2 - 2000 L/kg n = 7), β-ARLs (Vdssu ranges between 0.30 - 590 L/kg, n 
= 34) and opioids (Vdss
u ranges between 0.10 - 96 L/kg, n = 28).  
Vdss
 values do not show any significant trend with logD7.4 for opioids, β-ARLs and BZD, 
suggesting that the counteracting effects of logD7.4 on fu and Vdss
u resulted in no net change in 
the observed values of Vdss, while the net effect of logD7.4 on Vdss
u seem to drive the positive 
association of Vdss with logD7.4 for Class III AAR. Class III AAR also show significant positive 
association between Vdss
u (and Vdss) and MW; the most likely explanation for this trend is the 
high correlation between logD7.4 and MW (r = 0.98, n = 7). Furthermore, it can be observed that 
the slope is (significantly) steeper for the trend with logD7.4 than MW; the potential reason for 
such an occurrence is the larger diversity in logD7.4 values (-1.7 to 5.9, n = 7) than MW values 
(243 - 645 Da, n = 7). Within group III consisting of relatively hydrophilic compounds, namely 
TRP and β-LAs, Vdssu shows significant negative association with MW (rather than logD7.4) and; 
the slopes are comparable; however, for β-LAs, the variability explained by MW is lower than 
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the criteria set a-priori (r2 > 0.3). On the other hand, for relatively large MW and hydrophilic 
NMB, which have low Vdss
u values, suggesting very limited extravascular distribution, logD7.4 
shows significant positive association with Vdss
u (but not Vdss); this trend is possibly driven by 
succinylcholine, the most hydrophilic NMB with the lowest Vdss
u in the dataset (it should also be 
noted that there were several missing logD7.4 values for NMB). Lastly, the slope of the effect of 
logD7.4 on Vdss
u seems to be shallower to those shown by compounds belonging to 
pharmacological classes in groups I and II; a plausible explanation may be due to the limited 
range (0.10 - 1.2 L/kg, n = 14) and in general low values in Vdss
u compared to those in groups I 
and II 
Overall, non-specific hydrophobic interactions with tissue components and/or membranes2,133, is 
plausible explanation for the positive trends shown by BZD (in group I), Class III AAR, which 
on average, appears to be skewed more towards the lipophilic side. It is speculated that bases are 
involved in ionic interactions with the charged polar heads in the phospholipids, resulting in 
higher tissue binding and thus higher Vdss
u (and Vdss)
22,135. Furthermore, basic lipophilic 
compounds are also known to bind extensively to cellular components, such as mitochondria and 
lysosomes, which are believed to be the result of pH differences with the cytoplasm (pH 4 - 5 
and 6.7 - 7.0 in lysosomes and mitochondria versus pH 7.2 to 7.3 in cytoplasm respectively), 
commonly referred to ‘ion-trapping’20,29. The extent of ion-trapping is dependent on the 
lipophilicity and pKa of the drug, and the pH of and fraction of the hepatocyte volume occupied 
by these organelles20.  
Obach et al29, in their trend analysis of human systemic PK database of 670 compounds, reported 
a 2.5- to 10-fold increase in the median Vdss
u relative to median Vdss depending on the charge 
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type, suggesting that on an average, the drugs in the comprehensive dataset show PPB-restricted 
distribution (primarily due to the highly PPB drugs).  
The Vdss
u (but not Vdss) values of TRP, show a positive association with MW, suggesting that 
molecular size (which is highly correlated with nRot and logD7.4), is important for tissue 
distribution via passive or transporter-mediated uptake (which may rely on the flexibility of the 
drug molecule), but the exact mechanism is not fully understood. 
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Table 12.2 - Effect of LogD7.4 and MW on Vdssu and Vdss by Group 
 
Pharmacological 
Class 
LogD7.4 MW 
Group 
Log (Vdssu) Log (Vdss) Log (Vdssu) Log (Vdss) 
I 
BZD 
n = 16 
r2 = 0.57 
Slope = 0.60 
N.S. N.S. N.S. 
CCB N.S. N.S. N.S. N.S. 
II 
Class III AAR 
n = 7 
r2 = 0.97 
Slope = 0.39 
n = 7 
r2 = 0.74 
Slope = 0.15 
n = 7 
r2 = 0.81 
Slope = 0.0078 
n = 7 
r2 = 0.62 
Slope = 0.0029 
Opioids 
n = 28 
r2 = 0.49 
Slope = 0.30 
N.S. N.S. 
n = 36 
r2 = 0.22 
Slope =-0.004 
β - ARLs 
n = 34 
r2 = 0.75 
Slope = 0.45 
N.S. N.S. N.S. 
III 
TRP N.S. N.S. 
n = 7 
r2 = 0.58 
Slope = 0.0050 
n = 8 
r2 = 0.48 
Slope =-0.0015 
N.S. 
NMB 
n = 11 
r2 = 0.68 
Slope = 0.13 
n = 12 
r2 = 0.33 
Slope = 0.069 
N.S. 
N.S. N.S. 
β - LAs N.S. N.S. 
n = 57 
r2 = 0.19 
Slope = 0.0010 
N.S. 
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12.1.3. Effect of Molecular/PC Variables on CLtotu, (and CLtot) 
The effect of molecular/PC variables, namely, logD7.4 and MW on CLtot
u and CLtot across the 
eight pharmacological classes of compounds categorized by groups I - III is shown in Table 12.3. 
In general, the interpretation is limited because (a) CLtot encompasses various pathways 
depending on the pharmacological class, which is briefly summarized in Table 12.4 and (b) there 
are several missing values in the fe and fu data which reduced the number of compounds with 
information on CLren and CLnonren, their unbound PK counterparts, namely, CLren
u and CLnonren
u.  
Within group I, in general, the contribution of renal pathways is negligible and, there is limited 
confidence in the CLren estimates. Neither CLtot
u nor CLtot show any significant trend with 
logD7.4 while CLnonren
u (but not CLnonren) show a significant positive trend with logD7.4 for BZD. 
For CCB, on the other hand, both the large spread (and in general higher values) in the CLnonren
u 
values and/or higher logD7.4 values seem to drive the positive trend of CLtot
u versus logD7.4. The 
slopes for these significant trends of CLnonren
u of BZD, CLtot
u and CLnonren
u of CCB with logD7.4 
are comparable. A plausible explanation for the observed trend of CLnonren
u as a function of 
logD7.4 for BZD and CCB is non-specific hydrophobic interactions with hepatic membranes/drug 
metabolizing enzymes (e.g., CYP3A and CYP2C19 etc.) increasing hepatic uptake and/or 
enzymatic metabolism with increasing lipophilicity.  
 Owing to the diverse nature of the clearance mechanisms in which compounds belong 
pharmacological classes in group II, no further interpretation for CLnonren
u/CLnonren can be made. 
Although few of these compounds show significant renal contribution, none of the molecular/PC 
variables in the current dataset with available information could explain the relationships for 
CLren
u or CLren suggesting that they may driven by more specific molecular interactions with 
drug metabolizing enzymes and drug transporters.  
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Within group III, the significant positive trend of CLnonren
u (and more specifically, due to the 
MAO-substrates TRP) seems to drive the overall trend of CLtot
u as a function of MW. While 
none of the molecular/PC variables in the current dataset with available information could 
explain the relationships with the total systemic clearance or its mechanistic renal/nonrenal 
pathways, suggesting that they may be driven by more specific molecular interactions with drug 
metabolizing enzymes and drug transporters; CLnonren
 values seem to show significant negative 
trend with MW for β-LAs but MW could explain 30% or more of variability in neither of these 
relationships based on the criteria set a-priori (r2 > 0.3). Tables 12.5 and 12.6 show the 
relationships of CLren
u and CLren
; and CLnonren
u and CLnonren
 respectively.   
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Table 12.3 - Effect of LogD7.4 and MW on CLtotu and CLtot By Group 
Group 
Pharmacological 
Class 
LogD7.4 MW 
Log (CLtotu) Log (CLtot) Log (CLtotu) Log (CLtot) 
I 
BZD N.S. N.S. N.S. 
n = 20 
r2 = 0.40 
Slope = 0.012 
0.0048, 0.019 
CCB 
n = 12 
r2 = 0.61 
Slope = 0.97 
N.S. N.S. N.S. 
II 
Class III AAR 
n = 7 
r2 = 0.71 
Slope = 0.27 
0.072, 0.46 
N.S. 
n =7 
r2 = 0.47 
Slope = 0.0050 
N.S 
N.S. 
Opioids 
n = 29 
r2 = 0.31 
Slope = 0.21 
N.S. N.S. N.S. 
β - ARLs 
n = 34 
r2 = 0.54 
Slope = 0.41 
N.S. N.S. N.S. 
III 
TRP 
n = 7 
r2 = 0.39 
Slope = 0.24 
N.S 
N.S. 
n = 7 
r2 = 0.65 
Slope = 0.0058 
0.00085, 0.011 
N.S. 
NMB N.S. N.S. N.S. N.S. 
β - LAs N.S. N.S. N.S. 
n = 60 
r2 = 0.23 
Slope = -0.002 
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Table 12.4 - Mechanistic Pathways of CLtot By Group 
Group 
Pharmacological 
Class 
CLrenu CLnonren 
I 
BZD 
Majority show negligible renal 
clearance (and imprecisely 
estimated) 
Net tubular reabsorption 
Extensive hepatic metabolism 
(primarily by CYP3A and 2C9 
and a few by UGTs) 
No evidence of extrahepatic 
pathways 
CCB 
Majority show negligible renal 
clearance (and imprecisely 
estimated) 
Extensive hepatic metabolism 
(primarily by CYP3A and 2C9) 
II 
Class III AAR 
A few show net tubular 
reabsorption, while the rest 
show net tubular secretion  
Hepatobiliary excretion  
(drug transporters?) 
Hepatic metabolism 
Extrahepatic (unknown?) 
Opioids 
A few show net tubular 
reabsorption, while the rest 
show net tubular secretion 
Hepatobiliary excretion  
(drug transporters?) 
Hepatic metabolism 
Extrahepatic metabolism 
β - ARLs 
A few show net tubular 
reabsorption, while the rest 
show net tubular secretion 
Hepatobiliary excretion  
(drug transporters?) 
Hepatic metabolism 
Extrahepatic metabolism 
III 
TRP 
Majority show net tubular 
secretion (drug transporters?) 
Hepatic metabolism (?) 
Extrahepatic metabolism (MAO) 
Hepatobiliary excretion 
(drug transporters?) 
NMB 
Majority show net glomerular 
filtration, while a few show 
net tubular secretion (drug 
transporters?) 
Hepatobiliary excretion  
(drug transporters?) 
Hepatic metabolism (?) 
Extrahepatic - 
chemical/enzymatic degradation 
in plasma/tissues 
β - LAs 
Renal pathways is the major 
elimination pathway 
N.S. 
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Table 12.5 - Effect of LogD7.4 and MW on CLrenu and CLren By Group 
Group 
Pharmacological 
Class 
LogD7.4 MW 
Log (CLrenu) Log (CLren) Log (CLrenu) Log (CLren) 
I 
BZD N.S. 
n = 9 
r2 = 0.56 
Slope = -0.88 
n =8 
r2 = 0.40 
Slope = 0.019 
N.S 
n = 9 
r2 = 0.35 
Slope = 0.028 
N.S. 
CCB 
n = 3 
r2 = 0.91 
Slope = -0.66 
n = 3 
r2 = 0.80 
Slope = -1.1 
N.S 
n = 3 
r2 = 0.49 
Slope = -0.016 
N.S 
n =3 
r2 = 0.66 
Slope = -0.033 
N.S 
II 
Class III AAR 
n =6 
r2 = 0.43 
Slope = -0.10 
N.S 
n = 6 
r2 = 0.86 
Slope = -0.32 
n =6 
r2 = 0.39 
Slope = -0.0019 
N.S 
n = 6 
r2 = 0.79 
Slope = -0.0058 
Opioids N.S. 
n = 21 
r2 = 0.22 
Slope =-0.12 
N.S. N.S. 
β - ARLs N.S. 
n = 38 
r2 = 0.17 
Slope = -0.25 
N.S. N.S. 
III 
TRP 
n = 7 
r2 = 0.34 
Slope = 0.16 
N.S 
N.S. 
n = 7 
r2 = 0.37 
Slope = 0.0031 
N.S. 
N.S. 
NMB N.S. N.S. N.S. N.S. 
β - LAs N.S. N.S. N.S. 
n = 60 
r2 = 0.26 
Slope = -0.002 
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Table 12.6 - Effect of LogD7.4 and MW on CLnonrenu and CLnonren by Group 
Group 
Pharmacological 
Class 
LogD7.4 MW 
Log (CLnonrenu) Log (CLnonren) Log (CLnonrenu) Log (CLnonren) 
I 
BZD 
n = 8 
r2 = 0.81 
Slope = 0.66 
N.S. N.S. N.S. 
CCB 
n = 8 
r2 = 0.77 
Slope = 1.1 
N.S N.S. N.S. 
II 
Class III AAR 
n = 7 
r2 = 0.79 
Slope = 0.35 
N.S. 
n = 7 
r2 = 0.57 
Slope = 0.0064 
N.S 
Opioids 
n = 18 
r2 = 0.73 
Slope = 0.34 
n = 21 
r2 = 0.35 
Slope = 0.19 
N.S. 
n = 21 
r2 = 0.19 
Slope = - 0.004 
β - ARLs 
n = 29 
r2 = 0.43 
Slope = 0.51 
n = 38 
r2 = 0.15 
Slope = 0.22 
N.S. N.S. 
III 
TRP 
n = 7 
r2 = 0.32 
Slope = 0.26 
N.S 
N.S. 
n = 7 
r2 = 0.58 
Slope = 0.0064 
N.S. 
NMB N.S. N.S. N.S. N.S. 
β - LAs N.S. N.S. N.S. 
n = 60 
r2 = 0.08 
Slope = -0.001 
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CHAPTER 13. OVERALL CONCLUSIONS 
 
 This research project focuses on investigating two approaches of predicting PK 
properties, namely, QSPKR and AS-PK, for four pharmacological classes of compounds, 
namely, BZD, NMB, TRP and Class III AAR, selected based on the availability of pertinent 
human PK information after I.V. administration.  Biologically relevant, i.e, PPB-corrected, PK 
properties for drug distribution (Vdss
u) and elimination (CLtot
u, CLren
u, CLnonren
u) were evaluated 
consistently.  
 Overall, with the final QSPKR database that was compiled, the hypotheses investigated 
were: (1) if molecular/PC properties can be used for the quantitative prediction of in-vivo 
systemic and biologically relevant PK in humans; and if these relationships are consistent across 
the pharmacological classes; and (2) if in-vivo systemic and biologically relevant PK in humans 
can be successfully predicted from preclinical species using allometric approaches. 
 The present work focuses on testing the first hypothesis on four pharmacological classes 
of compounds namely, BZD, NMB, TRP and Class III AAR and comparing the results of 
previous work109, 110 carried out on opioids, β-ARLs, β-LAs and CCB.  These classes were 
chosen, (a) based on the availability of systemic PK information for an adequate number of 
compounds following the I.V. route of administration, and, more importantly, (b) with the intent 
of exploring the property spaces (both in terms of molecular/PC as well as PK) which are 
relatively distinct from that shown by the previous four classes.  This is particularly relevant in 
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the context of comparing the results and determining if they are generalizable across 
pharmacological classes.   
 Overall, lipophilicity (logD7.4) was found to be the major molecular/PC determinant 
affecting fu, Vdss
u and CLnonren
u for low MW, lipophilic molecules such as BZD, as well as for fu 
and Vdss
u for large MW, hydrophilic molecules such as NMB.  On the other hand, for 
intermediate MW and hydrophilic molecules such as TRP and the heterogeneous class III AAR, 
although logD7.4 was the important molecular/PC determinant, affecting fu, Vdss
u, CLtot
u and 
CLnonren
u, logD7.4 and MW were highly correlated (and similar trends are observed for both these 
descriptors), indicating that an independent effect of MW rather than logD7,4 cannot ruled out, 
 Across the different pharmacological classes of drugs, the slopes of the effect of logD7.4 
on fu and Vdss
u were similar in direction; however, in general, the magnitude of these slopes 
appear to be sensitive to the lipophilic nature of the molecules, i.e., for lipophilic molecules such 
as BZD, the slopes were found to be relatively steeper than those obtained for hydrophilic 
molecules such as TRP and NMB. 
 The final validated QSPKR models gave acceptable predictions only for: 
(1) Vdss
u and CLnonren
u (each as a function of logD7.4) for BZD; 
(2) fu, Vdss
u and CLnonren
u (each as a function of logD7.4) for Class III AAR, and 
(3) fu (as function of MW) for TRP. 
None of the other QSPKR models developed gave acceptable predictions. 
 In order to elicit an in-vivo PD response, a drug molecule must reach its biophase, and 
during this process, (a) it has to cross biological membranes composed of phospholipid layers 
(via passive and/or transporter-mediated uptake), (b) it interacts with extra- and intracellular 
proteins, such as, plasma proteins, membrane-bound proteins such as DT and DME2,29 etc. 
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 From the present work, it can be concluded that lipophilicity, a bulk molecular/PC 
property, drives the nonspecific hydrophobic interactions of drug molecules with plasma 
proteins, cell membranes and proteins in extravascular tissues; this mechanism is a plausible 
explanation for the observed trends and final validated QSPKR models for fu and Vdss
u, 
regardless of drug target (or pharmacological class). 
 Lipophilicity also seems to be responsible for the partitioning into the hepatocytes and/or 
nonspecific hydrophobic interactions with the hepatic drug metabolizing enzymes (e.g., CYP3A 
and 2C19), and this mechanism is a plausible explanation for the observed trends and final 
validated QSPKR model of CLnonren
u for BZD.  On the other hand, although similar trends were 
observed for CLtot
u and/or CLnonren
u as a function of logD7.4 (and/or MW) for BZD, TRP and 
Class III AAR, these trends cannot be mechanistically interpreted, as the underlying clearance 
mechanisms are highly diverse, e.g., extrahepatic via chemical/enzymatic degradation for NMB, 
enzymatic degradation by MAO for certain TRP, hepatobiliary pathways for Class III AAR, etc. 
 Lastly, none of the in-vitro/ex-vivo PD properties for BZD or TRP and in-vivo PD 
properties for NMB showed any significant trends with any of the molecular/PC descriptors, 
suggesting that these drug molecule-PD target interactions are driven by specific molecular 
interactions, presumably involving steric molecular properties, and cannot be explained by the 
bulk molecular/PC properties investigated in the present work. 
 The second hypothesis was tested for BZD using systemic and biologically relevant PK 
information in different animal species and for NMB in cats. 
Within the limitations of the methods (and sample size), ‘acceptable’ predictions for BZD 
were obtained only for Vdss
u and Vdss, and the fu-correction resulted in an improvement in the 
prediction; however, none of the CLtot
u or CLtot predictions were acceptable.  This suggests that - 
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for lipophilic BZD - Vdss
u (and Vdss) values scale well across species because of the underlying, 
similar nonspecific hydrophobic interactions with plasma membranes and extravascular tissues 
across animal species.  However, quantitative species differences observed in fu values were 
observed across species, in general, with high values in smaller animals and low values in larger 
animals (e.g., humans).  The prediction of Vdss
u values was improved by fu correction because it 
accounts for the differences in PPB. 
Furthermore, owing to quantitative and/or qualitative interspecies differences in drug 
metabolism, e.g., less phase I, oxidative metabolism of diazepam in humans relative to 
preclinical animal species136, that exist even after correcting for BW, CLtot predictions are 
unacceptable. 
NMB are intermediate to large MW, hydrophilic compounds that are restricted to blood 
or plasma volume in humans as well as in the preclinical animal species; as a result, relatively 
little distribution to extravascular spaces occurs across animal species,  Vdss predictions (based 
on BW) were acceptable for 83% of the compounds in the dataset.  CLren (based on GFR) 
predictions were acceptable in 67% of the compounds, suggesting that NMB are cleared by GFR 
across all animal species, and there are no interspecies differences in tubular handling.  The low 
percentage of acceptable predictions for CLtot (based on BW and LBF) and CLnonren (based on 
LBF) suggests that interspecies differences in clearance mechanisms resulted in poor CLtot (and 
CLnonren) predictions. 
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Appendix 1.1 - Human PK Study Summaries of BZD 
  
Chlordiazepoxide 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Boxenba
um et al1 
Healthy 
subjects, n = 6,  
Mean (SD) Age 
= 27 (2) years 
81  
(12) 0.34 
1 
min - 
0 - 48 
hrs Fluorescence  
Limit 
of 
sensitiv
ity = 
0.2 
µg/ml 
Limit 
of 
sensitiv
ity = 
0.2 
µg/ml 
Comp
artme
ntal 
(2) 
Fraction
ated 
0.30 
(± 
0.03) 
0.37 
(± 
0.06) 
0.04 
Sellers et 
al2 
Healthy males, 
n = 14,  
Mean Age = 25 
years 
73 0.61 10 min 
0 - 
48 
hrs 
- Fluorescence  
Limit 
of 
sensitiv
ity = 
0.2 
µg/ml 
- 
Comp
artme
ntal 
(2) 
- 
0.48 
(± 
0.04) 
0.54 
(± 
0.1) 
- 
Greenblat
t et al3 
Healthy males, 
n = 14,  
Mean Age = 27 
years 
67 0.67 60 min 
0 - 
72 
hrs 
- Fluorescence  
Limit 
of 
sensitiv
ity = 
0.2 
µg/ml 
- 
Comp
artme
ntal 
(2) 
- - 
0.41 
(± 
0.06) 
- 
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Urinary Excretion Studies 
1. Boxenbaum et al1 calculated the CLren by using CLren = Ae/AUC (Urine was collected in 2 fractions for 0-24 and 24 - 48 hrs); fe < 1% 
 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Boxenbaum et al1 Healthy humans, n = 3 Equilibrium dialysis 0.8 - 240.0 µg/ml - 7 (± 2) 
Moschitto et al4 In-vitro Equilibrium dialysis 10 - 10000 ng/ml Liquid Scintillation 4.1 
 
 
B:P Ratio 
Study Method Concentration Range  Assay B:P 
Boxenbaum et al1 In-vitro 1 - 2 µg/ml - 0.7 
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Metabolism 
Early studies of the fate of chlordiazepoxide in humans elucidated the metabolic scheme5 shown in Figure -1 below. Furthermore, it has been 
reported that all the four metabolites (shown in figure -1) have psychopharmacological activity similar to that of the parent compound.  
 
Schematic of Metabolism of Chlordiazepoxide5 
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Clonazepam 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Berlin et 
al6 
Healthy 
subjects, n = 8,  
Mean (SD) Age 
= 42 (14) years 
68  
(10) 0.03 
Bolu
s 
0 - 
96 h - GC-EC 
Sensitiv
ity limit 
= 0.5 
ng/ml 
- NCA - 
3.28 
(± 
1.1) 
0.95 
(± 
0.2) 
- 
Crevoisie
r et al7 
Healthy 
subjects, n = 12,  
Mean (Range) 
Age = 30 (23-
50) years 
63 
(52-
90) 
0.03 
4 
min 
Infus
ion 
0 - 
120 
hrs 
- GC-EC 
LLOQ 
= 0.5 
ng/ml 
- NCA - 
2.68 
(± 
0.7) 
0.87 
(± 
0.1) 
- 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Pacifici et al8 Healthy subjects, n = 6 Equilibrium dialysis Up to 0.2 µg/ml Liquid scintillation  13.9 
Lucek et al9 Healthy subjects, n = 3 Equilibrium dialysis 5 - 15 µg/ml Liquid scintillation  14.6 ± 1.5  
Moschitto et al4 In-vitro Equilibrium dialysis 10 - 10000 ng/ml Liquid Scintillation 14.9 
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Clorazepate 
 
 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Bertler et 
al10 
Healthy 
subjects, n = 8,  
Mean (Range) 
Age = 28 (23-
37) years 
- 0.3 
2 
min 
Infus
ion 
0 - 
96 
hrs 
0 - 24 
h HPLC 
Limit 
of 
sensitiv
ity = 10 
ng/ml 
Limit 
of 
sensitiv
ity = 
10 
ng/ml 
Comp
artmet
al (2) 
Cumulat
ive 
0.22 
(± 
0.01) 
0.02 
(± 
0.001
) 
0.002 
 
Urinary Excretion Studies 
1. Bertler et al10 calculated the CLren by using CLren = fe*CLtot (fe is the fraction of the dose that is excreted unchanged in the urine; urine 
samples were collected 0 - 3.5, 3.5 - 9 and 9 - 24 hrs), fe = 11.2% 
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Diazepam 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Klotz et 
al11 
Healthy 
subjects, n = 5 - 0.1 
2 
min 
Infus
ion 
0 - 
72 
hrs 
0 - 72 
hrs GC-EC 
Calibrat
ion 
curve 
linear 
from 1 
- 50 
ng/ml 
Calibr
ation 
curve 
linear 
from 1 
- 50 
ng/ml 
Comp
artmen
tal (2) 
Cumulat
ive 
1.13 
(± 
0.3) 
0.38 
(± 
0.06) 
0.001 
Klotz et 
al12 
Healthy 
volunteers, n = 
10, Age range = 
23 - 35 years 
- 0.1 
2 
min 
Infus
ion 
0 - 
72 
hrs 
- GC-EC 
Calibrat
ion 
curve 
linear 
from 1 
- 50 
ng/ml 
- 
Comp
artmen
tal (2) 
- 
0.89 
(± 
0.18) 
0.35 
(± 
0.11) 
- 
Cloyd et 
al13 
Healthy 
subjects, n = 20, 
Mean (SD) Age 
= 29 (9) years 
73 
(9) 0.1 
2 
min 
Infus
ion 
0 - 
240 
hrs 
- GC-EC 
LLOQ 
= 2 
ng/ml 
- NCA - 1.33 
0.27 
(± 
0.09) 
- 
Greenblat
t et al14 
Healthy 
subjects, n = 12, 
Mean (Range) 
Age = 62 (34 - 
79) years 
- 
5 - 
15 
mg/
70 
kg 
1 
min 
Infus
ion  
0 - 
72 
hrs, 
then 
q.d. 
for 7 
days 
- GC-EC 
LLOQ 
= 2 
ng/ml 
- 
Comp
artmen
tal (2 
or 3) 
- - 
0.40 
(± 
0.20) 
- 
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Ochs et 
al15 
Healthy 
subjects, n = 10, 
Mean (Range) 
Age = 27 (22-
37) years 
66 
5 - 
10 
mg/
66 
kg 
1 
min 
Infus
ion 
0 - 
24 
hrs, 
then 
q.d. 
for 7 
days 
- GC-EC 
LLOQ 
= 2 
ng/ml 
- 
Comp
artmen
tal (2 
or 3) 
- - 
0.44 
(± 
0.16) 
- 
Locniska
r et al16 
Healthy 
subjects, n = 10, 
Age Range = 18 
- 44 years 
68 
(14) 0.1 
1 
min 
Infus
ion 
0 - 
168 
hrs 
- GC-EC 
LLOQ 
= 2 
ng/ml 
- 
Comp
artmen
tal (2 
or 3) 
- - 
0.47 
(± 
0.16) 
- 
Giles et 
al17 
Healthy 
subjects, n = 11, 
Age Range = 20 
- 32 years 
65 
(11) 0.1 
20 
min 
Infus
ion 
0 - 
24 
hrs, 
up 
to 
28 
days 
- GC-EC 
LLOQ 
= 2 
ng/ml 
- NCA - - 
0.39 
(± 
0.10) 
- 
Divoll et 
al18 
Healthy 
subjects, n = 11, 
Mean (Range) 
Age = 30 (20 - 
39) years 
65 
(48 
- 
86) 
0.1 
1 
min 
Infus
ion 
0 - 
336 
hrs 
- GC-EC 
LLOQ 
= 2 
ng/ml 
- NCA - - 
0.41 
(0.22 
- 
0.66) 
- 
 
Urinary Excretion Studies 
1. Klotz et al11 calculated the CLren by using CLren = fe*CLtot (fe = % of the dose excreted unchanged in the urine; urine was sampled up 
to 72 hrs). fe = 0.3% 
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Plasma Protein Binding Studies 
 
Study Subjects Method Concentration Range  Assay fu (%) 
Klotz et al11 Healthy humans Equilibrium dialysis 100 ng/ml GC-EC 2.2 (± 1.0) 
Klotz et al12 Healthy humans Equilibrium dialysis 100 ng/ml GC-EC 3.2 (± 0.8) 
Ochs et al15 Healthy humans Equilibrium dialysis - GC-EC 1.4 (± 0.2) 
Divoll et al19 In-vitro Equilibrium dialysis 0.2 - 20 µg/ml GC-EC 2.3 
Moschitto et al4 In-vitro Equilibrium dialysis 10 - 10000 ng/ml Liquid Scintillation 1.6 (± 0.01) 
 
B:P Ratio 
Study Method Concentration Range  Assay B:P 
Klotz et al11 In-vitro 100 ng/ml GC-EC 0.58 (± 0.18) 
Klotz et al12 In-vitro 100 ng/ml GC-EC 0.58 (± 0.11) 
 
Metabolism Schematic 
The schematic of the metabolism for diazepam20 in shown below: 
 250 
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N-DesmethylDiazepam 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Greenblatt 
et al14 
Healthy 
subjects, n = 
12, Mean 
(Range) Age 
= 62 (34 - 79) 
years 
- 
5 - 
15 
mg/
70 
kg 
1 
min 
Infus
ion  
0 - 
72 
hrs, 
then 
q.d. 
for 7 
days 
- GC-EC 
LLOQ 
= 1 
ng/ml 
- 
Comp
artme
ntal (2 
or 3) 
- 
1.24 
(± 
0.31) 
0.17 
(± 
0.20) 
- 
 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Divoll et al19 In-vitro Equilibrium dialysis 0.2 - 20 µg/ml GC-EC 3.0 
Moschitto et al4 In-vitro Equilibrium dialysis 10 - 10000 ng/ml Liquid Scintillation 
3.5 (± 
0.05) 
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ChlordesmethylDiazepam 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Sennesael 
et al21 
Healthy 
subjects, n = 
11, Mean 
(SD) Age = 
51 (6) years 
63 
(12) 0.03 
Bolu
s 
0 - 
21 
days 
- GC-EC 
LLOQ 
= 0.2 
ng/ml 
- 
Comp
artme
ntal 
(2) 
- 
3.80 
(± 
1.32) 
0.26 
(± 
0.06) 
- 
Bareggi et 
al22 
Healthy 
subjects, n = 
12, Mean 
(SD) Age = 
56 (7) years 
70 
(9) 0.01 
Bolu
s 
0 - 
15 
days 
- GC-EC 
LLOQ 
= 0.2 
ng/ml 
- 
Comp
artme
ntal 
(2) 
- 
4.00 
(± 
1.67) 
0.25 
(± 
0.07) 
- 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Sennesael et al21 Healthy subjects Ultrafiltration - GC-EC 2.9 
Bareggi et al22 Healthy subjects Ultrafiltration - GC-EC 3.4 
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Lorazepam 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Greenblat
t et al23 
Healthy 
subjects, n = 7,  
Mean (SD) Age 
= 27 (3) years 
66 
(10) 
2 
mg, 
4 
mg/
66 
kg 
5 
min 
Infus
ion 
0 - 
48 h 
0 - 72 
h GC - EC 
Limit 
of 
sensitiv
ity = 1 
ng/ml 
Limit 
of 
sensitiv
ity = 1 
ng/ml 
Comp
artme
ntal 
(2) 
Cumulat
ive 
1.14 
(± 
0.08) 
1.05 
(± 
0.40) 
0.006 
Greenblat
t et al24 
Healthy 
subjects, n = 6, 
Mean (Range) 
Age = 35 (28 - 
33) years 
69 
0.02 
- 
0.05 
1 
min 
Infus
ion 
0 - 
24 
hr 
- GC - EC 
Limit 
of 
sensitiv
ity = 1 
ng/ml 
- 
Comp
artme
ntal (2 
- 3) 
- 
1.37 
(± 
0.12) 
1.98 
(± 
0.54) 
- 
Wermeli
ng et al25 
Healthy 
subjects, n = 7,  
Mean (SD) Age 
= 22 (3) years 
70 
(9) 0.03 
5 
min 
Infus
ion 
0 - 
36 
hrs 
- LC - MS/MS 
LLOQ 
= 0.1 
ng/ml 
- NCA - 
1.32 
(± 
0.23) 
1.98 
(± 
0.53) 
- 
Kudsk et 
al26 
Healthy 
subjects, n = 6,  
Mean (SD) Age 
= 30 (7) years 
71 
(12) 0.03 
10 
min 
Infus
ion 
0 - 
48 h - GC- EC 
LLOD 
= 1 
ng/ml 
- 
Comp
artme
ntal 
(2) 
- 
1.21 
(± 
0.17) 
1.04 
(± 
0.15) 
- 
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Ochs et 
al15 
Healthy 
subjects, n = 10, 
Mean (Range) 
Age = 27 (22-
37) years 
66 0.03 
1 
min 
Infus
ion 
0 - 
72 
hrs 
- GC-EC 
LLOQ 
= 2.5 
ng/ml 
- 
Comp
artme
ntal (2 
or 3) 
- - 
0.96 
(± 
0.28) 
- 
Abernert
hy et al27 
Healthy 
subjects, n = 14 
63 
(8) 0.03 
Bolu
s 
0 - 
72 
hrs 
- GC - EC 
LLOQ 
= 1 
ng/ml 
- 
Comp
artme
ntal (2 
or 3) 
- - 
1.00 
(± 
0.27) 
- 
Greenblat
t et al28 
Healthy 
subjects, n = 6,  
Mean (SD) Age 
= 27 (5) years 
- 0.03 
5 
min 
Infus
ion 
0 - 
72 
hrs 
- GC - EC 
LLOQ 
= 1 
ng/ml 
- 
Comp
artme
ntal (2 
or 3) 
- - 0.96  - 
 
Urinary Excretion Studies 
1. Greenblatt et al23 calculated the CLren by using CLren = fe*CLtot (fe = % of the dose excreted unchanged in the urine; urine was 
collected in intervals: 0 - 4, 4 - 8, 8 - 24, 24 - 48, 48 - 72 hrs). fe = 0.5% 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Ochs et al15 Healthy humans Equilibrium dialysis - GC-EC 8.0 (± 0.9) 
Abernerthy et al27 In-vitro Equilibrium dialysis - GC-EC 10.0 (± 0.7) 
Moschitto et al4 In-vitro Equilibrium dialysis 10 - 10000 ng/ml Liquid Scintillation 9.7 (± 0.04) 
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Nitrazepam 
 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Jochemsen 
et al29 
Healthy 
subjects, n = 
7, Age Range 
= 23 - 27 
years 
72 
(6) 0.07 
Bolu
s 
0 - 
80 h - GC-EC 
Limit 
of 
sensitiv
ity = 1 
ng/ml 
- 
Comp
artme
ntal 
(2) 
- 
1.90 
(± 
0.18) 
0.84 
(± 
0.15) 
- 
Jochemsen 
et al30 
Healthy 
subjects, n = 
8, Mean (SD) 
Age = 27 (9) 
years 
73 
(7) 0.07 
Bolu
s 
0 - 
96 h - GC-EC 
Limit 
of 
detectio
n = 1 
ng/ml 
- NCA - 
1.83 
(± 
0.25) 
0.83 
(± 
0.17) 
- 
 
Urinary Excretion Studies 
1. Jochemsen et al30 calculated fraction of the dose excreted unchanged in the urine to be ~1.0% 
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Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Jochemsen et al29 Healthy subjects Equilibrium dialysis 75 ng/ml GC-EC 12.3 
Jochemsen et al30 Healthy subjects Equilibrium dialysis - GC-EC 13 
Moschitto et al4 In-vitro Equilibrium dialysis 10 - 10000 ng/ml Liquid Scintillation 12.7 
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Flunitrazepam 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Kanto et 
al31 
Healthy 
subjects, n = 
20, Mean 
(SD) = 51 
(19) years 
79 
(9) 0.02 
10 
min 
Infus
ion 
0 - 
70 h - GC-EC 
Limit 
of 
sensitiv
ity = 
0.2 
ng/ml 
- NCA - 
2.44 
(± 
1.22) 
1.70 
(± 
0.67) 
- 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Moschitto et al4 In-vitro Equilibrium dialysis 10 - 10000 ng/ml Liquid Scintillation 22.5 (± 0.40) 
 
B:P Ratios 
Study Method Concentration Range  Assay 
B:P 
Ratio 
Kanto et al31 In-vitro - GC-EC 0.75 
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Oxazepam 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Sonne et 
al32 
Healthy 
subjects, n =6, 
Age range = 
26 - 38 years 
56 - 
87 0.22 
15 
min 
Infus
ion 
0 - 
24 h 
0 - 48 
h HPLC - UV 
LLOD 
= 5 
ng/ml 
- NCA Cumulative 
0.60 
(± 
0.19) 
1.05 
(± 
0.36) 
- 
 
Urinary Excretion Studies 
1. Sonne et al32 calculated renal clearance as CLren = fe*CLtot (fe is the fraction of the dose that is excreted unchanged, urinary samples 
collected from 0 -4, 4 - 8, 8 - 24 and 24 - 48 h after dose), fe = ~1% 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Abernerthy et al27 In-vitro Equilibrium dialysis - GC-EC 4.0 ± (0.7) 
Kanto et al31 In-vitro - - - 4.5 
Moschitto et al4 In-vitro Equilibrium dialysis 10 - 10000 ng/ml Liquid Scintillation 5.12 (± 0.08) 
Sonne et al32 Healthy subjects  Equilibrium dialysis 1 µg/ml HPLC 4.5 (3.7 - 5.5) 
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B:P Ratios 
Study Method Concentration Range  Assay 
B:P 
Ratio 
Shull et al33 In-vitro - GC-EC 1.04 
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Temazepam 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
van 
Steveninck 
et al34 
Healthy 
subjects, n = 
9, Age Range 
= 18 - 24 
years 
66 
(11) 0.4 
30 
min 
Infus
ion 
0 - 
24 
hrs 
- HPLC 
Limit 
of 
sensitiv
ity = 
1.1 
ng/ml 
- NCA - - 1.4 - 
 
Urinary Excretion Study 
1. Ghabrial et al35 estimated fe for temazepam to be 0.80% in the control group.  
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
van Steveninck et al34 In-vitro Equilibrium dialysis - GC-EC 2.3  
Moschitto et al4 In-vitro Equilibrium dialysis 10 - 10000 ng/ml Liquid Scintillation 3.6 (± 0.07) 
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Adinazolam 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Venkatak
rishnan et 
al36 
Healthy 
subjects, n = 9,  
Mean (Range) 
Age = 29 (20 - 
40) years 
80 0.1 
30 
min 
Infus
ion 
0 - 
24 h - HPLC-UV 
Limit 
of 
sensitiv
ity = 5 
ng/ml 
- 
Comp
artme
ntal 
(2) 
- 0.84 
5.55 
(± 
1.31) 
- 
Fleishake
r et al37 
Healthy 
subjects, n = 14,  
Age Range = 20 
- 48 years 
67 - 
95 0.06 
10 
min 
Infus
ion 
0 - 
24 h - HPLC-UV 
LLOQ 
= 2 
ng/ml 
- NCA - 
1.13 
(± 
0.19) 
7.11 
(± 
1.61) 
- 
Ajir et 
al38 
Healthy 
subjects, n = 39,  
Mean (SD) Age 
= 39 (8) years 
75 
(8) 0.11 
30 
min 
Infus
ion 
0 - 
24 h - HPLC-UV 
LLOQ 
= 2 
ng/ml 
- NCA - 0.74 
4.72 
(± 
1.18) 
- 
Fleishake
r et al39 
Healthy 
subjects, n = 18,  
Age Range = 21 
- 36 years 
52 - 
90 0.17 
30 
min 
Infus
ion 
0 - 
24 h - HPLC-UV 
LLOQ 
= 2 
ng/ml 
- NCA - 
1.58 
(± 
0.58) 
6.87 
(± 
2.40) 
- 
Fleishake
r et al40 
Healthy 
subjects, n = 16,  
Mean (Range) 
Age = 28 (19 - 
54) years 
73 
(58 
- 
91) 
0.16 
30 
min 
Infus
ion 
0 - 
24 h - HPLC-UV 
LLOQ 
= 2 
ng/ml 
- NCA - 
0.91 
(± 
0.13) 
4.88 
(± 
0.75) 
- 
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Fleishake
r et al41 
Healthy 
subjects, n = 24,  
Age Range = 18 
- 50 years 
68 
(64 
- 94 
5, 
10, 
15, 
20 
mg/
67.7 
kg 
30 
min 
Infus
ion 
0 - 
24 h - HPLC-UV 
LLOQ 
= 2 
ng/ml 
- NCA - - 
5.55 
(± 
1.19) 
- 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Fleishaker et al37 Healthy humans Equilibrium dialysis 50 ng/ml HPLC - UV 31 (± 3) 
Fleishaker et al39 Healthy humans Equilibrium dialysis 75 - 150 ng/ml HPLC - UV 31 (± 4) 
Fleishaker et al40 In-vitro Equilibrium dialysis 50 - 750 ng/ml HPLC - UV 29 (± 2) 
 
B:P Ratio 
Study Subjects Method Concentration Range  Assay B:P Ratio 
Fleishaker et al37 Healthy Humans In-vitro - HPLC - UV 0.70 (0.60 - 0.84) 
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N-DesmethylAdinazolam 
 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Venkatak
rishnan et 
al36 
Healthy 
subjects, n = 9,  
Mean (Range) 
Age = 29 (20 - 
40) years 
80 0.1 
30 
min 
Infus
ion 
0 - 
24 h - HPLC-UV 
Limit 
of 
sensitiv
ity = 5 
ng/ml 
- 
Comp
artme
ntal 
(1) 
- 0.74 4.0 (± 0.4) - 
Ajir et 
al38 
Healthy 
subjects, n = 39,  
Mean (SD) Age 
= 39 (8) years 
75 
(8) 0.3 
30 
min 
Infus
ion 
0 - 
24 h - HPLC-UV 
LLOQ 
= 10 
ng/ml 
- NCA - 0.54 
2.43 
(± 
0.32) 
- 
Fleishake
r et al40 
Healthy 
subjects, n = 16,  
Mean (Range) 
Age = 28 (19 - 
54) years 
73 
(58 
- 
91) 
0.3 
30 
min 
Infus
ion 
0 - 
24 h - HPLC-UV 
LLOQ 
= 2 
ng/ml 
- NCA - 
0.62 
(± 
0.08) 
2.47 
(± 
0.30) 
- 
Fleishake
r et al41 
Healthy 
subjects, n = 24,  
Age Range = 18 
- 50 years 
68 
(64 
- 94 
10, 
20, 
30, 
40 
mg/
68 
kg 
30 
min 
Infus
ion 
0 - 
24 h 
0 - 36 
hrs HPLC - UV 
LLOQ 
= 10 
ng/ml 
LLOQ 
= 10 
ng/ml 
NCA Cumulative 0.83 2.83  2.0 
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Urinary Excretion Studies 
1. Fleishaker et al41 calculated the CLren by using CLren = Ae/AUC (Urine was collected in intervals 0 - 2, 2 - 4, 4 - 8, 8 - 12, 12 - 24 and 24 - 
36 hrs); fe = 71% 
 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Fleishaker et al40 In-vitro Equilibrium dialysis 50 - 750 ng/ml HPLC - UV 65 (± 2) 
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Alprazolam 
 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Smith et 
al42 
Healthy 
subjects, n = 9,  
Mean (Range) 
Age = 29 (20 - 
40) years 
80 0.01 
1 
min 
Infus
ion 
10 
min 
- 36 
h 
- GC - EC 
Limit 
of 
sensitiv
ity = 
0.25 
ng/ml 
- NCA - 0.80 
0.74 
(0.56 
- 
1.05) 
- 
Fleishake
r et al43 
Healthy 
subjects, n = 42, 
Age range = 18 
- 54 years 
 0.01 
1 
min 
Infus
ion 
5 
min 
- 36 
h 
- HPLC-UV 
LLOD 
= 1 
ng/ml 
-   
1.03 
(± 
0.13) 
0.89 
(±0.2
8) 
 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Moschitto et al4 In-vitro Equilibrium dialysis 10 - 10000 ng/ml Liquid Scintillation 
31.6 
(± 0.6) 
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Midazolam 
 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Greenblat
t et al44 
Healthy 
subjects, n = 11,  
Age Range = 28 
- 42 years 
- 0.1 
1 
min 
Infus
ion 
0 -
24 h - GC-EC 
LLOQ 
= 1.5 
ng/ml 
- 
Comp
artme
ntal 
(2) 
- 1.6 
11.0 
(± 
3.6) 
- 
Heizman
n et al45 
Healthy 
subjects, n = 6,  
Age Range = 22 
- 27 years 
66 0.15 Bolus 
0 - 
12 h - GC-EC 
Limit 
of 
Detecti
on = 4 
ng/ml 
- 
Comp
artme
ntal 
(2) 
- 
0.72 
(± 
0.16) 
4.6 (± 
1.2) - 
Smith et 
al46 
Healthy 
subjects, n = 6,  
Mean (SD) Age 
= 22 (0.5) years 
73 
(6) 0.07 
Bolu
s 
0 - 8 
hrs 
0 - 8 
h GC - EC 
Limit 
of 
Detecti
on = 
0.5 
ng/ml 
- NCA Cumulative 
0.85 
(± 
0.42) 
6.39  
(± 
1.57) 
- 
Thummel 
et al47 
Healthy 
subjects, n = 20,  
Mean (SD) Age 
= 32 (7) years 
77 
(13) 0.01 
Bolu
s 
0 - 6 
hrs 
0 -24 
hours GC - MS - - NCA 
Cumulat
ive 
0.90 
(± 
0.39) 
4.62  
(± 
1.00) 
0.013 
Allonen 
et al48 
Healthy 
subjects, n = 6,  
Mean (SD) Age 
= 30 (4) years 
70 
(8) 0.08 
1 
min 
Infus
ion 
0 - 7 
hrs - GC - EC 
Sensitiv
ity limit 
= 5 
ng/ml 
- NCA - 
0.68 
(± 
0.15) 
4.12  
(± 
0.94) 
- 
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Clausen 
et al49 
Healthy 
subjects, n = 6,  
Mean (Range) 
Age = 27 (23 - 
37) years 
68 
(6) 0.3 
Bolu
s 
0 - 
12 
hrs 
- GC - EC 
Limit 
of 
detectio
n = 5 
ng/ml 
- 
Comp
artme
ntal 
(3) 
- 
1.10 
(± 
0.20) 
6.28  
(± 
1.03) 
- 
Macgilch
rist et al50 
Healthy 
subjects, n = 8,  
Age Range = 37 
- 42 years 
61 
(11) 0.08 
1 
min 
Infus
ion 
0 - 
24 h - GC - EC 
Sensitiv
ity limit 
= 5 
ng/ml 
- 
Comp
artme
ntal 
(2) 
- 0.87 
10.4 
(± 
3.7) 
- 
Ochs et 
al15 
Healthy 
subjects, n = 10, 
Mean (Range) 
Age = 27 (22-
37) years 
66 0.08 
1 
min 
Infus
ion 
0 - 
24 
hrs 
- GC-EC 
LLOQ 
= 2.5 
ng/ml 
- 
Comp
artme
ntal (2 
or 3) 
- - 9.6 (± 3.8) - 
 
 
Urinary Excretion Studies 
1. Smith et al46 calculated the CLren by using CLren = fe*CLtot (fe = % of the dose excreted unchanged in the urine; urine was sampled up 
to 8 hrs). fe = 0.02% 
2. Thummel et al47 calculated the CLren by using CLren = fe*CLtot (fe = % of the dose excreted unchanged in the urine; urine was sampled 
up to 8 hrs). fe = 0.28% 
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Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Thummel et al47 Healthy humans Equilibrium dialysis - GC - MS 1.9 (± 0.7) 
Allonen et al48 Healthy humans Equilibrium dialysis 130 ng/ml GC - EC 6.0 (± 1.9) 
Ochs et al15 Healthy humans Equilibrium dialysis - GC-EC 3.4 (± 0.3) 
Moschitto et al4 In-vitro Equilibrium dialysis 10 - 10000 ng/ml Liquid Scintillation 3.7 (± 0.03) 
 
B:P Ratio 
Study Subjects Method Concentration Range  Assay 
B:P 
Ratio 
Heizmann et al45 Healthy humans In-vitro - GC-EC 0.53 
Allonen et al48 Healthy humans In-vitro 130 ng/ml GC-EC 
0.57 
(± 
0.06) 
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Triazolam 
 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Kroboth 
et al51 
Healthy 
subjects, n = 12, 
Mean (Range) 
Age = 23 (20 - 
35) 
83 0.003 
Bolu
s 
Up 
to 
12 h 
- GC - EC 
LLOD 
= 0.25 
ng/ml 
- 
Non-
comp
artme
ntal 
- 
0.64 
(± 
0.18) 
2.6  
(± 
1.0) 
- 
Pete 
Vanderve
en52 
Healthy 
subjects, n = 12, 
Mean (Range) 
Age = 35 (19 - 
54) 
79 
(66 
- 
96) 
0.00
3 
5 
min 
Infus
ion 
Up 
to 
12 h 
- HPLC 
LLOQ 
= 0.2 
ng/ml 
- 
Non-
comp
artme
ntal 
- 0.59  
2.7  
(± 
0.70) 
- 
Smith et 
et al53 
Healthy 
subjects, n = 30, 
Mean (Range) 
Age = 28 (21 - 
38) 
74 
(60 
- 
103
) 
0.12
5 - 1 
mg  
Bolu
s 
Up 
to 8 
h 
- GC - EC 
Sensitiv
ity limit 
= 0.25 
ng/ml 
- 
Non-
comp
artme
ntal 
- 0.67 2.9 - 
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Plasma Protein Binding Studies 
 
Study Subjects Method Concentration Range  Assay fu (%) 
Moschitto et al4 In-vitro Equilibrium dialysis 10 - 10000 ng/ml Liquid Scintillation 11 
 
 
B:P Ratio 
 
Study Subjects Method Concentration Range  Assay 
B:P 
Ratio 
Pete Vanderveen52 Healthy subjects [
14C]-labelled 
Radioactivity - Liquid Scintillation Counter 
0.76 
(±0.050) 
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Ro 48 - 6791 
 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Dingema
nse et al54 
Healthy 
subjects, n = 10, 
Age range = 21 
- 26 kg 
64 - 
78 
0.1 - 
3 
mg 
20 
min 
Infus
ion 
Up 
to 
280 
min 
- HPLC -MS/MS 
LLOQ 
= 20 
pg/ml 
- 
Comp
artme
ntal 
(2) 
- 
2.41 
(± 
0.92) 
30.99 
(± 
12.7) 
- 
 
B:P Ratio 
 
Study Subjects Method Concentration Range  Assay 
B:P 
Ratio 
Dingemanse et al54 - - - - 1.33 
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Ro 48 - 8684 
 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
van 
Gerven et 
al55 
Healthy 
subjects, n = 10, 
Age range = 22 
- 32 years 
67 - 
89 
0.1 - 
10 
mg 
20 
min 
Infus
ion 
Up 
to 
300 
min 
- HPLC -MS/MS 
LLOQ 
= 50 
pg/ml 
- 
Comp
artme
ntal 
(2) 
- 
4.32 
(± 
1.46) 
30.77 
(± 
6.41) 
- 
 
B:P Ratio 
 
Study Subjects Method Concentration Range  Assay 
B:P 
Ratio 
van Gerven et al55 - - - - 1.36 
 
 
 
  
 273 
Brotizolam 
 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Jochemse
n et al56 
Healthy 
subjects, n = 8, 
Age range = 21 
- 26 years 
69 0.004 
4 
min 
Infus
ion 
Up 
to 
48 h 
- GC - EC 
Sensitiv
ity limit 
= 0.1 
ng/ml 
- 
Comp
artme
ntal 
(2) 
- 
0.66 
(± 
0.19) 
1.58 
(± 
0.39) 
- 
 
Plasma Protein Binding Studies 
 
Study Subjects Method Concentration Range  Assay fu (%) 
Bechtel et al57  In-vitro Equilibrium Dialysis 0.07 - 13.7 µg/ml Liquid Scintillation 9.8% 
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Flumazenil 
 
Study Population 
BW Dose (IV) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Roncari 
et al58 
Healthy 
subjects, n = 6; 
Mean (Range) 
Age = 26 (24 - 
27) years 
74 
(65 
- 
79) 
0.27 Bolus Up 
to 
6h 
Up to 
24 hrs HPLC-UV 
Sensitiv
ity limit 
= 10 
ng/ml 
Sensiti
vity 
limit = 
10 
ng/ml 
Non-
Comp
artme
ntal 
Cumulat
ive 
1.1±
0.23 
14.8±
2.3  
0.54 Bolus 
1.0±
0.17 
16.2±
2.8  
Klotz et 
al59 
Healthy 
subjects, n = 6; 
Age Range = 28 
- 42 years 
63 - 
82 
kg 
0.04 Bolus 
Up 
to 
3h 
- HPLC-UV 
Sensitiv
ity limit 
= 2 
ng/ml 
- 
Comp
artme
ntal 
(2) 
- 
0.63
±0.1
8 
10.1±
3.2 - 
Janssen 
et al60 
Healthy 
subjects, n = 8; 
Mean (Range) 
Age = 50 (45 - 
56) years 
73 
(57 
- 
87) 
0.03 Bolus 
Up 
to 
4h 
- HPLC-UV 
Sensitiv
ity limit 
= 3 
ng/ml 
- 
Non-
Comp
artme
ntal 
- 
0.97
±0.1
9 
16.5±
2.6 - 
Pomier - 
Layrargu
es et al61 
Healthy 
subjects, n = 8; 
Mean (SD) Age 
= 38 (1.6) years 
76 
(11) 0.03 
5 
min 
Infus
ion 
Up 
to 
7h 
- GC 
Sensitiv
ity limit 
= 0.05 
ng/ml 
- 
Non-
Comp
artme
ntal 
- 
0.62 
(± 
0.09
0) 
16.3 
(±2.6) - 
Klotz et 
al62 
Healthy 
subjects, n = 6; 
Age Range = 18 
- 36 years 
59 - 
87 0.1 
Bolu
s 
Up 
to 
5.75
h 
- HPLC-UV 
Sensitiv
ity limit 
= 2 
ng/ml 
- 
Non-
Comp
artme
ntal 
- - 15.1 (±2.8) - 
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Urinary Excretion Studies 
1. Boncari et al58 calculated the CLren by using CLren = fe*CLtot (fe = % of the dose excreted unchanged in the urine up to 24 hours = 0.1%) 
 
 
Plasma Protein Binding Studies 
 
Study Subjects Method Concentration Range  Assay fu (%) 
Klotz et al59 In-vitro Equilibrium Dialysis 50 ng/ml HPLC 60 (±8) 
Pomier - Layrargues et al61 In-vitro Equilibrium Dialysis 20 - 600 ng/ml Liquid Scintillation 55 (±4) 
 
 
B:P Ratio 
 
Study Subjects Method Concentration Range  Assay 
B:P 
Ratio 
Boncari et al58 Healthy subjects [
14C]-labelled 
Radioactivity - Liquid Scintillation Counter 0.88 
Klotz et al59 Healthy subjects - - HPLC 0.99 (±0.26) 
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Metabolism  
The schematic for metabolism of flumazenil60,63 is shown in figure below. 
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Appendix 1.2 - Hepatic Metabolism 
The contribution of a enzyme-specific metabolic pathway towards CLtot, fpathway can be assessed by looking into drug-drug interaction studies 
in the presence of the specific inhibitor and genetic polymorphisms in the drug metabolizing enzyme. For example, ketoconazole is a selective 
and a potent CYP3A inhibitor, and since the majority of the BZD in the present work are metabolized by the CYP3A pathway, drug-drug 
interaction studies between BZD and ketoconazole were compiled in the Appendix below: 
 
In the absence of inhibitor (Control):  
CLtotI.V.(Control) /Foral = Dose/AUC0-∞ (Control) 
CLtotI.V.  is the systemic total body clearance of BZD, which is primarily, CLnonren (since CLren is, in general, negligible). Furthermore, since 
there are no significant extrahepatic pathways reported in the literature, CLnonren is assumed to equal to the CLhep (which is sum of all the 
metabolic pathways). The majority of the BZD are low ERhep drugs and in general, they have high Foral, and therefore, the systemic exposure 
depends on CLhep only.   
 
In the presence of inhibitor (I): 
CLtotI.V. (I)/Foral (I) = Dose/AUC0-∞ (I) 
The assumptions are: (a) CLren is negligible and there are no significant extrahepatic metabolic pathways; CLtot = ~ CLnonren = ~ CLhep, (b) In 
the presence of inhibitor, only that specific pathway is inhibited (e.g., CYP3A for ketoconazole; genetic polymorphisms - poor versus 
extensive metabolizers), and (c) the inhibitor is selective and completely inhibits the specific metabolic pathway of interest.  
The contribution of specific pathway of interest to the overall hepatic clearance (assumed to be CLtot for BZD) can be estimated as (assuming 
the oral doses are identical): 
fpathway = 1 - (CLtotI.V (I) /CLtotI.V.(Control)) = 1 - (AUC0-∞(Control) /AUC0-∞ (I))    
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Chlordiazepoxide 
 
 Study Population 
Inhibitor Substrate PK 
Sampli
ng 
Sched
ule 
Assay 
Meth
od 
Analytic
al 
Method 
Paramet
ers 
PK 
Analysis 
AUC0 - 
∞ 
(Contr
ol) 
AUC 
0 - ∞  
(+ 
Inhibit
or) 
(1 - 
AUC 
Con/I
n) 
fpathwa
y 
Name Dosing Regimen 
Dosing 
Regimen 
Brown et 
al64 
Healthy subjects, 
n = 12, 
Age Range = 
25 - 36 years 
Ketocona
zole 
200 mg  
P.O. 
(1 dose) 
0.6 mg/kg 
I.V. 
(1 dose 1h 
after 
Ketoconaz
ole) 
0 - 48 
hrs 
HPL
C 
Sensitivi
ty limit = 
50 ng/ml 
Compartm
ental (2) 
1684 2042 18% 
400 mg. 
P.O. 
(1 dose) 
0.6 mg/kg 
I.V. 
(1 dose 1h 
after 
Ketoconaz
ole) 
1685 2076 19% 
400 mg.  
q.d for 6 
days 
P.O. 
(6 doses) 
0.6 mg/kg 
I.V. 
on day 6 
(1 dose 1h 
after 
Ketoconaz
ole)  
1470 2262 35% 
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Midazolam 
 Study Population 
Inhibitor Substrate PK 
Sampl
ing 
Sched
ule 
Assa
y 
Meth
od 
Analyti
cal 
Method 
Parame
ters 
PK 
Analysis 
AUC0 
- ∞ 
(Cont
rol) 
AUC 
0 - ∞  
(+ 
Inhibit
or) 
(1 - 
AUC 
Con/
In) 
fpathw
ay 
Name Dosing Regimen 
Dosing  
Regimen 
Lam et 
al65 
Healthy subjects, n = 
10, 
Mean (SD) Age = 34 
(8) years 
Ketocona
zole 
200 mg  
q.d. for 12 
days 
P.O. 
(12 doses) 
10 mg 
P.O. 
(1 dose 
1h after 
Ketocona
zole) 
0.25 - 
24 hrs 
HPL
C - 
UV 
LLOQ = 
5 ng/ml 
Non-
Compartm
ental 
195 
(±115) 
1280 
(±617) 85% 
Tsunoda 
et al66 
Healthy subjects, n = 
5, 
Mean (SD) Age = 26 
(6) years 
Ketocona
zole 
200 mg  
q.d. for 3 
days 
P.O. 
(3 doses) 
6 mg 
P.O. 
(1 dose 
on day 3)  Up to 
24 hrs 
GC - 
EC 
LLOQ = 
5 ng/ml 
Non-
Compartm
ental 
54 
(±37) 
651 
(±181) 92% 
2 mg 
I.V. 
(1 dose 
on day 3) 
56 
(±20) 
222 
(±65) 75% 
Tsunoda 
et al67 
Healthy subjects, n = 
9, 
Age range = 19 - 41 
years 
Ketocona
zole 
200 mg 
b.i.d for 3 
days 
P.O. 
6 mg 
P.O. 
(1 dose 
12 h after 
Ketocona
zole)   Up to 
24 hrs 
GC - 
EC 
LLOQ = 
5 ng/ml 
Non-
Compartm
ental 
54 
(±28) 
738 
(±191) 93% 
200 mg 
b.i.d for 3 
days 
P.O. 
2 mg 
I.V. 
(1 dose 
12 h after 
Ketocona
zole) 
70 
(±26) 
354 
(±185) 80% 
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Olkkola et 
al68 
Healthy subjects, n = 
9, 
Age range = 19 - 26 
years 
Ketocona
zole 
400 mg 
q.d. for 4 
days 
P.O. 
(4 doses) 
7.5 mg 
P.O. 
(1 dose 
1h after 
Ketocona
zole) 
 Up to 
17 hrs 
GC - 
EC 
LLOQ = 
5 ng/ml 
Non-
Compartm
ental 
4 (± 2) 42 (±18) 94% 
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Triazolam 
 Study Population 
Inhibitor Substrate PK 
Samp
ling 
Sche
dule 
Assa
y 
Met
hod 
Analyt
ical 
Metho
d 
Param
eters 
PK 
Analysis 
AUC
0 - ∞ 
(Cont
rol) 
AUC 
0 - ∞  
(+ 
Inhibi
tor) 
(1 - 
AU
C 
Con/
In) 
fpath
way 
Name Dosing Regimen 
Dosing  
Regime
n 
Greenblatt 
et al69 
Healthy subjects, n = 7, 
Age Range = 21 - 44 years 
Ketocon
azole 
200 mg  
b.i.d for 
2.5 days 
P.O. 
(5 doses) 
0.25 mg 
P.O. 
1 dose 
on day 
3 1 h 
after 
Ketocon
azole 
Up to 
48 hrs 
GC - 
EC  
LLOQ 
= 0.1 - 
0.2 
ng/ml 
ng/ml 
Non-
Compart
mental 
11 
(±4) 
145 
(±96) 92% 
von 
Moltke et 
al70 
Healthy subjects, n = 9, Age 
Range = 23 - 72 years 
Ketocon
azole 
200 mg 
1, 17h 
P.O. 
(2 doses) 
0.125 
mg 
P.O. 
1 dose 
on day 
2 
Upto 
24 hrs 
GC - 
EC 
LLOQ 
= 0.2 
ng/ml 
Non-
Compart
mental 
7 (±2) 62 (±30) 89% 
Varhe et 
al71 
Healthy subjects, n = 9, Age 
Range = 20 - 26 years 
Ketocon
azole 
400 mg 
q.d. for 4 
days 
P.O. 
(4 doses) 
0.25 mg 
P.O. 
1 dose 
on day 
4 
Up to 
17 hrs 
GC - 
EC 
LLOQ 
= 0.2 
ng/ml 
Non-
Compart
mental 
6 (±2) 132 (±75) 95% 
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Alprazolam 
 Study Population 
Inhibitor Substrate PK Sampl
ing 
Sched
ule 
Assa
y 
Meth
od 
Analyti
cal 
Method 
Parame
ters 
PK 
Analysis 
AUC0 
- ∞ 
(Cont
rol) 
AUC 
0 - ∞  
(+ 
Inhibit
or) 
(1 - 
AUC 
Con/
In) 
fpathw
ay 
Name Dosing Regimen 
Dosing  
Regimen 
Greenblatt 
et al69 
Healthy subjects, n 
= 7, 
Age Range = 21 - 
44 years 
Ketocona
zole 
200 mg  
b.i.d for 2.5 
days 
P.O. 
(5 doses) 
1 mg 
P.O. 
1 dose on 
day 3 1 h 
after 
Ketocona
zole 
Up to 
48 hrs 
GC - 
EC  
LLOQ = 
0.1 - 0.2 
ng/ml 
ng/ml 
Non-
Compartm
ental 
237 
(±114) 
944 
(±733) 75% 
Schmider et 
al72 
Healthy subjects, n 
= 7, 
Age Range = 22 - 
55 years 
Ketocona
zole 
200 mg 
b.i.d for 2 
days 
P.O. 
1 mg 
P.O. 
1 dose on 
day 3 1 h 
after 
Ketocona
zole 
Up to 
24 hrs 
HPL
C - 
UV 
LLOQ = 
0.5 
ng/ml 
ng/ml 
Non-
Compartm
ental 
242 
(±114) 
426 
(±86) 43% 
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Brotizolam 
 Study Population 
Inhibitor Substrate PK Sampli
ng 
Sched
ule 
Assay 
Meth
od 
Analytic
al 
Method 
Paramet
ers 
PK 
Analysis 
AUC0 - 
∞ 
(Contr
ol) 
AUC 
0 - ∞  
(+ 
Inhibit
or) 
(1 - 
AUC 
Con/I
n) 
fpathwa
y 
Name Dosing Regimen 
Dosing  
Regim
en 
Osanai et 
al73 
Healthy subjects, n = 
10, 
Mean (SD) Age = 34 
(5) years 
Itraconaz
ole 
200 mg  
q.d. for 4 
days 
P.O. 
(4 doses) 
0.5 mg 
P.O. 
1 dose 
on day 
4  
Up to 
24 hrs 
HPL
C - 
UV  
LLOQ = 
5 ng/ml 
Non-
Compartm
ental 
33 169 80% 
 
 
Diazepam 
 Study Population Genetic Polymorphisms 
Subst
rate PK Samp
ling 
Sched
ule 
Assa
y 
Met
hod 
Analyti
cal 
Metho
d 
Param
eters 
PK 
Analysis 
AUC0 
- ∞ 
(Cont
rol) 
AUC 
0 - ∞  
(+ 
Inhibi
tor) 
(1 - 
AUC 
Con/
In) 
fpathw
ay 
Dosin
g  
Regi
men 
Qin et 
al74 
Healthy subjects, n 
= 18, 
Mean (SD) Age = 
26 (6) years 
Wild type reflect - poor 
metabolizers (Control) 
Double homozygous reflect - 
extensive metabolizers 
5 mg 
P.O. 
 
Up to 
12 
days 
GC  
LLOQ 
= 8 
ng/ml 
Non-
Compart
mental 
5.3 (± 
2.7) 
32.4 
(±10.1
) 
84% 
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Appendix 2 - Human PK Study Summaries of NMB 
  
Rocuronium 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
van Miert 
et al75 
Healthy 
subjects, n = 21,  
Mean (SD) Age 
= 44 (12) years 
73  
(9) 0.60 
Bolu
s 
1 - 
480 
min 
- HPLC-Fluorescence  
Assay 
range: 
10 - 
20000 
ng/ml 
- 
Comp
artme
ntal 
(2, 3) 
- 
0.21 
(± 
0.05
5) 
3.7 (± 
1.0) - 
McCoy et 
al76 
Healthy 
subjects, n = 8,  
Age range =  
18 - 65 years 
 0.45 
Bolu
s 
follo
wed 
by 
Infus
ion 
at  
15 
µg/k
g/mi
n 
1 
min 
- 6.5 
h 
- HPLC - Fluorescence  
LLOQ 
= 3 
ng/ml 
- 
Comp
artme
ntal 
(2, 3) 
- 
0.21 
(± 
0.04
0) 
3.3 (± 
0.77) - 
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Wierda et 
al77 
Healthy 
subjects, n = 10,  
Mean (Range) 
Age = 51 (30 - 
60) years 
69 
(56 
- 
75) 
1.00 60 min 
1 
min 
- 8h 
Up to 
24 hrs 
HPLC - 
Fluorescence 
LLOQ 
= 5 
ng/ml 
LLOQ 
= 5 
ng/ml 
Comp
artme
ntal 
(2, 3) 
Cumulat
ive 
0.27 
(± 
0.15) 
4.0 (± 
0.95) 1.32 
Cooper et 
al78 
Healthy 
subjects, n = 9,  
Mean (Range) 
Age = 51 (21 - 
61) years 
63 
(19) 0.60 
Bolu
s 
1 
min 
- 6.5 
h 
- HPLC - Fluorescence 
LLOQ 
= 10 
ng/ml 
- 
Comp
artme
ntal 
(2, 3) 
- 
0.21 
(± 
0.04
9) 
3.7 (± 
1.4) - 
Van den 
Broek et 
al79 
Healthy 
subjects, n = 18 - 0.60 
Bolu
s 
1 
min 
- 8 h 
Up to 
24 hrs 
HPLC - 
Fluorescence 
LLOQ 
= 10 
ng/ml 
LLOQ 
= 25 
ng/ml 
Comp
artme
ntal 
(2, 3) 
Cumulat
ive 
0.20 
(± 
0.07
9) 
4.3 (± 
0.99) 0.73 
Khalil et 
al80 
Healthy 
subjects, n = 8,  
Mean (SD) Age 
= 53 (13) years 
72 
(8) 0.60 
3 
min 
2 
min 
- 6 h 
- HPLC - Fluorescence 
Sensitiv
ity limit 
= 20 
ng/ml 
- 
Comp
artme
ntal 
(2) 
- 
0.18 
(± 
0.04
1) 
2.8 (± 
0.62) - 
Magorian 
et al81 
Healthy 
subjects, n = 10,  
Mean (SD) Age 
= 44 (15) years 
78 
(12) 0.60 
Bolu
s 
2 
min 
- 6 h 
- GC 
Sensitiv
ity limit 
= 10 
ng/ml 
- 
Popul
ation 
PK 
- 0.21 2.8 - 
 
Urinary Excretion Studies 
1. Wierda et al77 calculated CLren = fe*CLtot (fe is the fraction of the dose that is excreted unchanged in the urine; urine samples were 
collected at 2, 4, 6, 9, 12, 18, 24 hrs), fe = 33% 
2. Van den Broek et al79 calculated CLren = fe*CLtot (fe is the fraction of the dose that is excreted unchanged in the urine; urine samples were 
collected up to 24 hrs), fe = 17% 
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Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Proost et al82 In-vitro Ultrafiltration Up to 2000 ng/ml HPLC - Fluorescence 75  
Roy et al83 In-vitro Ultrafiltration Up to 2000 ng/ml HPLC - Fluorescence 54 (4) 
 
Metabolism 
Of the 3 putative metabolites of rocuronium, measurable amount of only 17-desacetyl derivative was detected in plasma84. Biliary excretion 
and metabolism have not been detected in healthy human adults84.  
 
Pharmacodynamics 
Study Subjects PD Endpoint keo  (min-1) 
Cpss50 
(µg/ml) γ 
van Miert et al75 
Healthy subjects, n = 21,  
Mean (SD) Age = 44 (12) 
years 
> 70% Depression in the muscle twitch 
following train of four stimulus 
0.16 (± 
0.060) 
1.0 (± 
0.29) 
5.4  
(±1.2) 
Khalil et al80 
Healthy subjects, n = 8,  
Mean (SD) Age = 53 (13) 
years 
90% Depression in the muscle twitch 
following train of four stimulus 
0.18 (± 
0.058) 
1.2 (± 
0.25) 6.8 (±1.7) 
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Vecuronium 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Cronnell
y et al85 
Healthy 
subjects, n = 5 - 0.04 
10 
min 
2 
min 
- 24 
h 
- LC - MS 
Sensitiv
ity limit 
of 2 
ng/ml 
- 
Comp
artme
ntal 
(2, 3) 
- 
0.27 
(± 
0.04
0) 
5.2 (± 
0.7) - 
Caldwell 
et al86 
Healthy male 
subjects, n = 12,  
Mean (SD) Age 
= 26 (5) years 
74 
(8) 0.30 
10 
min 
2 
min 
- 6 h 
360 - 
480 
min 
GC-Nitrogen 
sensitive 
detector 
Sensitiv
ity limit 
of 5 
ng/ml 
Sensiti
vity 
limit of 
5 
ng/ml 
Comp
artme
ntal 
(2, 3) 
Fraction
ated 0.15 5.7 0.40 
Arden et 
al87 
Healthy 
subjects, n = 10,  
Mean (SD) Age 
= 41 (9) years 
70 
(13) 0.10 
Bolu
s 
2 
min 
- 8 h 
- 
GC-Nitrogen 
sensitive 
detector 
Sensitiv
ity limit 
of 5 
ng/ml 
- 
Comp
artme
ntal 
(2, 3) 
- 
0.18 
(± 
0.06
0) 
4.5 (± 
2.0) - 
Rupp et 
al88 
Healthy 
subjects, n = 5,  
Mean (SD) Age 
= 36 (4) years 
61 
(10) 
2.5 
µg/k
g/mi
n) 
Tinf 
base
d on 
PD 
endp
oint 
2 
min 
- 6 h 
- LC - MS 
Sensitiv
ity limit 
of 2 
ng/ml 
- 
Comp
artme
ntal 
(2, 3) 
- 
0.24 
(± 
0.04
0) 
5.2 (± 
0.8) - 
van der 
Veen et 
al89 
Healthy 
subjects, n = 6,  
Mean (SD) Age 
= 32 (16) years 
- 0.11 
80 - 
202 
min 
Up 
to 
60 
min 
(B) 
and 
125 
min 
- HPLC - - 
Comp
artme
ntal 
(2) 
- 
0.18 
(± 
0.07
0) 
6.1 - 
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(Inf) 
Fahey et 
al90 
Healthy 
subjects, n = 4 - 0.28 
Bolu
s 
4 
min 
- 4 h 
- HPLC 
Sensitiv
ity limit 
of 50 
ng/ml 
- 
Comp
artme
ntal 
(2) 
- 
0.19 
(± 
0.04
0) 
3.0 (± 
0.3) - 
 
Urinary Excretion Studies 
1. Caldwell et al86 calculated CLren by using CLren = Ae/AUC (Urine was collected in intervals 6 - 8 hrs); fe = 7% 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Proost et al82 In-vitro Ultrafiltration Up to 2000 ng/ml HPLC - Fluorescence 43 
Cameron et al91 Healthy subjects, n = 10 Ultrafiltration 0.5 - 2.0 µg/ml HPLC - Fluorescence 31 (± 4) 
Duvaldestin et al92 Healthy subjects, n = 6 Ultracentrifugation 0.3 µg/ml Liquid scintillation counting 70 (± 9) 
 
Pharmacodynamics 
Study Subjects PD Endpoint keo  (min-1) 
Cpss50 
(µg/ml) γ 
Cronnelly et al85 Healthy subjects, n = 5 - - 0.094 (± 0.033) - 
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Caldwell et al86 Healthy male subjects, n = 12,  Mean (SD) Age = 26 (5) years 
>90% Depression in the muscle twitch 
following train of four stimulus 0.28 0.10 - 
Rupp et al88 Healthy subjects, n = 5,  Mean (SD) Age = 36 (4) years - 
0.17 (± 
0.021) 
0.092 
(±0.037) 
5.8 (± 
0.95) 
van der Veen et 
al89 
Healthy subjects, n = 6,  
Mean (SD) Age = 32 (16) 
years 
- 0.27 (±0.07) 
0.14 (± 
0.027) 5.7 (±1.5) 
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Org 7268 (Vecuronium Metabolite) 
 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Caldwell 
et al86 
Healthy male 
subjects, n = 12,  
Mean (SD) Age 
= 26 (5) years 
74 
(8) 0.30 
10 
min 
2 
min 
- 6 h 
360 - 
480 
min 
GC-Nitrogen 
sensitive 
detector 
Sensitiv
ity limit 
of 5 
ng/ml 
Sensiti
vity 
limit of 
5 
ng/ml 
Comp
artme
ntal 
(2, 3) 
Fraction
ated 0.26 4.3 0.77 
 
Urinary Excretion Studies 
1. Caldwell et al86 calculated CLren by using CLren = Ae/AUC (Urine was collected in intervals 6 - 8 hrs); fe = 18% 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Proost et al82 In-vitro Ultrafiltration Up to 2000 ng/ml HPLC - Fluorescence 69 
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Pharmacodynamics 
Study Subjects PD Endpoint keo  (min-1) 
Cpss50 
(µg/ml) γ 
Caldwell et al86 Healthy male subjects, n = 12,  Mean (SD) Age = 26 (5) years 
>90% Depression in the muscle twitch 
following train of four stimulus 0.26 0.13 - 
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Pancuronium 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Cronnell
y et al85 
Healthy 
subjects, n = 4 - 0.04 
10 
min 
2 
min 
- 24 
h 
- LC - MS 
Sensitiv
ity limit 
of 2 
ng/ml 
- 
Comp
artme
ntal 
(2, 3) 
- 
0.26 
(± 
0.07
0) 
1.8 (± 
0.4) - 
Rupp et 
al88 
Healthy 
subjects, n = 5,  
Mean (SD) Age 
= 36 (4) years 
61 
(10) 
2.5 
µg/k
g/mi
n) 
Tinf 
base
d on 
PD 
endp
oint 
2 
min 
- 6 h 
- LC - MS 
Sensitiv
ity limit 
of 2 
ng/ml 
- 
Comp
artme
ntal 
(2, 3) 
- 
0.21 
(± 
0.07
9) 
1.5 (± 
0.5) - 
Caldwell 
et al93 
Healthy 
subjects, n = 18,  
Mean (SD) Age 
= 41 (15) years 
75 
(15) 0.10 
Bolu
s 
2 
min 
- 6 h 
- 
GC - Nitrogen 
sensitive 
detector 
Sensitiv
ity limit 
of 2 
ng/ml 
- 
Comp
artme
ntal 
(2, 3) 
- 
0.20 
(± 
0.05
4) 
1.5 (± 
0.4) - 
Urinary Excretion Studies 
Although the analytical method used for the quantification of the (parent) pancuronium was not specific, i.e., coloriemetry, from the urinary 
excretion studies carried out by Duvaldestin et al94–96 (although they state that it was specific), the mean value calculated from these studies 
for the fraction that appears in the urine (fe) was found to be 58%. The underlying assumption is that there are no major metabolites in the 
urine, i.e., only the unchanged drug appears in the urine. The PK parameter estimates, namely, Vdss and CLtot obtained for the parent 
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pancuronium from other studies (shown above) in which it was quantitated by specific and sensitive methods were similar to those obtained 
by Duvaldestin et al94–96 suggesting that there are no (major) metabolites.   
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Proost et al82 In-vitro Ultrafiltration Up to 2000 ng/ml HPLC - Fluorescence 79 
Duvaldestin et al92 Healthy subjects, n = 8 Ultracentrifugation 0.3 µg/ml Liquid scintillation counting 71 (± 9) 
 
Pharmacodynamics 
Study Subjects PD Endpoint keo  (min-1) 
Cpss50 
(µg/ml) γ 
Cronnelly et al85 Healthy subjects, n = 4 - - 0.088 (± 0.034) - 
Rupp et al88 Healthy subjects, n = 5,  Mean (SD) Age = 36 (4) years - 
0.17 (± 
0.075) 
0.11 
(±0.035) 
4.8  
(± 0.97) 
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Pipercuronium 
 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Caldwell 
et al93 
Healthy 
subjects, n = 20,  
Mean (SD) Age 
= 46 (15) years 
71 
(13) 0.07 
Bolu
s 
2 
min 
- 6 h 
- 
GC - Nitrogen 
sensitive 
detector 
Sensitiv
ity limit 
of 2 
ng/ml 
- 
Comp
artme
ntal 
(2, 3) 
and 
also 
NCA 
(simil
ar 
results
) 
- 
0.31 
(± 
0.05
4) 
2.4 (± 
0.60) - 
D’Honne
ur et al97 
Healthy 
subjects, n = 8,  
Mean (SD) Age 
= 56 (12) years 
64 
(8) 0.10 
Bolu
s 
2 
min 
- 5 h 
- HPLC - Fluorescence 
LLOD 
= 20 
ng/ml 
- 
Comp
artme
ntal 
(2, 3) 
- 
0.35 
(± 
0.08
1) 
3.0 (± 
1.1) - 
Ornstein 
et al98 
Healthy 
subjects, n = 10,  
Mean (SD) Age 
= 49 (7) years 
82 
(10) 0.07 
Bolu
s 
2 
min 
- 6 h 
- 
GC - Nitrogen 
sensitive 
detector 
Sensitiv
ity limit 
of 5 
ng/ml 
- 
Comp
artme
ntal 
(2, 3) 
- 
0.39 
(± 
0.13) 
2.5 (± 
0.7) - 
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Urinary Excretion Studies 
Although the analytical method used for the quantification of the (parent) pipercuronium was not specific, i.e., coloriemetry, from the urinary 
excretion study carried out by Wierda et al99 (although they state that it was specific), the fraction that appears in the urine (fe) was found to 
be 41%. The underlying assumption is that there are no major metabolites in the urine, i.e., only the unchanged drug appears in the urine. The 
PK parameter estimates, namely, Vdss and CLtot obtained for the parent pipercuronium from other studies (shown above) in which it was 
quantitated by specific and sensitive methods were similar to those obtained by Wierda et al99 suggesting that there are no (major) 
metabolites.   
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Obach et al100 - - - - 98 
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Rapacuronium 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Szenohra
dszky et 
al101 
Healthy 
subjects, n = 10,  
Mean (Range) 
Age = 26 (20 - 
42) years 
69 
(50 
- 
85) 
1.5 Bolus 
3 
min 
- 8h 
Up to 
48 h HPLC - MS 
Sensitiv
ity limit 
of 2 
ng/ml 
- 
Comp
artme
ntal 
(3) 
Cumulat
ive 0.41 9.4 0.75 
van Den 
Broek et 
al102 
Healthy 
subjects, n = 10,  
Mean (Range) 
Age = 28 (18 - 
57) years 
79 
(6) 1.5 
Bolu
s 
2 
min 
- 4h 
Up to 
24 h 
HPLC - 
Fluorescence 
LLOQ 
= 10 
ng/ml 
LLOQ 
= 10 
ng/ml 
Comp
artme
ntal 
(2, 3) 
Cumulat
ive 
0.29 
(± 
0.16) 
8.5 (± 
2.5) 1.3 
Schiere et 
al103 
Healthy 
subjects, n = 10,  
Mean (Range) 
Age = 54 (26 - 
64) years 
74 
(62 
- 
88) 
1.0 Bolus 
1 
min 
4 h 
Up to 
24 h HPLC - MS 
LLOQ 
= 10 
ng/ml 
LLOQ 
= 50 
ng/ml 
Comp
artme
ntal 
(3) 
Cumulat
ive 
0.19 
(0.11 
- 
0.25) 
7.3 
(3.9 - 
8.9) 
0.44 
Duvaldes
tin et 
al104 
Healthy 
subjects, n = 8,  
Mean (Range) 
Age = 49 (35 - 
68) years 
77 
(59 
- 
83) 
1.5 Bolus 
2 
min 
- 8h 
- HPLC - MS 
LLOQ 
= 10 
ng/ml 
- 
Comp
artme
ntal 
- 
0.22 
(0.12 
- 
0.29) 
5.3 
(4.2 - 
8.4) 
- 
Wierda et 
al105 
Healthy 
subjects, n = 3 - 1.5 
Bolu
s 
1 
min 
- 8 h 
Up to 
24 h 
HPLC - 
Fluorescence 
LLOQ 
= 10 
ng/ml 
LLOQ 
= 10 
ng/ml 
Comp
artme
ntal 
Cumulat
ive 
0.46 
(± 
0.25) 
11.1 
(± 
1.1) 
0.56 
 297 
 
Urinary Excretion Studies 
1. Szenohradszky et al101 calculated CLren = fe*CLtot (fe is the fraction of the dose that is excreted unchanged in the urine; urine samples were 
collected during the time periods 0 -2, 2 - 4, 4 - 6, 6 - 9, 12 - 18, 18 - 24, 24 - 36, 36 - 48h), fe = 8% 
2. van Den Broek et al102 calculated CLren = fe*CLtot (fe is the fraction of the dose that is excreted unchanged in the urine; urine samples were 
collected up to 24 h), fe = 15% 
3. Schiere et al103 calculated CLren = fe*CLtot (fe is the fraction of the dose that is excreted unchanged in the urine; urine samples were 
collected during the time periods 0 -2, 2 - 4, 4 - 6, 6 - 9, 12 - 18, 18 - 24, 24 - 36, 36 - 48h), fe = 6% 
4. Wierda et al105 calculated CLren = fe*CLtot (fe is the fraction of the dose that is excreted unchanged in the urine; urine samples were 
collected during the time periods 2, 4, 6, 9, 12, 18, 24 h), fe = 5% 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Proost et al82 In-vitro Ultrafiltration Up to 2000 ng/ml HPLC - Fluorescence 38 
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Org 9488 (Rapacuronium Metabolite) 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Schiere et 
al103 
Healthy 
subjects, n = 7,  
Mean (Range) 
Age = 45 (19 - 
62) years 
83 
(68 
- 
99) 
0.20 Bolus 
2 
min 
6 h 
Up to 
24 h HPLC - MS 
LLOQ 
= 10 
ng/ml 
LLOQ 
= 50 
ng/ml 
Comp
artme
ntal 
(3) 
Cumulat
ive 
0.23 
(0.14 
- 
0.31) 
1.3 
(0.76 
- 1.9) 
0.68 
Healthy 
subjects, n = 7,  
Mean (Range) 
Age = 49 (21 - 
63) years 
77 
(68 
- 
100
) 
0.68 
Tinf 
base
d on 
PD 
endp
oint 
1 
min 
- 6 h 
Up to 
24 h HPLC - MS 
LLOQ 
= 10 
ng/ml 
LLOQ 
= 50 
ng/ml 
Comp
artme
ntal 
(3) 
Cumulat
ive 
0.18 
(0.14 
- 
0.35) 
1.1 
(0.73 
- 2.1) 
0.59 
 
 
Urinary Excretion Studies 
1. Schiere et al103 calculated CLren = fe*CLtot (fe is the fraction of the dose that is excreted unchanged in the urine; urine samples were 
collected during the time periods 0 -2, 2 - 4, 4 - 6, 6 - 9, 12 - 18, 18 - 24, 24 - 36, 36 - 48h), fe = 52% (after I.V. bolus) and 54% (after 
short infusion) 
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Org 9489 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Wierda et 
al105 
Healthy 
subjects, n = 3 - 0.90 
Bolu
s 
1 
min 
- 8 h 
Up to 
24 h 
HPLC - 
Fluorescence 
LLOQ 
= 10 
ng/ml 
LLOQ 
= 25 
ng/ml 
Comp
artme
ntal 
Cumulat
ive 
0.46 
(± 
0.25) 
5.8 (± 
1.4) 0.46 
 
Urinary Excretion Studies 
1. Wierda et al105 calculated CLren = fe*CLtot (fe is the fraction of the dose that is excreted unchanged in the urine; urine samples were 
collected during the time periods 2, 4, 6, 9, 12, 18, 24 h), fe = 8% 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Proost et al82 In-vitro Ultrafiltration Up to 2000 ng/ml HPLC - Fluorescence 37 
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Org 9453 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Wierda et 
al105 
Healthy 
subjects, n = 3 - 1.3 
Bolu
s 
1 
min 
- 8 h 
Up to 
24 h 
HPLC - 
Fluorescence 
LLOQ 
= 10 
ng/ml 
LLOQ 
= 10 
ng/ml 
Comp
artme
ntal 
Cumulat
ive 
0.18 
(± 
0.01
8) 
6.9 (± 
1.5) 0.35 
 
Urinary Excretion Studies 
1. Wierda et al105 calculated CLren = fe*CLtot (fe is the fraction of the dose that is excreted unchanged in the urine; urine samples were 
collected during the time periods 2, 4, 6, 9, 12, 18, 24 h), fe = 5% 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Proost et al82 In-vitro Ultrafiltration Up to 2000 ng/ml HPLC - Fluorescence 28 
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Alcuronium 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Diefenba
ch et al106 
Healthy 
subjects, n = 10, 
Age Range = 18 
- 70 years 
50 - 
90 0.25 
Bolu
s 
3 
min 
- 
720 
min 
Up to 
24 
hours 
HPLC - UV 
Sensitiv
ity = 25 
ng/ml 
- 
Non-
Comp
artme
ntal 
Cumulat
ive 
0.31 
(± 
0.07
0) 
0.90 
(± 
0.29) 
- 
 
Urinary Excretion Studies 
1. Diefenbach et al106 calculated CLren = fe*CLtot (fe is the fraction of the dose that is excreted unchanged in the urine; urine samples were 
collected up to 48 hrs), fe = 72% 
 
Pharmacodynamics 
Study Subjects PD Endpoint keo  (min-1) 
Cpss50 
(µg/ml) γ 
Diefenbach et 
al106 
Healthy subjects, n = 10, Age 
Range = 18 - 70 years -  0.54 (±0.1) 5 
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Doxacurium 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Dresner 
et al107 
Healthy 
subjects, n = 8,  
Mean (SD) Age 
= 31 (9) years 
77 
(17) 0.03 
Bolu
s 
2 
min 
- 6h 
Up to 
24 h HPLC - UV 
LLOQ 
= 10 
ng/ml 
LLOQ 
= 10 
ng/ml 
Comp
artmen
tal (2, 
3) 
Cumulat
ive 
0.15 
(± 
0.04) 
2.2 (± 
1.1) - 
Gareipy 
et al108 
Healthy 
subjects, n = 9, 
Mean (SD) Age 
= 27 (9) years 
71 
(15) 0.03 
Bolu
s 
2 
min 
- 8 h 
Up to 
8 h HPLC - UV 
LLOQ 
= 4 
ng/ml 
LLOQ 
= 4 
ng/ml 
Comp
artmen
tal (2) 
Cumulat
ive 
0.23 
(± 
0.03) 
2.5 (± 
0.24) - 
Cook et 
al109 
Healthy 
subjects, n = 9, 
Mean (SD) age 
= 32 (7) 
82 
(12) 0.02 
Bolu
s 
2 
min 
- 6 
hr 
Up to 
12 h HPLC - UV 
LLOQ 
= 10 
ng/ml 
- NCA Cumulative 
0.22 
(± 
0.11) 
2.7 (± 
1.6) - 
 
Urinary Excretion Studies 
1. Dresner et al107 calculated the CLren by using CLren = fe*CLtot (urine was sampled up to 24 hrs). fe = 31% 
2. Gareipy et al108 calculated the CLren by using CLren = fe*CLtot (urine was sampled up to 8 hrs). fe = 25% 
3. Cook et al109 calculated the CLren by using CLren = fe*CLtot (urine was sampled up to 12 hrs). fe = 21%  
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Plasma Protein Binding Studies 
 
Study Subjects Method Concentration Range  Assay fu (%) 
Doxacurium FDA 
Label - - - - 53% 
 
Pharmacodynamics 
Study Subjects PD Endpoint keo  (min-1) 
Cpss50 
(µg/ml) γ 
Gareipy et al108 Healthy male subjects, n = 9,  Mean (SD) Age = 27 (9) years 
>90% Depression in the muscle twitch 
following train of four stimulus 
0.051  
(± 0.003) 
0.054 
(±0.0055) 
5.46 
(±0.34) 
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Atracurium 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Fahey et 
al110 
 
Healthy 
subjects, n = 10 - 0.50 
Bolu
s 
2 
min 
- 4 h 
- HPLC - Fluorescence  
Sensitiv
ity limit 
= 10 
ng/ml 
- 
Comp
artmen
tal (2, 
3) 
- - 6.1 (± 0.95) - 
Parker et 
al111 
Healthy 
subjects, n = 7, 
Mean (SD) Age 
= 56 (11) years 
69 
(15) 0.60 
Bolu
s 
2 
min 
- 6 h 
- HPLC - Fluorescence 
Sensitiv
ity limit 
= 25 
ng/ml 
- 
Comp
artmen
tal (2) 
- - 6.6 (± 1.2) - 
Fisher et 
al112 
Healthy 
subjects, n = 8, 
Age range = 22 
- 43 years 
- 0.15 Bolus 
1 
min 
- 2 
hrs 
- HPLC - Fluorescence 
Sensitiv
ity limit 
= 10 
ng/ml 
- 
Comp
artmen
tal (2) 
- 
0.08
7 (± 
0.03
1) 
4.8 (± 
1.1) - 
Ward et 
al113 
Healthy 
subjects, n = 7 
Age range = 24 
- 69 years 
75 
0.3 
or 
0.6 
Bolu
s 
1 
min 
- 2 
hrs 
- HPLC - Fluorescence 
Sensitiv
ity limit 
= 50 
ng/ml 
- 
Comp
artmen
tal (2) 
- - 5.5 (± 0.69) - 
Ward et 
al114 
Healthy 
subjects, n = 6 - 
0.3 
or 
0.4 
Bolu
s 
2 - 
500 
min 
Up to 
500 
min 
HPLC - 
Fluorescence 
LLOD 
= 10 
ng/ml 
LLOD 
= 10 
ng/ml 
Comp
artmen
tal (2 
or 3) 
Cumulat
ive - 
5.5 (± 
0.73) 0.33 
Smith et 
al115 
Healthy 
subjects, n = 10, 
Mean (SD) age 
= 39 (15) 
77 
(14) 0.50 
Tinf 
base
d on 
PD 
Endp
oint 
2 
min 
- 8 
hr 
- HPLC - Fluorescence 
LLOQ 
= 10 
ng/ml 
- 
Comp
artmen
tal (2) 
- 0.21 10 - 
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Kent et 
al116 
Healthy 
subjects, n = 10, 
Mean (SD) age 
= 24 (4) 
72 
(12) 0.60 
Bolu
s 
2 
min 
- 2 h 
- HPLC - Fluorescence 
Sensitiv
ity limit 
= 25 
ng/ml 
- NCA - 
0.17 
(± 
0.03
4) 
5.9 (± 
0.9) - 
 
Urinary Excretion Studies 
4. Ward et al114 calculated the CLren by using CLren = Ae/AUC0-500 min (urine was sampled up to 500 min). fe = 6% 
 
Plasma Protein Binding Studies 
 
Study Subjects Method Concentration Range  Assay fu (%) 
Cameron et al91 Healthy subjects, n = 10 Ultrafiltration 0.5 - 2.0 µg/ml HPLC - Fluorescence 57 (±7) 
 
Metabolism 
Atracurium is eliminated through several pathways, including Hofmann elimination, i.e., by spontaneous degradation in plasma (central 
compartment) and tissue(s) (peripheral compartment) at normal body pH and temperature) and ester hydrolysis (catalysis by nonspecific 
esterases)112,115. Ward et al114 proposed the pathways of breakdown of atracurium (shown below)  
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Cisatracurium 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Smith et 
al115 
Healthy 
subjects, n = 10, 
Mean (SD) age 
= 50 (11) 
66 
(8) 0.10 
Tinf 
base
d on 
PD 
Endp
oint 
2 
min 
- 8 
hr 
- HPLC - Fluorescence 
LLOQ 
= 10 
ng/ml 
- 
Comp
artmen
tal (2) 
- 0.21 
6.44 
(± 
0.85) 
- 
Lien et 
al117 
Healthy 
subjects, n = 10, 
Mean (SD) age 
= 37 (12) 
73 
(13) 0.10 
Bolu
s 
2 
min 
- 8 
hr 
- HPLC - Fluorescence 
LLOQ 
= 10 
ng/ml 
- 
Comp
artmen
tal 
- 
0.18 
(± 
0.04
8) 
5.1 (± 
0.84) 
- Healthy 
subjects, n = 10, 
Mean (SD) age 
= 39 (8) 
87 
(10) 0.20 
0.16 
(± 
0.03
6) 
4.9 (± 
0.64) 
Ornstein 
et al118 
Healthy 
subjects, n = 12, 
Mean (SD) age 
= 42 (5) 
78 
(16) 0.10 
Bolu
s 
2 
min 
- 8 
hr 
Up to 
10 h 
HPLC - 
Fluorescence 
Sensitiv
ity limit 
= 10 
ng/ml 
Sensiti
vity 
limit = 
10 
ng/ml 
Comp
artmen
tal (2, 
3) 
Cumulat
ive 
0.11 
(± 
0.01
3 
4.6 (± 
0.8) 0.83 
Tran et 
al119 
Healthy 
subjects, n = 14, 
Mean (SD) age 
= 46 (12) 
72 
(15) 0.10 
Bolu
s 
2 
min 
- 8 
hr 
- HPLC - Fluorescence - - 
Comp
artmen
tal 
- 
0.12 
(± 
0.02
7) 
3.7 (± 
0.8) - 
Wolf et 
al120 
Healthy 
subjects, n = 11, 
Mean (Range) 
age = 37 (21 - 
65) 
80 
(12) 0.10 
Bolu
s 
2 
min 
- 8 
hr 
Up to 
10 h 
HPLC - 
Fluorescence 
LLOQ 
= 10 
ng/ml 
LLOQ 
= 10 
ng/ml 
NCA Cumulative 
0.16 
(± 
0.02
3) 
5.7 (± 
0.8) 0.80 
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Urinary Excretion Studies 
1. Ornstein et al118 calculated CLren = fe*CLtot (fe is the fraction of the dose that is excreted unchanged in the urine; urine samples were 
collected at up to 10 hrs), fe = 18% 
2. Wolf et al120 calculated CLren = fe*CLtot (fe is the fraction of the dose that is excreted unchanged in the urine; urine samples were 
collected at up to 10 hrs), fe = 14% 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Roy et al83 In-vitro Ultrafiltration Up to 2000 ng/ml HPLC - Fluorescence 62 (9) 
 
Metabolism 
Cisatracurium undergoes pH and temperature-dependent Hofmann elimination in plasma and tissues121. The clearance of cisatracurium due to 
Hofmann elimination and organ elimination occurs from both central and peripheral compartments, i.e., in an organ independent manner121. 
Kisor et al122 proposed the metabolic elimination pathway for cisatracurium besylate in human plasma, the schematic of which is shown 
below.  
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Pharmacodynamics 
Study Subjects PD Endpoint keo  (min-1) 
Cpss50 
(µg/ml) γ 
Tran et al119 Healthy subjects, n = 14, Mean (SD) age = 46 (12) 
75% Depression in the muscle twitch 
following train of four stimulus 
0.054 (± 
0.013) 
0.15 (± 
0.033) 6.9 (±1.3) 
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Mivacurium 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Head-
Rapson et 
al123 
Healthy 
subjects, n = 
9, Mean 
(Range) Age 
= 40 (20 - 61) 
years 
71 
(48 
- 
84) 
0.23 Inf 
1 
min 
- 5h 
- HPLC 
LLOQ 
= 2 
ng/ml 
- 
Comp
artme
ntal 
- 0.24 71 - 
Cook et 
al124 
Healthy 
subjects, n = 
9, Mean 
(Range) Age 
= 27 (21 - 35) 
years 
77 
(12) 0.15 
Bolu
s 
1 
min 
- 
150 
min 
Up to 
6h HPLC 
Sensitiv
ity limit 
= 10 
ng/ml 
Sensiti
vity 
limit = 
10 
ng/ml 
Comp
artme
ntal 
Cumulat
ive 
0.11 
(± 
0.07
2) 
70 (± 
28) 4.9 
Head-
Rapson et 
al125 
Healthy 
subjects, n = 
10, Mean 
(Range) Age 
= 47 (31 - 62) 
years 
75 
(52 
- 
107
) 
0.15 Bolues 
1 
min 
- 
190 
min  
- HPLC 
LLOQ 
= 2.5 
ng/ml 
- 
Comp
artme
ntal 
- 0.21 75 - 
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Plasma Protein Binding Studies 
 
Study Subjects Method Concentration Range  Assay fu (%) 
Cameron et al91 Healthy subjects, n = 10 Ultrafiltration 0.5 - 2.0 µg/ml HPLC - Fluorescence 71 (±7) 
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Metabolism 
The schematic for the potential routes of metabolism for Mivacurium126 is shown below. 
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Fazadinium 
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Duvaldes
tin et 
al127 
Healthy 
subjects, n = 10, 
Mean (SD) Age 
= 33 (17) 
63 
(20) 1.5 
Bolu
s 
5 
min 
- 5 h 
Up to 
24 h Coloriemetry 
Limit 
of 
sensitiv
ity = 50 
ng/ml 
Limit 
of 
sensitiv
ity = 
40 
ng/ml 
Comp
artme
ntal 
Cumulat
ive 0.19 2.10 - 
 
Urinary Excretion Studies 
1. Duvaldestin et al127 calculated CLren = fe*CLtot (fe is the fraction of the dose that is excreted unchanged in the urine; urine samples were 
collected 24 h), fe = 50% 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Hollander et al128 - - - - 49 
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Succinylcholine  
 
Study Population 
BW Dose (I.V.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss/
Vdpss 
CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Roy et 
al129 
Healthy 
subjects - 1.0 
Bolu
s 
Up 
to 
10 
min 
- LC - MS 
Sensitiv
ity limit 
= 25 
ng/ml 
- 
Comp
artme
ntal 
- 
0.04 
(± 
0.00
6) 
37 
(±9) - 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Roy et al129 - - - - 80 
 
Pharmacodynamics 
Study Subjects PD Endpoint keo  (min-1) 
Cpss50 
(µg/ml) γ 
Roy et al129 - - 0.06 (±0.03) 
0.76 
(±0.21) 19.3 (±8.1) 
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Appendix 3.1 - Human PK Study Summaries of Triptans 
 
5-HT 
 
 
Sumatriptan 
 
 
 
 
Study Population BW Dose (IV/ Rate 
PK 
Sampling Assay Method 
Analytical 
Method 
PK 
Analy
Urine 
Collecti Vdss CLtot CLren 
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PO) Schedule Parameters sis on 
Method 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Lacey., F. 
et al130 
Healthy males, 
n = 18, Mean 
Age (Range) = 
27 (19 - 40) 
72 
(58 
- 
88) 
0.04 
15 
min 
Infus
ion 
Up 
to 
12 
hrs 
- 
HPLC - 
Electrochemical 
Detection 
LLOQ 
= 1 
ng/ml 
LLOQ 
= 400 
ng/ml 
Comp
artme
ntal 
(3) 
- 
2.6 
(1.3 
- 
4.4) 
16.1 
(8.8 - 
21.9) 
3.7 
(2.0 - 
6.5) 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Dixon. M. et al131 Healthy males, n = 4 Equilibrium dialysis 10 - 1000 ng/ml Liquid Scintillation Counting 84 
 
Metabolism 
In-vivo, sumatriptan undergoes extensive first-pass metabolism primarily mediated by MAO-A and the major metabolite obtained is indole 
acetic acid analogue (which is then eliminated mainly in the urine either as a free acid or as an ester glucuronide)132–134. 
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Almotriptan 
 
 
 
 
Study Population 
BW 
Dose 
(IV/ 
PO) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Janset et 
al135 
Healthy males, 
n = 18, Mean 
(Range) Age = 
25 (20 - 33) 
years 
74 
(64 
- 
88) 
0.04 
15 
min 
Infus
ion 
15 
min 
- 24 
hrs 
0 - 72 
hrs HPLC - UV 
LLOQ 
= 1 
ng/ml 
LLOQ 
= 50 
ng/ml 
Comp
artme
ntal 
(2) 
Fraction
ed 
2.3 
(± 
0.5) 
9.0 (± 
1.8) 
5.6 (± 
1.8) 
McEwen 
et al136 
Healthy males, 
n = 23, Mean 
(Range) Age = 
29 (19 - 46) 
years 
73 
(52 
- 
101
) 
0.07 
- 
2.74 
P.O. 
15 
min 
- 12 
hrs 
0 - 12 
hrs 
HPLC - 
Electrochemical 
for plasma and 
HPLC - UV for 
urine 
LLOQ 
= 1 
ng/ml 
LLOQ 
= 1 
µg/ml 
NCA Cumulative - - 
3.8 
(3.1 - 
4.6) 
Fleishake
r et al137 
Healthy 
subjects, n = 12, 
Mean (SD) Age 
= 34  (± 8) 
67 
(± 
10) 
0.19 P.O. 
30 
min 
- 24 
hrs 
0 -  
24 hrs 
LC/MS/MS for 
Plasma and 
HPLC - UV for 
Urine 
LLOQ 
= 1 
ng/ml 
LLOQ 
= 50 
ng/ml 
NCA Fractioned - - 
3.2 (± 
0.6) 
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years 
Fleishake
r et al138 
Healthy 
subjects, n = 14, 
Mean (SD) Age 
= 35  (± 10) 
years 
69 
(± 
10) 
0.18 P.O. 
30 
min 
- 24 
hrs 
0 - 24 
hrs 
LC/MS/MS for 
Plasma and 
HPLC - UV for 
Urine 
LLOQ 
= 0.5 
ng/ml 
LLOQ 
= 50 
ng/ml 
NCA Fractioned - - 
3.3 (± 
0.9) 
Fleishake
r et al139 
Healthy 
subjects, n = 12, 
Mean (SD) Age 
= 31  (± 11) 
years 
74 
(± 
13) 
0.17 P.O. 
30 
min 
- 24 
hrs 
0 - 24 
hrs 
LC/MS/MS for 
Plasma and 
HPLC - UV for 
Urine 
LLOQ 
= 0.5 
ng/ml 
LLOQ 
= 50 
ng/ml 
NCA Fractioned - - 
4.4 (± 
0.7) 
Fleishake
r et al140 
Healthy 
subjects, n = 16, 
Mean (SD) Age 
= 28  (± 9) 
years 
77 
(± 
12) 
0.16 P.O. 
30 
min 
- 48 
hrs 
0 - 48 
hrs 
LC/MS/MS for 
Plasma and 
HPLC - UV for 
Urine 
LLOQ 
= 0.5 
ng/ml 
LLOQ 
= 50 
ng/ml 
NCA Fractioned - - 
3.0 (± 
0.4) 
Baldwin 
et al141 
Healthy 
subjects, n = 18, 
Mean (Range) 
Age = 37 (18 - 
53) years 
74 
(53 
- 
94) 
0.17 P.O. 
30 
min 
- 24 
hrs 
0 - 24 
hrs LC/MS/MS 
LLOQ 
= 0.5 
ng/ml 
LLOQ 
= 50 
ng/ml 
NCA Fractioned - - 
3.3 (± 
0.7) 
 
 
Urinary Excretion Studies 
2. Janset et al135 calculated the CLren by using CLren = Ae/AUC (Urine was collected in 4 hr fractions for first 12 hrs, and then 12 hr fraction 
upto 24 hrs) 
3. McEwen et al136 calculated the CLren by using CLren = Ae/AUC (Ae is the cumulative amount = % dose excreted unchanged in urine; urine 
was collected in 4 hr fractions for 12 hrs) 
4. Fleishaker et al137 calculated the CLren by using CLren = Ae/AUC (Urine was collected in 4 hr fractions for first 12 hrs, and then 12 hr 
fraction upto 24 hrs) 
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5. Fleishaker et al138 calculated the CLren by using CLren = Ae/AUC (Urine was collected in 4 hr fractions for first 12 hrs, and then 12 hr 
fraction upto 24 hrs) 
6. Fleishaker et al139 calculated the CLren by using CLren = Ae/AUC (Urine was collected in 4 hr fractions for first 12 hrs, and then 12 hr 
fraction upto 24 hrs) 
7. Fleishaker et al140 calculated the CLren by using CLren = Ae/AUC (Urine was collected in 4 hr fractions for first 12 hrs, and then 12 hr 
fraction upto 48 hrs) 
8. Baldwin et al141 calculated the CLren by using CLren = Ae/AUC (Urine was collected in 4 hr fractions for first 12 hrs, and then 12 hr 
fraction upto 24 hrs) 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Almotriptan FDA Label - - - - 65
142–
144 
 
Metabolism 
In-vivo, it is metabolized by two major pathways144,145: (1) Monoamine oxidase (MAO)-mediated oxidative deamination (and consequent 
oxidation by aldehyde dehydrogenase) to indolacetic acid metabolite (which then forms a glucuronide conjugate) and (2) Cytochrome-
mediated (primarily involving CYP3A4, CYP2D6 and other CYP enzymes contributing to a minor extent) hydroxylation of the pyrrolidine 
ring to form and intermediate which is further oxidized by aldehyde dehydrogenase to form a gamma-aminobutyric acid derivative. Another 
minor pathway by which almotriptan is metabolized is flavin monooxygenase-mediated N-oxidation. The metabolic profile of almotriptan in 
urine, faeces and plasma show highest amounts of indolacetic acid and oxidized pyrrolidine product146.  The scheme is shown in Figure - 1.  
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Figure 1 - Pathways of almotriptan metabolism in humans144,146 
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Naratriptan 
 
 
Study Population 
BW 
Dose 
(IV/ 
PO) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Fuseau E., 
et al147 
Healthy n = 
23, Age range 
= 20 - 47 years 
50 - 
95 0.02 
15 
min 
Infus
ion 
Up 
to 
36 
hrs 
Up to 
36 hrs - - - 
Comp
artme
ntal 
(2) 
- - - - 
Kempsfor
d et al148 
Healthy 
females n = 26, 
Age range = 18 
- 45 years 
50 - 
78 
0.04 
- 
0.14 
P.O. 
Up 
to 
24 
hrs 
Up to 
24 hrs - - - NCA - - - 
2.4 (± 
0.1) 
Naratripta
n FDA 
Approval 
Package149 
  0.02 
15 
min 
Infus
ion 
Up 
to 
36 
hrs 
Up to 
36 hrs - - - 
Comp
artme
ntal 
(2) 
- 2.4 6.6 - 
 
Urinary Excretion Studies 
2. Kempsford et al148 calculated the CLren by using CLren = Ae/AUC (Urine was collected upto 24 hrs) 
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Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Naratriptan FDA Approval 
Package149 - - 
50 - 1000 
ng/ml - 25 
FDA Label150 - - 50 - 1000 ng/ml - 28 - 31 
 
Metabolism 
In-vivo, the major metabolites found in human plasma and urine include N-oxide and piperidineone metabolite149. CYP450 enzyme system is 
believed to be involved in the metabolism of naratriptan149–151 (and is not a substrate for MAO)152.  
 
Blood-to-Plasma Ratio Studies 
Study Subjects Method Concentration Range  Assay 
B:P 
Ratio 
Naratriptan FDA Approval 
Package149 - - - Radioactivity 1.2 
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Frovatriptan 
 
 
 
 
Study Population 
BW 
Dose 
(IV/ 
PO) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Buchan et 
al153 
Healthy males 
n = 6 - 0.01 
15 
min 
Infus
ion 
- - LC-MS/MS 
LLOQ 
= 0.5 
ng/ml 
LLOQ 
= 50 
ng/ml 
- 
Cumulat
ive 
4.2 ± 
1.4 
3.2 ± 
0.6 1.2 
Buchan et 
al154 
Healthy 
females n = 6 - 0.01 
15 
min 
Infus
ion 
- - LC-MS/MS 
LLOQ 
= 0.5 
ng/ml 
LLOQ 
= 50 
ng/ml 
- 3.0 ± 0.8 
2.3 ± 
0.9 1.1 
 
 
Urinary Excretion Studies 
 
1. Buchan et al153,154 calculated the CLren by using CLren = fe*CLtot (fe is the percent of the dose excreted in urine to the administered dose, 
urine was collected up to 24 hrs) 
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Plasma Protein Binding Studies 
 
Study Subjects Method Concentration Range  Assay fu (%) 
Frovatriptan FDA Approval 
Package155 and FDA Label156 - - 2 - 1220 ng/ml - 85 
 
 
Metabolism 
 
In-vivo, the major metabolites of frovatriptan in blood, urine and feces are hydroxyl-, desmethyl-, N-acetyldesmethyl-, and hydroxyl-N-
acetyldesmethyl-frovatriptan154,156–159. Additionally, indole acid of frovatriptan is found only in the feces154,155. The schematic for metabolism 
of frovatriptan is shown in Figure - 2 below. Cytochrome P450 enzymes, predominantly by CYP 1A2, mediate hepatic metabolism of 
frovatriptan158–160 (and not a substrate for CYP3A4 and/or MAO)161.  
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Figure 2 - Metabolic Scheme for Frovatriptan154,155 
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Blood-to-Plasma Ratio Studies 
 
Study Subjects Method Concentration Range  Assay 
B:P 
Ratio 
Frovatriptan FDA Approval 
Package155 and FDA Label156 - - - - 2.0 
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Rizatriptan 
 
 
 
 
 
Study Population 
BW 
Dose 
(IV/ 
PO) 
Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters PK Analy
sis 
Urine 
Collecti
on 
Method 
Vdss CLtot CLren 
(kg) (mg/kg)  
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Lee. Y., et 
al162 
Healthy 
females, n=8, 
Age range = 
21 - 30 years 
59 - 
77 
0.007 
30 
min 
Infusi
on 
15 
min 
- 24 
hrs 
0 - 24 
hrs LC-MS/MS 
LLOQ 
= 0.5 
ng/ml 
LLOQ 
= 5 
ng/ml 
NCA Cumulative 
1.3 
(± 
0.3) 
13.4 
(± 
1.9) 
2.0  
0.014 
1.5 
(± 
0.4) 
12.8 
(± 
1.4) 
2.6 
0.04 
1.5 
(± 
0.2) 
12.3 
(± 
1.5) 
3.4  
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- 
0.01 
15 
min 
Infusi
on 
15 
min 
- 24 
hrs 
 
LC-MS/MS 
LLOQ 
= 0.5 
ng/ml 
- NCA - 
1.9 
(± 
0.4) 
16.2 
(± 
3.2) 
- 
Cheng. H., 
et al163 
Healthy 
males, n = 6 
0.02 - 
1.5 
(± 
0.3) 
16.7 
(± 
2.2) 
- 
0.04  
2.0 
(± 
0.5) 
18.7 
(± 
4.1) 
- 
  0.06  
1.7 
(± 
0.3) 
17.0 
(± 
3.5) 
- 
Lee. Y., et 
al164 
Healthy, n = 
24, Age 
Range = 22 - 
41 years 
Mal
es: 
78 
(61 
- 
93) 
0.05 
30 
min 
Infusi
on 
15 
min 
- 12 
hrs 
0 - 24 
hrs LC-MS/MS 
LLOQ 
= 0.5 
ng/ml 
LLOQ 
=  5 
ng/ml 
NCA Fractioanted 
1.8 
(± 
0.4) 
13.4 
(± 
3.6) 
2.9 (± 
0.5) 
Fe
mal
es: 
61 
(54 
- 
71) 
0.07 
1.7 
(± 
0.5) 
13.5 
(± 
2.4) 
2.8 (± 
0.5) 
Mal
es: 
78 
(61 
- 
93) 
0.03 
P.O 
LLOQ 
= 1 
ng/ml 
- - 2.9 (± 1.1) 
0.06 - - 4.4 (± 1.6) 
0.13 
LLOQ 
=  5 
ng/ml 
- - 3.8 (± 1.6) 
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Fe
mal
es: 
61 
(54 
- 
71) 
0.04 LLOQ 
= 1 
ng/ml 
- - 2.9 (± 0.4) 
0.08 - - 4.0 (± 0.9) 
0.16 
LLOQ 
= 5 
ng/ml 
- - 4.0 (± 2.2) 
Vyas. P., 
et al165 
Healthy 
males, n = 6 - 
0.04 
30 
min 
Infusi
on 
Up 
to 5 
days 
Up to 
5 
days 
LC-MS/MS - - NCA - 
2.0 
(± 
0.4) 
17.6 
(± 
2.6) 
4.5 (± 
0.6) 
0.14 P.O - - 5.2 (± 1.5) 
 
Urinary Excretion Studies 
1. Lee. Y., et al162 calculated the CLren by using CLren by using CLren = fe*CLtot (fe is the percent of the dose excreted in urine to the 
administered dose, urine was collected up to 24 hrs) 
2. Lee. Y., et al164 calculated the CLren by using CLren = Ae/AUC (Urine was collected in 6 hr fractions for up to 12 hrs and a 12 hr fraction 
up to 24 hrs) 
3. Vyas. P., et al165 calculated the CLren by using CLren = Ae/AUC (Urine was collected up to 5 days) 
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Plasma Protein Binding Studies 
 
Study Subjects Method Concentration Range  Assay fu (%) 
Rizatriptan FDA Approval 
Package166 and FDA Label167 - - 
50 - 5000 
ng/ml - 86 
 
Metabolism 
 
In-vivo, rizatriptan undergoes oxidative deamination mediated by MAO-A to indole acetic acid metabolite, which is primary route of 
metabolism166,167. N-monodesmethyl-rizatriptan is a metabolite, which has shown similar activity at 5-HT1B/1D receptors as the parent 
compound. Other minor metabolites include N-oxide, 6-hydroxy compound and its sulfate conjugate166,167. The schematic of metabolism of 
rizatriptan is shown in Figure - 3.  
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Figure 3 - Schematic of Metabolism of Rizatriptan165,166 
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Zolmitriptan 
 
Study Population 
BW 
Dose 
(IV/ 
P.O.) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Seaber. E., 
et al168 
Healthy males, 
n = 6, Mean 
Age (Range) = 
33 (25 - 38) 
years  
78 
(61 
- 
95) 
0.04 240 
min 
Infus
ion  
15 
min 
- 24 
hrs 
Up to 
24 hrs 
HPLC-
Fluoroscence 
LLOQ 
= 2 
ng/ml 
LLOQ 
= 100 
ng/ml 
NCA 
Fraction
ated 
4.2 ± 
1.4 
9.2 (± 
1.7) 
3.0 (± 
0.5) 
Healthy 
females, n = 6, 
Mean Age 
(Range) = 27 
(21 - 34) years  
65 
(58 
- 
72) 
0.05 3.0 ± 0.8 
8.3 (± 
1.7) 
3.0 (± 
0.7) 
Healthy males, 
n = 6, Mean 
Age (Range) = 
33 (25 - 38) 
years  
78 
(61 
- 
95) 
0.13 P.O. 
Up to 
168 
hrs 
- - 2.5 (± 1.0) 
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Healthy 
females, n = 6, 
Mean Age 
(Range) = 27 
(21 - 34) years  
65 
(58 
- 
72) 
0.15 P.O.  2.5 (± 0.7) 
Seaber. E., 
et al169 
Healthy males, 
n = 10, Mean 
Age (Range) = 
23 (20 - 28) 
years 
78 
(65 
- 
90) 
0.01 
120 
min 
Infus
ion 
30 
min 
- 15 
hrs 
- HPLC-MS 
LLOQ 
= 0.1 
ng/ml 
- NCA - 
 11.8 
- 
0.02  12.3 
Healthy 
females, n = 
10, Mean Age 
(Range) = 23 
(19 - 34) years 
69 
(52 
- 
85) 
0.02  11.2 
0.04  10.2 
Peck., W. 
et al170 
Healthy young 
adults, n  = 12, 
Mean Age 
(Range) = 29 
(18 - 39) years 
70 
(54 
- 
72) 
0.07 
P.O. 
30 
min 
- 24 
hrs 
0 - 24 
hrs 
HPLC-
Fluoroscence 
LLOQ 
= 2 
ng/ml 
LLOQ 
= 100 
ng/ml 
NCA Cumulative - - 
2.9 (± 
0.9) 
0.14 3.2 (± 1.0) 
0.21 3.2 (± 1.0) 
Peck., W. 
et al171 
Healthy 
subjects, n = 
14, Age Range 
= 20 - 39 years 
55 - 
89 0.14 P.O. 
30 
min 
- 24 
hrs 
0 - 24 
hrs 
HPLC-
Fluoroscence 
LLOQ 
= 2 
ng/ml 
LLOQ 
= 100 
ng/ml 
NCA Cumulative - - 
3.5 
(2.8 - 
5.1) 
 
Urinary Excretion Studies 
1. Seaber. E., et al168 calculated the CLren by using CLren = Ae/AUC (Urine was collected in 3 free fractions up to 12 hrs) after I.V. 
administration and also after P.O. administration (but the urine was reported to be sampled up to 168 hrs) 
2. Peck., W. et al170,171 calculated the CLren by using CLren = Ae/AUC (Ae is the amount excreted in urine for 24 hrs) 
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Plasma Protein Binding 
 
Study Subjects Method Concentration Range  Assay fu (%) 
Rolan., PE et. al 172 - - 10 - 1000 ng/ml - 75 
 
 
Metabolism 
In-vivo, three major metabolites have been identified, namely, N-desmethyl metabolite (which is 2- to 6-times more potent at 5-HT1B/1D 
receptors in animal models), N-oxide and indole acetic acid metabolite which is a major metabolite in plasma)172–174. Since indole acetic acid 
metabolite is also produced by sumatriptan via MAO-A mediated pathway, presumably, it plays a role in the disposition of zolmitriptan. 
Additionally, in-vitro studies175 indicate the involvement of CYP450 enzymes (namely CYP1A2) in the metabolism of zolmitriptan and the 
schematic for the same is shown in Figure - 4.   
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Figure 4 - Schematic for in-vitro metabolism of Zolmitriptan175 
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Eletriptan 
 
Study Population 
BW 
Dose 
(IV/ 
PO) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss CLtot CLren 
(kg) (µg/kg)* 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Milton. 
K., et al176 
Healthy males, 
n = 8 - 11, 
Mean (Range) 
Age = 25 (18 - 
38) years 
76 
(60 
- 
87) 
5 
15 
min 
Infus
ion 
7.5 
min 
- 24 
hrs 
- 
HPLC - UV 
LLOQ 
= 0.5 
ng/ml 
- 
NCA 
 
1.9 
(0.8 
- 
2.8) 
6.3 
(4.0 - 
9.8) 
- 
17 
2.0 
(1.5 
- 
2.4) 
5.8 
(4.4 - 
6.7) 
50 0 - 24 hrs 
LLOQ 
= 0.5 
ng/ml 
Cumulat
ive 
2.0 
(1.4 
- 
2.4) 
5.6 
(3.7 - 
6.7) 
0.5 
Healthy males, 
n = 8 - 9, Mean 
(Range) Age = 
25 (19 - 33) 
years 
75 
(63 
- 
89) 
50 
- - - 
3.0 
(2.4 
- 4) 
7.0 
(5.6 - 
8.8)  
75 2.6 (1.7 
6.4 
(4.7 - 
 337 
- 
3.4) 
7.6) 
100 
2.6 
(1.8 
- 
4.1) 
6.7 
(5.5 - 
9.1) 
**Please note that the doses were administered as µg/kg 
 
Urinary Excretion Studies 
1. Milton. K., et al176 calculated the CLren by using CLren by using CLren = fe*CLtot (fe is the percent of the dose excreted in urine to the 
administered dose, urine was collected up to 24 hrs) 
 
Plasma Protein Binding 
Study Subjects Method Concentration Range  Assay fu (%) 
Eletriptan FDA Label177 - - - - 15 
 
Metabolism 
In-vivo, N-demethylated metabolite is the major metabolite found in the plasma (and also shows activity at 5-HT1B/1D receptors)177. In-vitro 
studies in human liver CYP450 microsomes suggest that it is metabolized primarily by CYP3A4177,178.    
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Avitriptan 
 
 
Study Population 
BW 
Dose 
(IV/ 
PO) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Sharma. 
A., et al179 
Healthy, n = 
24, 6 (2 PL) in 
each dose 
group; Mean 
(Range) Age = 
28 (21 - 43) 
years 
74 
(± 
15) 
0.17 
30 
min 
Infus
ion 
5 
min 
- 36 
hrs 
- 
HPLC - 
Electrochemical 
detection 
LLOQ 
= 1 
ng/ml 
- 
Comp
artme
ntal 
(3) 
- 
1.5 
(± 
0.9) 
6.8 (± 
0.4) 
- 
72 
(± 
15) 
0.35 
1.1 
(± 
0.2) 
7.6 (± 
2.3) 
76 
(± 
10) 
0.50 
0.8 
(± 
0.3) 
7.7 (± 
1.4) 
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Appendix 3.2. TRP - MAO-mediated metabolic clearance  
For TRP that are substrates of MAO, the contribution of MAO-mediated metabolic clearance towards CLtot, i.e., fpathway, can be 
assessed using exposure changes from  human drug-drug interaction studies in the presence (and absence) of MAO-specific inhibitors such as 
mocloblemide (see also Appendix Ib): 
 
In the absence of inhibitor (Control): 
CLtotI.V.(Control) /Foral(Control) = Dose/AUC0-∞ (Control) 
 
CLtotI.V.  is the systemic total body clearance of TRP, which includes CLren, CLnonren encompassing CLhep (both MAO-mediated, 
CLhepMAO as well as non-MAO, i.e., by other DME, CLhepnon-MAO) and also CLextrahepatic (primarily by MAO).  Foral information can be obtained 
from absolute bioavailability studies, but also requires information with respect to GI solubility, GI permeability and hepatic first-pass 
metabolism, ERhepA (encompassing both MAO-mediated and non-MAO-mediated pathways). 
Furthermore, the amount of the parent drug appearing in the feces from radioactive mass balance studies, provides information about 
the fraction of the dose that is absorbed from the GI tract, Fabs, assuming that there are GI no solubility issues. 
The hepatic first pass, ERhepB can also be estimated (independently) from systemic CLnonren as the ratio of CLnonren to LBF, assuming 
that there are no extrahepatic clearance pathways, i.e., CLnonren = CLhep.  However, in case of MAO-substrate TRP, since there is evidence of 
MAO-mediated extrahepatic clearance pathways, and therefore ERhepA is expected to be lower than ERhepB, if the Fabs is accurately estimated. 
CLtotI.V. (Control) = CLren + CLhepMAO + CLhepnon-MAO + CLextrahepaticMAO 
Foral (Control) = Fabs * (1 - ERhepA) 
ERhepB = CLnonren/LBF 
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In the presence of inhibitor (I): 
CLtotI.V. (I)/Foral (I) = Dose/AUC0-∞ (I) 
 
The MAO-specific inhibitor is assumed to completely shut off the MAO-mediated metabolic clearance, i.e., CLhepMAO and 
CLextrahepaticMAO and therefore, CLtotI.V. includes only CLren  and CLhepnon-MAO (both of which are assumed to remain unchanged in the presence 
of the MAO inhibitor).  The value for Foral(I) includes both Fabs and ERhepA’ which encompasses only non-MAO-mediated, i.e., non-inhibited 
presystemic metabolic pathways. 
 
CLtotI.V. (I) = CLren + CLhepnon-MAO 
Foral = Fabs * (1 - ERhepA’) 
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Based on the available oral bioavailability studies in the absence of inhibitor, oral mass balance studies, the information on TRP that 
are MAO-substrates is compiled below: 
 
TRP 
Foral 
(%) 
Fabs 
(%) 
100 - %Dose 
excreted in the feces 
ERhepA 
(1- Foral/Fabs) 
(%) 
ERhepB 
(CLnonren/LBF) 
(%) 
%Increase in AUC 
(1 - AUCControl/AUC(I)) 
Almotriptan135,137,142,143,146,180 70 87 20 25 27 
Zolmitriptan168,169,173,174 50 70 29 36 25 
Rizatriptan162,165–167 43 89 51 54 55 
Sumatriptan131,132,134 14 96 85 59 - 
 
Interpretation: 
1. Despite evidence of extrahepatic pathways for the four MAO-substrates, it can be observed that ERhepA is comparable to or greater 
than ERhepB, suggesting that the Fabs estimates may not be well estimated from the residual radioactivity in feces (which may have 
included not only radiolabeld parent drug, but also metabolites). 
2. There, the contribution of the MAO-mediated metabolic clearance towards CLtot could not be resolved for the four TRP, owing to the 
lack of information of ERhepA that is accounted for by non-MAO pathways and also because of the low confidence in Fabs estimates.  
As a result, the observed systemic exposure increase in presence of a MAO inhibitor could not be translated in fpathway as was the case 
for BZD (see Appendix 1.2).  
 342 
Appendix 4 - Human PK Study Summaries of Class III Anti-Arrhythmics 
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Azimilide 
 
 
 
 
Study Population 
BW 
Dose 
(IV/ 
PO) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Corey et 
al181 
Healthy males, 
n = 25,  
Mean (SD) Age 
= 26 (1) years 
74  
(0.7
) 
1.0 
18 
min 
Infus
ion 
8.5 
min 
- 
648 
hrs 
0 h - 
48h, 
qd for 
25 
days 
HPLC - UV 
LLOQ 
= 5.2 
ng/ml 
LLOQ 
= 90 
ng/ml 
NCA Fractionated 
13.2 
(± 
3.1) 
2.4 (± 
0.9) 
0.23 
(± 
0.08) 
 
2.0 
 
P.O. - - 
0.22 
(± 
0.07) 
Corey et 
al182 
Healthy males, 
n = 82,  
Mean (SD) Age 
= 27 (7) years 
73 
(10) 
4.5 - 
9.0 
15 - 
60 
min 
5 
min 
- 
336 
hrs 
Every 
24 hrs 
for 96 
hrs 
Rp-HPLC-
MS/MS 
LLOQ 
= 5 
ng/ml 
LLOQ 
= 40 
ng/ml 
NCA Fractionated 10 2.0 0.22 
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Corey et 
al183 
Healthy males, 
n = 33, Mean 
Age = 49 years 
80 1.88 P.O. 
0.5 - 
480 
hrs 
Every 
24 hrs 
for 
216 
hrs 
HPLC-UV 
LLOQ 
= 10 
ng/ml 
LLOQ 
= 100 
ng/ml 
NCA Fractionated - - 
0.15 
(± 
0.04) 
Healthy 
females, n = 33, 
Mean Age = 53 
years 
66 2.27 P.O. 
0.18 
(± 
0.05) 
Corey et 
al184 
Healthy males, 
n = 12,  
Mean (SD) Age 
= 52 (11) years 
84 
(13) 1.79 P.O. 
0.5 
hrs - 
22 
days 
Every 
24 
hours 
for 10 
days 
HPLC-UV 
LLOQ 
= 5 
ng/ml 
LLOQ 
= 50 
ng/ml 
NCA Fractionated - - 
0.23 
(± 
0.13) 
 
 
rinary Excretion Studies 
1. Corey et al181 calculated the CLren by using CLren = Ae/AUC (Urine was collected in 2 hr fractions for first 12 hrs, 12-16, 16-24, 24-36, 
36-48 hours, and then every 24 hr fraction for an additional 25 days) 
2. Corey et al182 calculated the CLren by using CLren = Ae/AUC (Urine was collected in 24 hr fractions up to 96 hours) 
3. Corey et al183 calculated the CLren by using CLren = Ae/AUC (Urine was collected in 24 hr fractions up to 216 hours) 
4. Corey et al184 calculated the CLren by using CLren = Ae/AUC (Urine was collected in 24 hr fractions up to 10 days) 
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Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Corey et al183 Healthy males, n = 33 Equilibrium dialysis - Liquid Scintillation Counting 6 Healthy females, n = 33 - 6 
Corey et al184 Healthy males, n = 12 Equilibrium dialysis Assessed at 7 h Liquid Scintillation Counting 8 
Mouelhi et al185 - Equilibrium dialysis 13 - 173 ng/ml Liquid Scintillation Counting 3 
 
 
 
 
Metabolism 
Azimilide metabolic clearance is claimed184 to be mediated via (a) cleavage of the azomethine bond (up to 30%), (b) CYP1A1 (up to 25%) 
and (c) CYP3A4 (up to 25%). However, this was based on the internal report184 and was inaccessible for further evaluation. It was also 
reported that azimilide did not form any active metabolites. The schematic of the metabolic routes for azimilide is shown in Figure - 1 
below184. An in-vivo DDI study with ketoconazole, a selective and potent CYP3A inhibitor and (p.o. administration of) azimilide showed a 
16% reduction in the apparent clearance - suggesting the reduction could have been due to either decrease in systemic clearance and/or 
increase in Foral, although the latter is less likely to be clinically relevant, given the low ERhep drug azimilide is181.  
 
 348 
Figure 5 - Schematic of Metabolism of Azimilide185 
 
  
 349 
 
Amiodarone 
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Study Population 
BW 
Dose 
(IV/ 
PO) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Ujhelyi et 
al186 
Healthy 
subjects, n = 11,  
Mean (SD) Age 
= 49 (14) years 
79 
(17) 5 
15 
min 
15 
min 
- 76 
days 
0 h - 
34 h HPLC - UV 
LLOQ 
= 5 
ng/ml 
LLOQ 
= 5 
ng/ml 
NCA Fractionated 
60 
(± 
28) 
1.88 
(± 
1.1) 
- 
Cushing 
et al187 
Healthy 
subjects, n = 78,  
Mean (SD) Age 
= 37 (12) years 
- 2 10 min 
1 
min 
- 72 
hrs 
- LC-MS/MS 
LLOQ 
= 5 
ng/ml 
- NCA - - 3.72 - 
Vadiei et 
al188 
Healthy 
subjects, n = 11,  
Mean (SD) Age 
= 48 (10) years 
77 
(11) 5 
15 
min 
15 
min 
- 76 
days 
- HPLC-UV 
LLOQ 
= 5 
ng/ml 
- NCA - 
59 
(± 
22) 
1.7 (± 
0.7) - 
 
Urinary Excretion Studies 
1. Ujhelyi et al186 calculated the CLren by using CLren = Ae/AUC (Urine was collected 0-2, 2-4, 4-8, 8-12, 12-24 and 24-34 hours) 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Ujhelyi et al186 Healthy subjects Ultrafiltration 30 min Sample HPLC-UV 3.2 (± 1.0) 
Neyroz et al189 In-vitro Ultracentrifugation 10 µg/ml HPLC-UV 3.7 
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Metabolism 
Amiodarone is known to show variable oral bioavailability (20 - 80%)190,191 and it is primarily eliminated by metabolism with only less than 
1% of excreted unchanged in the urine186. Biliary excretion may also play a role in the overall elimination of the drug190. The schematic of 
potential metabolic routes of amiodarone is shown in Figure below191. Desethylamiodarone (DEA) is the major active metabolite and the 
enzymes responsible for the metabolism of amiodarone are present in both liver and intestine192.   
 
Figure 6 - Potential Pathways of Metabolism of Amiodarone191 
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Blood-to-Plasma Ratio 
Study Subjects Method Concentration Range  Assay B:P Ratio 
Andreasen et al193 Healthy subjects Centrifugation - HPLC 0.6 
 
  
 353 
Dofetilide 
 
 
 
Study Population 
BW 
Dose 
(IV/ 
PO) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Tham et. 
al194 
Healthy 
subjects, n = 9,  
Mean (SD) Age 
= 23 (3) years 
66 
(6) 0.01 
10 
min 
0.5 
h - 
96 h 
0 h - 
48 h 
Radioimmunoas
say for plasma 
and HPLC for 
urine 
LLOQ 
= 0.05 
ng/ml 
LLOQ 
= 2.5 
ng/ml 
NCA Fractionated 
3.5 
(± 
0.3) 
5.3 (± 
0.3) 2.8 
Sedgwick 
et al195 
Subjects with 
suspected 
coronary artery 
disease, Mean 
(Range) Age = 
55 (42-65) 
- 
0.00
1 - 
0.00
6 
15 
min 
0 h - 
24 h - 
Radioimmunoas
say 
LLOQ 
= 0.05 
ng/ml 
- NCA - - 4.7 - 
Coz et 
al196 
Healthy 
subjects, n = 10, 
Mean (Range) 
Age = 23.4 (19 
- 30) years 
68.4 
(58 
- 
86) 
0.5 30 min 
10 
min 
- 72 
h 
- Radioimmunoassay 
LLOQ 
= 0.05 
ng/ml 
- NCA - 
3.3 
(± 
0.5) 
5.8 (± 
0.8) - 
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Abel et 
al197 
Healthy 
subjects, n = 20, 
Mean (Range) 
Age = 29 (19 - 
42) years 
79 
(59 
- 
89) 
0.01 - 0 h - 72 h 
0 h - 
48 h 
Radioimmunoas
say for plasma 
and HPLC for 
urine 
LLOQ 
= 0.05 
ng/ml 
LLOQ 
= 5 
ng/ml 
NCA Fractionated - - 
3.5 (± 
0.5) 
 
Urinary Excretion Studies 
1. Tham et al194 calculated the CLren by using CLren = Ae/AUC (Urine was collected 0-12, 12-24 and 24-48 hours) 
2. Abel et al197 calculated the CLren by using CLren = Ae/AUC (Urine was collected 0-12, 12-24 and 24-48 hours) 
 
Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
Smith et al198 In-vitro Equilibrium Dialysis 10 - 100 ng/ml Liquid Scintillation Counting  36 
 
Metabolism 
In humans, dofetilide was the only detectable component present in plasma extracts, as a discrete peak by radiochemical HPLC (i.e., no single 
metabolite accounted for > 5% of plasma radioactivity)198. The potential pathways of metabolism of dofetilide have also been shown in the 
figure below198.  
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Figure 7 - Possible Metabolic Pathways of Dofetilide198 
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Ibutilide 
 
 
Study Population 
BW 
Dose 
(IV/ 
PO) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Jungbluth 
et al199 
Healthy 
subjects, n = 6 - 0.01 
10 
min - - 
HPLC - Chiral 
specific 
separation 
- - - Cumulative 
12 
(± 5) 
26 (± 
5) 2.6 
Jungbluth 
et al200 
Healthy 
volunteers, n = 
44 
- 0.01 - 0.1 
10 
min - 
8 hrs 
- - HPLC - - - Cumulative 13 27 - 
FDA 
Label201 - - - - - - - - - - - 11 29  
 
Urinary Excretion Studies 
1. Jungbluth et al199 calculated the CLren by using CLren = fe*CLtot (fe = % of the dose excreted unchanged in the urine = 10±3) 
2. Jungbluth et al200 calculated the CLren by using CLren = fe*CLtot (fe = % of the dose excreted unchanged in the urine < 5%??) 
3. FDA Label201 - fe = 6% 
 357 
 
Dronedarone 
 
 
 
Study Population 
BW 
Dose 
(IV/ 
PO) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
FDA 
Label202 - - - - - - - - - - - 20 33.3 - 
FDA 
Approval 
Package203 
- - - - - - - - - - - - 33.3 - 
 
Urinary Excretion Study 
It was reported202 that a very negligible amount is excreted unchanged in the urine.  
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Plasma Protein Binding Studies 
Study Subjects Method Concentration Range  Assay fu (%) 
FDA Label202 and  
FDA Approval Package203 - - - - 1% 
 
Metabolism 
In humans, dronedarone203 is extensively metabolized and N-debutylation is reported to the major metabolic pathway. The other reported203 
pathways of metabolism include oxidative deamination and direct oxidation. It is also reported that over 30 metabolites are excreted in urine 
and feces.   
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Bretylium 
 
 
Study Population 
BW 
Dose 
(IV/ 
PO) Rate 
PK 
Sampling 
Schedule Assay Method 
Analytical 
Method 
Parameters 
PK 
Analy
sis 
Urine 
Collecti
on 
Method 
Vdss CLtot CLren 
(kg) (mg/kg) 
Plas
ma Urine Plasma Urine 
(L/k
g) 
[ml/m
in/kg] 
[ml/m
in/kg] 
Narang et 
al204 
Healthy 
subjects, n = 4; 
Mean (SD) Age 
= 26 (6) years 
64 
(3) 4.0 
5 
min 
0 - 
72 h 
0 - 72 
h 
GC - Electron 
Capture 
LLOQ 
= 5 
ng/ml 
LLOQ 
= 5 
ng/ml 
Comp
artme
ntal 
(2) 
Cumulat
ive 6 12 2.6 
Garrett et 
al205  
Healthy 
volunteers, n = 
9; Age range = 
21 - 30 years 
- 3 - 6 60 min  
0 - 
48 h 
0 - 72 
h 
GC - Electron 
Capture 
LLOQ 
= 5 
ng/ml 
- 
Comp
artme
ntal 
(3) 
Fraction
ated 8 11 - 
 
Urinary Excretion Studies 
1. Narang et al204. calculated the CLren by using CLren = fe*CLtot (fe = % of the dose excreted unchanged in the urine = 77%) 
2. Garett at al205. calculated the CLren by using CLren = Ae/AUC (Urine was collected at 2 hrs intervals up to 10 hrs, then at 10 -14, 14-18, 18-
24, 24-30, 30-36, 36-48, 48-72 hours) 
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Plasma Protein Binding Study 
 
Study Subjects Method Concentration Range  Assay fu (%) 
Garrett et al205 In-vitro Ultrafiltration 10 - 10000 ng/ml - 94% 
 
 
 
 
  
 361 
 
Appendix References 
1. Boxenbaum, H. G. et al. Pharmacokinetic and biopharmaceutic profile of chlordiazepoxide HC1 in healthy subjects: single-dose 
studies by the intravenous, intramuscular, and oral routes. J. Pharmacokinet. Biopharm. 5, 3–23 (1977). 
2. Sellers, E. M. et al. Chlordiazepoxide and oxazepam disposition in cirrhosis. Clin. Pharmacol. Ther. 26, 240–6 (1979). 
3. Greenblatt, D. J. et al. Kinetics of intravenous chlordiazepoxide: sex differences in drug distribution. Clin. Pharmacol. Ther. 22, 893–
903 (1977). 
4. Moschitto, L. J. & Greenblatt, D. J. Concentration-independent plasma protein binding of benzodiazepines. J. Pharm. Pharmacol. 35, 
179–80 (1983). 
5. Greenblatt, D. J., Shader, R. I., MacLeod, S. M. & Sellers, E. M. Clinical pharmacokinetics of chlordiazepoxide. Clin. Pharmacokinet. 
3, 381–94 (1978). 
6. Berlin, a & Dahlström, H. Pharmacokinetics of the anticonvulsant drug clonazepam evaluated from single oral and intravenous doses 
and by repeated oral administration. Eur. J. Clin. Pharmacol. 9, 155–9 (1975). 
7. Crevoisier, C., Delisle, M. C., Joseph, I. & Foletti, G. Comparative single-dose pharmacokinetics of clonazepam following intravenous, 
intramuscular and oral administration to healthy volunteers. Eur. Neurol. 49, 173–7 (2003). 
8. Pacifici, G. M., Viani, A., Rizzo, G., Carrai, M. & Rane, A. Plasma protein binding of clonazepam in hepatic and renal insufficiency 
and after hemodialysis. Ther. Drug Monit. 9, 369–73 (1987). 
9. Lucek, R. W. & Countinho, C. B. The Role of Substituents in the Hydrophobic binding of 1, 4 Benzodiazepines by Human plasma 
proteins. Mol. Pharmacol. 12, 612 (1976). 
10. Bertler, Lindgren, S., Magnusson, J.-O. & Malmgren, H. Pharmacokinetics of chlorazepate after intravenous and intramuscular 
administration. Psychopharmacology (Berl). 80, 236–239 (1983). 
11. Klotz, U., Avant, G. R., Hoyumpa, a, Schenker, S. & Wilkinson, G. R. The effects of age and liver disease on the disposition and 
elimination of diazepam in adult man. J. Clin. Invest. 55, 347–59 (1975). 
 362 
12. Klotz, U., Antonin, K. H. & Bieck, P. R. Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. J. 
Pharmacol. Exp. Ther. 199, 67–73 (1976). 
13. Cloyd, J. C., Lalonde, R. L., Beniak, T. E. & Novack, G. D. A single-blind, crossover comparison of the pharmacokinetics and 
cognitive effects of a new diazepam rectal gel with intravenous diazepam. Epilepsia 39, 520–6 (1998). 
14. Greenblatt, D. J. et al. Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral 
clorazepate, and intravenous diazepam. J. Clin. Pharmacol. 28, 853–9 (1988). 
15. Ochs, H. R. Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. CHEST J. 87, 223 (1985). 
16. Locniskar, A., Greenblatt, D. J., Zinny, M. A., Harmatz, J. S. & Shader, R. I. Absolute bioavailability and effect of food and antacid on 
diazepam absorption from a slow-release preparation. J. Clin. Pharmacol. 24, 255–63 (1984). 
17. Giles, H. G., Sellers, E. M., Naranjo, C. a, Frecker, R. C. & Greenblatt, D. J. Disposition of intravenous diazepam in young men and 
women. Eur. J. Clin. Pharmacol. 20, 207–13 (1981). 
18. Divoll, M., Greenblatt, D. J., Ochs, H. R. & Shader, R. I. Absolute bioavailability of oral and intramuscular diazepam: effects of age 
and sex. Anesth. Analg. 62, 1–8 (1983). 
19. Divoll, M. & Greenblatt, D. J. Binding of diazepam and desmethyldiazepam to plasma protein: Concentration-dependence and 
interactions. Psychopharmacology (Berl). 75, 380–382 (1981). 
20. Mandelli, M., Tognoni, G. & Garattini, S. Clinical Pharmacokinetics of Diazepam. Clin. Pharmacokinet. 3, 72 (1978). 
21. Sennesael, J., Verbeelen, D., Vanhaelst, L., Pirola, R. & Bareggi, S. R. Pharmacokinetics of intravenous and oral 
chlordesmethyldiazepam in patients on regular haemodialysis. Eur. J. Clin. Pharmacol. 41, 65–8 (1991). 
22. Bareggi, S. R., Pirola, R., Potvin, P. & Devis, G. Effects of liver disease on the pharmacokinetics of intravenous and oral 
chlordesmethyldiazepam. Eur. J. Clin. Pharmacol. 48, 265–8 (1995). 
23. Greenblatt, D. J. et al. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J. Pharm. 
Sci. 68, 57–63 (1979). 
24. Greenblatt, D. J. et al. Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. J. Pharmacol. 
Exp. Ther. 250, 134–40 (1989). 
 363 
25. Wermeling, D. P. H. & Miller, J. L. Bioavailability and Pharmacokinetics of Lorazepam after Intranasal, Intravenous, and 
Intramuscular Administration. J. Clin. Endocrinol. Metab. 96, 1900–7 (2001). 
26. Nielsen-Kudsk, F. et al. Pharmacokinetics and bioavailability of intravenous and intramuscular lorazepam with an adjunct test of the 
inattention effect in humans. Acta Pharmacol. Toxicol. (Copenh). 52, 121–7 (1983). 
27. Abernethy, D. R., Greenblatt, D. J., Divoll, M. & Shader, R. I. Enhanced glucuronide conjugation of drugs in obesity: studies of 
lorazepam, oxazepam, and acetaminophen. J. Lab. Clin. Med. 101, 873–80 (1983). 
28. Greenblatt, D. J., Allen, M. D., Locniskar, A., Harmatz, J. S. & Shader, R. I. Lorazepam kinetics in the elderly. Clin. Pharmacol. Ther. 
26, 103–13 (1979). 
29. Jochemsen, R. et al. Pharmacokinetics and bioavailability of intravenous, oral, and rectal nitrazepam in humans. J. Pharmacokinet. 
Biopharm. 10, 231–45 (1982). 
30. Jochemsen, R., Van Beusekom, B. R., Spoelstra, P., Janssens, A. R. & Breimer, D. D. Effect of age and liver cirrhosis on the 
pharmacokinetics of nitrazepam. Br. J. Clin. Pharmacol. 15, 295–302 (1983). 
31. Kanto, J., Kangas, L., Aaltonen, L. & Hilke, H. Effect of age on the pharmacokinetics and sedative of flunitrazepam. Int. J. Clin. 
Pharmacol. Ther. Toxicol. 19, 400–4 (1981). 
32. Sonne, J. et al. Bioavailability and pharmacokinetics of oxazepam. Eur. J. Clin. Pharmacol. 35, 385–9 (1988). 
33. Shull, H. J., Wilkinson, G. R., Johnson, R. & Schenker, S. Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann. 
Intern. Med. 84, 420–5 (1976). 
34. Van Steveninck, a L. et al. Effects of intravenous temazepam. II. A study of the long-term reproducibility of pharmacokinetics, 
pharmacodynamics, and concentration-effect parameters. Clin. Pharmacol. Ther. 55, 546–55 (1994). 
35. Ghabrial, H. et al. The effects of age and chronic liver disease on the elimination of temazepam. Eur. J. Clin. Pharmacol. 30, 93–7 
(1986). 
36. Venkatakrishnan, K. et al. Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy 
volunteers. J. Clin. Pharmacol. 45, 529–37 (2005). 
 364 
37. Fleishaker, J. C., Friedman, H. & Pollock, S. R. Extent and variability of the first-pass elimination of adinazolam mesylate in healthy 
male volunteers. Pharm. Res. 8, 162–167 (1991). 
38. Ajir, K. et al. The pharmacokinetics and pharmacodynamics of adinazolam: multi-ethnic comparisons. Psychopharmacology (Berl). 
129, 265–70 (1997). 
39. Fleishaker, J. C., Hulst, L. K., Ekernäs, S. A. & Grahnén, A. Pharmacokinetics and pharmacodynamics of adinazolam and N-
desmethyladinazolam after oral and intravenous dosing in healthy young and elderly volunteers. J. Clin. Psychopharmacol. 12, 403–14 
(1992). 
40. Fleishaker, J., Smith, T., Friedman, H. & Hulst, L. Separation of the pharmacokinetic/pharmacodynamic properties of oral and IV 
adinazolam mesylate and N-desmethyladinazolam mesylate in healthy volunteers. Drug Investig. 4, 155–165 (1992). 
41. Fleishaker, J. C., Friedman, H., Pollock, S. R. & Smith, T. C. Clinical pharmacology of adinazolam and N-desmethyladinazolam 
mesylate after single oral doses of each compound in healthy volunteers. Clin. Pharmacol. Ther. 48, 652–664 (1990). 
42. Smith, R. B., Kroboth, P. D., Vanderlugt, J. T., Phillips, J. P. & Juhl, R. P. Pharmacokinetics and pharmacodynamics of alprazolam 
after oral and IV administration. Psychopharmacology (Berl). 84, 452–6 (1984). 
43. Fleishaker, J. C., Phillips, J. P., Eller, M. G. & Smith, R. B. Pharmacokinetics and pharmacodynamics of alprazolam following single 
and multiple oral doses of a sustained-release formulation. J. Clin. Pharmacol. 29, 543–9 (1989). 
44. Greenblatt, D. J. et al. Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. Clin. 
Pharmacol. Ther. 45, 356–65 (1989). 
45. Heizmann, P., Eckert, M. & Ziegler, W. H. Pharmacokinetics and bioavailability of midazolam in man. Br. J. Clin. Pharmacol. 16 
Suppl 1, 43S–49S (1983). 
46. Smith, M. & Eadie, M. The pharmacokinetics of Midazolam in man. Eur. J. Clin. 278, 271–278 (1981). 
47. Thummel, K. E. et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated 
metabolism. Clin. Pharmacol. Ther. 59, 491–502 (1996). 
48. Allonen, H., Ziegler, G. & Klotz, U. Midazolam kinetics. Clin. Pharmacol. Ther. 30, 653–61 (1981). 
 365 
49. Clausen, T. G. et al. Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration. 
Br. J. Clin. Pharmacol. 25, 457–63 (1988). 
50. MacGilchrist, a J. et al. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis. 
Gut 27, 190–5 (1986). 
51. Kroboth, P. D., McAuley, J. W., Kroboth, F. J., Bertz, R. J. & Smith, R. B. Triazolam pharmacokinetics after intravenous, oral, and 
sublingual administration. J. Clin. Psychopharmacol. 15, 259–62 (1995). 
52. Vanderveen, R., Jirak, J., Peters, G., Cox, S. & Bombardt, P. Effect of ranitidine on the disposition of orally and intravenously 
administered triazolam. Clin. Pharm. 10, 539 (1991). 
53. Smith, R. B., Kroboth, P. D. & Varner, P. D. Pharmacodynamics of triazolam after intravenous administration. J. Clin. Pharmacol. 27, 
971–9 (1987). 
54. Dingemanse, J. et al. Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with 
midazolam during first administration to healthy male subjects. Br. J. Clin. Pharmacol. 44, 477–86 (1997). 
55. Van Gerven, J. M. et al. Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison 
with midazolam during first administration to healthy male subjects. Br. J. Clin. Pharmacol. 44, 487–93 (1997). 
56. Jochemsen, R., Wesselman, J. G., Hermans, J., van Boxtel, C. J. & Breimer, D. D. Pharmacokinetics of brotizolam in healthy subjects 
following intravenous and oral administration. Br. J. Clin. Pharmacol. 16 Suppl 2, 285S–290S (1983). 
57. D, B. W. Pharmacokinetics and metabolism of brotizolam in humans. Br. J. Clin. Pharmacol. 16 Suppl 2, 279S–283S (1983). 
58. Roncari, G., Ziegler, W. H. & Guentert, T. W. Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following 
intravenous and oral administration. Br. J. Clin. Pharmacol. 22, 421–8 (1986). 
59. Klotz, U., Ziegler, G. & Reimann, I. Pharmacokinetics of the Selective Benzodiazepine Antagonist Ro 15-1788 in Man. Eur. J. Clin. 
Pharmacol. 27, 115–117 (1984). 
60. Janssen, U., Walker, S., Maier, K., von Gaisberg, U. & Klotz, U. Flumazenil disposition and elimination in cirrhosis. Clin. Pharmacol. 
Ther. 46, 317–23 (1989). 
 366 
61. Pomier-Layrargues, G., Giguère, J. & others. Pharmacokinetics of Benzodiazepine Antagonist Ro 15-1788 in Cirrhotic Patients with 
Moderate or Severe Liver Dysfunction. Hepatology 10, 969–972 (1989). 
62. Klotz, U., Duka, T., Dorow, R. & Doenicke, a. Flunitrazepam and lormetazepam do not affect the pharmacokinetics of the 
benzodiazepine antagonist Ro 15-1788. Br. J. Clin. Pharmacol. 19, 95–8 (1985). 
63. Klotz, U. & Kanto, J. Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). Clin. Pharmacokinet. 14, 1–12 (1988). 
64. Brown, M. W., Maldonado, a L., Meredith, C. G. & Speeg, K. V. Effect of ketoconazole on hepatic oxidative drug metabolism. Clin. 
Pharmacol. Ther. 37, 290–7 (1985). 
65. Lam, Y. W. F., Alfaro, C. L., Ereshefsky, L. & Miller, M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with 
ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J. Clin. Pharmacol. 43, 1274–82 (2003). 
66. TSUNODA, S., VELEZ, R. & GREENBLATT, D. Ketoconazole (K) inhibition of intestinal and hepatic cytochrome P450 3A4 
(CYP3A4) activity using midazolam (M) as an in vivo probe. Clin. Pharmacol. Ther. 65, 172–172 (1999). 
67. Tsunoda, S. M., Velez, R. L., von Moltke, L. L. & Greenblatt, D. J. Differentiation of intestinal and hepatic cytochrome P450 3A 
activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin. Pharmacol. Ther. 66, 461–71 (1999). 
68. Olkkola, K. T., Backman, J. T. & Neuvonen, P. J. Midazolam should be avoided in patients receiving the systemic antimycotics 
ketoconazole or itraconazole. Clin. Pharmacol. Ther. 55, 481–5 (1994). 
69. Greenblatt, D. J. et al. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. 
Clin. Pharmacol. Ther. 64, 237–47 (1998). 
70. Von Moltke, L. L. et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical 
confirmation of a predicted interaction with ketoconazole. J. Pharmacol. Exp. Ther. 276, 370–9 (1996). 
71. Varhe, A., Olkkola, K. T. & Neuvonen, P. J. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics 
ketoconazole or itraconazole. Clin. Pharmacol. Ther. 56, 601–7 (1994). 
72. Schmider, J., Brockmöller, J., Arold, G., Bauer, S. & Roots, I. Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with 
alprazolam and caffeine. Pharmacogenetics 9, 725–34 (1999). 
 367 
73. Osanai, T., Ohkubo, T., Yasui, N., Kondo, T. & Kaneko, S. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a 
single oral dose of brotizolam. Br. J. Clin. Pharmacol. 58, 476–81 (2004). 
74. Qin, X. P. et al. Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects. Clin. Pharmacol. Ther. 66, 642–
6 (1999). 
75. Van Miert, M. M., Eastwood, N. B., Boyd, a H., Parker, C. J. & Hunter, J. M. The pharmacokinetics and pharmacodynamics of 
rocuronium in patients with hepatic cirrhosis. Br. J. Clin. Pharmacol. 44, 139–44 (1997). 
76. McCoy, E. P., Mirakhur, R. K., Maddineni, V. R., Wierda, J. M. & Proost, J. H. Pharmacokinetics of rocuronium after bolus and 
continuous infusion during halothane anaesthesia. Br. J. Anaesth. 76, 29–33 (1996). 
77. Wierda, J. M., Kleef, U. W., Lambalk, L. M., Kloppenburg, W. D. & Agoston, S. The pharmacodynamics and pharmacokinetics of Org 
9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can. 
J. Anaesth. 38, 430–5 (1991). 
78. Cooper, R. a, Mirakhur, R. K., Wierda, J. M. & Maddineni, V. R. Pharmacokinetics of rocuronium bromide in patients with and 
without renal failure. Eur. J. Anaesthesiol. Suppl. 12, 43–4 (1995). 
79. Van den Broek, L. et al. Clinical pharmacology of rocuronium (Org 9426): study of the time course of action, dose requirement, 
reversibility, and pharmacokinetics. J. Clin. Anesth. 6, 288–96 (1994). 
80. Khalil, M. et al. Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. Anesthesiology 80, 1241–7 (1994). 
81. Magorian, T. et al. The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. Anesth. 
Analg. 80, 754–9 (1995). 
82. Proost, J. H., Roggeveld, J., Wierda, J. M. & Meijer, D. K. Relationship between chemical structure and physicochemical properties of 
series of bulky organic cations and their hepatic uptake and biliary excretion rates. J. Pharmacol. Exp. Ther. 282, 715–26 (1997). 
83. Roy, J. J. & Varin, F. Physicochemical properties of neuromuscular blocking agents and their impact on the pharmacokinetic-
pharmacodynamic relationship. Br. J. Anaesth. 93, 241–8 (2004). 
84. Khuenl-Brady, K. S. & Sparr, H. Clinical pharmacokinetics of rocuronium bromide. Clin. Pharmacokinet. 31, 174–83 (1996). 
 368 
85. Cronnelly, R. et al. Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized humans. 
Anesthesiology 58, 405–8 (1983). 
86. Caldwell, J. E. et al. The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its 
parent compound, vecuronium, in human volunteers. J. Pharmacol. Exp. Ther. 270, 1216–22 (1994). 
87. Arden, J. R. et al. Vecuronium in alcoholic liver disease: a pharmacokinetic and pharmacodynamic analysis. Anesthesiology 68, 771–6 
(1988). 
88. Rupp, S. M., Castagnoli, K. P., Fisher, D. M. & Miller, R. D. Pancuronium and vecuronium pharmacokinetics and pharmacodynamics 
in younger and elderly adults. Anesthesiology 67, 45–9 (1987). 
89. Van der Veen, F. & Bencini, A. Pharmacokinetics and pharmacodynamics of Org NC 45 in man. Br. J. Anaesth. 52 Suppl 1, 37S–41S 
(1980). 
90. Fahey, M. R., Morris, R. B., Miller, R. D., Nguyen, T. L. & Upton, R. a. Pharmacokinetics of Org NC45 (norcuron) in patients with 
and without renal failure. Br. J. Anaesth. 53, 1049–53 (1981). 
91. Cameron, M., Donati, F. & Varin, F. In vitro plasma protein binding of neuromuscular blocking agents in different subpopulations of 
patients. Anesth. Analg. 81, 1019–25 (1995). 
92. Duvaldestin, P. & Henzel, D. Binding of tubocurarine, fazadinium, pancuronium and Org NC 45 to serum proteins in normal man and 
in patients with cirrhosis. Br. J. Anaesth. 54, 513–6 (1982). 
93. Caldwell, J. E. et al. Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action. Br. J. Anaesth. 61, 693–
7 (1988). 
94. Duvaldestin, P., Demetriou, M. & D’Hollander, a. Pharmacokinetics of pancuronium in man: a linear system. Eur. J. Clin. Pharmacol. 
23, 369–72 (1982). 
95. Duvaldestin, P., Agoston, S., Henzel, D., Kersten, U. W. & Desmonts, J. M. Pancuronium pharmacokinetics in patients with liver 
cirrhosis. Br. J. Anaesth. 50, 1131–6 (1978). 
96. Duvaldestin, P., Saada, J., Berger, J. L., D’Hollander, a & Desmonts, J. M. Pharmacokinetics, pharmacodynamics, and dose-response 
relationships of pancuronium in control and elderly subjects. Anesthesiology 56, 36–40 (1982). 
 369 
97. D’Honneur, G. et al. Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. Anesth. Analg. 77, 1203–6 
(1993). 
98. Ornstein, E., Matteo, R. S., Schwartz, a E., Jamdar, S. C. & Diaz, J. Pharmacokinetics and pharmacodynamics of pipecuronium 
bromide (Arduan) in elderly surgical patients. Anesth. Analg. 74, 841–4 (1992). 
99. Wierda, J. M. et al. Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. Can. J. 
Anaesth. 37, 183–91 (1990). 
100. Obach, R. S., Lombardo, F. & Waters, N. J. Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 
670 Drug Compounds. Drug Metab. Dispos. 36, 1385 (2008). 
101. Szenohradszky, J. et al. Influence of renal failure on the pharmacokinetics and neuromuscular effects of a single dose of rapacuronium 
bromide. Anesthesiology 90, 24–35 (1999). 
102. Van den Broek, L., Wierda, J. M., Smeulers, N. J. & Proost, J. H. Pharmacodynamics and pharmacokinetics of an infusion of Org 
9487, a new short-acting steroidal neuromuscular blocking agent. Br. J. Anaesth. 73, 331–5 (1994). 
103. Schiere, S., Proost, J. H., Schuringa, M. & Wierda, J. M. Pharmacokinetics and pharmacokinetic-dynamic relationship between 
rapacuronium (Org 9487) and its 3-desacetyl metabolite (Org 9488). Anesth. Analg. 88, 640–7 (1999). 
104. Duvaldestin, P., Slavov, V. & Rebufat, Y. Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. 
Anesthesiology 91, 1305–10 (1999). 
105. Wierda, J. M., Beaufort, A. M., Kleef, U. W., Smeulers, N. J. & Agoston, S. Preliminary investigations of the clinical pharmacology of 
three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. Can. J. Anaesth. 41, 213–20 
(1994). 
106. Diefenbach, C., Künzer, T., Buzello, W. & Theisohn, M. Alcuronium: a pharmacodynamic and pharmacokinetic update. Anesth. 
Analg. 80, 373–7 (1995). 
107. Dresner, D. L. et al. Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane 
anesthesia. Anesth. Analg. 71, 498–502 (1990). 
108. Gariepy, L. P., Varin, F., Donati, F., Salib, Y. & Bevan, D. R. Influence of aging on the pharmacokinetics and pharmacodynamics of 
doxacurium. Clin. Pharmacol. Ther. 53, 340–7 (1993). 
 370 
109. Cook, D. R. et al. Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal 
failure. Anesth. Analg. 72, 145–50 (1991). 
110. Fahey, M. R. et al. The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. 
Anesthesiology 61, 699–702 (1984). 
111. Parker, C. J. & Hunter, J. M. Pharmacokinetics of atracurium and laudanosine in patients with hepatic cirrhosis. Br. J. Anaesth. 62, 
177–83 (1989). 
112. Fisher, D. M. et al. Elimination of atracurium in humans: contribution of Hofmann elimination and ester hydrolysis versus organ-based 
elimination. Anesthesiology 65, 6–12 (1986). 
113. Ward, S., Neill, E. a, Weatherley, B. C. & Corall, I. M. Pharmacokinetics of atracurium besylate in healthy patients (after a single i.v. 
bolus dose). Br. J. Anaesth. 55, 113–8 (1983). 
114. Ward, S., Boheimer, N., Weatherley, B. C., Simmonds, R. J. & Dopson, T. A. Pharmacokinetics of atracurium and its metabolites in 
patients with normal renal function, and in patients in renal failure. Br. J. Anaesth. 59, 697–706 (1987). 
115. Smith, C. E., van Miert, M. M., Parker, C. J. & Hunter, J. M. A comparison of the infusion pharmacokinetics and pharmacodynamics 
of cisatracurium, the 1R-cis 1’R-cis isomer of atracurium, with atracurium besylate in healthy patients. Anaesthesia 52, 833–41 (1997). 
116. Kent, A. P., Parker, C. J. & Hunter, J. M. Pharmacokinetics of atracurium and laudanosine in the elderly. Br. J. Anaesth. 63, 661–6 
(1989). 
117. Lien, C. a et al. Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 84, 
300–8 (1996). 
118. Ornstein, E. et al. Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. Anesthesiology 84, 520–5 
(1996). 
119. Tran, T. V, Fiset, P. & Varin, F. Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under 
propofol anesthesia. Anesth. Analg. 87, 1158–63 (1998). 
120. De Wolf, a M. et al. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing 
liver transplantation. Br. J. Anaesth. 76, 624–8 (1996). 
 371 
121. Kisor, D. F. et al. Importance of the organ-independent elimination of cisatracurium. Anesth. Analg. 83, 1065–71 (1996). 
122. Kisor, D. F. & Schmith, V. D. Clinical pharmacokinetics of cisatracurium besilate. Clin. Pharmacokinet. 36, 27–40 (1999). 
123. Head-Rapson, a G., Devlin, J. C., Parker, C. J. & Hunter, J. M. Pharmacokinetics and pharmacodynamics of the three isomers of 
mivacurium in health, in end-stage renal failure and in patients with impaired renal function. Br. J. Anaesth. 75, 31–6 (1995). 
124. Cook, D. R. et al. Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure. Br. J. Anaesth. 69, 
580–5 (1992). 
125. Head-Rapson, a G., Devlin, J. C., Parker, C. J. & Hunter, J. M. Pharmacokinetics of the three isomers of mivacurium and 
pharmacodynamics of the chiral mixture in hepatic cirrhosis. Br. J. Anaesth. 73, 613–8 (1994). 
126. Savarese, J. J. et al. The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). A short-acting nondepolarizing 
ester neuromuscular blocking drug. Anesthesiology 68, 723–32 (1988). 
127. Duvaldestin, P., Henzel, D., Demetriou, M. & Desmonts, J. M. Pharmacokinetics of Fazadinium in Man. Br. J. Anaesth. 50, 773–7 
(1978). 
128. d’Hollander, a a et al. Analytical model of some pharmacokinetic and pharmacodynamic properties of fazadinium in man. Eur. J. Clin. 
Pharmacol. 24, 407–13 (1983). 
129. Roy, J. J., Donati, F., Boismenu, D. & Varin, F. Concentration-effect relation of succinylcholine chloride during propofol anesthesia. 
Anesthesiology 97, 1082–92 (2002). 
130. Lacey, L., Hussey, E. & Fowler, P. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur. J. Clin. Pharmacol. 47, 
543–548 (1995). 
131. Dixon, C. M. et al. Disposition of sumatriptan in laboratory animals and humans. Drug Metab. Dispos. 21, 761–9 (1993). 
132. Fowler, P. et al. The Clinical Pharmacology, Pharmacokinetics and Metabolism of Sumatriptan. Eur. Neurol. 31, 291–294 (1991). 
133. Tfelt-Hansen, P. & Hougaard, A. Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment 
of migraine. Expert Opin. Drug Metab. Toxicol. 9, 91–103 (2013). 
134. Scott, A. K. Sumatriptan clinical pharmacokinetics. Clin. Pharmacokinet. 27, 337–44 (1994). 
 372 
135. Jansat, J. M., Costa, J., Salvà, P., Fernandez, F. J. & Martinez-Tobed, A. Absolute bioavailability, pharmacokinetics, and urinary 
excretion of the novel antimigraine agent almotriptan in healthy male volunteers. J. Clin. Pharmacol. 42, 1303–10 (2002). 
136. McEwen, J., Salva, M., Jansat, J. M. & Cabarrocas, X. Pharmacokinetics and safety of oral almotriptan in healthy male volunteers. 
Biopharm. Drug Dispos. 25, 303–11 (2004). 
137. Fleishaker, J. C. et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br. J. 
Clin. Pharmacol. 51, 437–41 (2001). 
138. Fleishaker, J. C., Ryan, K. K., Carel, B. J. & Azie, N. E. Evaluation of the potential pharmacokinetic interaction between almotriptan 
and fluoxetine in healthy volunteers. J. Clin. Pharmacol. 41, 217–23 (2001). 
139. Fleishaker, J. C., Sisson, T. a, Carel, B. J. & Azie, N. E. Pharmacokinetic interaction between verapamil and almotriptan in healthy 
volunteers. Clin. Pharmacol. Ther. 67, 498–503 (2000). 
140. Fleishaker, J. C., Herman, B. D., Carel, B. J. & Azie, N. E. Interaction between ketoconazole and almotriptan in healthy volunteers. J. 
Clin. Pharmacol. 43, 423–7 (2003). 
141. Baldwin, J. R., Fleishaker, J. C., Azie, N. E. & Carel, B. J. A comparison of the pharmacokinetics and tolerability of the anti-migraine 
compound almotriptan in healthy adolescents and adults. Cephalalgia 24, 288–92 (2004). 
142. Almotriptan FDA Label. at <http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021001s010s011lbl.pdf> 
143. Almotriptan Drug Approval Package from Drugs@FDA. at 
<http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert.cfm> 
144. Gras, J. et al. Almotriptan, a new anti-migraine agent: a review. CNS Drug Rev. 8, 217–34 (2002). 
145. Negro, A. et al. Pharmacokinetic evaluation of almotriptan for the treatment of migraines. Expert Opin. Drug Metab. Toxicol. 9, 637–
44 (2013). 
146. McEnroe, J. D. & Fleishaker, J. C. Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the 
treatment of migraine. Clin. Pharmacokinet. 44, 237–46 (2005). 
147. Fuseau, E., Baille, P. & Kempsford, R. A study to determine the absolute oral bioavailability of naratriptan. Cephalalgia 17, 417 
(1997). 
 373 
148. Kempsford, R., Baille, P. & Fuseau, E. Oral naratriptan tablets (2.5 to 10 mg) exhibit dose-proportional pharmacokinetics. Cephalalgia 
17, 408 (1997). 
149. Naratriptan FDA Approval Package. at <http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20763_Amerge_Bioeqr.pdf> 
150. Naratriptan FDA Label. at <http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020763s001s002s010lbl.pdf> 
151. Jhee, S. S., Shiovitz, T., Crawford, a W. & Cutler, N. R. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a 
comparative review. Clin. Pharmacokinet. 40, 189–205 (2001). 
152. Mathew, N. T. Naratriptan: a review. Expert Opin. Investig. Drugs 8, 687–95 (1999). 
153. Buchan, P., Keywood, C., Ward, C. The pharmacokinetics of Frovatriptan a potent selective 5-HT agonist following single dose 
administration by oral and intravenous routes to healthy male and female volunteers. Headache 38, 410 (1998). 
154. Buchan, P., Keywood, C., Wade, a & Ward, C. Clinical pharmacokinetics of frovatriptan. Headache 42 Suppl 2, S54–62 (2002). 
155. Frovatriptan Drug Approval Package from Drugs@FDA. at <http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-
006_Frova_biopharmr.pdf> 
156. Frovatriptan FDA Label. 1, 
157. Negro, A. et al. Pharmacokinetic evaluation of frovatriptan. Expert Opin. Drug Metab. Toxicol. 7, 1449–58 (2011). 
158. Balbisi, E. A. Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine. Int. J. Clin. Pract. 58, 695–705 (2004). 
159. Sanford, M. Frovatriptan: a review of its use in the acute treatment of migraine. CNS Drugs 26, 791–811 (2012). 
160. Goldstein, J. Frovatriptan: A review. Expert Opin. Pharmacother. 4, 83–93 (2003). 
161. Markus, F. & Mikko, K. Frovatriptan review. Expert Opin. Pharmacother. 8, 3029–33 (2007). 
162. Lee, Y. et al. Pharmacokinetics and tolerability of intravenous rizatriptan in healthy females. Biopharm. Drug Dispos. 19, 577–81 
(1998). 
163. Cheng, H. et al. Pharmacokinetics and food interaction of MK-462 in healthy males. Biopharm. Drug Dispos. 17, 17–24 (1996). 
 374 
164. Lee, Y. et al. Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. Br. J. Clin. Pharmacol. 47, 
373–8 (1999). 
165. Vyas, K. P. et al. Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. Drug Metab. Dispos. 28, 89–95 
(2000). 
166. Rizatriptan FDA Approval Package. at <http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020864a-pharm-10.pdf> 
167. Rizatriptan FDA Label. at 
<http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020864s011s016s017s018s019,020865s012s016s018s020s021lbl.pdf> 
168. Seaber, E. et al. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). Br. 
J. Clin. Pharmacol. 43, 579–87 (1997). 
169. Seaber, E. J. et al. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. Br. J. 
Clin. Pharmacol. 46, 433–9 (1998). 
170. Peck, R. W. et al. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly 
men and women. Clin. Pharmacol. Ther. 63, 342–53 (1998). 
171. Peck, R. W. et al. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). Br. J. Clin. Pharmacol. 
44, 595–9 (1997). 
172. Rolan, P. & Martin, G. Zolmitriptan: a new acute treatment for migraine. Expert Opin. Investig. … 7, 633–52 (1998). 
173. Dixon, R. & Warrander, A. The clinical pharmacokinetics of zolmitriptan. Cephalalgia 17 Suppl 1, 15–20 (1997). 
174. Peterlin, B. L. & Rapoport, A. M. Clinical pharmacology of the serotonin receptor agonist, zolmitriptan. Expert Opin. Drug Metab. 
Toxicol. 3, 899–911 (2007). 
175. Wild, M. J., McKillop, D. & Butters, C. J. Determination of the human cytochrome P450 isoforms involved in the metabolism of 
zolmitriptan. Xenobiotica. 29, 847–57 (1999). 
176. Milton, K. A. et al. Pharmacokinetics, pharmacodynamics, and safety of the 5-HT(1B/1D) agonist eletriptan following intravenous and 
oral administration. J. Clin. Pharmacol. 42, 528–39 (2002). 
 375 
177. Eletriptan FDA Label. at <http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021016s018lbl.pdf> 
178. Gawel, M. J. & Grujich, N. N. Eletriptan. Expert Opin. Investig. Drugs 10, 1869–74 (2001). 
179. Sharma, A. et al. Pharmacokinetics and pharmacodynamics of avitriptan during intravenous administration in healthy subjects. J. Clin. 
Pharmacol. 39, 685–94 (1999). 
180. Pascual, J., Vila, C. & McGown, C. C. Almotriptan: a review of 10 years’ clinical experience. Expert Rev. Neurother. 10, 1505–17 
(2010). 
181. Corey, a E. et al. Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation. J. 
Clin. Pharmacol. 39, 1272–6 (1999). 
182. Corey, A. et al. Pharmacokinetics and pharmacodynamics following intravenous doses of azimilide dihydrochloride. J. Clin. 
Pharmacol. 39, 1263–71 (1999). 
183. Corey, a et al. Effect of age and gender on azimilide pharmacokinetics after a single oral dose of azimilide dihydrochloride. J. Clin. 
Pharmacol. 37, 946–53 (1997). 
184. Corey, A. E. et al. Effect of severe renal impairment on the pharmacokinetics of azimilide following single dose oral administration. 
Br. J. Clin. Pharmacol. 54, 449–52 (2002). 
185. El Mouelhi, M., Worley, D. J., Kuzmak, B., Destefano, A. J. & Thompson, G. a. Influence of ketoconazole on azimilide 
pharmacokinetics in healthy subjects. Br. J. Clin. Pharmacol. 58, 641–7 (2004). 
186. Ujhelyi, M. R. et al. Disposition of intravenous amiodarone in subjects with normal and impaired renal function. J. Clin. Pharmacol. 
36, 122–30 (1996). 
187. Cushing, D. J., Adams, M. P., Cooper, W. D., Kowey, P. R. & Lipicky, R. J. Bioequivalence of 2 intravenous amiodarone formulations 
in healthy participants. J. Clin. Pharmacol. 49, 407–15 (2009). 
188. Vadiei, K. et al. Pharmacokinetics of intravenous amiodarone in patients with impaired left ventricular function. J. Clin. Pharmacol. 
36, 720–7 (1996). 
189. Neyroz, P. & Bonati, M. In vitro amiodarone protein binding and its interaction with warfarin. Experientia 41, 361–3 (1985). 
 376 
190. Latini, R., Tognoni, G. & Kates, R. E. Clinical pharmacokinetics of amiodarone. Clin. Pharmacokinet. 9, 136–56 (1984). 
191. Freedman, M. D. & Somberg, J. C. Pharmacology and pharmacokinetics of amiodarone. J. Clin. Pharmacol. 31, 1061–9 (1991). 
192. Gonzalez, E. R., Kannewurf, B. S. & Ornato, J. P. Intravenous amiodarone for ventricular arrhythmias: overview and clinical use. 
Resuscitation 39, 33–42 (1998). 
193. Andreasen, F., Agerbaek, H., Bjerregaard, P. & Gøtzsche, H. Pharmacokinetics of amiodarone after intravenous and oral 
administration. Eur. J. Clin. Pharmacol. 19, 293–9 (1981). 
194. Tham, T. C., MacLennan, B. A., Burke, M. T. & Harron, D. W. Pharmacodynamics and pharmacokinetics of the class III 
antiarrhythmic agent dofetilide (UK-68,798) in humans. J. Cardiovasc. Pharmacol. 21, 507–12 (1993). 
195. Sedgwick, M., Rasmussen, H. S., Walker, D. & Cobbe, S. M. Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new 
potential class III antiarrhythmic drug. Br. J. Clin. Pharmacol. 31, 515–9 (1991). 
196. Le Coz, F., Funck-Brentano, C., Morell, T., Ghadanfar, M. M. & Jaillon, P. Pharmacokinetic and pharmacodynamic modeling of the 
effects of oral and intravenous administrations of dofetilide on ventricular repolarization. Clin. Pharmacol. Ther. 57, 533–42 (1995). 
197. Abel, S., Nichols, D. J., Brearley, C. J. & Eve, M. D. Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics 
of a single dose of dofetilide. Br. J. Clin. Pharmacol. 49, 64–71 (2000). 
198. Smith, D. a, Rasmussen, H. S., Stopher, D. a & Walker, D. K. Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and 
man. Xenobiotica. 22, 709–19 (1992). 
199. Jungbluth, G., Della-Coletta, A. & VanderLugt, J. Evaluation of the Pharmacokineticsand Pharmacodynamics of Ibutilide Fumarate 
and its Enantiomers in Healthy Male Volunteers. Pharm Res 8, S249 (1991). 
200. Jungbluth, G., VanderLugt, J., Kabell, G. & Walters, R. The pharmacokinetics and pharmacodynamics of ibutilide fumarate after 
intravenous infusions in healthy volunteers. Pharm Res 7, S211 (1990). 
201. Ibutilide FDA Label. at <http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-491S003.pdf> 
202. Dronedarone FDA Label. at <http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022425s023lbl.pdf> 
203. Dronedarone FDA Approval Package. at <http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf> 
 377 
204. Narang, P. K., Adir, J., Josselson, J., Yacobi, a & Sadler, J. Pharmacokinetics of bretylium in man after intravenous administration. J. 
Pharmacokinet. Biopharm. 8, 363–72 (1980). 
205. Garrett, E., Green, J. & Bialer, M. Bretylium Pharmacokinetics and Bioavailabilities in Man With Various Doses and Modes of 
Administration. Biopharm. drug … 3, 129–164 (1982).  
 
 
VITA 
 
Gopichand Gottipati was born on February 28, 1988 in Vijayawada, Andhra Pradesh, India and 
is an Indian citizen. He graduated from College of Pharmaceutical Sciences, Andhra University, 
Visakhapatnam, India, with a Bachelors degree in Pharmaceutical Sciences in 2010 before 
joining the PK-PD research group at Department of Pharmaceutics, Virginia Commonwealth 
University (VCU), Richmond, VA. 
During his tenure as a graduate student at VCU, Gopichand has published six abstracts. He 
presented her research extramurally at American Society of Clinical Pharmacology and 
Therapeutics (ASCPT 2012, 2013 and 2014), in addition to intramural presentation both within 
the Department and School of Pharmacy. During the summer of 2013, he was selected as a 
‘Ph.D. summer intern’ at the Center for Pharmacometrics and Systems Pharmacology (CPSP), 
University of Lake Nona, Orlando, FL, under the supervision of Dr. Larry Lesko and Dr. An 
Guohua. He received Presidential Trainee Award for the abstract based on his summer internship 
work at CPSP submitted to ASCPT Annual Meeting in Atlanta, 2014. He was selected to 
participate in the inaugural Personal and Professional Development Program (PPDP, now BEST 
program). In addition, he also received VCU Department of Pharmaceutics Pfizer Consumer 
Healthcare R & D Leading for Innovation Award, 2014 for his excellence in teaching, research 
and scholarly activities within the department, and VCU Graduate School Dissertation Award for 
Fall 2013 and Spring 2014.  
Gopichand served as President for Graduate Student Association (GSA) within the Department 
from 2012-13 and GSA webmaster from 2010 - 2013. He also served as VCU - AAPS Student 
Chapter Chair-elect (2012-2013) and VCU - AAPS Student Chapter Chair (2013-14). He was a 
student advisor, University Honor Council and served as a student representative in Tompkins 
McCaw Library Graduate Advisory Committee (2011 - 13), Student Health Advisory committee 
(2012-13) and member of VCU School of Pharmacy Diversity Committee (2011-2014). He was 
awarded University Service and Leadership Award 2012-13 for his commitment towards 
leadership and service activities. She is a member of professional organizations: AAPS and 
ASCPT.  
Abstracts: 
• Gottipati, G., Trame, M. N., Lin, C. W., Venitz, J., Lesko, L.J., An, G., Model-Based Meta-
Analysis of Efficacy at End-of-Trial and Efficacy-Time Course for Drugs Evaluated for the 
Treatment of Fibromyalgia Pain - presented at ASCPT Annual Meeting, Atlanta, GA, March 
18-22, 2014. 
     Clin Pharmacol Ther 95 (Suppl 1): S12, PT - 015 (2014) 
     (Recipient of ASCPT Presidential Trainee Award 2014) 
• Gottipati, G., Lin, C. W., Venitz, J., Lesko, L. J., An, G., Model-Based Meta-Analysis of 
Adverse Events and Dropouts for Drugs Evaluated for the Treatment of Fibromyalgia Pain - 
presented at ASCPT Annual Meeting, Atlanta, GA, March 18-22, 2014. 
     Clin Pharmacol Ther 95 (Suppl 1): S22, P-I - 016 (2014) 
• Gottipati, G., Venitz, J. Quantitative Structure-Pharmacokinetic/Pharmacodynamic 
Properties-Relationships for Neuromuscular Blockers - presented at ASCPT Annual 
Meeting, Atlanta, GA, March 18-22, 2014. 
     Clin Pharmacol Ther 95 (Suppl 1): S22, P-I - 015 (2014) 
• Gottipati, G., Venitz, J. Interspecies Pharmacokinetic - Allometric Scaling for 
Benzodiazepines  - presented at ASCPT Annual Meeting, Indianapolis, IN, March 5-9, 2013. 
      Clin Pharmacol Ther 93 (Suppl 1): S43, P-I 83 (2013) 
• Gottipati, G., Venitz, J. Quantitative Structure-Pharmacokinetic Property Relationship(s) 
for Benzodiazepines in Humans (significant update)  - presented at ASCPT Annual Meeting, 
Indianapolis, IN, March 5-9, 2013. 
      Clin Pharmacol Ther 93 (Suppl 1): S43, P-I 82 (2013) 
• Gottipati, G., Venitz, J. Quantitative Structure-Pharmacokinetic Properties-Relationships 
for Benzodiazepines - presented at ASCPT Annual Meeting, National Harbor, MD, March 
12-17, 2012. 
      Clin Pharmacol Ther 91 (Suppl 1): S70, P-II 50 (2012) 
